"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to New Merck's Fourth Quarter 2009 Earnings Release Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead.",38,"Good day, everyone, and welcome to New Merck's Fourth Quarter 2009 Earnings Release Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Cynthia, and good morning, everyone. And welcome to the 2009 Fourth Quarter Conference Call for the new Merck. This is our first quarter of combined operations, so there are a number of items in the GAAP results, such as gains associated with the",441,"Thanks, Cynthia, and good morning, everyone. And welcome to the 2009 Fourth Quarter Conference Call for the new Merck. This is our first quarter of combined operations, so there are a number of items in the GAAP results, such as gains associated with the controlling interest in the cholesterol [ph] (00:12:00) joint venture, purchase accounting adjustments, there are merger-related expenses and also restructuring costs. And so as a result of having those many items, we have excluded those items in our non-GAAP reconciliation tables, so that you can get a better sense of the underlying performance of our business. Also, since the merger was completed on November 3, the GAAP quarterly results only include two months of combined operations. So we have also provided tables to help you understand the revenue trends as well. So in the press release there are five tables. Table 1 is the GAAP results. Table 2 and 3 reconcile our GAAP P&L to our non-GAAP P&L for the fourth quarter and also for the full year 2009. Table 4 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products, as if the company had been combined for the full year and also for the full fourth quarter of 2009. Table 5 is a supplemental non-GAAP table, which provides sales for the major products and businesses, as if the company had been combined in 2008. That will help you make some growth comparisons in the 2009 period. During the call, we will be referring to Tables 2 and 3 when we discuss the P&L, and Table 4 for the revenue performance. So you may want to have those tables available. In addition, I would like to remind you that some of the statements we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs of Merck management and are subject to significant risk and uncertainties. The company's SEC filings, including Item 1A in the 2008 10-K, identifies certain factors and cautionary statements that could cause the company's actual results to differ materially from any forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. You can find our SEC filings, as well as today's earnings release and tables, on merck.com.This morning, I'm joined by Dick Clark, our Chairman, President and CEO; Ken Frazier, the President of our Global Human Health business; and Peter Kellogg, our Chief Financial Officer. Now I'd like to turn it over to Dick Clark."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. It was a little less than a year ago last March when we announced our plan to merge Merck and Schering-Plough. At the time, I told you that the combination made great strategic and financial sense and held exce",1187,"Thank you, Alex, and good morning, everyone. It was a little less than a year ago last March when we announced our plan to merge Merck and Schering-Plough. At the time, I told you that the combination made great strategic and financial sense and held exceptional promise, thanks to our stronger pipeline, more diverse product offerings across our broader range of businesses and an expanded global reach. In other words, our merger was and is about science and the increased relevance we now have to our customers. While this merger is about more than just cost, we stand firmly behind the financial targets we set last March. Today, we are pleased to report solid fourth quarter and full year 2009 results for the combined company. These results demonstrate the strong business focus each company maintained last year. That is a significant accomplishment, considering that the results were achieved in the midst of uncertain global economy, an ever-shifting healthcare landscape, extensive merger planning and then the start of integration once the merger was completed. In terms of top line, the company had sales of $10.1 billion for the fourth quarter and full year 2009 revenue are $27.4 billion. The combined company had fourth-quarter non-GAAP earnings per share of $0.79 and GAAP earnings per share of $2.35. Full year 2009 non-GAAP earnings were $3.25 per share, which excludes certain items in GAAP earnings of $5.65.  Our fourth quarter results were driven in part by the inclusion of legacy Schering-Plough sales in our results, as well as the strong sales from JANUVIA, SINGULAIR and ISENTRESS. Peter Kellogg will provide you further financial details, as well as some thoughts on our outlook for the future.Since the merger closed in early November, we have moved quickly around the world to integrate our operations and begin taking advantage of the opportunities that come with the new Merck. Thus far, we are quite pleased with the pace of our progress in adopting best practices from each company, integrating the commercial organizations, planning our network strategy and consolidating the pipeline. In fact, since the merger's completion, our combined pipeline has been a top priority. I spend a considerable amount of time with Peter Kim and other senior Merck leaders to conduct a thorough review of the new combined pipeline, so we may better prioritize our efforts by franchise, phase, cost and geographic importance. I'm very enthusiastic about the work we've done on our powerful R&D pipeline, with more than 20 late-stage programs. We look forward to talking with you about that soon. By advancing the highest potential pipeline candidates, accelerating product development and launches and maximizing the value of our medicines to full life-cycle management, we're focused on driving sustained innovation and revenue growth. We see three ways of new product opportunities over the near and long term the should contribute to our growth. Wave one is happening now, with products that are already in launch mode, such as SIMPONI, SAPHRIS and JANUVIA in Japan. Wave two focuses on near-term approvals. Just in the last few weeks, we had two key approvals, BRIDION and ELONVA. And we have four other key products on review as we speak. Wave three highlights our long-stage pipeline opportunities, which we believe are the best in the industry. Our strategy also includes continuing to tap into external sources of innovation to complement the work that is underway in our labs. We completed 51 licensing deals in 2009, with more to come this year; all of which could further our shareholder value.On the commercial side, we are building our capabilities and growth potential in vaccines, biologics and emerging markets. And they are sources of real focus and excitement within the new Merck. We are working hard on the strategies that will advance us to the next level in each of these growth areas. Here's a recent example. The acquisition of Avecia Biologics will allow Merck to build upon the biological expertise and manufacturing capability acquired during the past three decades at Schering-Plough. The new Merck's healthy and diversified product portfolio includes offerings from A-Z in a wide range of therapeutic areas from animal health to women's health. Each of our top 10 selling brands from our expanded product portfolio exceeds $1 billion in annual sales in 2009. In a few moments, Ken will talk about the performance of our key brands and how we're positioned the company's full portfolio of healthcare offerings for near term and future growth.Since late last year, we filled up the senior ranks of our new company with the best executives from both companies, as well as respected leaders with new capabilities and external experience. We're proud to welcome two new vaccine leaders: Former CDC Director, Dr. Julie Gerberding, as the leader of our Vaccine franchise; and Dr. Michael Kamarck, previously President at Product Supply at Wyeth, will lead Vaccines and Biologics manufacturing. We're also pleased to welcome to Merck Executive Committee former Dean of Tufts School of Medicine, Dr. Michael Rosenblatt, as Merck's new Chief Medical Officer; and Bridgette Heller, as the head of our Consumer Health Care business. Moving forward, we must realize the enormous value of our merger for patients, customers and shareholders. That includes gaining the benefit of fully integrating all aspects of the two formerly separate companies.We remain absolutely committed to our previously announced target of realizing merger synergies of $3.5 billion in annual savings in 2012. As part of these plans, we unveiled today a new multiphase global restructuring program designed to integrate and further optimize our operations and cost structure to support the more nimble, customer-focused and diversified healthcare leader Merck is becoming. We expect to complete the first phase of the program we announced today by the end of 2012. Additional phases of the merger restructuring program are expected to be announced later this year. We also expect to realize our savings through priority initiatives in areas, such as procurement. Building on earlier work begun in 2005, we're making progress in putting in place a best-in-industry cost structure. It will take time before we fully integrate off the access [ph] (00:21:15) of the two companies. The restructuring and integration process is complex, and includes changes that require our hard choices and difficult decisions, especially those that affect our colleagues throughout workforce reductions. But as we said all along, the majority of our colleagues from both legacy companies will be part of the new Merck going forward. Looking ahead into 2010 and beyond, we remain enthusiastic about our goal in becoming the best healthcare company in the world. We continue to be committed to our long-term financial targets. But the real value driver of our merger will be science and innovation, because Merck's long-term strength will come from our ability to develop critical medicines and vaccines. What will set this merger apart is not just the what but the how, the clarity of our vision, our ability to hit the ground running and the thoughtfulness, which we will manage through the integration of our businesses, our operations and our people. Now I'd like to turn the call over to Ken."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and good morning, everyone. As Dick mentioned, in the fourth quarter, we drove solid performance across the Global Human Health portfolio, thanks to the strong growth of many of our key brands in markets around the world. As a newly combi",1830,"Thank you, Dick, and good morning, everyone. As Dick mentioned, in the fourth quarter, we drove solid performance across the Global Human Health portfolio, thanks to the strong growth of many of our key brands in markets around the world. As a newly combined company, we were off to a great start following the merger, and we will continue to focus on driving top line performance in 2010, especially for our new and faster growing brands. Overall, Global Human Health delivered a solid quarter, with recorded sales of $9.1 billion. When you would include all three months of Schering-Plough sales, our non-GAAP sales were $10.8 billion, which represents 9% growth from the previous year. The growth was broad-based, with eight of our top 10 product families growing in the fourth quarter. These eight franchises accounted for more than half of total sales, and grew a combined 15% over the previous year. We drove this growth across a diverse base of markets. Sales outside the U.S. increased by 13%,  which includes the favorable impact of foreign exchange. And inside the U.S., we generated growth of 3% compared to the previous year. In the U.S., sales in the fourth quarter were aided by approximately $100 million of wholesaler inventory buy-in, stockpile purchases of certain vaccines by the CDC [Centers for Disease Control and Prevention] and the initial stocking for the SAPHRIS launch. Overall, I believe our fourth quarter performance is a good indicator that we are maintaining strong focus and momentum, while we integrate our teams. Before I discuss the performance of individual brands, I want to update you on the progress we have made since the completion of the merger. We will be integrating our businesses in markets around the world at different times, taking local considerations into account. As we do so, we will be leveraging the new commercial models that we had already implemented in nearly 30 markets.In the U.S., our experience with implementing Merck's new commercial model over the past two years prepared us to make critical staffing decisions quickly, with three very specific goals in mind: Retaining top talent, maintaining business momentum and minimizing disruption to our customers. In fact, by late January, we've completed the design and blending process to stand up the entire U.S. sales organization. Our U.S. sales force is now fully operational and completely focused on meeting customer needs. Our broader primary care offerings are ideally suited to the portfolio-based selling approach of the new commercial model, because the merger enables us to be more relevant to our customers across key franchises, such as cardiovascular, respiratory, women's health and other franchises.I want to emphasize one additional point about our integration efforts. While we focus on delivering the synergies that the merger creates, we are also making conscious, explicit decisions to invest to grow our business. So while we are reducing the size and cost of our commercial operations in more developed markets like the U.S., we are also making resource allocation decisions to grow our presence in major emerging markets. In fact, despite the economic volatility that we saw in these markets, our business grew by double digits in key emerging markets, like China and Brazil, during the fourth quarter.Also, as we indicated on the third quarter call, we made strategic investments to maintain and grow our key in-line growth drivers through additional promotional spending in the fourth quarter, and we'll continue to do so this year. For JANUVIA, ISENTRESS and SINGULAIR, for example, we made strategic investments in the fourth quarter to grow these brands. We also invested in our new product launches this quarter. These investments contributed to strong top line performance for many of our key brands. Now as I turn to individual product performance, I'll refer you to Table 4 from our supplemental financial package provided with our press release, so you can follow along. Starting with SINGULAIR, sales in the fourth quarter were $1.3 billion, up 12% versus the prior year. We saw double-digit growth in key markets, including the U.S., where we grew by 14% versus the fourth quarter of 2008. Moving to JANUVIA and JANUMET, global revenue grew to a combined $760 million in the fourth quarter, up 43% versus the prior year. Now in the fourth year since its launch, we continue to drive strong performance for the JANUVIA/JANUMET franchise in markets around the world. JANUVIA and JANUMET remain the most prescribed products in the DPP-4 [dipeptidyl peptidase-4 inhibitor] class. We continue to invest in JANUVIA and JANUMET to maintain our leadership position in the diabetes markets and to grow this franchise. In the U.S., where we have recently seen the first DPP-4 competitor, we generated 24% growth versus fourth quarter 2008. We believe we can grow the franchise by taking share from the sulfonylureas as second-line treatment for appropriate patients. In addition, we are continuing our coupon program, which has been a success today.In the EU, we also have a labeling advantage. JANUVIA is the only DPP-4 approved for restricted first-line use and for use as an add-on to insulin. In Japan, which is a fast-growing oral diabetes market, we are in early stages of the JANUVIA launch. JANUVIA has an extremely strong value proposition, and is being reimbursed at a premium price to ACTOS. Despite Japan's practice of limiting new medicines to only a two-week patient supply in the first year, the initial tracking shows that the JANUVIA launch is going very well. We are building this franchise for the long term, indication-by-indication and country-by-country. We've submitted three sNDAs [supplemental New Drug Application] for sitagliptin in the U.S. to allow use with insulin, which would make sitagliptin the only DPP-4 approved for use with insulin, for initial use with pioglitazone and for use as add-on therapy with PPAR [peroxisome proliferator-activated receptor] agonists and metformin. As you can see, there are many reasons why we expect that this franchise will continue to be a growth driver for Merck. I'd like to REMICADE and our newly launched biologic SIMPONI. We believe REMICADE and SIMPONI offer two great options for patients: REMICADE for rapidly progressing RA [rheumatoid arthritis] patients; and SIMPONI, the only once-monthly subcutaneous anti-TNF [tumor necrosis factor] available in the EU. In our first quarter combined operations, REMICADE delivered another quarter of double-digit sales growth and reached a new quarterly high, with sales of $635 million, an increase of 29% over last year. The growth was broad-based, as we saw increased utilization across all six indications. We're maintaining our market share in rheumatoid arthritis despite new entrance to the market, and we continue to see solid performance and growth from the gastro indications, especially ulcerative colitis. For SIMPONI, we now have launched in five countries. To date, we have full reimbursement in Germany and Denmark. We plan to launch in many of the other large EU markets in the second half of 2010, as we gain reimbursement for SIMPONI from both public and private payers. In infectious disease, ISENTRESS continues to perform well and had another quarter of strong growth. Sales in the fourth quarter were $234 million, up 80% year-over-year and 19% sequentially. The continued growth of ISENTRESS reflects the unique efficacy and safety profile of this product, which has been widely embraced by physicians, patients and health organizations.  ISENTRESS has become the new benchmark for an HIV launch and with the new treatment-naive indication, ISENTRESS is now approved for use across each stage in the treatment continuum.Turning to ZETIA and VYTORIN, sales were $1.2 billion this quarter, which represents 6% growth compared to the fourth quarter last year driven primarily by a 10% increase in the sales of ZETIA. For the franchise, sales in the U.S. declined 5%. However, this was more than offset by the strong growth of the brand outside the U.S., where the two brands grew by 23%, including the favorable impact of foreign exchange.The unique value proposition for these brands remains strong. And we continue to see growth opportunities in many markets around the world. I will now move two our Vaccine business, starting with GARDASIL. Sales as reported by Merck in the fourth quarter were $277 million, a 3% decline when compared to the fourth quarter of last year. In the U.S., we had about $70 million of favorability due mostly to a CDC stockpile purchase. Keep this in mind, as you model GARDASIL sales in subsequent quarters. X U.S. sales of GARDASIL as reported by Merck decreased 15%, attributable to the high-penetration rate and impact of large orders in 2008 in early-adopting countries, such as Mexico, Canada and Australia. Globally, we continue to outperform the competition, achieving an x U.S. market share of 77% in dollar terms in the fourth quarter and a global share of 87%.Sales of ProQuad, M-M-R II and VARIVAX combined increased 13% in the fourth quarter due to a CDC stockpile purchase of $64 million. If you exclude this favorability, sales would have decreased 9% year-over-year, largely due to the saturation in the varicella second dose catch-up cohort.Now moving to ZOSTAVAX, fourth quarter sales as reported by Merck were $76 million, down 53% from the previous year, largely due to the release of a very significant number of back orders in the fourth quarter of 2008. While we anticipate that ZOSTAVAX this will be available in 2010 in the U.S., customers may experience back orders throughout this year. International launches of ZOSTAVAX will be delayed until 2011. Now, I'd like to make a few comments about COZAAR/HYZAAR, which grew 8% year-over-year. As you know, COZAAR/HYZAAR will lose marketing exclusivity in the U.S. in early April, and COZAAR/HYZAAR will lose exclusivity at most major EU markets in the first quarter of 2010. In the U.S., we anticipate that multisource generics will be available immediately following the patent expiry, which we believe will lead to rapid erosion of sales from the current levels. And because internationally rose in [ph] (00:35:05) rates have accelerated in recent years, we expect that the generic uptake in the EU will also be rapid.As we head further into 2010, I want to share with you how we are prioritizing our work in GHH, Global Human Health. First, we are focused on driving in-line brand performance and we will continue to make the necessary investments to grow as we integrate our operations. Second, we are focused on the launches of our new products. In addition to SIMPONI, which I mentioned previously, we have recently put more promotional resources behind the SAPHRIS launch in the U.S. Other opportunities we have this year in markets around the world include the launches of SAFLUTAN, TREDAPTIVE, ELONVA and BRIDION. Finally, while we focus on these opportunities, we are also creating a leaner, even more customer-focused organization that builds on the best of the Merck and Schering-Plough commercial organizations. I look forward to sharing more with you as the year progresses. And now, it's my pleasure to pass it over to my colleague, Peter Kellogg."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, our merger is off to a great start. We generated good sales and earnings results, while making a lot of headway on the integration. Today, I'd like to cover three items with you. First,",2235,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, our merger is off to a great start. We generated good sales and earnings results, while making a lot of headway on the integration. Today, I'd like to cover three items with you. First, I will cover what is included in our results. Second, I will provide an update on our fourth quarter performance. And third, I will comment on our outlook for 2010. So let's go to the results.We recognize that there are a lot of moving parts this quarter. The merger closed in the middle of the quarter and therefore, there are only two months of Schering-Plough included in the results. Our results also included the add-in complexity of purchase price accounting adjustments and restructuring charges, and the joint venture that is being unwound and reported in the combined company's results rather than in equity income. As Alex discussed in the opening, we included new tables in our press release and supplemental charts to help you navigate through the accounting. To make it easier for you to follow, I will speak mostly to the non-GAAP results in our remarks.Our non-GAAP results exclude restructuring costs, purchase price accounting adjustments, which included a $7.5 billion gain on the step-up of Merck's share in the MSP [Merck/Schering-Plough Pharmaceuticals] partnership to current market value; merger-related costs; and a $400 million gain related to the sale of Merial in the quarter. On this basis, the new Merck reported fourth quarter non-GAAP earnings per share of $0.79. There are a number of factors that are reflected in our performance this quarter. First, we drove operational sales growth in many markets around the world, in part through higher promotional spending in support of our key brands and new launches. Second, we continued investing in our strong late-stage pipeline. Third, we had lower equity income from partnerships. And finally, we benefited from a lower combined company tax rate. In addition, as a result of the merger financing, our interest expense is higher and our interest income lower. And the number of common shares outstanding has substantially increased.Let's get into some of the individual items beginning with revenue. Total revenue for the quarter, as reported by Merck, was $10.1 billion, with about a 1% benefit from foreign exchange. On a supplemental-combined non-GAAP basis, which assumes Schering-Plough was included for all three months of the quarter in 2009 and 2008, sales were $12.2 billion, up 7%. You can see this in Table 4 provided today in our financial supplement.Ken just walked through the Human Health business results, so let me touch for a moment on our Animal and Consumer Health businesses. Animal Health sales totaled $759 million for the fourth quarter of 2009 on a supplemental combined non-GAAP basis, reflecting continued growth among companion animal and poultry products. Consumer Health Care sales were $232 million for the fourth quarter of 2009 on a supplemental combined non-GAAP basis, reflecting solid demand for OTC CLARITIN and foot care products.Now moving on to the expense items on the P&L. First, let's look at materials and production. The gross margin in the fourth quarter was approximately 74% versus 76% in the same quarter of the prior year. The decline is primarily attributed to the inclusion of results from Schering-Plough, which has historically had a lower gross margin due to some major partnerships. Foreign exchange also had an unfavorable impact on the gross margin from Schering-Plough. Turning to marketing and administrative costs, M&A expenses in the fourth quarter were $3.2 billion on a non-GAAP basis. The majority of the increase over the fourth quarter of 2008 is attributable to the addition of Schering-Plough expenses and inclusion of the expenses from the Merck/Schering-Plough JV in the P&L and the impact of foreign exchange. Additionally, as we had anticipated, Merck had higher marketing expenses during the fourth quarter than in the first three quarters of 2009. We increased promotion in support of our key brands, and we are also investing to ensure the success of our new launches around the globe, including JANUVIA in Japan and TREDAPTIVE in the EU.As Ken mentioned, we have a number of launches in major markets underway today. And we have more on the way. We want to ensure the success of these launches by supporting them with the right level of promotion in 2010. Now let's turn to R&D. Research and development expenses for the new Merck and the fourth quarter where approximately $2 billion. On a non-GAAP basis, R&D spending is up approximately $700 million this quarter. This increase is primarily driven by the addition of Schering-Plough R&D costs and the continued investment in late-stage opportunities such as TRA, boceprevir, demicative [ph], CORDAPTIVE, in our CETP inhibitor. Now let's move to equity income. In the fourth quarter, Merck recorded $374 million of equity income, a decline of $346 million over the prior year. The decline is attributable to three factors which you can derive from Table 6 in the financial supplement.  First, equity income in the quarter includes only one month of results from the MSP joint venture versus three months in the prior year. Post-closing of the merger, these results are reflected in sales and expenses of the new Merck. Second, a $75 million decline in the income from the AZLP joint ventures due to the timing variability of payments from AZLP. And third, the sale of Merial to our partner sanofi in the third quarter.Now let's talk about other income and expense. For the fourth quarter of 2009, other expense on a non-GAAP basis is $92 million compared to other income of $27 million in the fourth quarter of the prior year. There are a few items driving this year-over-year change. First, most notable is the inclusion of interest expense from the Schering-Plough debt and the merger-related debt post closing. Second, interest income of $11 million was $137 million lower when compared to the prior year as a result of lower interest rates and lower cash and investment balances.  Third, in the same quarter of last year, Merck recognized $74 million of exchange losses which did not recur this quarter. That helped to offset a portion of the negative interest expense and interest income comparisons. Now let's turn to the tax rate.  The new Merck non-GAAP tax rate is 15% for the fourth quarter. This reflects two dynamics. First, on the Merck side, there was some one-time benefits that aren't likely to recur. Second, we had the benefit related to the inclusion of legacy Schering-Plough during the two-month sub-period. And this sub-period had a much lower tax rate than legacy Merck.  For 2010, we don't anticipate a significant change in the rate that we saw in 2009 on a full year basis excluding discreet items. Our full year 2009 rate was approximately 23% when you exclude discreet items in the first and second quarters.Okay, so that's the fourth quarter. As you can see, there a lot of moving parts. Here's how I think about our performance this quarter. We had strong growth in sales of our key brands. At the same time, we continued investment in the future success of our newest products and our late-stage pipeline. So overall, a solid start to the new Merck. Now let's talk about where we're going beginning with 2010.  As we already indicated, we'll provide 2010 financial guidance around the timing of our first quarter earnings call. Today, I'd like to provide you with some perspective that I believe will be helpful. As we step back and look at new Merck, we are pleased with our many opportunities ahead. We continue to target a high single digit, non-GAAP EPS compound annual growth rate from 2009 to 2013 for the combined company when compared to Merck 2009 non-GAAP EPS.  Looking ahead over this next four-year period, we do anticipate that some years will be stronger than others. For example, 2010 has several factors that will be challenging. During 2010, we will begin to realize synergies from the merger. However, we also face the loss of patent protection for COZAAR/HYZAAR and TEMODAR, products that contribute $3.1 billion of revenues in the Europe U.S. last year. And we will continue to invest in launched brands.So as we think about 2010, there are four areas that I'd like to specifically call to your attention. First, let's start with the sales line. The merger has improved our longer term patent position and we are launching many new products like SAPHRIS and SIMPONI. However, we do faced significant patent losses in 2010. The biggest is COZAAR/HYZAAR. So how should you think about that in 2010? Well, first, in the first quarter, we expect to pullback in the COZAAR/HYZAAR trade inventory levels to below-normal levels as the patent expiry date approaches. Second, as Ken mentioned, we believe that the erosion rate will be fast as multiple generics enter the market after the patent expires. The second 2010 patent issue were not as large as TEMODAR, one of our high-margin products. In the U.S., we were disappointed by the recent District Court judgment and then filed an appeal in a motion for a preliminary injunction to allow the Court time to hear our appeal. In addition, TEMODAR lost patent protection in Europe in 2009 and we expect continued erosion. Despite the impressive number of new product launches in 2010, they will not be able to compensate for these two patent losses.Now second, let's talk abut synergies. We are committed to a merger-related cost synergies of $3.5 billion annually in 2012. The first phase of our Merger Restructuring Program that Dick told you about is expected to contribute $2.6 billion to $3 billion to this annual target. As we said, additional phases will be announced by the end of 2010.  We expect to see significant synergies, mostly on the M&A line in 2010. As a result, we expect the M&A line to be down on a full year basis in 2010 versus what the two companies spent individually in 2009. Please keep in mind that these synergies build over time. Very importantly, we expect the synergies in 2010 to be back-end loaded with about two-thirds of the synergies coming in the second half of the year. This will cause the shape of the earnings curve during 2010 to be quite back-end loaded.Now let's talk about the third area which is R&D where we have two dynamics underway. On the one hand, we are investing in our late-stage pipeline. On the other hand, we're driving efficiencies through the combined R&D infrastructure. Coming into the merger, Schering-Plough and Merck each had strong and growing R&D pipelines. And on a stand-alone basis, each company expected to significantly increase its level of R&D investment in 2010 due to the richness of its late-stage pipeline and the many ongoing large outcomes trials.Let me give you a sense of scale. In cardiovascular disease alone, we had more than 80,000 patients currently in our clinical trials. And that number is expected to grow to more than 100,000 patients before those trials end. So therefore, based on this level of Phase III project activity, we expect that the level of R&D investments in 2010 will be similar to slightly higher than levels seen in 2009 for both companies on a combined basis. We believe that making these 2010 investments are the best way to drive shareholder value. Lastly, let's talk about the timing of certain items this year. There are a number of items that will affect the early part of the year and specifically Q1. First, Q1 is typically the softest quarter of the year due to the seasonality of our respiratory and vaccine franchises. We saw this in the first quarter of 2009. Second, we have the expected pull down in COZAAR/HYZAAR trade inventories in Q1 that I mentioned earlier. Third, there was approximately $135 million of favorable vaccine revenue in Q4 primarily due to a number of CDC stockpile purchases, and these will not recur in the first quarter.  Fourth, we had a low tax rate in the fourth quarter that we do not expect to recur this year. Also, aside from the seasonality, these items relate to Q1 but obviously, they want a similar impact on the full year results. So let me summarize. As I mentioned earlier, we expect that non-GAAP earnings in the second half of 2010 will be considerably higher than non-GAAP earnings in the first half of 2010 due to the phasing in of synergies. In fact, we believe our non-GAAP EPS run rate in the second half of this year will provide strong evidence that we are heading towards our long-term EPS goal. We are on track to have a good first full year as a combined company. We will continue our business momentum for key brands and launch products. We remain very excited about the future of the new Merck. And we continue to target high single digit non-GAAP EPS compound annual growth rate in 2009 to 2013 for the combined company.  As Dick emphasized, this is a company that will build its long-term strength through science and innovation. We look forward to speaking with you about the products, the pipeline and the strategy of the new Merck during our second quarter R&D and business update meeting. Thank you. Now I'll turn the call over to Alex. Alex?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Peter. Now we're ready to open up the call to answer your questions. In order to get through as many callers as possible, we ask that you extend the courtesy to the other callers by only asking one or two questions. We are not planning to take any",63,"Thanks, Peter. Now we're ready to open up the call to answer your questions. In order to get through as many callers as possible, we ask that you extend the courtesy to the other callers by only asking one or two questions. We are not planning to take any follow-up questions but if you have other questions, please join the queue again. Cynthia?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts",",First question on the R&D budget, kind of reaching this $8 billion, $8.5 million kind of level on a pro forma basis in '09. Obviously, it's a much larger number than you've had in the past. And can you just elaborate what you're doing to manage an organi",161,",First question on the R&D budget, kind of reaching this $8 billion, $8.5 million kind of level on a pro forma basis in '09. Obviously, it's a much larger number than you've had in the past. And can you just elaborate what you're doing to manage an organization this large and avoid maybe some of the pitfalls that some of your competitors have run into as they've scaled organization their R&D organizations this size? And maybe just a follow up on the R&D side, on an absolute's basis, how do you kind of think about the R&D budget as going beyond 2010? Is this is a budget that kind of remains on that flat level or above current levels or will some of these deficiencies in program cuts you've targeted with the restructuring push that down over time, I guess especially as you think about some of these big outcome studies starting to ramp up, working out two or three years?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","This is Dick Clark. I think, the answer to the first part of your question, what we've been focusing on from a research standpoint is our prioritization really beginning with the portfolio. So as we said, we're spending a great deal of time understanding",214,"This is Dick Clark. I think, the answer to the first part of your question, what we've been focusing on from a research standpoint is our prioritization really beginning with the portfolio. So as we said, we're spending a great deal of time understanding the portfolio and making decisions by phase, by value, by geography, by medical need of what we need to do to put a portfolio together for the new company. We're also spending a great deal of time now focusing in on talent and scientific capabilities and the people that we need to be able to run this research organization. And obviously, the last thing that we spend time on then is the site. So once you have the portfolio, the projects and the people decided [indiscernible]. I think one of the advantages we have and how we run the entire company is not only in research but in Global Human Health as well. We really have franchise heads. And so having a general manager for franchise in the commercial side and one on the research side, allows us to think about franchises both in the commercial and research standpoint, allows better focus and allows us to make portfolio decisions even though the research capability has expanded as we move forward."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So if I can take some of the financial perspective on this. So you're right, as I highlighted, 2010 is here in many ways, a very exciting year for us because we have a lot going on in the late-stage pipeline and some very exciting trials that offer a lot",289,"So if I can take some of the financial perspective on this. So you're right, as I highlighted, 2010 is here in many ways, a very exciting year for us because we have a lot going on in the late-stage pipeline and some very exciting trials that offer a lot of potential for us in the near-term future. So clearly, while we're going through the portfolio prioritization, we made sure that these really high-priority pipelines get full resource and full attention. Secondly, we haven't really given R&D launch some guidance yet. And obviously, that's something we'll do when we get out towards the first quarter earnings call. But I do want to remind everybody that our long-term perspective on the company is that we will have high single-digit non-GAAP EPS growth over the time period that we talked about. And that we are going to see a nice pretax margin improvement as we go from today to that time frame. We highlighted on the time of  merger that we are shooting something that begins to approach the 40% level. It's obviously based on the current expectations on what we know at this point. But that implies there will be productivity in all the lines as we go through the P&L and that will be something you'll be seeing particularly, as all the different integration steps are going on in our R&D organizations come to bear. But I do think, as Dick said, in the beginning, this is about science and innovation and global expansion and having really world-class organizations in every function. And so we are going to be making sure that we make the right investments in all areas and yet still drive great productivity throughout the company."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your next question comes from the line of Jami Rubin with Goldman Sachs."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick and Peter, maybe you could help to clarify the $3.5 billion in integration synergies. Is that a gross number or a net number? And if it is a gross number, could you quantify the level of re-investment spending? And the question to Dick, there's not a",101,"Dick and Peter, maybe you could help to clarify the $3.5 billion in integration synergies. Is that a gross number or a net number? And if it is a gross number, could you quantify the level of re-investment spending? And the question to Dick, there's not a whole lot of focus on the consumer business, you just announced a new executive hired to run that business, it's only about 3% of total sales obviously, subscale compared to your competitors. What is your strategy with this business and would you consider spinning it off to similar to what Bristol did with Mead-Johnson?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","It's peter. So let me start with the synergy piece. Let me just begin by saying, nothing in our guidance has changed. We are definitely focused and targeted and confident about achieving the $3.5 billion of synergies. This announcement today is just the f",167,"It's peter. So let me start with the synergy piece. Let me just begin by saying, nothing in our guidance has changed. We are definitely focused and targeted and confident about achieving the $3.5 billion of synergies. This announcement today is just the first phase and obviously, it has the dramatic -- significant portion of a benefit against that $3.5 billion. And there'll be other phases that we'll be announcing as other plans are finalized and concluded on. And those will also contribute to the $3.5 billion goal that we have. Obviously, as we've highlighted, with an improving operating margin and particularly, as go out that time frame, if we have an operating margin that goes from where it is today, pretax to approaching 40%, we're going to be putting a lot of these synergies at the bottom line. And so while we don't necessarily talk about gross or net, you know us, we will make sure that we get the benefit at the bottom line."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Jami, as you know me, gross isn't in my vocabulary. So it's certainly is a net that we're looking forward to in the $3.5 billion. Turning to your question with the Consumer Health, we're excited about having a leader now at Consumer Health. We think it is",120,"Jami, as you know me, gross isn't in my vocabulary. So it's certainly is a net that we're looking forward to in the $3.5 billion. Turning to your question with the Consumer Health, we're excited about having a leader now at Consumer Health. We think it is a very good business. We think its a global business. We think Schering-Plough has done an outstanding job of building the business within the U.S. and started to look at it globally. We think it's a very important part of our emerging market going forward, example's in China and Brazil and other countries. And obviously, we need to grow the business and we're looking forward to putting a strategy together to do that."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Tim Anderson Sanford Bernstein.",12,"Your next question comes from the line of Tim Anderson Sanford Bernstein."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","On 2010, it seems like you kind of paint a cautious picture on the outlook because of a few different factors. And I understand complete guidance will come a little bit later. But directionally, can you just tell us whether 2010 will be a positive growth",94,"On 2010, it seems like you kind of paint a cautious picture on the outlook because of a few different factors. And I understand complete guidance will come a little bit later. But directionally, can you just tell us whether 2010 will be a positive growth year in terms of earnings relative to 2009? And second question is, can you give us an update of where we are in REMICADE? And when we might hear something with Johnson & Johnson? Do you expect that this will have to go to arbitration to get resolved?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Tim, it's Peter. We will have to hold off until around the first quarter call to talk about the P&L and so forth. We did, obviously, around the time of the earnings indicate that we thought 2010 would be an accretive year. And so it's a positive year. But",134,"Tim, it's Peter. We will have to hold off until around the first quarter call to talk about the P&L and so forth. We did, obviously, around the time of the earnings indicate that we thought 2010 would be an accretive year. And so it's a positive year. But we really want to hold off until we got the complete portfolio worked on, all decisions finalized and we have processes put together which will be happening over the course of next month. And then the way we always like to do it is to make sure we have the complete proper plan put to bed and then we come out with our guidance based on that. Bruce Kuhlik is here with us. So I'd like to ask Bruce if can comment just on REMICADE."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Just on the arbitration, the panel's been collected, we've met with the panel. The hearing is scheduled for September of this year and we're working towards that.",27,"Just on the arbitration, the panel's been collected, we've met with the panel. The hearing is scheduled for September of this year and we're working towards that."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","I was wondering if you could give us a flavor for the level of resources that you're putting behind the VYTORIN instead of your franchise relative to the way the JV had, the spending levels? And then second question is, can you just talk about the resumpt",59,"I was wondering if you could give us a flavor for the level of resources that you're putting behind the VYTORIN instead of your franchise relative to the way the JV had, the spending levels? And then second question is, can you just talk about the resumption of supply for some of the other vaccines you didn't mention?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","On VYTORIN and ZETIA, we are looking across our commercial operations for opportunities to do two things. At a high level, we're obviously, achieving synergies when you put together the sales forces that supported Merck for VYTORIN and ZETIA, Schering-Plo",239,"On VYTORIN and ZETIA, we are looking across our commercial operations for opportunities to do two things. At a high level, we're obviously, achieving synergies when you put together the sales forces that supported Merck for VYTORIN and ZETIA, Schering-Plough for VYTORIN and ZETIA and the JV for VYTORIN and ZETIA. So they are synergies across those groups. At the same time, we continue to invest behind the products from a promotional standpoint to ensure that they're competitively resourced. And as I said earlier, we feel very optimistic about the stabilization of trends as well as the continued growth outside the U.S. On the vaccine issues around supply, we mentioned earlier on that we aren't continuing to make ZOSTAVAX available in 2010. But customers may experience some back orders throughout the year as our best-seller product continues to be prioritized for use in manufacturing VARIVAX. So that will delay our launches outside the U.S. RECOMBIVAX pediatric became fully available in the U.S. as of early December, Pedvax here became fully available in the U.S. market as in January. Beyond that, we continue to make significant investments in our vaccine manufacturing capabilities. We've recently invested over $1 billion in new manufacturing resources and we expect our North Carolina facility to begin operations by the middle of this year. So we have some issues with respect to our varicella vaccines which we continue to work diligently on to minimize any disruption."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of David Risinger with Morgan Stanley.",13,"Your next question comes from the line of David Risinger with Morgan Stanley."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","First, could you please highlight the top three to four pipeline events to watch in 2010? And then second, Dick, I was hoping you could talk about CEO succession process and timing?",32,"First, could you please highlight the top three to four pipeline events to watch in 2010? And then second, Dick, I was hoping you could talk about CEO succession process and timing?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","The CEO succession planning process, David, as I had said many times, it's probably the most important priority I've given since I've become CEO in 2005. So working with the Board, I feel very confident we have a excellent process in place. As you know, p",111,"The CEO succession planning process, David, as I had said many times, it's probably the most important priority I've given since I've become CEO in 2005. So working with the Board, I feel very confident we have a excellent process in place. As you know, putting the management team together that we have has really been a focus of mine. And I think with the leadership team that I have today and that we recently announced, there is excellent leaders within the company. And obviously, the process will continue to evolve throughout this year. But I think we're in pretty good shape from a planning process as well as internal candidates."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","I think the things to keep in mind this year would be obviously the continued progress of both cepravir, the improvement interims, disclosures that will happen as well as our TRA enrollment. And I think we're very pleased on the last issue that our second",100,"I think the things to keep in mind this year would be obviously the continued progress of both cepravir, the improvement interims, disclosures that will happen as well as our TRA enrollment. And I think we're very pleased on the last issue that our secondary prevention study is fully enrolled. And we continue to work on the traces study where we have more than 9,000 patients enrolled in the study with the target enrollment of 12,500. I think, you'd expect to see four filings this year. So it's going to be a very strong year for advancing our late-stage pipeline."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of John Boris with Citi.",12,"Your next question comes from the line of John Boris with Citi."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","On cash flows, Peter, can you just identify or provide us with an idea what cash flows were in the quarter? And Dick, if you can just give some color on your focus on shareholder value and how you're going to be allocating cache going forward towards busi",112,"On cash flows, Peter, can you just identify or provide us with an idea what cash flows were in the quarter? And Dick, if you can just give some color on your focus on shareholder value and how you're going to be allocating cache going forward towards business development, share repo, dividends? And then a broader macro question for you Dick, obviously, Billy Tauzin has indicated that he's going to be stepping down at Pharma. Can you just provide some color on healthcare reform, where you see healthcare reform going and what's currently on the table that was negotiated by Billy Tauzin? How you see that potentially been impacted by his successor?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Talking about Pharma, I think the process that we utilize as an association will Billy as our leader was to involve the entire Pharma board. And so the positon that we've taken early on to be proactive with the President Obama's administration and the Con",157,"Talking about Pharma, I think the process that we utilize as an association will Billy as our leader was to involve the entire Pharma board. And so the positon that we've taken early on to be proactive with the President Obama's administration and the Congress is still the strategy that we have. And I think it's important that we continue to be proactive, we continue to come up what the right solutions are to make sure that everyone in our country is insured. And so that strategy that we put together with Billy's help was -- continue in the future. Billy is staying on as a consultant with us as well. And I think that's important. And the CEOs of the association are really committed to making healthcare reform work and working with Congress and the Obama administration. So even though we'll have some change in leadership at the association level, the focus will remain the same."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","John, this is Peter. If I can just taker the cash flow question. And first, let me just say, I applaud the focus on cash flow question first upon the focus on cash flow. As you know I'm a cash flow believer totally, as well. However I will have to ask tha",137,"John, this is Peter. If I can just taker the cash flow question. And first, let me just say, I applaud the focus on cash flow question first upon the focus on cash flow. As you know I'm a cash flow believer totally, as well. However I will have to ask that if you can wait for the 10-K, it will be out just a couple of the weeks and the balance sheet cash flow statements, because those are -- until they're final in the 10-K, I want to be careful not to -- since we haven't put them in the earnings release, we don't normally to do that. I want to hold until we actually publish the 10-K. But we focus on that tremendously and I just want to go through these normal steps and process."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Eric Lo with Bank of America.",14,"Your next question comes from the line of Eric Lo with Bank of America."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","What were SAPHRIS sales in the quarter and how much of your GARDASIL sales came from the male indication? And then also, can you provide a status update on [indiscernible] and what are your discussions with the FDA on that front?",41,"What were SAPHRIS sales in the quarter and how much of your GARDASIL sales came from the male indication? And then also, can you provide a status update on [indiscernible] and what are your discussions with the FDA on that front?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So on SAPHRIS issue, the sales were $40 million, almost all of that is stocking. I will take a second on SAPHRIS to say that we continue to be extremely strong in our belief that SAPHRIS has the potential to really make difference to patients who have sch",155,"So on SAPHRIS issue, the sales were $40 million, almost all of that is stocking. I will take a second on SAPHRIS to say that we continue to be extremely strong in our belief that SAPHRIS has the potential to really make difference to patients who have schizophrenia and bipolar disease without some of the metabolic issues. And that I think, we view this from our standpoint as being a launch that started on January 25 when we are able to provide full promotional support to our representatives, who before that, were essentially detailing what just a product inserts. So we view this launch as being a new one. On the GARDASIL issue, we look forward to growth opportunities from males. But right now, I think the males have not been a very significant contributor to our GARDASIL sales, although we continue to look forward to that as well as to the adult woman indication."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Seamus Fernandez with Leerink Swann.",13,"Your next question comes from the line of Seamus Fernandez with Leerink Swann."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","I just wanted to verify the comment on the second TRA study. Ken, you had mentioned that 9,000 patients were enrolled and there's a target enrollment of 12,500 patients. To my recollection, that may be approximately an increase of about 2,500 patients. An",133,"I just wanted to verify the comment on the second TRA study. Ken, you had mentioned that 9,000 patients were enrolled and there's a target enrollment of 12,500 patients. To my recollection, that may be approximately an increase of about 2,500 patients. And I'm just wondering what the reasons are for that increase? I know that you may not know that off the top of your head but just wanted to verify that that actually is an increase. And then separately, can you estimate the currency contribution to costs? Again, at least historical Merck costs in the quarter, just wondering if we can at least have a historical look at that? And if you have an estimate of what the contribution to the cost lines where for Schering-Plough, that would be very helpful."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","I will take the first comment of the traces study. You are correct that it was an increase of about 2,500 patients. While I'm not a scientist, I understand that when you have an event-driven study, the people who are running the study try to model what it",73,"I will take the first comment of the traces study. You are correct that it was an increase of about 2,500 patients. While I'm not a scientist, I understand that when you have an event-driven study, the people who are running the study try to model what it takes to make sure that you have a robust sample to get the event rate that you're looking for. And that's why it was increased."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","And Seames, if I can just note on that, this is Alex, that that was updated previously. That's not a new disclosure the 2,500 patient increase that's been out for a few months.",33,"And Seames, if I can just note on that, this is Alex, that that was updated previously. That's not a new disclosure the 2,500 patient increase that's been out for a few months."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So if I can take the foreign question, on the P&L. As I mentioned in my talk, we felt that the revenue benefited from about 1% from foreign exchange. Now Merck's year-over-year benefit from foreign exchange is not as pronounced as you might see in some ot",167,"So if I can take the foreign question, on the P&L. As I mentioned in my talk, we felt that the revenue benefited from about 1% from foreign exchange. Now Merck's year-over-year benefit from foreign exchange is not as pronounced as you might see in some other pharma companies in the call, that we had the benefit of a hedging program in the fourth quarter of last year when the currencies where really moving rapidly. We have some nice gains from a hedging position that we had. That moderates the year-over-year benefit. But net-net, what I can say is the EPS benefit on the bottom line is moderately better than what you see on the top line but not really dramatic. So really in some ways, it's probably net-net foreign exchange didn't benefit from our P&L on the fourth quarter versus last year, as much in part of that is because we had a nice hedging program that made the prior year stand up a little better."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question comes from the line of Bert Hazlett with BMO Capital Markets.",14,"Your final question comes from the line of Bert Hazlett with BMO Capital Markets."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","Maybe for Ken, was there any wholesale or stocking benefiting the U.S. results? And could you comment on the specific marketing increases that you made in the fourth quarter? And then regarding ISENTRESS which is a growth driver for the company. Clearly,",72,"Maybe for Ken, was there any wholesale or stocking benefiting the U.S. results? And could you comment on the specific marketing increases that you made in the fourth quarter? And then regarding ISENTRESS which is a growth driver for the company. Clearly, there's some competition and actually some news out regarding Gilead this morning. Could you comment on the relative positioning of ISENTRESS compared to Gilead's therapy, upcoming in the HIV market?"
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Looking backwards, I have not seen the latest news on Gilead but we continue to be confident in the profile of ISENTRESS and its prospects. We continue to work very hard on ensuring that we have a once-daily version of that drug. We continue to look forwa",283,"Looking backwards, I have not seen the latest news on Gilead but we continue to be confident in the profile of ISENTRESS and its prospects. We continue to work very hard on ensuring that we have a once-daily version of that drug. We continue to look forward to fix those combinations which we believe will put it in a position where it will continue to be successful. And all I know that I can say about the Gilead pill is obviously, we're talking about an experimental pill with an anticipated launch that's many years away. We said earlier in the U.S. that we did see some wholesalers stocking this quarter. I think we view that as being reasonable in terms of comparing the fourth quarter '09 to the fourth quarter '08, although it was up from the third quarter of '09. And your general question about marketing expenditures, I can just summarize by saying, we continue to put money behind our growth drivers. We're very pleased, for example, with the recent trends around JANUVIA. We mentioned before that we were really going to focus on JANUVIA before we had put the focus on messaging, the importance of maximizing BBP IV inhibition, to try to blog [ph] the introduction of in-class competition, we've expanded our approach. We've now started to focus on the ability to work competitively against so far in areas and we have been encouraged by the focus and the resources that put behind JANUVIA in terms of the increased volumes in December and January. So we continue to view JANUVIA and JANUMET as well as some of our other in-line products as key growth drivers in the U.S. market and beyond."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","If I can just amplify on something that Ken mentioned earlier, that we have four filings under review now with regulatory authorities around the world. So with that, I think that's the end of our Q&A and we thank you all for listening to the call. Have a",51,"If I can just amplify on something that Ken mentioned earlier, that we have four filings under review now with regulatory authorities around the world. So with that, I think that's the end of our Q&A and we thank you all for listening to the call. Have a good day. Goodbye."
288502,84103586,50106,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Ladies and gentlemen, this concludes today's New Merck's Fourth Quarter 2009 Earnings Release Conference Call. You may now disconnect.",19,"Ladies and gentlemen, this concludes today's New Merck's Fourth Quarter 2009 Earnings Release Conference Call. You may now disconnect."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to New Merck's Fourth Quarter 2009 Earnings Release Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead.",38,"Good day, everyone, and welcome to New Merck's Fourth Quarter 2009 Earnings Release Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Cynthia, and good morning, everyone. And welcome to the 2009 Fourth Quarter Conference Call for the new Merck. This is our first quarter of combined operations, so there are a number of items in the GAAP results, such as gains associated with the",439,"Thanks, Cynthia, and good morning, everyone. And welcome to the 2009 Fourth Quarter Conference Call for the new Merck. This is our first quarter of combined operations, so there are a number of items in the GAAP results, such as gains associated with the controlling interest in the cholesterol joint venture, purchase accounting adjustments, there are merger-related expenses and also restructuring costs. And so as a result of having those many items, we have excluded those items in our non-GAAP reconciliation tables, so that you can get a better sense of the underlying performance of our business. Also, since the merger was completed on November 3, the GAAP quarterly results only include two months of combined operations. So we have also provided tables to help you understand the revenue trends as well. So in the press release there are five tables. Table 1 is the GAAP results. Table 2 and 3 reconcile our GAAP P&L to our non-GAAP P&L for the fourth quarter and also for the full year 2009. Table 4 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products, as if the company had been combined for the full year and also for the full fourth quarter of 2009. Table 5 is a supplemental non-GAAP table, which provides sales for the major products and businesses, as if the company had been combined in 2008. That will help you make some growth comparisons in the 2009 period. During the call, we will be referring to Tables 2 and 3 when we discuss the P&L, and Table 4 for the revenue performance. So you may want to have those tables available. In addition, I would like to remind you that some of the statements we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs of Merck management and are subject to significant risk and uncertainties. The company's SEC filings, including Item 1A in the 2008 10-K, identifies certain factors and cautionary statements that could cause the company's actual results to differ materially from any forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. You can find our SEC filings, as well as today's earnings release and tables, on merck.com.This morning, I'm joined by Dick Clark, our Chairman, President and CEO; Ken Frazier, the President of our Global Human Health business; and Peter Kellogg, our Chief Financial Officer. Now I'd like to turn it over to Dick Clark."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. It was a little less than a year ago last March when we announced our plan to merge Merck and Schering-Plough. At the time, I told you that the combination made great strategic and financial sense and held exce",1188,"Thank you, Alex, and good morning, everyone. It was a little less than a year ago last March when we announced our plan to merge Merck and Schering-Plough. At the time, I told you that the combination made great strategic and financial sense and held exceptional promise, thanks to our stronger pipeline, more diverse product offerings across our broader range of businesses and an expanded global reach. In other words, our merger was and is about science and the increased relevance we now have to our customers. While this merger is about more than just cost, we stand firmly behind the financial targets we set last March. Today, we are pleased to report solid fourth quarter and full year 2009 results for the combined company. These results demonstrate the strong business focus each company maintained last year. That is a significant accomplishment, considering that the results were achieved in the midst of uncertain global economy, an ever-shifting healthcare landscape, extensive merger planning and then the start of integration once the merger was completed. In terms of top line, the company had sales of $10.1 billion for the fourth quarter and full year 2009 revenue of $27.4 billion. The combined company had fourth quarter non-GAAP earnings per share of $0.79 and GAAP earnings per share of $2.35. Full year 2009 non-GAAP earnings were $3.25 per share, which excludes certain items in GAAP earnings of $5.65.  Our fourth quarter results were driven in part by the inclusion of legacy Schering-Plough sales in our results, as well as the strong sales from JANUVIA, SINGULAIR and ISENTRESS. Peter Kellogg will provide you further financial details, as well as some thoughts on our outlook for the future.Since the merger closed in early November, we have moved quickly around the world to integrate our operations and begin taking advantage of the opportunities that come with the new Merck. Thus far, we are quite pleased with the pace of our progress in adopting best practices from each company, integrating the commercial organizations, planning our network strategy and consolidating the pipeline. In fact, since the merger's completion, our combined pipeline has been a top priority. I spent a considerable amount of time with Peter Kim and other senior Merck leaders to conduct a thorough review of the new combined pipeline, so we may better prioritize our efforts by franchise, phase, cost and geographic importance. I'm very enthusiastic about the work we've done on our powerful R&D pipeline, with more than 20 late-stage programs. We look forward to talking with you about that soon. By advancing the highest potential pipeline candidates, accelerating product development and launches, and maximizing the value of our medicines to full life-cycle management, we're focused on driving sustained innovation and revenue growth. We see three waves of new product opportunities over the near and long term that should contribute to our growth. Wave one is happening now, with products that are already in launch mode, such as SIMPONI, SAPHRIS and JANUVIA in Japan. Wave two focuses on near-term approvals. Just in the last few weeks, we had two key approvals, BRIDION and ELONVA. And we have four other key products under review as we speak. Wave three highlights our long-stage pipeline opportunities, which we believe are the best in the industry. Our strategy also includes continuing to tap into external sources of innovation to complement the work that is underway in our labs. We completed 51 licensing deals in 2009, with more to come this year; all of which could further our shareholder value.On the commercial side, we are building our capabilities and growth potential in vaccines, biologics and emerging markets. And they are sources of real focus and excitement within the new Merck. We are working hard on the strategies that will advance us to the next level in each of these growth areas. Here's a recent example. The acquisition of Avecia Biologics will allow Merck to build upon the biological expertise and manufacturing capability acquired during the past three decades at Schering-Plough. The new Merck's healthy and diversified product portfolio includes offerings from A to Z in a wide range of therapeutic areas from animal health to women's health. Each of our top 10 selling brands from our expanded product portfolio exceeds $1 billion in annual sales in 2009. In a few moments, Ken will talk about the performance of our key brands and how we're positioned the company's full portfolio of healthcare offerings for near term and future growth.Since late last year, weve built up the senior ranks of our new company with the best executives from both companies, as well as respected leaders with new capabilities and external experience. We're proud to welcome two new vaccine leaders: Former CDC Director, Dr. Julie Gerberding, as the leader of our Vaccine franchise; and Dr. Michael Kamarck, previously President of Product Supply at Wyeth, will lead Vaccines and Biologics manufacturing. We're also pleased to welcome to Merck Executive Committee former Dean of Tufts School of Medicine, Dr. Michael Rosenblatt, as Merck's new Chief Medical Officer; and Bridgette Heller, as the head of our Consumer Health Care business. Moving forward, we must realize the enormous value of our merger for patients, customers and shareholders. That includes gaining the benefit of fully integrating all aspects of the two formerly separate companies.We remain absolutely committed to our previously announced target of realizing merger synergies of $3.5 billion in annual savings in 2012. As part of these plans, we unveiled today a new multiphase global restructuring program designed to integrate and further optimize our operations and cost structure to support the more nimble, customer-focused and diversified healthcare leader Merck is becoming. We expect to complete the first phase of the program we announced today by the end of 2012. Additional phases of the merger restructuring program are expected to be announced later this year. We also expect to realize our savings through priority initiatives in areas, such as procurement. Building on earlier work begun in 2005, we're making progress in putting in place a best-in-industry cost structure. It will take time before we fully integrate off the axis of the two companies. The restructuring and integration process is complex, and includes changes that require our hard choices and difficult decisions, especially those that affect our colleagues throughout workforce reductions. But as we said all along, the majority of our colleagues from both legacy companies will be part of the new Merck going forward. Looking ahead into 2010 and beyond, we remain enthusiastic about our goal in becoming the best healthcare company in the world. We continue to be committed to our long-term financial targets. But the real value driver of our merger will be science and innovation, because Merck's long-term strength will come from our ability to develop critical medicines and vaccines. What will set this merger apart is not just the what but the how, the clarity of our vision, our ability to hit the ground running and the thoughtfulness, which we will manage through the integration of our businesses, our operations and our people. Now I'd like to turn the call over to Ken."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and good morning, everyone. As Dick mentioned, in the fourth quarter, we drove solid performance across the Global Human Health portfolio, thanks to the strong growth of many of our key brands in markets around the world. As a newly combi",1826,"Thank you, Dick, and good morning, everyone. As Dick mentioned, in the fourth quarter, we drove solid performance across the Global Human Health portfolio, thanks to the strong growth of many of our key brands in markets around the world. As a newly combined company, we were off to a great start following the merger, and we will continue to focus on driving top line performance in 2010, especially for our new and faster growing brands. Overall, Global Human Health delivered a solid quarter, with recorded sales of $9.1 billion. When you would include all three months of Schering-Plough sales, our non-GAAP sales were $10.8 billion, which represents 9% growth from the previous year. The growth was broad-based, with eight of our top 10 product families growing in the fourth quarter. These eight franchises accounted for more than half of total sales, and grew a combined 15% over the previous year. We drove this growth across a diverse base of markets. Sales outside the U.S. increased by 13%,  which includes the favorable impact of foreign exchange. And inside the U.S., we generated growth of 3% compared to the previous year. In the U.S., sales in the fourth quarter were aided by approximately $100 million of wholesaler inventory buy-in, stockpile purchases of certain vaccines by the CDC [Centers for Disease Control and Prevention] and the initial stocking for the SAPHRIS launch. Overall, I believe our fourth quarter performance is a good indicator that we are maintaining strong focus and momentum, while we integrate our teams. Before I discuss the performance of individual brands, I want to update you on the progress we have made since the completion of the merger. We will be integrating our businesses in markets around the world at different times, taking local considerations into account. As we do so, we will be leveraging the new commercial models that we had already implemented in nearly 30 markets.In the U.S., our experience with implementing Merck's new commercial model over the past two years prepared us to make critical staffing decisions quickly, with three very specific goals in mind: Retaining top talent, maintaining business momentum and minimizing disruption to our customers. In fact, by late January, we've completed the design and blending process to stand up the entire U.S. sales organization. Our U.S. sales force is now fully operational and completely focused on meeting customer needs. Our broader primary care offerings are ideally suited to the portfolio-based selling approach of the new commercial model, because the merger enables us to be more relevant to our customers across key franchises, such as cardiovascular, respiratory, women's health and other franchises.I want to emphasize one additional point about our integration efforts. While we focus on delivering the synergies that the merger creates, we are also making conscious, explicit decisions to invest to grow our business. So while we are reducing the size and cost of our commercial operations in more developed markets like the U.S., we are also making resource allocation decisions to grow our presence in major emerging markets. In fact, despite the economic volatility that we saw in these markets, our business grew by double digits in key emerging markets, like China and Brazil, during the fourth quarter.Also, as we indicated on the third quarter call, we made strategic investments to maintain and grow our key in-line growth drivers through additional promotional spending in the fourth quarter, and we'll continue to do so this year. For JANUVIA, ISENTRESS and SINGULAIR, for example, we made strategic investments in the fourth quarter to grow these brands. We also invested in our new product launches this quarter. These investments contributed to strong top line performance for many of our key brands. Now as I turn to individual product performance, I'll refer you to Table 4 from our supplemental financial package provided with our press release, so you can follow along. Starting with SINGULAIR, sales in the fourth quarter were $1.3 billion, up 12% versus the prior year. We saw double-digit growth in key markets, including the U.S., where we grew by 14% versus the fourth quarter of 2008. Moving to JANUVIA and JANUMET, global revenue grew to a combined $760 million in the fourth quarter, up 43% versus the prior year. Now in the fourth year since its launch, we continue to drive strong performance for the JANUVIA/JANUMET franchise in markets around the world. JANUVIA and JANUMET remain the most prescribed products in the DPP-4 [dipeptidyl peptidase-4 inhibitor] class. We continue to invest in JANUVIA and JANUMET to maintain our leadership position in the diabetes markets and to grow this franchise. In the U.S., where we have recently seen the first DPP-4 competitor, we generated 24% growth versus fourth quarter 2008. We believe we can grow the franchise by taking share from the sulfonylureas as second-line treatment for appropriate patients. In addition, we are continuing our coupon program, which has been a success today.In the EU, we also have a labeling advantage. JANUVIA is the only DPP-4 approved for restricted first-line use and for use as an add-on to insulin. In Japan, which is a fast-growing oral diabetes market, we are in early stages of the JANUVIA launch. JANUVIA has an extremely strong value proposition, and is being reimbursed at a premium price to ACTOS. Despite Japan's practice of limiting new medicines to only a two-week patient supply in the first year, the initial tracking shows that the JANUVIA launch is going very well. We are building this franchise for the long term, indication-by-indication and country-by-country. We've submitted three sNDAs [supplemental New Drug Application] for sitagliptin in the U.S. to allow use with insulin, which would make sitagliptin the only DPP-4 approved for use with insulin, for initial use with pioglitazone and for use as add-on therapy with PPAR [peroxisome proliferator-activated receptor] agonists and metformin. As you can see, there are many reasons why we expect that this franchise will continue to be a growth driver for Merck. I'd like to REMICADE and our newly launched biologic SIMPONI. We believe REMICADE and SIMPONI offer two great options for patients: REMICADE for rapidly progressing RA [rheumatoid arthritis] patients; and SIMPONI, the only once-monthly subcutaneous anti-TNF [tumor necrosis factor] available in the EU. In our first quarter combined operations, REMICADE delivered another quarter of double-digit sales growth and reached a new quarterly high, with sales of $635 million, an increase of 29% over last year. The growth was broad-based, as we saw increased utilization across all six indications. We're maintaining our market share in rheumatoid arthritis despite new entrance to the market, and we continue to see solid performance and growth from the gastro indications, especially ulcerative colitis. For SIMPONI, we now have launched in five countries. To date, we have full reimbursement in Germany and Denmark. We plan to launch in many of the other large EU markets in the second half of 2010, as we gain reimbursement for SIMPONI from both public and private payers. In infectious disease, ISENTRESS continues to perform well and had another quarter of strong growth. Sales in the fourth quarter were $234 million, up 80% year-over-year and 19% sequentially. The continued growth of ISENTRESS reflects the unique efficacy and safety profile of this product, which has been widely embraced by physicians, patients and health organizations.  ISENTRESS has become the new benchmark for an HIV launch and with the new treatment-naive indication, ISENTRESS is now approved for use across each stage in the treatment continuum.Turning to ZETIA and VYTORIN, sales were $1.2 billion this quarter, which represents 6% growth compared to the fourth quarter last year driven primarily by a 10% increase in the sales of ZETIA. For the franchise, sales in the U.S. declined 5%. However, this was more than offset by the strong growth of the brand outside the U.S., where the two brands grew by 23%, including the favorable impact of foreign exchange.The unique value proposition for these brands remains strong. And we continue to see growth opportunities in many markets around the world. I will now move two our Vaccine business, starting with GARDASIL. Sales as reported by Merck in the fourth quarter were $277 million, a 3% decline when compared to the fourth quarter of last year. In the U.S., we had about $70 million of favorability due mostly to a CDC stockpile purchase. Keep this in mind, as you model GARDASIL sales in subsequent quarters. X U.S. sales of GARDASIL as reported by Merck decreased 15%, attributable to the high-penetration rate and impact of large orders in 2008 in early-adopting countries, such as Mexico, Canada and Australia. Globally, we continue to outperform the competition, achieving an x U.S. market share of 77% in dollar terms in the fourth quarter and a global share of 87%.Sales of ProQuad, M-M-R II and VARIVAX combined increased 13% in the fourth quarter due to a CDC stockpile purchase of $64 million. If you exclude this favorability, sales would have decreased 9% year-over-year, largely due to the saturation in the varicella second dose catch-up cohort.Now moving to ZOSTAVAX, fourth quarter sales as reported by Merck were $76 million, down 53% from the previous year, largely due to the release of a very significant number of back orders in the fourth quarter of 2008. While we anticipate that ZOSTAVAX will be available in 2010 in the U.S., customers may experience back orders throughout this year. International launches of ZOSTAVAX will be delayed until 2011. Now, I'd like to make a few comments about COZAAR/HYZAAR, which grew 8% year-over-year. As you know, COZAAR/HYZAAR will lose marketing exclusivity in the U.S. in early April, and COZAAR/HYZAAR will lose exclusivity in most major EU markets in the first quarter of 2010. In the U.S., we anticipate that multisource generics will be available immediately following the patent expiry, which we believe will lead to rapid erosion of sales from the current levels. And because internationally rosin rates have accelerated in recent years, we expect that the generic uptake in the EU will also be rapid.As we head further into 2010, I want to share with you how we are prioritizing our work in GHH, Global Human Health. First, we are focused on driving in-line brand performance and we will continue to make the necessary investments to grow as we integrate our operations. Second, we are focused on the launches of our new products. In addition to SIMPONI, which I mentioned previously, we have recently put more promotional resources behind the SAPHRIS launch in the U.S. Other opportunities we have this year in markets around the world include the launches of SAFLUTAN, TREDAPTIVE, ELONVA and BRIDION. Finally, while we focus on these opportunities, we are also creating a leaner, even more customer-focused organization that builds on the best of the Merck and Schering-Plough commercial organizations. I look forward to sharing more with you as the year progresses. And now, it's my pleasure to pass it over to my colleague, Peter Kellogg."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, our merger is off to a great start. We generated good sales and earnings results, while making a lot of headway on the integration. Today, I'd like to cover three items with you. First,",2235,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, our merger is off to a great start. We generated good sales and earnings results, while making a lot of headway on the integration. Today, I'd like to cover three items with you. First, I will cover what is included in our results. Second, I will provide an update on our fourth quarter performance. And third, I will comment on our outlook for 2010. So let's go to the results.We recognize that there are a lot of moving parts this quarter. The merger closed in the middle of the quarter and therefore, there are only two months of Schering-Plough included in the results. Our results also included the add-in complexity of purchase price accounting adjustments and restructuring charges, and the joint venture that is being unwound and reported in the combined company's results rather than in equity income. As Alex discussed in the opening, we included new tables in our press release and supplemental charts to help you navigate through the accounting. To make it easier for you to follow, I will speak mostly to the non-GAAP results in our remarks.Our non-GAAP results exclude restructuring costs, purchase price accounting adjustments, which included a $7.5 billion gain on the step-up of Merck's share in the MSP [Merck/Schering-Plough Pharmaceuticals] partnership to current market value; merger-related costs; and a $400 million gain related to the sale of Merial in the quarter. On this basis, the new Merck reported fourth quarter non-GAAP earnings per share of $0.79. There are a number of factors that are reflected in our performance this quarter. First, we drove operational sales growth in many markets around the world, in part through higher promotional spending in support of our key brands and new launches. Second, we continued investing in our strong late-stage pipeline. Third, we had lower equity income from partnerships. And finally, we benefited from a lower combined company tax rate. In addition, as a result of the merger financing, our interest expense is higher and our interest income lower. And the number of common shares outstanding has substantially increased.Let's get into some of the individual items beginning with revenue. Total revenue for the quarter, as reported by Merck, was $10.1 billion, with about a 1% benefit from foreign exchange. On a supplemental-combined non-GAAP basis, which assumes Schering-Plough was included for all three months of the quarter in 2009 and 2008, sales were $12.2 billion, up 7%. You can see this in Table 4 provided today in our financial supplement.Ken just walked through the Human Health business results, so let me touch for a moment on our Animal and Consumer Health businesses. Animal Health sales totaled $759 million for the fourth quarter of 2009 on a supplemental combined non-GAAP basis, reflecting continued growth among companion animal and poultry products. Consumer Health Care sales were $232 million for the fourth quarter of 2009 on a supplemental combined non-GAAP basis, reflecting solid demand for OTC CLARITIN and foot care products.Now moving on to the expense items on the P&L. First, let's look at materials and production. The gross margin in the fourth quarter was approximately 74% versus 76% in the same quarter of the prior year. The decline is primarily attributed to the inclusion of results from Schering-Plough, which has historically had a lower gross margin due to some major partnerships. Foreign exchange also had an unfavorable impact on the gross margin from Schering-Plough. Turning to marketing and administrative costs, M&A expenses in the fourth quarter were $3.2 billion on a non-GAAP basis. The majority of the increase over the fourth quarter of 2008 is attributable to the addition of Schering-Plough expenses and inclusion of the expenses from the Merck/Schering-Plough JV in the P&L and the impact of foreign exchange. Additionally, as we had anticipated, Merck had higher marketing expenses during the fourth quarter than in the first three quarters of 2009. We increased promotion in support of our key brands, and we are also investing to ensure the success of our new launches around the globe, including JANUVIA in Japan and TREDAPTIVE in the EU.As Ken mentioned, we have a number of launches in major markets underway today. And we have more on the way. We want to ensure the success of these launches by supporting them with the right level of promotion in 2010. Now let's turn to R&D. Research and development expenses for the new Merck and the fourth quarter where approximately $2 billion. On a non-GAAP basis, R&D spending is up approximately $700 million this quarter. This increase is primarily driven by the addition of Schering-Plough R&D costs and the continued investment in late-stage opportunities such as TRA, boceprevir, demicative [ph], CORDAPTIVE, in our CETP inhibitor. Now let's move to equity income. In the fourth quarter, Merck recorded $374 million of equity income, a decline of $346 million over the prior year. The decline is attributable to three factors which you can derive from Table 6 in the financial supplement.  First, equity income in the quarter includes only one month of results from the MSP joint venture versus three months in the prior year. Post-closing of the merger, these results are reflected in sales and expenses of the new Merck. Second, a $75 million decline in the income from the AZLP joint ventures due to the timing variability of payments from AZLP. And third, the sale of Merial to our partner sanofi in the third quarter.Now let's talk about other income and expense. For the fourth quarter of 2009, other expense on a non-GAAP basis is $92 million compared to other income of $27 million in the fourth quarter of the prior year. There are a few items driving this year-over-year change. First, most notable is the inclusion of interest expense from the Schering-Plough debt and the merger-related debt post closing. Second, interest income of $11 million was $137 million lower when compared to the prior year as a result of lower interest rates and lower cash and investment balances.  Third, in the same quarter of last year, Merck recognized $74 million of exchange losses which did not recur this quarter. That helped to offset a portion of the negative interest expense and interest income comparisons. Now let's turn to the tax rate.  The new Merck non-GAAP tax rate is 15% for the fourth quarter. This reflects two dynamics. First, on the Merck side, there was some one-time benefits that aren't likely to recur. Second, we had the benefit related to the inclusion of legacy Schering-Plough during the two-month sub-period. And this sub-period had a much lower tax rate than legacy Merck.  For 2010, we don't anticipate a significant change in the rate that we saw in 2009 on a full year basis excluding discreet items. Our full year 2009 rate was approximately 23% when you exclude discreet items in the first and second quarters.Okay, so that's the fourth quarter. As you can see, there a lot of moving parts. Here's how I think about our performance this quarter. We had strong growth in sales of our key brands. At the same time, we continued investment in the future success of our newest products and our late-stage pipeline. So overall, a solid start to the new Merck. Now let's talk about where we're going beginning with 2010.  As we already indicated, we'll provide 2010 financial guidance around the timing of our first quarter earnings call. Today, I'd like to provide you with some perspective that I believe will be helpful. As we step back and look at new Merck, we are pleased with our many opportunities ahead. We continue to target a high single digit, non-GAAP EPS compound annual growth rate from 2009 to 2013 for the combined company when compared to Merck 2009 non-GAAP EPS.  Looking ahead over this next four-year period, we do anticipate that some years will be stronger than others. For example, 2010 has several factors that will be challenging. During 2010, we will begin to realize synergies from the merger. However, we also face the loss of patent protection for COZAAR/HYZAAR and TEMODAR, products that contribute $3.1 billion of revenues in the Europe U.S. last year. And we will continue to invest in launched brands.So as we think about 2010, there are four areas that I'd like to specifically call to your attention. First, let's start with the sales line. The merger has improved our longer term patent position and we are launching many new products like SAPHRIS and SIMPONI. However, we do faced significant patent losses in 2010. The biggest is COZAAR/HYZAAR. So how should you think about that in 2010? Well, first, in the first quarter, we expect to pullback in the COZAAR/HYZAAR trade inventory levels to below-normal levels as the patent expiry date approaches. Second, as Ken mentioned, we believe that the erosion rate will be fast as multiple generics enter the market after the patent expires. The second 2010 patent issue were not as large as TEMODAR, one of our high-margin products. In the U.S., we were disappointed by the recent District Court judgment and then filed an appeal in a motion for a preliminary injunction to allow the Court time to hear our appeal. In addition, TEMODAR lost patent protection in Europe in 2009 and we expect continued erosion. Despite the impressive number of new product launches in 2010, they will not be able to compensate for these two patent losses.Now second, let's talk abut synergies. We are committed to a merger-related cost synergies of $3.5 billion annually in 2012. The first phase of our Merger Restructuring Program that Dick told you about is expected to contribute $2.6 billion to $3 billion to this annual target. As we said, additional phases will be announced by the end of 2010.  We expect to see significant synergies, mostly on the M&A line in 2010. As a result, we expect the M&A line to be down on a full year basis in 2010 versus what the two companies spent individually in 2009. Please keep in mind that these synergies build over time. Very importantly, we expect the synergies in 2010 to be back-end loaded with about two-thirds of the synergies coming in the second half of the year. This will cause the shape of the earnings curve during 2010 to be quite back-end loaded.Now let's talk about the third area which is R&D where we have two dynamics underway. On the one hand, we are investing in our late-stage pipeline. On the other hand, we're driving efficiencies through the combined R&D infrastructure. Coming into the merger, Schering-Plough and Merck each had strong and growing R&D pipelines. And on a stand-alone basis, each company expected to significantly increase its level of R&D investment in 2010 due to the richness of its late-stage pipeline and the many ongoing large outcomes trials.Let me give you a sense of scale. In cardiovascular disease alone, we had more than 80,000 patients currently in our clinical trials. And that number is expected to grow to more than 100,000 patients before those trials end. So therefore, based on this level of Phase III project activity, we expect that the level of R&D investments in 2010 will be similar to slightly higher than levels seen in 2009 for both companies on a combined basis. We believe that making these 2010 investments are the best way to drive shareholder value. Lastly, let's talk about the timing of certain items this year. There are a number of items that will affect the early part of the year and specifically Q1. First, Q1 is typically the softest quarter of the year due to the seasonality of our respiratory and vaccine franchises. We saw this in the first quarter of 2009. Second, we have the expected pull down in COZAAR/HYZAAR trade inventories in Q1 that I mentioned earlier. Third, there was approximately $135 million of favorable vaccine revenue in Q4 primarily due to a number of CDC stockpile purchases, and these will not recur in the first quarter.  Fourth, we had a low tax rate in the fourth quarter that we do not expect to recur this year. Also, aside from the seasonality, these items relate to Q1 but obviously, they want a similar impact on the full year results. So let me summarize. As I mentioned earlier, we expect that non-GAAP earnings in the second half of 2010 will be considerably higher than non-GAAP earnings in the first half of 2010 due to the phasing in of synergies. In fact, we believe our non-GAAP EPS run rate in the second half of this year will provide strong evidence that we are heading towards our long-term EPS goal. We are on track to have a good first full year as a combined company. We will continue our business momentum for key brands and launch products. We remain very excited about the future of the new Merck. And we continue to target high single digit non-GAAP EPS compound annual growth rate in 2009 to 2013 for the combined company.  As Dick emphasized, this is a company that will build its long-term strength through science and innovation. We look forward to speaking with you about the products, the pipeline and the strategy of the new Merck during our second quarter R&D and business update meeting. Thank you. Now I'll turn the call over to Alex. Alex?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Peter. Now we're ready to open up the call to answer your questions. In order to get through as many callers as possible, we ask that you extend the courtesy to the other callers by only asking one or two questions. We are not planning to take any",63,"Thanks, Peter. Now we're ready to open up the call to answer your questions. In order to get through as many callers as possible, we ask that you extend the courtesy to the other callers by only asking one or two questions. We are not planning to take any follow-up questions but if you have other questions, please join the queue again. Cynthia?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts",",First question on the R&D budget, kind of reaching this $8 billion, $8.5 million kind of level on a pro forma basis in '09. Obviously, it's a much larger number than you've had in the past. And can you just elaborate what you're doing to manage an organi",161,",First question on the R&D budget, kind of reaching this $8 billion, $8.5 million kind of level on a pro forma basis in '09. Obviously, it's a much larger number than you've had in the past. And can you just elaborate what you're doing to manage an organization this large and avoid maybe some of the pitfalls that some of your competitors have run into as they've scaled organization their R&D organizations this size? And maybe just a follow up on the R&D side, on an absolute's basis, how do you kind of think about the R&D budget as going beyond 2010? Is this is a budget that kind of remains on that flat level or above current levels or will some of these deficiencies in program cuts you've targeted with the restructuring push that down over time, I guess especially as you think about some of these big outcome studies starting to ramp up, working out two or three years?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","This is Dick Clark. I think to answer the first part of your question, what we've been focusing on from a research standpoint is our prioritization really beginning with the portfolio. So as we said, we're spending a great deal of time understanding the p",220,"This is Dick Clark. I think to answer the first part of your question, what we've been focusing on from a research standpoint is our prioritization really beginning with the portfolio. So as we said, we're spending a great deal of time understanding the portfolio and making decisions by phase, by value, by geography, by unmet medical need of what we need to do to put a portfolio together for the new company. We're also spending a great deal of time now focusing in on talent and scientific capabilities and the people that we need to be able to run this research organization. And obviously, the last thing that we spend time on then is the site. So once you have the portfolio, the projects and the people decided you can look at price. I think one of the advantages we have in how we run the entire company is not only in research but in Global Human Health as well is that we really have franchise heads. And so having a general manager for franchise in the commercial side and one on the research side, allows us to think about franchises both in the commercial and research standpoint, allows better focus and allows us to make portfolio decisions even though the research capability has expanded as we move forward."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So if I can take some of the financial perspective on this. So you're right, as I highlighted, 2010 is here in many ways, a very exciting year for us because we have a lot going on in the late-stage pipeline and some very exciting trials that offer a lot",289,"So if I can take some of the financial perspective on this. So you're right, as I highlighted, 2010 is here in many ways, a very exciting year for us because we have a lot going on in the late-stage pipeline and some very exciting trials that offer a lot of potential for us in the near-term future. So clearly, while we're going through the portfolio prioritization, we made sure that these really high-priority pipelines get full resource and full attention. Secondly, we haven't really given R&D long-term guidance yet. And obviously, that's something we'll do when we get out towards the first quarter earnings call. But I do want to remind everybody that our long-term perspective on the company is that we will have high single-digit non-GAAP EPS growth over the time period that we talked about. And that we are going to see a nice pretax margin improvement as we go from today to that timeframe. We highlighted on the time of merger that were shooting for something that begins to approach the 40% level. It's obviously based on the current expectations and what we know at this point. But that implies that there will be productivity in all the lines as we go through the P&L and that will be something you'll be seeing particularly, as all the different integration steps are going on in our R&D organizations come to bear. But I do think, as Dick said, in the beginning, this is about science and innovation and global expansion and having really world-class organizations in every function. And so we are going to be making sure that we make the right investments in all the areas and yet still drive great productivity throughout the company."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your next question comes from the line of Jami Rubin with Goldman Sachs."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick and Peter, maybe you could help to clarify the $3.5 billion in integration synergies. Is that a gross number or a net number? And if it is a gross number, could you quantify the level of re-investment spending? And a question to Dick, there's not a w",100,"Dick and Peter, maybe you could help to clarify the $3.5 billion in integration synergies. Is that a gross number or a net number? And if it is a gross number, could you quantify the level of re-investment spending? And a question to Dick, there's not a whole lot of focus on the consumer business. You just announced a new executive hire to run that business. It's only about 3% of total sales, obviously subscale compared to your competitors. What is your strategy with this business and would you consider spinning it off similar to what Bristol did with Mead-Johnson?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","It's Peter. So let me start with the synergy piece. Let me just begin by saying, nothing in our guidance has changed. We are definitely focused and targeted and confident about achieving the $3.5 billion of synergies. This announcement today is just the f",166,"It's Peter. So let me start with the synergy piece. Let me just begin by saying, nothing in our guidance has changed. We are definitely focused and targeted and confident about achieving the $3.5 billion of synergies. This announcement today is just the first phase and obviously, it has a dramatic -- significant portion of a benefit against that $3.5 billion. And there'll be other phases that we'll be announcing as other plans are finalized and concluded on. And those will also contribute to the $3.5 billion goal that we have. Obviously, as we've highlighted, with an improving operating margin and particularly, as go out that timeframe, if we have an operating margin that goes from where it is today, pretax to approaching 40%, we're going to be putting a lot of this synergy to the bottom line. And so while we don't necessarily talk about gross or net, you know us, we will make sure that we get the benefit at the bottom line."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Jami, as you know me, gross isn't in my vocabulary. So it certainly is a net that we're looking forward to in the $3.5 billion. Concerning your question with the Consumer Health, we're excited about having a leader now at Consumer Health. We think it is a",119,"Jami, as you know me, gross isn't in my vocabulary. So it certainly is a net that we're looking forward to in the $3.5 billion. Concerning your question with the Consumer Health, we're excited about having a leader now at Consumer Health. We think it is a very good business. We think its a global business. We think Schering-Plough has done an outstanding job of building the business within the U.S. and starting to look at it globally. We think it's a very important part of our emerging market going forward, example's in China and Brazil and other countries. And obviously, we need to grow the business and we're looking forward to putting a strategy together to do that."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Tim Anderson Sanford Bernstein.",12,"Your next question comes from the line of Tim Anderson Sanford Bernstein."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","On 2010, it seems like you kind of paint a cautious picture on the outlook because of a few different factors. And I understand complete guidance will come a little bit later. But directionally, can you just tell us whether 2010 will be a positive growth",94,"On 2010, it seems like you kind of paint a cautious picture on the outlook because of a few different factors. And I understand complete guidance will come a little bit later. But directionally, can you just tell us whether 2010 will be a positive growth year in terms of earnings relative to 2009? And second question is, can you give us an update of where we are in REMICADE? And when we might hear something with Johnson & Johnson? Do you expect that this will have to go to arbitration to get resolved?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Tim, it's Peter. We will have to hold off until around the first quarter call to talk about the P&L and so forth. We did, obviously, around the time of the earnings indicate that we thought 2010 would be an accretive year. And so it's a positive year. But",134,"Tim, it's Peter. We will have to hold off until around the first quarter call to talk about the P&L and so forth. We did, obviously, around the time of the earnings indicate that we thought 2010 would be an accretive year. And so it's a positive year. But we really want to hold off until we got the complete portfolio worked on, all decisions finalized and we have processes put together which will be happening over the course of next month. And then the way we always like to do it is to make sure we have the complete proper plan put to bed and then we come out with our guidance based on that. Bruce Kuhlik is here with us. So I'd like to ask Bruce if can comment just on REMICADE."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Just on the arbitration, the panel's been collected, we've met with the panel. The hearing is scheduled for September of this year and we're working towards that.",27,"Just on the arbitration, the panel's been collected, we've met with the panel. The hearing is scheduled for September of this year and we're working towards that."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","I was wondering if you could give us a flavor for the level of resources that you're putting behind the VYTORIN instead of your franchise relative to the way the JV had, the spending levels? And then second question is, can you just talk about the resumpt",59,"I was wondering if you could give us a flavor for the level of resources that you're putting behind the VYTORIN instead of your franchise relative to the way the JV had, the spending levels? And then second question is, can you just talk about the resumption of supply for some of the other vaccines you didn't mention?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","On VYTORIN and ZETIA, we are looking across our commercial operations for opportunities to do two things. At a high level, we're obviously, achieving synergies when you put together the sales forces that supported Merck for VYTORIN and ZETIA, Schering-Plo",239,"On VYTORIN and ZETIA, we are looking across our commercial operations for opportunities to do two things. At a high level, we're obviously, achieving synergies when you put together the sales forces that supported Merck for VYTORIN and ZETIA, Schering-Plough for VYTORIN and ZETIA and the JV for VYTORIN and ZETIA. So they are synergies across those groups. At the same time, we continue to invest behind the products from a promotional standpoint to ensure that they're competitively resourced. And as I said earlier, we feel very optimistic about the stabilization of trends as well as the continued growth outside the U.S. On the vaccine issues around supply, we mentioned earlier on that we aren't continuing to make ZOSTAVAX available in 2010. But customers may experience some back orders throughout the year as our best-seller product continues to be prioritized for use in manufacturing VARIVAX. So that will delay our launches outside the U.S. RECOMBIVAX pediatric became fully available in the U.S. as of early December, Pedvax here became fully available in the U.S. market as in January. Beyond that, we continue to make significant investments in our vaccine manufacturing capabilities. We've recently invested over $1 billion in new manufacturing resources and we expect our North Carolina facility to begin operations by the middle of this year. So we have some issues with respect to our varicella vaccines which we continue to work diligently on to minimize any disruption."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of David Risinger with Morgan Stanley.",13,"Your next question comes from the line of David Risinger with Morgan Stanley."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","First, could you please highlight the top three to four pipeline events to watch in 2010? And then second, Dick, I was hoping you could talk about CEO succession process and timing?",32,"First, could you please highlight the top three to four pipeline events to watch in 2010? And then second, Dick, I was hoping you could talk about CEO succession process and timing?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","The CEO succession planning process, David, as I have said many times, it's probably the most important priority I've given since I've become CEO in 2005. So working with the board, I feel very confident we have a excellent process in place. As you know,",110,"The CEO succession planning process, David, as I have said many times, it's probably the most important priority I've given since I've become CEO in 2005. So working with the board, I feel very confident we have a excellent process in place. As you know, putting the management team together that we have has really been a focus of mine. And I think with the leadership team that I have today and that we recently announced, theres excellent leaders within the company. And obviously, the process will continue to evolve throughout this year. But I think we're in pretty good shape from a planning process as well as internal candidates."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","I think the things to keep in mind this year would be obviously the continued progress of boceprevir, IMPROVE-IT interim, disclosures that will happen as well as our TRA enrollment. And I think we're very pleased on the last issue that our secondary preve",98,"I think the things to keep in mind this year would be obviously the continued progress of boceprevir, IMPROVE-IT interim, disclosures that will happen as well as our TRA enrollment. And I think we're very pleased on the last issue that our secondary prevention study is fully enrolled. And we continue to work on the tracer study where we have more than 9,000 patients enrolled in the study with the target enrollment of 12,500. I think, you'd expect to see four filings this year. So it's going to be a very strong year for advancing our late-stage pipeline."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of John Boris with Citi.",12,"Your next question comes from the line of John Boris with Citi."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","On cash flows, Peter, can you just identify or provide us with an idea what cash flows were in the quarter? And Dick, if you can just give some color on your focus on shareholder value and how you're going to be allocating cache going forward towards busi",112,"On cash flows, Peter, can you just identify or provide us with an idea what cash flows were in the quarter? And Dick, if you can just give some color on your focus on shareholder value and how you're going to be allocating cache going forward towards business development, share repo, dividends? And then a broader macro question for you Dick, obviously, Billy Tauzin has indicated that he's going to be stepping down at Pharma. Can you just provide some color on healthcare reform, where you see healthcare reform going and what's currently on the table that was negotiated by Billy Tauzin? How you see that potentially been impacted by his successor?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Talking about Pharma, I think the process that we utilize as an association will Billy as our leader was to involve the entire Pharma board. And so the positon that we've taken early on to be proactive with the President Obama's administration and the Con",157,"Talking about Pharma, I think the process that we utilize as an association will Billy as our leader was to involve the entire Pharma board. And so the positon that we've taken early on to be proactive with the President Obama's administration and the Congress is still the strategy that we have. And I think it's important that we continue to be proactive, we continue to come up what the right solutions are to make sure that everyone in our country is insured. And so that strategy that we put together with Billy's help was -- continue in the future. Billy is staying on as a consultant with us as well. And I think that's important. And the CEOs of the association are really committed to making healthcare reform work and working with Congress and the Obama administration. So even though we'll have some change in leadership at the association level, the focus will remain the same."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","John, this is Peter. If I can just taker the cash flow question. And first, let me just say, I applaud the focus on cash flow question first upon the focus on cash flow. As you know I'm a cash flow believer totally, as well. However I will have to ask tha",137,"John, this is Peter. If I can just taker the cash flow question. And first, let me just say, I applaud the focus on cash flow question first upon the focus on cash flow. As you know I'm a cash flow believer totally, as well. However I will have to ask that if you can wait for the 10-K, it will be out just a couple of the weeks and the balance sheet cash flow statements, because those are -- until they're final in the 10-K, I want to be careful not to -- since we haven't put them in the earnings release, we don't normally to do that. I want to hold until we actually publish the 10-K. But we focus on that tremendously and I just want to go through these normal steps and process."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Eric Lo with Bank of America.",14,"Your next question comes from the line of Eric Lo with Bank of America."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","What were SAPHRIS sales in the quarter and how much of your GARDASIL sales came from the male indication? And then also, can you provide a status update on [indiscernible] and what are your discussions with the FDA on that front?",41,"What were SAPHRIS sales in the quarter and how much of your GARDASIL sales came from the male indication? And then also, can you provide a status update on [indiscernible] and what are your discussions with the FDA on that front?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So on SAPHRIS issue, the sales were $40 million, almost all of that is stocking. I will take a second on SAPHRIS to say that we continue to be extremely strong in our belief that SAPHRIS has the potential to really make difference to patients who have sch",155,"So on SAPHRIS issue, the sales were $40 million, almost all of that is stocking. I will take a second on SAPHRIS to say that we continue to be extremely strong in our belief that SAPHRIS has the potential to really make difference to patients who have schizophrenia and bipolar disease without some of the metabolic issues. And that I think, we view this from our standpoint as being a launch that started on January 25 when we are able to provide full promotional support to our representatives, who before that, were essentially detailing what just a product inserts. So we view this launch as being a new one. On the GARDASIL issue, we look forward to growth opportunities from males. But right now, I think the males have not been a very significant contributor to our GARDASIL sales, although we continue to look forward to that as well as to the adult woman indication."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Seamus Fernandez with Leerink Swann.",13,"Your next question comes from the line of Seamus Fernandez with Leerink Swann."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","I just wanted to verify the comment on the second TRA study. Ken, you had mentioned that 9,000 patients were enrolled and there's a target enrollment of 12,500 patients. To my recollection, that may be approximately an increase of about 2,500 patients. An",133,"I just wanted to verify the comment on the second TRA study. Ken, you had mentioned that 9,000 patients were enrolled and there's a target enrollment of 12,500 patients. To my recollection, that may be approximately an increase of about 2,500 patients. And I'm just wondering what the reasons are for that increase? I know that you may not know that off the top of your head but just wanted to verify that that actually is an increase. And then separately, can you estimate the currency contribution to costs? Again, at least historical Merck costs in the quarter, just wondering if we can at least have a historical look at that? And if you have an estimate of what the contribution to the cost lines where for Schering-Plough, that would be very helpful."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","I will take the first comment of the traces study. You are correct that it was an increase of about 2,500 patients. While I'm not a scientist, I understand that when you have an event-driven study, the people who are running the study try to model what it",73,"I will take the first comment of the traces study. You are correct that it was an increase of about 2,500 patients. While I'm not a scientist, I understand that when you have an event-driven study, the people who are running the study try to model what it takes to make sure that you have a robust sample to get the event rate that you're looking for. And that's why it was increased."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","And Seames, if I can just note on that, this is Alex, that that was updated previously. That's not a new disclosure the 2,500 patient increase that's been out for a few months.",33,"And Seames, if I can just note on that, this is Alex, that that was updated previously. That's not a new disclosure the 2,500 patient increase that's been out for a few months."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So if I can take the foreign question, on the P&L. As I mentioned in my talk, we felt that the revenue benefited from about 1% from foreign exchange. Now Merck's year-over-year benefit from foreign exchange is not as pronounced as you might see in some ot",167,"So if I can take the foreign question, on the P&L. As I mentioned in my talk, we felt that the revenue benefited from about 1% from foreign exchange. Now Merck's year-over-year benefit from foreign exchange is not as pronounced as you might see in some other pharma companies in the call, that we had the benefit of a hedging program in the fourth quarter of last year when the currencies where really moving rapidly. We have some nice gains from a hedging position that we had. That moderates the year-over-year benefit. But net-net, what I can say is the EPS benefit on the bottom line is moderately better than what you see on the top line but not really dramatic. So really in some ways, it's probably net-net foreign exchange didn't benefit from our P&L on the fourth quarter versus last year, as much in part of that is because we had a nice hedging program that made the prior year stand up a little better."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question comes from the line of Bert Hazlett with BMO Capital Markets.",14,"Your final question comes from the line of Bert Hazlett with BMO Capital Markets."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","Maybe for Ken, was there any wholesale or stocking benefiting the U.S. results? And could you comment on the specific marketing increases that you made in the fourth quarter? And then regarding ISENTRESS which is a growth driver for the company. Clearly,",72,"Maybe for Ken, was there any wholesale or stocking benefiting the U.S. results? And could you comment on the specific marketing increases that you made in the fourth quarter? And then regarding ISENTRESS which is a growth driver for the company. Clearly, there's some competition and actually some news out regarding Gilead this morning. Could you comment on the relative positioning of ISENTRESS compared to Gilead's therapy, upcoming in the HIV market?"
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Looking backwards, I have not seen the latest news on Gilead but we continue to be confident in the profile of ISENTRESS and its prospects. We continue to work very hard on ensuring that we have a once-daily version of that drug. We continue to look forwa",283,"Looking backwards, I have not seen the latest news on Gilead but we continue to be confident in the profile of ISENTRESS and its prospects. We continue to work very hard on ensuring that we have a once-daily version of that drug. We continue to look forward to fix those combinations which we believe will put it in a position where it will continue to be successful. And all I know that I can say about the Gilead pill is obviously, we're talking about an experimental pill with an anticipated launch that's many years away. We said earlier in the U.S. that we did see some wholesalers stocking this quarter. I think we view that as being reasonable in terms of comparing the fourth quarter '09 to the fourth quarter '08, although it was up from the third quarter of '09. And your general question about marketing expenditures, I can just summarize by saying, we continue to put money behind our growth drivers. We're very pleased, for example, with the recent trends around JANUVIA. We mentioned before that we were really going to focus on JANUVIA before we had put the focus on messaging, the importance of maximizing BBP IV inhibition, to try to blog [ph] the introduction of in-class competition, we've expanded our approach. We've now started to focus on the ability to work competitively against so far in areas and we have been encouraged by the focus and the resources that put behind JANUVIA in terms of the increased volumes in December and January. So we continue to view JANUVIA and JANUMET as well as some of our other in-line products as key growth drivers in the U.S. market and beyond."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","If I can just amplify on something that Ken mentioned earlier, that we have four filings under review now with regulatory authorities around the world. So with that, I think that's the end of our Q&A and we thank you all for listening to the call. Have a",51,"If I can just amplify on something that Ken mentioned earlier, that we have four filings under review now with regulatory authorities around the world. So with that, I think that's the end of our Q&A and we thank you all for listening to the call. Have a good day. Goodbye."
288502,84103586,54594,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Ladies and gentlemen, this concludes today's New Merck's Fourth Quarter 2009 Earnings Release Conference Call. You may now disconnect.",19,"Ladies and gentlemen, this concludes today's New Merck's Fourth Quarter 2009 Earnings Release Conference Call. You may now disconnect."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to New Merck's Fourth Quarter 2009 Earnings Release Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead.",38,"Good day, everyone, and welcome to New Merck's Fourth Quarter 2009 Earnings Release Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Cynthia, and good morning, everyone. And welcome to the 2009 Fourth Quarter Conference Call for the new Merck. This is our first quarter of combined operations, so there are a number of items in the GAAP results, such as gains associated with the",439,"Thanks, Cynthia, and good morning, everyone. And welcome to the 2009 Fourth Quarter Conference Call for the new Merck. This is our first quarter of combined operations, so there are a number of items in the GAAP results, such as gains associated with the controlling interest in the cholesterol joint venture, purchase accounting adjustments, there are merger-related expenses and also restructuring costs. And so as a result of having those many items, we have excluded those items in our non-GAAP reconciliation tables, so that you can get a better sense of the underlying performance of our business. Also, since the merger was completed on November 3, the GAAP quarterly results only include two months of combined operations. So we have also provided tables to help you understand the revenue trends as well. So in the press release there are five tables. Table 1 is the GAAP results. Table 2 and 3 reconcile our GAAP P&L to our non-GAAP P&L for the fourth quarter and also for the full year 2009. Table 4 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products, as if the company had been combined for the full year and also for the full fourth quarter of 2009. Table 5 is a supplemental non-GAAP table, which provides sales for the major products and businesses, as if the company had been combined in 2008. That will help you make some growth comparisons in the 2009 period. During the call, we will be referring to Tables 2 and 3 when we discuss the P&L, and Table 4 for the revenue performance. So you may want to have those tables available. In addition, I would like to remind you that some of the statements we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs of Merck management and are subject to significant risk and uncertainties. The company's SEC filings, including Item 1A in the 2008 10-K, identifies certain factors and cautionary statements that could cause the company's actual results to differ materially from any forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. You can find our SEC filings, as well as today's earnings release and tables, on merck.com.This morning, I'm joined by Dick Clark, our Chairman, President and CEO; Ken Frazier, the President of our Global Human Health business; and Peter Kellogg, our Chief Financial Officer. Now I'd like to turn it over to Dick Clark."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. It was a little less than a year ago last March when we announced our plan to merge Merck and Schering-Plough. At the time, I told you that the combination made great strategic and financial sense and held exce",1188,"Thank you, Alex, and good morning, everyone. It was a little less than a year ago last March when we announced our plan to merge Merck and Schering-Plough. At the time, I told you that the combination made great strategic and financial sense and held exceptional promise, thanks to our stronger pipeline, more diverse product offerings across our broader range of businesses and an expanded global reach. In other words, our merger was and is about science and the increased relevance we now have to our customers. While this merger is about more than just cost, we stand firmly behind the financial targets we set last March. Today, we are pleased to report solid fourth quarter and full year 2009 results for the combined company. These results demonstrate the strong business focus each company maintained last year. That is a significant accomplishment, considering that the results were achieved in the midst of uncertain global economy, an ever-shifting healthcare landscape, extensive merger planning and then the start of integration once the merger was completed. In terms of top line, the company had sales of $10.1 billion for the fourth quarter and full year 2009 revenue of $27.4 billion. The combined company had fourth quarter non-GAAP earnings per share of $0.79 and GAAP earnings per share of $2.35. Full year 2009 non-GAAP earnings were $3.25 per share, which excludes certain items in GAAP earnings of $5.65.  Our fourth quarter results were driven in part by the inclusion of legacy Schering-Plough sales in our results, as well as the strong sales from JANUVIA, SINGULAIR and ISENTRESS. Peter Kellogg will provide you further financial details, as well as some thoughts on our outlook for the future.Since the merger closed in early November, we have moved quickly around the world to integrate our operations and begin taking advantage of the opportunities that come with the new Merck. Thus far, we are quite pleased with the pace of our progress in adopting best practices from each company, integrating the commercial organizations, planning our network strategy and consolidating the pipeline. In fact, since the merger's completion, our combined pipeline has been a top priority. I spent a considerable amount of time with Peter Kim and other senior Merck leaders to conduct a thorough review of the new combined pipeline, so we may better prioritize our efforts by franchise, phase, cost and geographic importance. I'm very enthusiastic about the work we've done on our powerful R&D pipeline, with more than 20 late-stage programs. We look forward to talking with you about that soon. By advancing the highest potential pipeline candidates, accelerating product development and launches, and maximizing the value of our medicines to full life-cycle management, we're focused on driving sustained innovation and revenue growth. We see three waves of new product opportunities over the near and long term that should contribute to our growth. Wave one is happening now, with products that are already in launch mode, such as SIMPONI, SAPHRIS and JANUVIA in Japan. Wave two focuses on near-term approvals. Just in the last few weeks, we had two key approvals, BRIDION and ELONVA. And we have four other key products under review as we speak. Wave three highlights our long-stage pipeline opportunities, which we believe are the best in the industry. Our strategy also includes continuing to tap into external sources of innovation to complement the work that is underway in our labs. We completed 51 licensing deals in 2009, with more to come this year; all of which could further our shareholder value.On the commercial side, we are building our capabilities and growth potential in vaccines, biologics and emerging markets. And they are sources of real focus and excitement within the new Merck. We are working hard on the strategies that will advance us to the next level in each of these growth areas. Here's a recent example. The acquisition of Avecia Biologics will allow Merck to build upon the biological expertise and manufacturing capability acquired during the past three decades at Schering-Plough. The new Merck's healthy and diversified product portfolio includes offerings from A to Z in a wide range of therapeutic areas from animal health to women's health. Each of our top 10 selling brands from our expanded product portfolio exceeds $1 billion in annual sales in 2009. In a few moments, Ken will talk about the performance of our key brands and how we're positioned the company's full portfolio of healthcare offerings for near term and future growth.Since late last year, weve built up the senior ranks of our new company with the best executives from both companies, as well as respected leaders with new capabilities and external experience. We're proud to welcome two new vaccine leaders: Former CDC Director, Dr. Julie Gerberding, as the leader of our Vaccine franchise; and Dr. Michael Kamarck, previously President of Product Supply at Wyeth, will lead Vaccines and Biologics manufacturing. We're also pleased to welcome to Merck Executive Committee former Dean of Tufts School of Medicine, Dr. Michael Rosenblatt, as Merck's new Chief Medical Officer; and Bridgette Heller, as the head of our Consumer Health Care business. Moving forward, we must realize the enormous value of our merger for patients, customers and shareholders. That includes gaining the benefit of fully integrating all aspects of the two formerly separate companies.We remain absolutely committed to our previously announced target of realizing merger synergies of $3.5 billion in annual savings in 2012. As part of these plans, we unveiled today a new multiphase global restructuring program designed to integrate and further optimize our operations and cost structure to support the more nimble, customer-focused and diversified healthcare leader Merck is becoming. We expect to complete the first phase of the program we announced today by the end of 2012. Additional phases of the merger restructuring program are expected to be announced later this year. We also expect to realize our savings through priority initiatives in areas, such as procurement. Building on earlier work begun in 2005, we're making progress in putting in place a best-in-industry cost structure. It will take time before we fully integrate off the axis of the two companies. The restructuring and integration process is complex, and includes changes that require our hard choices and difficult decisions, especially those that affect our colleagues throughout workforce reductions. But as we said all along, the majority of our colleagues from both legacy companies will be part of the new Merck going forward. Looking ahead into 2010 and beyond, we remain enthusiastic about our goal in becoming the best healthcare company in the world. We continue to be committed to our long-term financial targets. But the real value driver of our merger will be science and innovation, because Merck's long-term strength will come from our ability to develop critical medicines and vaccines. What will set this merger apart is not just the what but the how, the clarity of our vision, our ability to hit the ground running and the thoughtfulness, which we will manage through the integration of our businesses, our operations and our people. Now I'd like to turn the call over to Ken."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and good morning, everyone. As Dick mentioned, in the fourth quarter, we drove solid performance across the Global Human Health portfolio, thanks to the strong growth of many of our key brands in markets around the world. As a newly combi",1826,"Thank you, Dick, and good morning, everyone. As Dick mentioned, in the fourth quarter, we drove solid performance across the Global Human Health portfolio, thanks to the strong growth of many of our key brands in markets around the world. As a newly combined company, we were off to a great start following the merger, and we will continue to focus on driving top line performance in 2010, especially for our new and faster growing brands. Overall, Global Human Health delivered a solid quarter, with recorded sales of $9.1 billion. When you would include all three months of Schering-Plough sales, our non-GAAP sales were $10.8 billion, which represents 9% growth from the previous year. The growth was broad-based, with eight of our top 10 product families growing in the fourth quarter. These eight franchises accounted for more than half of total sales, and grew a combined 15% over the previous year. We drove this growth across a diverse base of markets. Sales outside the U.S. increased by 13%,  which includes the favorable impact of foreign exchange. And inside the U.S., we generated growth of 3% compared to the previous year. In the U.S., sales in the fourth quarter were aided by approximately $100 million of wholesaler inventory buy-in, stockpile purchases of certain vaccines by the CDC [Centers for Disease Control and Prevention] and the initial stocking for the SAPHRIS launch. Overall, I believe our fourth quarter performance is a good indicator that we are maintaining strong focus and momentum, while we integrate our teams. Before I discuss the performance of individual brands, I want to update you on the progress we have made since the completion of the merger. We will be integrating our businesses in markets around the world at different times, taking local considerations into account. As we do so, we will be leveraging the new commercial models that we had already implemented in nearly 30 markets.In the U.S., our experience with implementing Merck's new commercial model over the past two years prepared us to make critical staffing decisions quickly, with three very specific goals in mind: Retaining top talent, maintaining business momentum and minimizing disruption to our customers. In fact, by late January, we've completed the design and blending process to stand up the entire U.S. sales organization. Our U.S. sales force is now fully operational and completely focused on meeting customer needs. Our broader primary care offerings are ideally suited to the portfolio-based selling approach of the new commercial model, because the merger enables us to be more relevant to our customers across key franchises, such as cardiovascular, respiratory, women's health and other franchises.I want to emphasize one additional point about our integration efforts. While we focus on delivering the synergies that the merger creates, we are also making conscious, explicit decisions to invest to grow our business. So while we are reducing the size and cost of our commercial operations in more developed markets like the U.S., we are also making resource allocation decisions to grow our presence in major emerging markets. In fact, despite the economic volatility that we saw in these markets, our business grew by double digits in key emerging markets, like China and Brazil, during the fourth quarter.Also, as we indicated on the third quarter call, we made strategic investments to maintain and grow our key in-line growth drivers through additional promotional spending in the fourth quarter, and we'll continue to do so this year. For JANUVIA, ISENTRESS and SINGULAIR, for example, we made strategic investments in the fourth quarter to grow these brands. We also invested in our new product launches this quarter. These investments contributed to strong top line performance for many of our key brands. Now as I turn to individual product performance, I'll refer you to Table 4 from our supplemental financial package provided with our press release, so you can follow along. Starting with SINGULAIR, sales in the fourth quarter were $1.3 billion, up 12% versus the prior year. We saw double-digit growth in key markets, including the U.S., where we grew by 14% versus the fourth quarter of 2008. Moving to JANUVIA and JANUMET, global revenue grew to a combined $760 million in the fourth quarter, up 43% versus the prior year. Now in the fourth year since its launch, we continue to drive strong performance for the JANUVIA/JANUMET franchise in markets around the world. JANUVIA and JANUMET remain the most prescribed products in the DPP-4 [dipeptidyl peptidase-4 inhibitor] class. We continue to invest in JANUVIA and JANUMET to maintain our leadership position in the diabetes markets and to grow this franchise. In the U.S., where we have recently seen the first DPP-4 competitor, we generated 24% growth versus fourth quarter 2008. We believe we can grow the franchise by taking share from the sulfonylureas as second-line treatment for appropriate patients. In addition, we are continuing our coupon program, which has been a success today.In the EU, we also have a labeling advantage. JANUVIA is the only DPP-4 approved for restricted first-line use and for use as an add-on to insulin. In Japan, which is a fast-growing oral diabetes market, we are in early stages of the JANUVIA launch. JANUVIA has an extremely strong value proposition, and is being reimbursed at a premium price to ACTOS. Despite Japan's practice of limiting new medicines to only a two-week patient supply in the first year, the initial tracking shows that the JANUVIA launch is going very well. We are building this franchise for the long term, indication-by-indication and country-by-country. We've submitted three sNDAs [supplemental New Drug Application] for sitagliptin in the U.S. to allow use with insulin, which would make sitagliptin the only DPP-4 approved for use with insulin, for initial use with pioglitazone and for use as add-on therapy with PPAR [peroxisome proliferator-activated receptor] agonists and metformin. As you can see, there are many reasons why we expect that this franchise will continue to be a growth driver for Merck. I'd like to REMICADE and our newly launched biologic SIMPONI. We believe REMICADE and SIMPONI offer two great options for patients: REMICADE for rapidly progressing RA [rheumatoid arthritis] patients; and SIMPONI, the only once-monthly subcutaneous anti-TNF [tumor necrosis factor] available in the EU. In our first quarter combined operations, REMICADE delivered another quarter of double-digit sales growth and reached a new quarterly high, with sales of $635 million, an increase of 29% over last year. The growth was broad-based, as we saw increased utilization across all six indications. We're maintaining our market share in rheumatoid arthritis despite new entrance to the market, and we continue to see solid performance and growth from the gastro indications, especially ulcerative colitis. For SIMPONI, we now have launched in five countries. To date, we have full reimbursement in Germany and Denmark. We plan to launch in many of the other large EU markets in the second half of 2010, as we gain reimbursement for SIMPONI from both public and private payers. In infectious disease, ISENTRESS continues to perform well and had another quarter of strong growth. Sales in the fourth quarter were $234 million, up 80% year-over-year and 19% sequentially. The continued growth of ISENTRESS reflects the unique efficacy and safety profile of this product, which has been widely embraced by physicians, patients and health organizations.  ISENTRESS has become the new benchmark for an HIV launch and with the new treatment-naive indication, ISENTRESS is now approved for use across each stage in the treatment continuum.Turning to ZETIA and VYTORIN, sales were $1.2 billion this quarter, which represents 6% growth compared to the fourth quarter last year driven primarily by a 10% increase in the sales of ZETIA. For the franchise, sales in the U.S. declined 5%. However, this was more than offset by the strong growth of the brand outside the U.S., where the two brands grew by 23%, including the favorable impact of foreign exchange.The unique value proposition for these brands remains strong. And we continue to see growth opportunities in many markets around the world. I will now move two our Vaccine business, starting with GARDASIL. Sales as reported by Merck in the fourth quarter were $277 million, a 3% decline when compared to the fourth quarter of last year. In the U.S., we had about $70 million of favorability due mostly to a CDC stockpile purchase. Keep this in mind, as you model GARDASIL sales in subsequent quarters. X U.S. sales of GARDASIL as reported by Merck decreased 15%, attributable to the high-penetration rate and impact of large orders in 2008 in early-adopting countries, such as Mexico, Canada and Australia. Globally, we continue to outperform the competition, achieving an x U.S. market share of 77% in dollar terms in the fourth quarter and a global share of 87%.Sales of ProQuad, M-M-R II and VARIVAX combined increased 13% in the fourth quarter due to a CDC stockpile purchase of $64 million. If you exclude this favorability, sales would have decreased 9% year-over-year, largely due to the saturation in the varicella second dose catch-up cohort.Now moving to ZOSTAVAX, fourth quarter sales as reported by Merck were $76 million, down 53% from the previous year, largely due to the release of a very significant number of back orders in the fourth quarter of 2008. While we anticipate that ZOSTAVAX will be available in 2010 in the U.S., customers may experience back orders throughout this year. International launches of ZOSTAVAX will be delayed until 2011. Now, I'd like to make a few comments about COZAAR/HYZAAR, which grew 8% year-over-year. As you know, COZAAR/HYZAAR will lose marketing exclusivity in the U.S. in early April, and COZAAR/HYZAAR will lose exclusivity in most major EU markets in the first quarter of 2010. In the U.S., we anticipate that multisource generics will be available immediately following the patent expiry, which we believe will lead to rapid erosion of sales from the current levels. And because internationally rosin rates have accelerated in recent years, we expect that the generic uptake in the EU will also be rapid.As we head further into 2010, I want to share with you how we are prioritizing our work in GHH, Global Human Health. First, we are focused on driving in-line brand performance and we will continue to make the necessary investments to grow as we integrate our operations. Second, we are focused on the launches of our new products. In addition to SIMPONI, which I mentioned previously, we have recently put more promotional resources behind the SAPHRIS launch in the U.S. Other opportunities we have this year in markets around the world include the launches of SAFLUTAN, TREDAPTIVE, ELONVA and BRIDION. Finally, while we focus on these opportunities, we are also creating a leaner, even more customer-focused organization that builds on the best of the Merck and Schering-Plough commercial organizations. I look forward to sharing more with you as the year progresses. And now, it's my pleasure to pass it over to my colleague, Peter Kellogg."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, our merger is off to a great start. We generated good sales and earnings results, while making a lot of headway on the integration. Today, I'd like to cover three items with you. First,",2243,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, our merger is off to a great start. We generated good sales and earnings results, while making a lot of headway on the integration. Today, I'd like to cover three items with you. First, I will cover what is included in our results. Second, I will provide an update on our fourth quarter performance. And third, I will comment on our outlook for 2010. So let's go to the results.We recognize that there are a lot of moving parts this quarter. The merger closed in the middle of the quarter and therefore, there are only two months of Schering-Plough included in the results. Our results also included the add-in complexity of purchase price accounting adjustments and restructuring charges, and the joint venture that is being unwound and reported in the combined company's results rather than in equity income. As Alex discussed in the opening, we included new tables in our press release and supplemental charts to help you navigate through the accounting. To make it easier for you to follow, I will speak mostly to the non-GAAP results in our remarks.Our non-GAAP results exclude restructuring costs, purchase price accounting adjustments, which included a $7.5 billion gain on the step-up of Merck's share in the MSP [Merck/Schering-Plough Pharmaceuticals] partnership to current market value; merger-related costs; and a $400 million gain related to the sale of Merial in the quarter. On this basis, the new Merck reported fourth quarter non-GAAP earnings per share of $0.79. There are a number of factors that are reflected in our performance this quarter. First, we drove operational sales growth in many markets around the world, in part through higher promotional spending in support of our key brands and new launches. Second, we continued investing in our strong late-stage pipeline. Third, we had lower equity income from partnerships. And finally, we benefited from a lower combined company tax rate. In addition, as a result of the merger financing, our interest expense is higher and our interest income lower. And the number of common shares outstanding has substantially increased.Let's get into some of the individual items beginning with revenue. Total revenue for the quarter, as reported by Merck, was $10.1 billion, with about a 1% benefit from foreign exchange. On a supplemental-combined non-GAAP basis, which assumes Schering-Plough was included for all three months of the quarter in 2009 and 2008, sales were $12.2 billion, up 7%. You can see this in Table 4 provided today in our financial supplement.Ken just walked through the Human Health business results, so let me touch for a moment on our Animal and Consumer Health businesses. Animal Health sales totaled $759 million for the fourth quarter of 2009 on a supplemental combined non-GAAP basis, reflecting continued growth among companion animal and poultry products. Consumer Health Care sales were $232 million for the fourth quarter of 2009 on a supplemental combined non-GAAP basis, reflecting solid demand for OTC CLARITIN and foot care products.Now moving on to the expense items on the P&L. First, let's look at materials and production. The gross margin in the fourth quarter was approximately 74% versus 76% in the same quarter of the prior year. The decline is primarily attributed to the inclusion of results from Schering-Plough, which has historically had a lower gross margin due to some major partnerships. Foreign exchange also had an unfavorable impact on the gross margin from Schering-Plough. Turning to marketing and administrative costs, M&A expenses in the fourth quarter were $3.2 billion on a non-GAAP basis. The majority of the increase over the fourth quarter of 2008 is attributable to the addition of Schering-Plough expenses and inclusion of the expenses from the Merck/Schering-Plough JV in the P&L and the impact of foreign exchange. Additionally, as we had anticipated, Merck had higher marketing expenses during the fourth quarter than in the first three quarters of 2009. We increased promotion in support of our key brands, and we are also investing to ensure the success of our new launches around the globe, including JANUVIA in Japan and TREDAPTIVE in the EU.As Ken mentioned, we have a number of launches in major markets underway today. And we have more on the way. We want to ensure the success of these launches by supporting them with the right level of promotion in 2010. Now let's turn to R&D. Research and development expenses for the new Merck in the fourth quarter where approximately $2 billion. On a non-GAAP basis, R&D spending is up approximately $700 million this quarter. This increase is primarily driven by the addition of Schering-Plough R&D costs and the continued investment in late-stage opportunities such as TRA, boceprevir, demicative [ph] (41:08), CORDAPTIVE and our CETP inhibitor. Now let's move to equity income. In the fourth quarter, Merck recorded $374 million of equity income, a decline of $346 million over the prior year. The decline is attributable to three factors which you can derive from Table 6 in the financial supplement.  First, equity income in the quarter includes only one month of results from the MSP joint venture versus three months in the prior year. Post-closing of the merger, these results are reflected in sales and expenses of the new Merck. Second, a $75 million decline in the income from the AZLP joint venture is due to the timing variability of payments from AZLP. And third, the sale of Merial to our partner sanofi in the third quarter.Now let's talk about other income and expense. For the fourth quarter of 2009, other expense on a non-GAAP basis is $92 million compared to other income of $27 million in the fourth quarter of the prior year. There are a few items driving this year-over-year change. First, most notable is the inclusion of interest expense from the Schering-Plough debt and the merger-related debt post closing. Second, interest income of $11 million was $137 million lower when compared to the prior year as a result of lower interest rates and lower cash and investment balances.  Third, in the same quarter of last year, Merck recognized $74 million of exchange losses which did not recur this quarter. That helped to offset a portion of the negative interest expense and interest income comparisons. Now let's turn to the tax rate.  The new Merck non-GAAP tax rate is 15% for the fourth quarter. This reflects two dynamics. First, on the Merck side, there was some one-time benefits that aren't likely to recur. Second, we have the benefit related to the inclusion of legacy Schering-Plough during the two-month stub period, and this stub period had a much lower tax rate than legacy Merck.  For 2010, we don't anticipate a significant change to the rate that we saw in 2009 on a full year basis, excluding discreet items. Our full year 2009 rate was approximately 23% when you exclude the discreet items in the first and second quarters.Okay, so that's the fourth quarter. As you can see, there are a lot of moving parts. Here's how I think about our performance this quarter. We had strong growth in sales of our key brands. At the same time, we continued investment in the future success of our newest products and our late-stage pipeline. So overall, a solid start to the new Merck. Now let's talk about where we're going, beginning with 2010.  As we already indicated, we will provide 2010 financial guidance around the timing of our first quarter earnings call. Today, I'd like to provide you with some perspective that I believe will be helpful. As we step back and look at new Merck, we are pleased with our many opportunities ahead. We continue to target a high single digit, non-GAAP EPS compound annual growth rate from 2009 to 2013 for the combined company when compared to Merck 2009 non-GAAP EPS.  Looking ahead over this next four-year period, we do anticipate that some years will be stronger than others. For example, 2010 has several factors that will be challenging. During 2010, we will begin to realize synergies from the merger. However, we also face the loss of patent protection for COZAAR/HYZAAR and TEMODAR, products that contributed $3.1 billion of revenue in the U.S. and Europe last year. And we will continue to invest in launched brands.So as we think about 2010, there are four areas that I'd like to specifically call to your attention. First, let's start with the sales line. The merger has improved our longer-term patent position, and we are launching many new products like SAPHRIS and SIMPONI. However, we do face significant patent losses in 2010. The biggest is COZAAR/HYZAAR. So how should you think about that in 2010? Well, first, in the first quarter, we expect to pullback in the COZAAR/HYZAAR trade inventory levels to below-normal levels as the patent expiry date approaches. Second, as Ken mentioned, we believe that the erosion rate will be fast as multiple generics enter the market after the patent expires. The second 2010 patent issue were not as large as TEMODAR, one of our high-margin products. In the U.S., we were disappointed by the recent District Court judgment, and then filed an appeal in a motion for a preliminary injunction to allow the Court time to hear our appeal. In addition, TEMODAR lost patent protection in Europe in 2009, and we expect continued erosion. Despite the impressive number of new product launches in 2010, they will not be able to compensate for these two patent losses.Now second, let's talk abut synergies. We are committed to merger-related cost synergies of $3.5 billion annually in 2012. The first phase of our Merger Restructuring Program that Dick told you about is expected to contribute $2.6 billion to $3 billion to this annual target. As we said, additional phases will be announced by the end of 2010.  We expect to see significant synergies mostly on the M&A line in 2010. As a result, we expect the M&A line to be down on a full year basis in 2010 versus what the two companies spent individually in 2009. Please keep in mind that these synergies build over time. Very importantly, we expect the synergies in 2010 to be back-end loaded with about 2/3 of the synergies coming in the second half of the year. This will cause the shape of the earnings curve during 2010 to be quite back-end loaded.Now let's talk about the third area which is R&D where we have two dynamics underway. On the one hand, we are investing in our late-stage pipeline. On the other hand, we are driving efficiencies through the combined R&D infrastructure. Coming into the merger, Schering-Plough and Merck each had strong and growing R&D pipelines. And on a stand-alone basis, each company expected to significantly increase its level of R&D investment in 2010 due to the richness of its late-stage pipeline and the many ongoing large outcomes trials.Let me give you a sense of scale. In cardiovascular disease alone, we had more than 80,000 patients currently in our clinical trials, and that number is expected to grow to more than 100,000 patients before those trials end. So therefore, based on this level of Phase III project activity, we expect that the level of R&D investments in 2010 will be similar to slightly higher than the levels seen in 2009 for both companies on a combined basis. We believe that making these 2010 investments are the best way to drive shareholder value. Lastly, let's talk about the timing of certain items this year. There are a number of items that will affect the early part of the year and specifically Q1. First, Q1 is typically the softest quarter of the year due to the seasonality of our respiratory and vaccine franchises. We saw this in the first quarter of 2009. Second, we have the expected pull down in COZAAR/HYZAAR trade inventories in Q1 that I mentioned earlier. Third, there was approximately $135 million of favorable vaccine revenue in Q4, primarily due to a number of CDC stockpile purchases, and these will not recur in the first quarter.  Fourth, we had a low tax rate in the fourth quarter that we do not expect to recur this year. Also, aside from the seasonality, these items relate to Q1 but obviously, they wanted a similar impact on the full year results. So let me summarize. As I mentioned earlier, we expect that non-GAAP earnings in the second half of 2010 will be considerably higher than non-GAAP earnings in the first half of 2010 due to the phasing in of synergies. In fact, we believe our non-GAAP EPS run rate in the second half of this year will provide strong evidence that we are heading towards our long-term EPS goal. We are on track to have a good first full year as a combined company. We will continue our business momentum for key brands and launch products. We remain very excited about the future of the new Merck. And we continue to target high single digit non-GAAP EPS compound annual growth rate in 2009 to 2013 for the combined company.  As Dick emphasized, this is a company that will build its long-term strength through science and innovation. We look forward to speaking with you about the products, the pipeline and the strategy of the new Merck during our second quarter R&D and business update meeting. Thank you. Now I'll turn the call back to Alex. Alex?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Peter. Now we're ready to open up the call to answer your questions. In order to get through as many callers as possible, we ask that you extend the courtesy to the other callers by only asking one or two questions. We are not planning to take any",63,"Thanks, Peter. Now we're ready to open up the call to answer your questions. In order to get through as many callers as possible, we ask that you extend the courtesy to the other callers by only asking one or two questions. We are not planning to take any follow-up questions, but if you have other questions, please join the queue again. Cynthia?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts",",First question on the R&D budget, kind of reaching this $8 billion, $8.5 million kind of level on a pro forma basis in '09. Obviously, it's a much larger number than you've had in the past. And can you just elaborate what you're doing to manage an organi",160,",First question on the R&D budget, kind of reaching this $8 billion, $8.5 million kind of level on a pro forma basis in '09. Obviously, it's a much larger number than you've had in the past. And can you just elaborate what you're doing to manage an organization this large and avoid maybe some of the pitfalls that some of your competitors have run into as they've scaled their R&D organizations this size? And maybe just a follow up on the R&D side, on an absolute's basis, how do we kind of think about the R&D budget as going beyond 2010? Is this is a budget that kind of remains in that flat level or above current levels or will some of these efficiencies and program cuts you've targeted with the restructuring push that down over time, I guess especially as you think about some of these big outcome studies starting to ramp up, working out two or three years?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","This is Dick Clark. I think to answer the first part of your question, what we've been focusing on from a research standpoint is our prioritization really beginning with the portfolio. So as we said, we're spending a great deal of time understanding the p",220,"This is Dick Clark. I think to answer the first part of your question, what we've been focusing on from a research standpoint is our prioritization really beginning with the portfolio. So as we said, we're spending a great deal of time understanding the portfolio and making decisions by phase, by value, by geography, by unmet medical need of what we need to do to put a portfolio together for the new company. We're also spending a great deal of time now focusing in on talent and scientific capabilities and the people that we need to be able to run this research organization. And obviously, the last thing that we spend time on then is the site. So once you have the portfolio, the projects and the people decided you can look at price. I think one of the advantages we have in how we run the entire company is not only in research but in Global Human Health as well is that we really have franchise heads. And so having a general manager for franchise in the commercial side and one on the research side, allows us to think about franchises both in the commercial and research standpoint, allows better focus and allows us to make portfolio decisions even though the research capability has expanded as we move forward."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So if I can take some of the financial perspective on this. So you're right, as I highlighted, 2010 is here in many ways, a very exciting year for us because we have a lot going on in the late-stage pipeline and some very exciting trials that offer a lot",289,"So if I can take some of the financial perspective on this. So you're right, as I highlighted, 2010 is here in many ways, a very exciting year for us because we have a lot going on in the late-stage pipeline and some very exciting trials that offer a lot of potential for us in the near-term future. So clearly, while we're going through the portfolio prioritization, we made sure that these really high-priority pipelines get full resource and full attention. Secondly, we haven't really given R&D long-term guidance yet. And obviously, that's something we'll do when we get out towards the first quarter earnings call. But I do want to remind everybody that our long-term perspective on the company is that we will have high single-digit non-GAAP EPS growth over the time period that we talked about. And that we are going to see a nice pretax margin improvement as we go from today to that timeframe. We highlighted on the time of merger that were shooting for something that begins to approach the 40% level. It's obviously based on the current expectations and what we know at this point. But that implies that there will be productivity in all the lines as we go through the P&L and that will be something you'll be seeing particularly, as all the different integration steps are going on in our R&D organizations come to bear. But I do think, as Dick said, in the beginning, this is about science and innovation and global expansion and having really world-class organizations in every function. And so we are going to be making sure that we make the right investments in all the areas and yet still drive great productivity throughout the company."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your next question comes from the line of Jami Rubin with Goldman Sachs."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick and Peter, maybe you could help to clarify the $3.5 billion in integration synergies. Is that a gross number or a net number? And if it is a gross number, could you quantify the level of re-investment spending? And a question to Dick, there's not a w",100,"Dick and Peter, maybe you could help to clarify the $3.5 billion in integration synergies. Is that a gross number or a net number? And if it is a gross number, could you quantify the level of re-investment spending? And a question to Dick, there's not a whole lot of focus on the consumer business. You just announced a new executive hire to run that business. It's only about 3% of total sales, obviously subscale compared to your competitors. What is your strategy with this business and would you consider spinning it off similar to what Bristol did with Mead-Johnson?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","It's Peter. So let me start with the synergy piece. Let me just begin by saying, nothing in our guidance has changed. We are definitely focused and targeted and confident about achieving the $3.5 billion of synergies. This announcement today is just the f",166,"It's Peter. So let me start with the synergy piece. Let me just begin by saying, nothing in our guidance has changed. We are definitely focused and targeted and confident about achieving the $3.5 billion of synergies. This announcement today is just the first phase and obviously, it has a dramatic -- significant portion of a benefit against that $3.5 billion. And there'll be other phases that we'll be announcing as other plans are finalized and concluded on. And those will also contribute to the $3.5 billion goal that we have. Obviously, as we've highlighted, with an improving operating margin and particularly, as go out that timeframe, if we have an operating margin that goes from where it is today, pretax to approaching 40%, we're going to be putting a lot of this synergy to the bottom line. And so while we don't necessarily talk about gross or net, you know us, we will make sure that we get the benefit at the bottom line."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Jami, as you know me, gross isn't in my vocabulary. So it certainly is a net that we're looking forward to in the $3.5 billion. Concerning your question with the Consumer Health, we're excited about having a leader now at Consumer Health. We think it is a",120,"Jami, as you know me, gross isn't in my vocabulary. So it certainly is a net that we're looking forward to in the $3.5 billion. Concerning your question with the Consumer Health, we're excited about having a leader now at Consumer Health. We think it is a very good business. We think its a global business. We think Schering-Plough has done an outstanding job of building the business within the U.S. and starting to look at it globally. We think it's a very important part of our emerging market going forward, example is in China and Brazil and other countries. And obviously, we need to grow the business and we're looking forward to putting a strategy together to do that."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Tim Anderson with Sanford Bernstein.",13,"Your next question comes from the line of Tim Anderson with Sanford Bernstein."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","On 2010, it seems like you kind of paint a cautious picture on the outlook because of a few different factors. And I understand complete guidance will come a little bit later. But directionally, can you just tell us whether 2010 will be a positive growth",94,"On 2010, it seems like you kind of paint a cautious picture on the outlook because of a few different factors. And I understand complete guidance will come a little bit later. But directionally, can you just tell us whether 2010 will be a positive growth year in terms of earnings relative to 2009? And second question is, can you give us an update of where we are in REMICADE? And when we might hear something with Johnson & Johnson? Do you expect that this will have to go to arbitration to get resolved?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Tim, it's Peter. We will have to hold off until around the first quarter call to talk about the P&L and so forth. We did, obviously, around the time of the earnings indicate that we thought 2010 would be an accretive year, and so it's a positive year. But",136,"Tim, it's Peter. We will have to hold off until around the first quarter call to talk about the P&L and so forth. We did, obviously, around the time of the earnings indicate that we thought 2010 would be an accretive year, and so it's a positive year. But we really want to hold off until we got the complete portfolio worked on, all decisions finalized and we have the profit plan put together, which will be happening over the course of next month. And then the way we always like to do it is make sure we have the complete profit plan put to bed and then we come out with our guidance based on that. Bruce Kuhlik is here with us. So I'd like to ask Bruce if he could comment just on REMICADE."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Just on the arbitration, the panel has been collected, we've met with the panel. The hearing is scheduled for September of this year and we're working towards that.",28,"Just on the arbitration, the panel has been collected, we've met with the panel. The hearing is scheduled for September of this year and we're working towards that."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","I was wondering if you could give us a flavor for the level of resources that you're putting behind the VYTORIN and ZETIA franchise relative to the way the JV had, the spending levels? And then second question is, can you just talk about the resumption of",58,"I was wondering if you could give us a flavor for the level of resources that you're putting behind the VYTORIN and ZETIA franchise relative to the way the JV had, the spending levels? And then second question is, can you just talk about the resumption of supply for some of the other vaccines you didn't mention?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","On VYTORIN and ZETIA, we are looking across our commercial operations for opportunities to do two things. At a high level, we're obviously achieving synergies when you put together the sales forces that supported Merck for VYTORIN and ZETIA, Schering-Plou",239,"On VYTORIN and ZETIA, we are looking across our commercial operations for opportunities to do two things. At a high level, we're obviously achieving synergies when you put together the sales forces that supported Merck for VYTORIN and ZETIA, Schering-Plough for VYTORIN and ZETIA and the JV for VYTORIN and ZETIA. So they are synergies across those groups. At the same time, we continue to invest behind the products from a promotional standpoint to ensure that they're competitively resourced. And as I said earlier, we feel very optimistic about the stabilization of trends as well as the continued growth outside the U.S. On the vaccine issues around supply, we mentioned earlier on that we aren't continuing to make ZOSTAVAX available in 2010. But customers may experience some back orders throughout the year as our varicella product continues to be prioritized for use in manufacturing VARIVAX. So that will delay our launches outside the U.S. RECOMBIVAX pediatric became fully available in the U.S. as of early December. Pedvax here became fully available in the U.S. market as in January. Beyond that, we continue to make significant investments in our vaccine manufacturing capabilities. We've recently invested over $1 billion in new manufacturing resources and we expect our North Carolina facility to begin operations by the middle of this year. So we have some issues with respect to our varicella vaccines which we continue to work diligently on to minimize any disruption."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of David Risinger with Morgan Stanley.",13,"Your next question comes from the line of David Risinger with Morgan Stanley."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","First, could you please highlight the top three to four pipeline events to watch in 2010? And then second, Dick, I was hoping you could talk about CEO succession process and timing?",32,"First, could you please highlight the top three to four pipeline events to watch in 2010? And then second, Dick, I was hoping you could talk about CEO succession process and timing?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","The CEO succession planning process, David, as I have said many times, it's probably the most important priority I've given since I've become CEO in 2005. So working with the board, I feel very confident we have a excellent process in place. As you know,",110,"The CEO succession planning process, David, as I have said many times, it's probably the most important priority I've given since I've become CEO in 2005. So working with the board, I feel very confident we have a excellent process in place. As you know, putting the management team together that we have has really been a focus of mine. And I think with the leadership team that I have today and that we recently announced, theres excellent leaders within the company. And obviously, the process will continue to evolve throughout this year. But I think we're in pretty good shape from a planning process as well as internal candidates."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","I think the things to keep in mind this year would be obviously the continued progress of boceprevir, IMPROVE-IT interim, disclosures that will happen as well as our TRA enrollment. And I think we're very pleased on the last issue that our secondary preve",98,"I think the things to keep in mind this year would be obviously the continued progress of boceprevir, IMPROVE-IT interim, disclosures that will happen as well as our TRA enrollment. And I think we're very pleased on the last issue that our secondary prevention study is fully enrolled. And we continue to work on the tracer study where we have more than 9,000 patients enrolled in the study with the target enrollment of 12,500. I think, you'd expect to see four filings this year. So it's going to be a very strong year for advancing our late-stage pipeline."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of John Boris with Citi.",12,"Your next question comes from the line of John Boris with Citi."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","On cash flows, Peter, can you just identify or provide us with an idea what cash flows were in the quarter? And Dick, if you can just give some color on your focus on shareholder value and how you're going to be allocating cache going forward towards busi",112,"On cash flows, Peter, can you just identify or provide us with an idea what cash flows were in the quarter? And Dick, if you can just give some color on your focus on shareholder value and how you're going to be allocating cache going forward towards business development, share repo, dividends? And then a broader macro question for you Dick, obviously, Billy Tauzin has indicated that he's going to be stepping down at Pharma. Can you just provide some color on healthcare reform, where you see healthcare reform going and what's currently on the table that was negotiated by Billy Tauzin? How you see that potentially been impacted by his successor?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Talking about Pharma, I think the process that we utilize as an association with Billy as our leader was to involve the entire Pharma board. And so the positon that we've taken early on to be proactive with the President Obama's administration and the Con",156,"Talking about Pharma, I think the process that we utilize as an association with Billy as our leader was to involve the entire Pharma board. And so the positon that we've taken early on to be proactive with the President Obama's administration and the Congress is still the strategy that we have. And I think it's important that we continue to be proactive, we continue to come up what the right solutions are to make sure that everyone in our country is insured. And so that strategy that we put together with Billy's help will continue in the future. Billy is staying on as a consultant with us as well, and I think that's important. And the CEOs of the association are really committed to making healthcare reform work and working with Congress and the Obama administration. So even though we'll have some change in leadership at the association level, the focus will remain the same."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","John, this is Peter. If I can just take the cash flow question. And first let me just say I applaud the focus on cash flow question first upon the focus on cash flow. As you know, I'm a cash flow believer totally as well. However, I will have to ask that,",137,"John, this is Peter. If I can just take the cash flow question. And first let me just say I applaud the focus on cash flow question first upon the focus on cash flow. As you know, I'm a cash flow believer totally as well. However, I will have to ask that, if you can, wait for the 10-K, it will be out just a couple of the weeks and the balance sheet and cash flow statements, because those are -- until they're final in the 10-K, I want to be careful not to -- since we haven't put them in the earnings release, we don't normally do that. I want to hold until we actually publish the 10-K. But we focus on that tremendously and I just want to go through these normal steps and process."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Eric Lo with Bank of America.",14,"Your next question comes from the line of Eric Lo with Bank of America."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","What were your SAPHRIS sales in the quarter and how much of your GARDASIL sales came from the male indication? And then also, can you provide a status update on [indiscernible] (1:04:43) and how are your discussions with the FDA on that front?",43,"What were your SAPHRIS sales in the quarter and how much of your GARDASIL sales came from the male indication? And then also, can you provide a status update on [indiscernible] (1:04:43) and how are your discussions with the FDA on that front?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So on SAPHRIS issue, the sales were $40 million, almost all of that is stocking. I will take a second on SAPHRIS to say that we continue to be extremely strong in our belief that SAPHRIS has the potential to really make a difference to patients who have s",156,"So on SAPHRIS issue, the sales were $40 million, almost all of that is stocking. I will take a second on SAPHRIS to say that we continue to be extremely strong in our belief that SAPHRIS has the potential to really make a difference to patients who have schizophrenia and bipolar disease without some of the metabolic issues. And that I think we view this from our standpoint as being a launch that started on January 25 when we were able to provide full promotional support to our representatives, who before that, were essentially detailing with just a product inserts. So we're viewing this launch as being a new one. On the GARDASIL issue, we look forward to growth opportunities from males. But right now, I think the males have not been a very significant contributor to our GARDASIL sales, although we continue to look forward to that as well as to the adult woman indication."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from the line of Seamus Fernandez with Leerink Swann.",13,"Your next question comes from the line of Seamus Fernandez with Leerink Swann."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","I just wanted to verify the comment on the second TRA study. Ken, you had mentioned that 9,000 patients were enrolled and there's a target enrollment of 12,500 patients. To my recollection, that may be approximately an increase of about 2,500 patients, an",133,"I just wanted to verify the comment on the second TRA study. Ken, you had mentioned that 9,000 patients were enrolled and there's a target enrollment of 12,500 patients. To my recollection, that may be approximately an increase of about 2,500 patients, and I'm just wondering what the reasons are for that increase. I know that you may not know that off the top of your head, but just wanted to verify that that actually is an increase. And then separately, can you estimate the currency contribution to costs? Again, at least historical Merck costs in the quarter? Just wondering if we can at least have a historical look at that. And if you have an estimate of what the contribution to the cost lines where for Schering-Plough, that would be very helpful."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So I'll take the first comment of the tracer study. You are correct that it was an increase of about 2,500 patients. And while I'm not a scientist, I understand that when you have an event-driven study, the people who are running the study try to model wh",75,"So I'll take the first comment of the tracer study. You are correct that it was an increase of about 2,500 patients. And while I'm not a scientist, I understand that when you have an event-driven study, the people who are running the study try to model what it takes to make sure that you have a robust sample to get the event rate that you're looking for. And that's why it was increased."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","And, Seamus, if I can just note on that, this is Alex, that, that was updated previously. That's not a new disclosure about the 2,500 patient increase. That's been out for a few months.",34,"And, Seamus, if I can just note on that, this is Alex, that, that was updated previously. That's not a new disclosure about the 2,500 patient increase. That's been out for a few months."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","So if I can take the foreign exchange question, on the P&L. As I mentioned in my talk, we felt that the revenue benefited about 1% from foreign exchange. Now Merck's year-over-year benefit from foreign exchange is not as pronounced as you might see in som",166,"So if I can take the foreign exchange question, on the P&L. As I mentioned in my talk, we felt that the revenue benefited about 1% from foreign exchange. Now Merck's year-over-year benefit from foreign exchange is not as pronounced as you might see in some other pharma companies, and recall that we had the benefit of a hedging program in the fourth quarter of last year when the currencies were really moving rapidly. We have some nice gains from a hedging position that we had. So that moderates the year-over-year benefit. But net-net, what I can say is that the EPS benefit on the bottom line is moderately better than what you see on the top line, but not really dramatic. So really, in some ways, probably net-net foreign exchange didn't benefit our P&L in the fourth quarter versus last year as much, and part of that is because we had a nice hedging program that made the prior year stand up a little better."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question comes from the line of Bert Hazlett with BMO Capital Markets.",14,"Your final question comes from the line of Bert Hazlett with BMO Capital Markets."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Analysts","Maybe for Ken, was there any wholesale or stocking benefiting the U.S. results? And could you comment on the specific marketing increases that you made in the fourth quarter? And then regarding ISENTRESS which is a growth driver for the company clearly. T",72,"Maybe for Ken, was there any wholesale or stocking benefiting the U.S. results? And could you comment on the specific marketing increases that you made in the fourth quarter? And then regarding ISENTRESS which is a growth driver for the company clearly. There's some competition and actually some news out regarding Gilead this morning. Could you comment on the relative positioning of ISENTRESS compared to Gilead's therapy upcoming in the HIV market?"
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","Looking backwards, I have not seen the latest news on Gilead, but we continue to be confident in the profile of ISENTRESS and its growth prospects. We continue to work very hard on ensuring that we have a once-daily version of that drug. We continue to lo",290,"Looking backwards, I have not seen the latest news on Gilead, but we continue to be confident in the profile of ISENTRESS and its growth prospects. We continue to work very hard on ensuring that we have a once-daily version of that drug. We continue to look forward to fix those combinations which we believe will put it in a position where it will continue to be successful. And all I know that I can say about the Gilead pill is obviously, we're talking about an experimental pill with an anticipated launch that's many years away. We said earlier in the U.S. that we did see some wholesalers stocking this quarter. I think we view that as being reasonable in terms of comparing the fourth quarter '09 to the fourth quarter '08, although it was up from the third quarter of '09. And your general question about marketing expenditures, I can just summarize by saying, we continue to put money behind our growth drivers. We're very pleased, for example, with the recent trends around JANUVIA. We mentioned before that we were really going to focus on JANUVIA before we had put the focus on messaging, the importance of maximizing DPP-4 inhibition, to try to blog [ph] (1:10:12) the introduction of in-class competition. We've expanded our approach. We have now started to focus on the ability to work competitively against so far in the areas [ph] (1:10:23) and we have been encouraged by the focus and the resources that we put behind JANUVIA in terms of the increased volumes in December and in January. So we continue to view JANUVIA and JANUMET, as well as some of our other in-line products as key growth drivers in the U.S. market and beyond."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Executives","And if I can just amplify on something that Ken mentioned earlier, that we have four filings under review now with regulatory authorities around the world. So with that, I think that's the end of our Q&A, and we thank you all for listening to the call. Ha",52,"And if I can just amplify on something that Ken mentioned earlier, that we have four filings under review now with regulatory authorities around the world. So with that, I think that's the end of our Q&A, and we thank you all for listening to the call. Have a good day. Goodbye."
288502,84103586,54672,"Merck & Co. Inc., Q4 2009 Earnings Call, Feb-16-2010",2010-02-16,"Earnings Calls","Merck & Co., Inc.","Operator","Ladies and gentlemen, this concludes today's New Merck's Fourth Quarter 2009 Earnings Release Conference Call. You may now disconnect.",19,"Ladies and gentlemen, this concludes today's New Merck's Fourth Quarter 2009 Earnings Release Conference Call. You may now disconnect."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's First Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead.",36,"Good day, everyone, and welcome to Merck's First Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I'd like to turn the call over to Alex Kelly, Vice President of Investor Relations. Please go ahead."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Amanda, and good morning, everyone. And welcome to the 2010 First Quarter Conference Call for the new Merck. This is our first full quarter of combined operations, so there are a number of items in the GAAP results, such as purchase accounting adj",388,"Thanks, Amanda, and good morning, everyone. And welcome to the 2010 First Quarter Conference Call for the new Merck. This is our first full quarter of combined operations, so there are a number of items in the GAAP results, such as purchase accounting adjustments, merger-related expenses and restructuring costs that we've excluded from our non-GAAP results. We've also excluded the impact of the tax charge related to healthcare reform, as Peter Kellogg will discuss. 
We've provided you a number of tables in our earnings release to help you understand the trend, and in particular, there are five tables. There's a table on the GAAP sales results. Table 2 and 3 deal with our reconciled GAAP P&L to our non-GAAP results. There's also a supplemental Table 4, which provides the sales performance for the company, the business units and the products, as if the company had been in operation in the first quarter of 2009. And Table 5 is a supplemental non-GAAP table, which provides the sales for the major products. 
So during the call, we'll be referring mostly to Tables 2 and 3 when we discuss the P&L, and Table 4 when we discussed the revenue performance. I'd also like to remind you that next Tuesday, May 11, we are hosting our first R&D and business briefing, and as a result, we won't be discussing individual R&D projects on this call. 
In addition, I'd like to remind you that some of the statements we make during this call today may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs of Merck's management team and are subject to significant risks and uncertainties.
The company's SEC filings, including Item 1A in the 2009 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. You can find the SEC filings and today's earnings release on our website at merck.com. 
This morning, I'm joined by Dick Clark, our Chairman and Chief Executive Officer; Ken Frazier, the President of Merck; and Peter Kellogg, our Chief Financial Officer. Now I'd like to introduce Dick Clark."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. Today, we reported the first full quarter of financial results for the new Merck. Our first quarter 2010 results demonstrate early success in the integration of Merck's worldwide operations, and we are well-pos",940,"Thank you, Alex, and good morning, everyone. Today, we reported the first full quarter of financial results for the new Merck. Our first quarter 2010 results demonstrate early success in the integration of Merck's worldwide operations, and we are well-positioned to continue the grow globally and achieve our overarching goal of becoming the best healthcare company in the world. 
On the top line, the company recorded worldwide sales of $11.4 billion for the first quarter. Earnings per share for the first quarter on a non-GAAP basis was $0.83 versus $0.74 for the last year's first quarter for the standalone Merck. So you can see that our merger is already producing positive results. These results reflect the new Merck's expanded global footprint and the strong sales performance of key brands, including JANUVIA, JANUMET, REMICADE, SINGULAIR, ISENTRESS and TEMODAR. I think you can see from our results that we are focused on driving revenue growth, maintaining the momentum of the business and reducing our cost structure.
In a few moments, Ken will provide you with additional details around our specific global product performance. In today's announcement, we shared our financial targets for the full year 2010, and also reaffirmed our long-range financial target. Peter will have more to say about our financial outlook in just a few minutes.
On the integration front, we remain on course and continue to build momentum on multiple fronts. We have accomplished a lot in just six months. In the first quarter, we moved rapidly on executing our integration plans while maintaining our business momentum, growing the top line this quarter by 7%. We announced, with sanofi-aventis, our plan to create a global leader in Animal Health by combining Intervet/Schering-Plough with Merial into a proposed new joint venture that will equally be owned by Merck and sanofi-aventis. 
We completed the prioritization of R&D portfolio. Merck now has one of the industry's best pipelines, with more than 20 compounds in late-stage development. And we are well into the implementation of our previously announced global restructuring program. This includes the full integration of commercial operations in 12 out of our top 20 markets around the world.
I've also spent quite a bit of time in the past few months meeting with employees, customers and other key external stakeholders at various sites around the world, and what I saw was exciting. It is clear to me that there's considerable energy and disciplined thinking going on at Merck to ensure that we capture the many opportunities before us. Already, I am seeing signs of a more productive and sustainable culture beginning to emerge. We are intensely focused on what will add value, and most importantly, satisfy our customers' needs by providing them with innovative distinctive products and services that save and improve lives. And today, given our expanded worldwide presence and broader product portfolio, many more individuals have access to the valuable and diverse set of healthcare solution Merck provides than they did just a few months ago.
Turning to U.S. healthcare reform. While the legislation passed by Congress in March is not perfect, we continue to believe that overall, it will have a positive impact. Ultimately, the legislation passed will ensure that 32 million more Americans will have access to critical healthcare products and services. That's why we believe that healthcare reform, well not without its costs, will position Merck to better help patients to obtain the medicine and vaccine they need. For a company like Merck with a long history in vaccines, we are particularly pleased to see first dollar coverage of preventive services and vaccines for all new plans commencing in October 2010.
Also, defining the day exclusivity period for Biologics is 12 years will help protect innovation that our company has and will generate. I believe that protecting innovation goes hand-in-hand with expanding access to millions of Americans in need for healthcare, because our innovation can improve their care and reduce overall costs. We intend to remain on top of the issues related to healthcare reform and support our customers as we all navigate these significant changes to the U.S. healthcare system.
No matter what challenges we may face from generic competition to the new requirements of healthcare reform, we are prepared to tackle them, because we understand it truly because to be the best healthcare company in the world, we must execute on many levels. We will continue to remain intensely focused throughout the rest of this year and beyond on executing our strategy, discovering new therapies, successfully launching new products and delivering growth from our in-line products throughout the world. At the same time, we remain committed to achieving our merger synergy target of $3.5 billion in annual savings in 2012. We look forward to telling you more about our accomplishments, our pipeline and our areas of opportunity next week at our R&D and business briefing. 
Before I turn the call over to Ken, I want to say a few words about the senior leadership announcements we've made last week. As you know, Ken was elected President of Merck with responsibility for our three largest operating divisions, Global Human Health, Merck Manufacturing division and Merck Research Laboratories. We also announced that Adam Schechter was elected to succeed Ken as President of Global Human Health. I'm very confident in Ken and Adam are the right leaders and that these changes further strengthen an already outstanding senior leadership team. As CEO and Chairman, I remain fully committed to Merck and with Ken, to steering the company through this critical post-merger launch phase and positioning us for success in the future. 
Now I'll turn it over to Ken."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick. At the outset, please allow me to say that I am actually deeply, deeply honored to have been asked to serve in this new role. Because I believe still passionately in the company and its people and its mission. I look forward to working wi",1502,"Thank you, Dick. At the outset, please allow me to say that I am actually deeply, deeply honored to have been asked to serve in this new role. Because I believe still passionately in the company and its people and its mission. I look forward to working with you, Dick, Peter Kim, Willie Deese and all the rest of my senior management colleagues to help ensure that we deliver on the full promise of the merger and achieve sustainable performance going forward.
As Dick mentioned, we were off to a great start in 2010. Overall, Global Human Health delivered a strong quarter with sales of $9.8 billion, which represents 6% growth on a supplemental combined non-GAAP basis from the previous year. In describing in our first quarter performance, please note that I will refer to supplemental combined non-GAAP results, which includes the impact of foreign exchange for the rest of my comments. 
While my focus today is to review the strong performance of the Global Human Health business during the first quarter, I do want to make a few comments about the focus and resilience our marketing and sales team showed in delivering these strong results. At the same time, we were integrating our operations and markets around the world.
As I shared with you during the fourth quarter call, we fully integrated our U.S. customer facing organization in January. And since then, we've made substantial progress in a number of other markets. As we integrated our customer facing groups, our primary focus was on minimizing customer disruption in order to maintain business momentum, while at the same time becoming both more effective and more efficient. 
Throughout the first quarter, our commercial teams around the world were required to take time off territory for brand and portfolio training as we merge the portfolios of the two legacy company. Nonetheless, I believe it is clear from the first quarter results that our sales force is focused on their customers and the new portfolio opportunities available to them. I think what our customer facing organization achieved was outstanding. Fully-integrated, trained, energized and refocused teams in a number of our major markets that delivered strong results.
We'll share additional insights into the progress we're making across the business next week during our R&D and business briefing meeting. For the rest of today's call, I'll focus my comments on our first quarter performance.
We drove growth and most of our markets and international sales grew at 10% in the first quarter. Taking a look at our largest market, we drove growth in nine of our top 10 country, and seven of the top 10 grew at double-digit rates. We also continued to see double-digit growth in our core emerging markets. We will discuss our emerging market strategy at the business briefing next week also.
Turning to individual brand performance. We continue to see broad-based growth with eight of our top 10 product families growing in the first quarter. As I address the individual product performance, you can feel free to follow along in Table 3 from our supplemental financial package. 
Starting with SINGULAIR, sales in the first quarter were $1.2 billion, an increase of 10% versus the prior year. SINGULAIR's growth was largely driven by strong performance in Japan and double-digit growth across the emerging markets. In the U.S., the allergy season in the first quarter was generally mild and comparable to the previous year. However, we started to see pollen counts intensified in late March. One of our main priorities following the close of the merger was to rapidly and effectively co-position the products in our respiratory portfolio. As the allergy season accelerated in March and April, our teams leverage our broad respiratory portfolio to drive volume growth. In addition to the growth of SINGULAIR, sales of NASONEX grew 4% to $320 million, driven by results in the EU, Japan and the emerging markets.
Moving to JANUVIA and JANUMET, global revenue grew 32% to a combined $172 million (sic) [$712 million]. The JANUVIA franchise continues its strong performance, despite the introduction of new branded competition and the continued utilization of generics, because JANUVIA has a differentiated label and brings real benefit to patients with type 2 diabetes. Sales in the U.S. grew 16% this quarter. We continue to invest in the promotion of JANUVIA and JANUMET to maintain our leadership position in the diabetes market and to grow this franchise.
We are focused on highlighting the strong value proposition of JANUVIA versus sulfonylurea. We also plan to capitalize on the new label changes for JANUVIA, which includes the label changed to allow use with insulin. We believe this represents a significant opportunity for growth and differentiation going forward. 
Outside the U.S., we continue to see growth in the EU, and the launch of JANUVIA in Japan is tracking well. Due to the strong product profile and significant labeling advantages, we expect that this franchise will continue to be a major growth driver for Merck. 
Our immunology franchise also achieved strong growth during the quarter. REMICADE continues to be a leading immunologic therapy. Sales in the quarter were $674 million, an increase of 30% from the previous year. REMICADE continues to deliver growth across all indications rheumatology, gastroenterology and dermatology. 
In rheumatology, REMICADE is maintaining its market share despite multiple new product launches in the class. In fact, we're seeing some benefit in REMICADE's performance from the launch of SIMPONI which I'll discuss shortly. REMICADE's market share and growth in the GI indications remains class leading. 
In April, the New England Journal of Medicine published the Sonic study. Sonic showed that patients with Crohn's disease were more likely to achieve steroid free clinical remission with REMICADE compared to patients taking azathioprine. 
Moving to SIMPONI, while we're still in the early stages of the launches, we are encouraged by the quick adoption in key markets where we have reimbursement. We are driving SIMPONI primarily to take share from Humira and Enbrel, not REMICADE. In addition to the five countries where we currently have reimbursement, we plan to launch SIMPONI in many of the other EU markets and key emerging markets in the second half of this year. We continue to view REMICADE and SIMPONI as significant growth drivers.
Turning to ZETIA and VYTORIN. Sales were $1 billion this quarter, which in the aggregate, represents 2% growth compared to the previous year. Sales in the U.S. declined due to market share erosion and movement in inventory. VYTORIN and ZETIA remain a key focus of our promotional efforts this year. We continue to see solid growth in many markets outside the U.S. and are encouraged by the performance of our teams in the EU and Japan.
Moving on to COZAAR/HYZAAR. As you know, the brands recently lost marketing exclusivity in the U.S. and most major EU markets. Globally, sales in the first quarter were down 7%. Recent weekly prescription data in the U.S. indicates that there has been a rapid erosion of the brands now that we are no longer enjoying market exclusivity. I will now move to our Vaccine business.
In the first quarter, the Vaccine business benefited from an inventory build of approximately $75 million to $100 million. First quarter sales of ZOSTAVAX, as reported by Merck, were $95 million, a 27% increase from the previous year. We did see an inventory build due to the timing of customer orders in the first quarter. While demand remains high for ZOSTAVAX, we continue to be constrained by supply. 
Moving to GARDASIL. Sales as reported by Merck in the first quarter were $233 million, an 11% decline. GARDASIL continues to maintain market share leadership in the U.S. and also remains the global market leader. 
In infectious diseases, ISENTRESS continues its outstanding launch performance and is now one of Merck's top 10 brand. Sales in the first quarter were $232 million, an increase of 57%. The continued growth of ISENTRESS reflects the unique efficacy and tolerability profile of this product, which has been widely embraced by physicians, patients and health organizations.
In closing, I want to thank my colleagues across the new Merck for a successful quarter. Since the close of the merger, I've spent a great deal of time with our teams and our customers around the world in the U.S., Latin America, U.K., Greece, Italy, Switzerland and other places. 
And while growing our business, in the midst of integration was an enormous challenge, the progress and enthusiasm of our teams to build a new commercial organization that embodies the best of legacy Schering-Plough and Merck commercial organizations with minimal customer disruption was truly a tribute to the organization's focus and execution. 
I look forward to updating you all on our progress during the business briefing next week. We've had another strong quarter, and I think our review of the business will help you better appreciate exactly what is driving this success. 
And so now it is my pleasure to pass the call over to my colleague, Peter Kellogg."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, we are pleased with our first quarter performance and our integration efforts are well underway. Ken shared with you how our key brands contributed to our strong growth this quarter. I w",1484,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, we are pleased with our first quarter performance and our integration efforts are well underway. Ken shared with you how our key brands contributed to our strong growth this quarter. I would like to cover two areas with you. First, our earnings performance this quarter and second, I will provide some commentary on our targets for full year 2010 and beyond that, our long-term EPS target. 
Let's begin with our results. This is the first quarter that we are reporting a full three months of results for the combined company. You'll see the tables in our news release and supplemental charts that we added last quarter to help you navigate through our non-GAAP adjustments to the P&L, which exclude purchase price accounting adjustments, merger-related costs, restructuring charges and a $150 million tax charge related to elimination of a tax benefit for retiree prescription drug coverage. To simplify my remarks today, I will speak mostly to the non-GAAP results. On this basis, the new Merck reported first quarter non-GAAP earnings per share of $0.83.
Our performance this quarter is characterized by the strong operational sales that Ken just discussed. The cost management and benefits of merger synergies in our cost base, lower equity income from partnerships, due to the elimination of Merial and the cholesterol joint venture and lower interest income and higher interest expense due to the merger financing. 
In addition, we also had about a 4% benefit from foreign exchange on the top line, which also had the effect of increasing our operating expenses. So let's get into some of the individual items beginning with revenue. 
Total revenue for the quarter was $11.4 billion. On a supplemental combined non-GAAP basis, sales were up 7%. This basis assumes that Schering-Plough and the cholesterol joint venture were included for all three months of the first quarter of 2009 as well. Our Global Human Health business grew 6% in the quarter. Our Animal business grew 14% to $709 million, reflecting continued growth among companion animal and poultry products. Meanwhile, our Consumer Care sales were $379 million, slightly lower than prior year due to the launch purchases of Claritin Liqui-Gels in the first quarter of 2009. 
Now moving on to the expense side in the P&L. As you know, our cost base now includes the cost from Schering-Plough, Merck and the cholesterol joint venture, whereas only the Merck costs were included in the first quarter of 2009, so it's a little hard to see underlying trends. So this quarter though, we reduced our headcount, we generated savings from procurement actions and discontinued certain R&D projects through our pipeline prioritization process. As a result of these and other actions, we are on track to realize our $3.5 billion synergy target by the end of 2012. Over time, I am confident that you will see even more evidence that our costs are coming down. 
So let's move on to materials and production. The non-GAAP gross margin in the first quarter was approximately 75%, which was similar to the rate in the first quarter of 2009 when Merck was a stand-alone company. On a non-GAAP basis, marketing and administrative expenses in the first quarter were $3.2 billion. While research and development expenses for the first quarter were approximately $2 billion, slightly lower than we expected. Included in the R&D expenses this quarter was continued investment in late-stage projects, such as TRA [thrombin receptor antagonist], boceprevir,  [indiscernible] (40:05), CORDAPTIVE and our CETP-Inhibitor. 
Let's move to equity income. In the first quarter, Merck recorded $138 million of equity income, a $450 million decline over the prior year. This decline is primarily attributable to the unwind of the cholesterol joint venture and the sale of Merial. There was also a $43 million decline in income from the AZLP partnership. Now as you're aware, AstraZeneca gave us notice that their intent to exercise their option to buy the non-PPI products, which will result in a one-time gain of approximately $440 million in the second quarter. This gain will not be included in our non-GAAP results. 
Going forward, Merck equity income will be earned from three partnerships AZLP, our vaccine joint venture with sanofi in Europe, and the J&J Merck OTC partnership. Beginning in 2011, we expect to also have equity income from our new Animal Health joint venture once it is completed. Until that time, we continue to own and consolidate the interventuring Plough business in our full P&L. This quarter's equity income is a good barometer of the anticipated quarterly equity income in 2010. 
Now let's discuss other income and expense. In the first quarter of 2010, other expense on a non-GAAP basis is $160 million compared to other income of $80 million in the first quarter of 2009. There are a few items driving this year-over-year change. First, and most notably, is the inclusion of interest expense from the Schering-Plough debt and the merger related debt. Second, interest income was lower as a result of lower interest rates and lower cash and investment balances. Third, the current quarter's expense includes an $80 million exchange loss, as a result of the currency devaluation in Venezuela, and the translation of assets in Venezuela on our balance sheet. Lastly, a favorable settlement of a dispute contributed approximately $100 million to the line.
Moving to the tax line. The new Merck non-GAAP tax rate was 23% for the first quarter. This is consistent with the rate that we saw in 2009 on a full year basis, excluding discrete items. So that's the first quarter, a strong start for the new Merck. 
Now let's talk about our financial targets beginning with our long-term targets. We remain very excited about the future of the new Merck and we continue to target a high single digit non-GAAP EPS compound annual growth rate from 2009 to 2013 regardless of the outcome of the REMICADE arbitration. As we indicated in our press release on April 23, this guidance is also still applicable, despite the anticipated impacts from healthcare reform. 
So specifically in 2010, the company is targeting a full year 2010 non-GAAP EPS range of $3.27 to $3.41 excluding certain items. On a GAAP basis, we are targeting an EPS range of $1.15 to $1.50. We have also provided guidance on the reconciliation of the GAAP to non-GAAP EPS on Page 3 of our news release.  Our 2010 EPS target and other financial targets assume that Merck retains full rights to REMICADE and SIMPONI in our markets. 
Now I'd like to provide targets in a few select areas to help you better understand the earnings targets. First, beginning with the sales line. We are launching an impressive number of new products globally, and we anticipate that sales from these new products, combined with strong growth in our key brands JANUVIA, ISENTRESS, REMICADE and SINGULAIR will replace the significant sales loss from patent expiry of this year. 
COZAAR/HYZAAR would represent the third major patent expiry after ZOCOR in 2006 and FOSAMAX in 2008, that Merck has grown through in the years of expiry. We anticipate full year 2010 sales to be in the range of $45.4 billion to $46.4 billion at current exchange rates. This range reflects the unfavorable $170 million impact from the healthcare reform as previously discussed on April 23. Now let's discuss R&D.
In 2010, we will continue to invest in our late-stage pipeline. We are also driving efficiencies through the combined R&D  infrastructure. We anticipate full year non-GAAP R&D expense to be in the range of $8.3 billion to $8.7 billion. 
Moving to the tax line, we anticipate a non-GAAP tax rate in the range of 22% to 24% in 2010. So let me summarize. We are pleased with our strong first quarter results. We clearly had a stronger-than-expected first quarter, and our expense management contributed to that performance. Three other factors contributed to our strong first quarter performance. First, we had about $75 million to $100 million in U.S. inventory build in the vaccines area. Second, our R&D expenses were lower than expected, due to timing of clinical trials. We do expect to make up that spending in subsequent quarters of 2010 and currently target R&D expenses of $8.3 billion to $8.7 billion that I just mentioned, which implies higher quarterly spending going forward. Finally, foreign exchange gave us a lift this quarter, and we don't expect the same degree of benefit going forward based on current ForEx rates. 
Our results and the targets provided demonstrate that we are on track, had a good first full year as a combined company. We expect to continue our business momentum for key brands, launch products globally and make significant investments in our promising late-stage pipeline, and we expect to realize substantial cost synergies. Thank you. And now I'll turn the call back over to Alex. Alex?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Peter. Now we'd like to open up the call to answer your questions. In order to help us get through as many of your questions as possible, please limit yourself to one or two questions and note that we won't take any follow-up questions. But fee",94,"Thank you, Peter. Now we'd like to open up the call to answer your questions. In order to help us get through as many of your questions as possible, please limit yourself to one or two questions and note that we won't take any follow-up questions. But feel free to join the queue, if you have additional questions. Also, as a reminder to what I said at the beginning of the call, we will take your R&D related questions next Tuesday, during our R&D and business briefing. Operator, we're now ready for the Q&A."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question is from John Boris, Citi.",10,"[Operator Instructions] Your first question is from John Boris, Citi."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","First question just for Peter Kellogg, just on your cash flow. Can you comment on what your cash flows were in the quarter and any color around what cash flow targets could it potentially be for the new co in 2010? And then, a question for Ken, congratula",84,"First question just for Peter Kellogg, just on your cash flow. Can you comment on what your cash flows were in the quarter and any color around what cash flow targets could it potentially be for the new co in 2010? And then, a question for Ken, congratulations on your broader responsibilities. As you do take on those broader responsibilities, can you outline what your top three priorities will be going forward as you now assume responsibility for Human Health, Manufacturing, R&D, et cetera?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","John, it's Peter. So unfortunately, we really haven't state, talk about cash flow and the balance sheet on this call until the 10-Q goes out. So if I can, I'll defer on that. But I would focus everyone back on where we were at year end, obviously, from a",145,"John, it's Peter. So unfortunately, we really haven't state, talk about cash flow and the balance sheet on this call until the 10-Q goes out. So if I can, I'll defer on that. But I would focus everyone back on where we were at year end, obviously, from a cash balance standpoint and we do expect to have a strong cash flows. I think at year end and as we go through this quarter, we have roughly $12 billion in cash and about $19 billion of debt, and we expect to have very strong cash flow performance even this first year of the merger. And we've highlighted that by the end of the guidance period, we actually expect that cash flow to be a very strong operational cash flow by that time period so that also is instead, the second question for Ken, I guess."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Yes, I would say that my top three priorities, so first of all, to continue to work with Dick, with Peter and Willie and in this vein to actually learn a lot from the three of them regarding the new areas of responsibility that I have, so that would be my",137,"Yes, I would say that my top three priorities, so first of all, to continue to work with Dick, with Peter and Willie and in this vein to actually learn a lot from the three of them regarding the new areas of responsibility that I have, so that would be my first responsibility. The second one is, obviously, to ensure that these three operating divisions continue to collaborate and work jointly in order to produce value, and I would say the third one is continuing to push for the kinds of product performance that we've seen in the first quarter. We're still in the middle of integrating many of our markets and while my colleague, Adam Schechter is very able, I think we want to be sure that we have a seamless transition on the commercial side."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Marc Goodman with UBS.",9,"Your next question is from Marc Goodman with UBS."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","You mentioned that there was inventory changes in ZETIA/VYTORIN. Can you just help quantify that? And then second of all, in the diabetes market, DPP-4 class, I would have expected this market to be growing a little bit faster. And can you comment on what",101,"You mentioned that there was inventory changes in ZETIA/VYTORIN. Can you just help quantify that? And then second of all, in the diabetes market, DPP-4 class, I would have expected this market to be growing a little bit faster. And can you comment on what's happening with your competitor along coming in, usually we see a second player coming in and market start to expand faster. We're not really seeing that and your thoughts on just  [indiscernible] (49:16) had an impact at all? Or how these longer acting are going to play into the impact of the DPP-4 over time."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","So I think on VYTORIN and ZETIA, I think we saw inventory patterns this quarter that we thought were consistent with our expectations and consistent with what we saw frankly in the first quarter of 2009. As it relates to the oral diabetes market, we were",141,"So I think on VYTORIN and ZETIA, I think we saw inventory patterns this quarter that we thought were consistent with our expectations and consistent with what we saw frankly in the first quarter of 2009. As it relates to the oral diabetes market, we were very pleased that JANUVIA and JANUMET continue to grow very strongly. They have shown strongest growth in that market. Remember that we are up against established entrenched generic entities that are used by a lot of physicians, and that's our primary focus. We're pleased with -- there are in-class market share that we've maintained in the U.S. against on class and around the world, against other DPP-4 inhibitors. And I think what you're seeing with the new class is that while you have seen the COZAAR/HYZAAR inroads, they're really not at the expense of JANUVIA."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tim Anderson with Sanford Bernstein.",10,"Your next question is from Tim Anderson with Sanford Bernstein."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","Just going back to JANUVIA, you mentioned that being a growth driver for Merck, but if I look at what you reported in the Q, quarter for the U.S., it was flat with third quarter, and it was below fourth quarter levels. JANUMET pretty much the same thing,",117,"Just going back to JANUVIA, you mentioned that being a growth driver for Merck, but if I look at what you reported in the Q, quarter for the U.S., it was flat with third quarter, and it was below fourth quarter levels. JANUMET pretty much the same thing, so it's not clear to me how the U.S. is going to be a driver of growth going forward. So I'm just wondering if you can clarify that. And then on VYTORIN and ZETIA, I know those products have been through a lot, but can we get an update on the timing of the sharp trial, that if I remember correctly, should be coming out in the current year?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","We're starting on the sharp trial, I think we'll be able to provide that information next week at our business briefing. As it relates to, again, the issue around JANUVIA and JANUMET in the first quarter, sequentially, we also experienced a pretty strong",75,"We're starting on the sharp trial, I think we'll be able to provide that information next week at our business briefing. As it relates to, again, the issue around JANUVIA and JANUMET in the first quarter, sequentially, we also experienced a pretty strong inventory build in the fourth quarter and we're seeing some adjustments downward in this quarter. I think, overall, we're pleased though with the volume growth of JANUVIA and JANUMET across markets."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Eric Lo with Bank of America.",11,"Your next question is from Eric Lo with Bank of America."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","First, on reform. In terms of your guidance for next year of $300 million to $350 million in revenue impact, so hoping you guys could potentially break that down between what industry fee is and what your assumptions are in terms of Part D donut hole impa",129,"First, on reform. In terms of your guidance for next year of $300 million to $350 million in revenue impact, so hoping you guys could potentially break that down between what industry fee is and what your assumptions are in terms of Part D donut hole impact? And also, how much of that might actually fall to the bottom line. Second question is on your geographic sales. I noticed you guys book up what your sales were in terms of Latin America, Asia-Pac and Eastern Europe. I was hoping you guys could 
provide some color in terms of what the sales growth year-over-year was, and how that compares to performance in 2009 sales growth and maybe some color in terms of profitability in these regions, maybe rank order them?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","From your question with healthcare reform, although we don't give specific breakdown of details, we can tell you about 50% is from Medicaid rebates and 50% from fee in the donut hole plus the 340B. That's the breakdown, it's about a 50-50 breakdown.",43,"From your question with healthcare reform, although we don't give specific breakdown of details, we can tell you about 50% is from Medicaid rebates and 50% from fee in the donut hole plus the 340B. That's the breakdown, it's about a 50-50 breakdown."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","And as it relates to the regional breakdown that we provided in Table 3b, I would say that we're pleased with the double-digit growth that we're seeing across Latin America, Asia Pacific and Eastern Europe, Middle East, Africa. Everyone has a definition o",129,"And as it relates to the regional breakdown that we provided in Table 3b, I would say that we're pleased with the double-digit growth that we're seeing across Latin America, Asia Pacific and Eastern Europe, Middle East, Africa. Everyone has a definition of emerging markets, but if you look at those three together, we had growth of in the high teens. And so we are pleased with where we are. We know that that is where the growth is for this industry going forward. We are very focused on getting more than our per capita share of that growth. We want to grow faster than those markets and we'll talk next week at the business briefing about our strategies for ensuring that we do get that kind of growth."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Risinger from Morgan Stanley.",10,"Your next question is from David Risinger from Morgan Stanley."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","First of all, with respect to the second quarter sequentially, I know that you don't provide guidance, but can you please just run through -- and I know you mentioned some anomalies in the first quarter, but could you please run through how we should thin",112,"First of all, with respect to the second quarter sequentially, I know that you don't provide guidance, but can you please just run through -- and I know you mentioned some anomalies in the first quarter, but could you please run through how we should think about the second quarter, sequentially, in terms of revenue and EPS trends? And then second, another revenue question. Could you just talk to the revenue outlook longer term? So you've provided high single-digit EPS growth guidance, but it's unclear if you're assuming revenue growth from 2010 to 2013 or revenue to be flat. So if you could provide some color on that, that would be helpful."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","This is Peter. So the first quarter, obviously, we did a little better than we thought, and some of the factors that I mentioned were net build in our U.S. vaccines inventory out in the channels and that was to a multitude of different effects. Some of it",541,"This is Peter. So the first quarter, obviously, we did a little better than we thought, and some of the factors that I mentioned were net build in our U.S. vaccines inventory out in the channels and that was to a multitude of different effects. Some of it was the fact that we were seeing some increased customer purchasing of vaccines, because we're going live on SAP in the beginning of April. Some of it was actually some advance purchasing of ZOSTAVAX due to some concerns about the fact that we'd mentioned there might be some back orders and so people were picking up some inventory. And probably we would expect that not to be sustained as we go forward. So in the second quarter, you'd probably see that balance out. We don't have a perfect crystal ball on that, but it would be reasonable for that, I think. The second thing is as I mentioned, the R&D expenses were a little lower than we would've expected, but really everything's still moving ahead. I just think that we maybe didn't quite get the exact calendarization rate. We did give you the full year guidance or target of $8.3 billion to $8.7 billion. And obviously, the math would tell you that that implies higher quarter spending going forward. And then  third, we got a nice benefit from foreign exchange in the first quarter, which I don't think we'll get quite as much of going forward in the balance of the year. In fact, I think the foreign exchange rates are moving a little bit as we speak. And obviously that's a volatile state in [ph] rate now. I think that, obviously, we do have some seasonality in our revenue, and I think that probably that will cause the second half of the year to look a little stronger. And likewise, we're seeing COZAAR/HYZAAR, as we mentioned earlier, went off patent so that's really, as Ken mentioned, start to have a very strong impact in Q2, Q3 and Q4. And what we you mentioned in the Q4 call was that we did see that the second half of the year be a little bit stronger than the first half, and we do think that continues to be true from a calendarization standpoint. Longer-term basis, we haven't guided to revenue. We've focused on EPS as obviously a lot of moving parts here, and so I don't want to just kind of quickly give guidance that showing on the revenue line. I think that obviously everyone knows where clearly what all of the moving parts are and we're launching a lot of products. We've got a lot of exciting late stage pipeline items. We've got some in-line commercial asset, as Ken's talked about, have tremendous potential so exactly where those land, it's hard to call. Going against that, obviously, we're in a challenging global economy right now with a lot of fiscal budgets and governments trying to manage through that. So at this point, what we do know is we have the right levers in place through putting these two companies together to manage the EPS guidance, we think we're in very good shape on that. Dick or Ken, do you want to add anything?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","I would say that from a commercial standpoint, obviously, we believe that this is a very strong portfolio when you've put these products together, and we're very much committed to driving very strong growth within the portfolio without making any specific",111,"I would say that from a commercial standpoint, obviously, we believe that this is a very strong portfolio when you've put these products together, and we're very much committed to driving very strong growth within the portfolio without making any specific comments around guidance. I want you to know that our commercial organization believes in this portfolio, they're motivated. And I think we are seeing the beginning of some benefits from putting these products together. For example, in the respiratory portfolio this quarter, when we look at SINGULAIR's performance and you look at MASONEX's performance from a volume issue [ph] basis recently, I actually think we're starting to see some benefits."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Jami Rubin from Goldman Sachs.",10,"Your next question is from Jami Rubin from Goldman Sachs."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","First, for you Peter, after the fourth quarter call, you've signaled a very weak first half followed by a very strong second half. It sounds to me like based on the pushes and pull with R&D, currency, et cetera, that we should now expect a more even, even",171,"First, for you Peter, after the fourth quarter call, you've signaled a very weak first half followed by a very strong second half. It sounds to me like based on the pushes and pull with R&D, currency, et cetera, that we should now expect a more even, even quarters throughout the year. Second question for you, Dick, is given your strong operational cash flow, curious to know how you are thinking about the dividend, which I would point out, hasn't been raised since 2004 because of the Vioxx overhang, which has been lifted now long ago. And third question for Ken, and again I offer my congratulations to you, too, Ken, if you can provide us any color on the reimbursement environment for SIMPONI. It would be great if you could share with us what your revenues were. But more importantly, what is the tenor of discussions with European regulators given the economic budget crisis and some of the reform programs that we've seen put in place such as in Germany?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","On the calendarization this year, obviously, we did signal on the fourth quarter call that we thought the first half would be weaker, and we did get some benefits in the first quarter. A part of it was just good expense management, and some of the invento",122,"On the calendarization this year, obviously, we did signal on the fourth quarter call that we thought the first half would be weaker, and we did get some benefits in the first quarter. A part of it was just good expense management, and some of the inventory build that we talked about certainly helped and we got a nice ForEx impact as well. We do expect the second half to be stronger than the first half, and think Q2, I just would be cautious that inventories may reverse. But overall, though, versus what we originally thought, I think you're right that the quarters won't be quite as different as we first thought because we obviously were anticipating a weaker first quarter. Dick?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Certainly, Jami, from a dividend standpoint, and we look at it [indiscernible] dollar value is that the dividend was sharply increased particularly as to the Schering-Plough shareholders, based on the merger that took place and so there has been an increa",93,"Certainly, Jami, from a dividend standpoint, and we look at it [indiscernible] dollar value is that the dividend was sharply increased particularly as to the Schering-Plough shareholders, based on the merger that took place and so there has been an increase. Just as important as we look forward to our cash flow and we look toward how to continue to invest in the company, and think about dividend and think about share buybacks is just something that is a part of our strategic review and something that we will consider in the future."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","On SIMPONI, the sales in the quarter were about $10 million which is roughly double the sales that we saw on the fourth quarter. We're still very much in the early days. We have reimbursement in five countries. We have Germany, we have the private part of",185,"On SIMPONI, the sales in the quarter were about $10 million which is roughly double the sales that we saw on the fourth quarter. We're still very much in the early days. We have reimbursement in five countries. We have Germany, we have the private part of the Canadian market. I think what I would say about the overall background is, obviously, all these European countries are struggling with budgetary issues including healthcare issues. We know that the anti-TNF category is a significant cost item to them. But we think SIMPONI really brings to the table a lot of benefits. And so for us right now, it's actually going in with the dossiers that we prepare, which we feel very good about, to convince both national and regional price and HTA organizations to actually see the benefit of SIMPONI, its convenience and its benefit to patients. And so we're very confident that over time, we'll be able to persuade people to include SIMPONI within the reimbursement, but I have to say that it's a very difficult economic environment in which we are launching this drug."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Steve Scala with Cowen.",9,"Your next question is from Steve Scala with Cowen."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","First, Dick, you started by saying that healthcare reform will have a positive impact. Are you saying that reform will be accretive Merck profits over the long term? So that's the first question. Secondly, regarding the impact of REMICADE and golimumab on",103,"First, Dick, you started by saying that healthcare reform will have a positive impact. Are you saying that reform will be accretive Merck profits over the long term? So that's the first question. Secondly, regarding the impact of REMICADE and golimumab on 2010 guidance, would you say that guidance will only change if you lose arbitration or will it change if you settle as well? In other words, must Merck win arbitration to maintain guidance? I appreciate that the answer requires knowledge of any proposed but not public settlement, so based on any proposed but not public settlement now contemplated, would guidance change?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","This is Peter. First of all, just to kind of clarify, we're really not making any comments about the REMICADE situation at all. Obviously, we have indicated that that'll start to come together in late September. So by the time that is sorted through, I th",173,"This is Peter. First of all, just to kind of clarify, we're really not making any comments about the REMICADE situation at all. Obviously, we have indicated that that'll start to come together in late September. So by the time that is sorted through, I think we're through a lot of the year anyway. And I think that's the spirit in which we said as you think about guidance for 2010, assume that REMICADE and SIMPONI are in our portfolio for most of this year. I would just like to highlight there's a lot of pluses and minuses in any given year at the revenue line so I wouldn't go too far on that. And then long term, as we said a year ago when we announced this merger, we have thought about our long-term guidance so that the EPS guidance that we're providing is achievable with or without the REMICADE, SIMPONI portfolio just to settle those questions or concerns as people think about the financial prospects of the company. On healthcare reform?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Steve, it's hard to tell yet when we think about all the details that need to be rolled out with healthcare reform, what it does long term. Having said that, though, I am optimistic because we are a company that focuses on innovation and if innovation has",200,"Steve, it's hard to tell yet when we think about all the details that need to be rolled out with healthcare reform, what it does long term. Having said that, though, I am optimistic because we are a company that focuses on innovation and if innovation has unmet medical needs that are being satisfied, certainly, there are patients both in Medicare and [indiscernible] not covered today that will need our medicines and vaccines in the future. There's a stronger component within the donut hole that people don't have to go off their medicines. As we continue to think about our Merck Bio ventures and Biologics in the future that the fact that we've got the type of patent protection we need from an innovation standpoint is important. The first they covered for prevention and vaccine is important. There are enough positives on one side of the equation even though there are fees and increased Medicaid rebates on the other side that you would think over time that as healthcare reform is put in place and that we are a major component to help reduce healthcare costs by innovation and by prevention, that it would be a positive for the company."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Catherine Arnold from Credit Suisse.",10,"Your next question is from Catherine Arnold from Credit Suisse."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","I wanted to ask Dick if you can give us an update. You have made some public comments in the past about Merck's mindset on acquisitions. Now, I guess I wondered what you thought the organization [indiscernible] in regards to transaction size and timing as",105,"I wanted to ask Dick if you can give us an update. You have made some public comments in the past about Merck's mindset on acquisitions. Now, I guess I wondered what you thought the organization [indiscernible] in regards to transaction size and timing as you move through the integration. And if you could specify whether your interest is primarily in pharmaceuticals or whether you would also be considering augmenting non-pharma or increasing your diversification. And then I had a follow-up on your dividend comment. I just wondered if you could give us a sense for your preferential interest in dividend increase versus share repurchase."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Certainly from an acquisition standpoint, our focus right now has to be on execution. We have a tremendous opportunity here to bring two very important assets together from a merger standpoint and whether, as Ken said, that we're integrating from a commer",292,"Certainly from an acquisition standpoint, our focus right now has to be on execution. We have a tremendous opportunity here to bring two very important assets together from a merger standpoint and whether, as Ken said, that we're integrating from a commercial standpoint in the top 20 markets we've already integrated it across our top 12 of the 20, whether we're just bringing our network together or portfolio together, it's very, very important as we go forward. So we can't lose focus around the capabilities both on the topline and the cost standpoint around this valuable merger that we're putting together. And so that is extremely important. And then we have this very strong pipeline that we had to continue to build both internally because we have a strong late-stage development process in place. But we're always looking externally to make sure that from a licensing or an acquisitions, whether it's something that will help our individual franchises move forward, and so that support bodes well. Having said that, Animal Health, Consumer Health, what we're doing in emerging markets are very critical to us as part of our strategy, and we will continue to look at those as being an important part of organic as well as inorganic growth. I don't see diversification outside of that core as important, but as we continue to grow on the global stage, it's important that we build our global presence in many of the division I just talked about, so I think that's important. On your question concerning dividends or share buyback, they're very important to us and it's very difficult at this stage to bring the companies together on where we are from a cash flow to really tell you a priority on that."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Chris Schott with JPMorgan.",9,"Your next question is from Chris Schott with JPMorgan."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","First question just following up on business development. Many of your pharma peers obviously are making a big push in the emerging markets. I know Merck is doing that as well, but expanding their generic or brand generic portfolio as a way to target come",137,"First question just following up on business development. Many of your pharma peers obviously are making a big push in the emerging markets. I know Merck is doing that as well, but expanding their generic or brand generic portfolio as a way to target come of these opportunities, can you just maybe talk a little bit about Merck's efforts on this front and again interest in expanding its, again, genetic or brand generic portfolio? And then a second question on currency, can you just give us a little bit more color on what exchange rates and EPS impact is reflected in the 2010 guidance provided this morning? And I know Merck and Schering had different hedging policies. Can you just also update us on the policy of the newly combined company as it relates to currency hedges?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","As I mentioned, we intend to spend some time next week going through our strategy. But generally speaking, I would say that we continue to look at all opportunities to have profitable growth in the emerging markets. So that includes, obviously, continuing",198,"As I mentioned, we intend to spend some time next week going through our strategy. But generally speaking, I would say that we continue to look at all opportunities to have profitable growth in the emerging markets. So that includes, obviously, continuing to drive our innovative portfolio, but also we recognize that branded generics or should I say branded off patent products actually play a significant role. We have, in our own portfolio, a significant number of key brands. Let's talk about Zocor or COZAAR or FOSAMAX. Those are very significant contributors to the standard of care and they are ringing our portfolio. And one of the things that we got from the Schering merger is the capability of really driving those kinds of mature products through formulations, et cetera. So that's a big part of it. Lastly, in terms of expanding the portfolio, we do have interest in creating the kinds of partnerships that would actually also expand the number of products in the representative's bags. We have really expanded our commercial infrastructure so we look for those as of partnerships; but again, against the background of ensuring that we are driving profitable growth in emerging markets."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","This is Peter, let me talk about foreign exchange questions and hedging. So we did highlight that foreign exchange do give us a benefit this quarter and base on the current rates, we don't expect the same benefit going forward as we go through sequential",301,"This is Peter, let me talk about foreign exchange questions and hedging. So we did highlight that foreign exchange do give us a benefit this quarter and base on the current rates, we don't expect the same benefit going forward as we go through sequential quarters and that is obviously comparing to prior year. And I should remind everybody, obviously, last year was a great volatile year. Foreign exchange rates have really moved tremendously from the first quarter through the third and fourth quarters. So we have to take that all into account and that's the basis that we were saying. I think mostly that would be thinking about the current rates that are out there in terms of how we think about the outlook. In terms of hedging, we do have -- as you know, the two companies do have slightly different programs. As the merger took place, we have thought about how we put that together and I think you will see that we'll continue to use hedging as one of the tools to help us manage the business. We had about a $200 million favorable impact from foreign exchange this quarter and included a benefit from hedging of about $50 million. And so there have been some changes at the company together [ph] in terms of how we run that program. It's fairly technically really so it provides [indiscernible] too meaningful from an investor standpoint. But we do continue to believe that the hedging program is helpful to reduce the impact of unfavorable changes, taking the short term, bopping around on foreign exchange as well at because it's more of a longer term stability to devalue the U.S. dollar performance. So we think we will continue for the most part with that kind of a program going forward."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Operator, we have time for just two more questions. If I can ask the people asking questions to be brief and we'll try to be brief on our end to make sure that we get through the next two.",39,"Operator, we have time for just two more questions. If I can ask the people asking questions to be brief and we'll try to be brief on our end to make sure that we get through the next two."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Our next question is from Seamus Fernandez with Leerink Swann.",10,"Our next question is from Seamus Fernandez with Leerink Swann."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","Just a quick question on the manufacturing side. Can you update us on the manufacturing situation with the vaccines and timing of when we should expect a full return to steady state in terms of vaccine manufacturing? And then separately, can you update us",85,"Just a quick question on the manufacturing side. Can you update us on the manufacturing situation with the vaccines and timing of when we should expect a full return to steady state in terms of vaccine manufacturing? And then separately, can you update us on what's happening with ROTATEQ versus ROTOREX, and should we expect a recovery or even an acceleration in sales? Or are you actually seeing some concerns on the part of pediatricians such that they're slowing purchases because of any safety fears?"
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","I would say first of all, on ROTATEQ, we actually have not seen significant concerns arising from pediatricians about the overall safety of rotavirus vaccine. And so we anticipate being able to supply the market adequately to meet the U.S. demand during t",186,"I would say first of all, on ROTATEQ, we actually have not seen significant concerns arising from pediatricians about the overall safety of rotavirus vaccine. And so we anticipate being able to supply the market adequately to meet the U.S. demand during the ROTOREX temporary suspension. The overall vaccine manufacturing issues, I'll just hit the high points. Obviously, we are investing a significant amount, over $1 billion in new resources to ensure that we have long-term supply capabilities and our North Carolina facility, which exemplifies that, begins operations in mid-2010. For ZOSTAVAX, we've had it in supply since 2009, but we're now seeing back orders. No new launches planned outside of the U.S. for 2010 or 2011. RECOMBIVAX pediatric became fully available this past quarter. Pedvax HIB is now fully available in the U.S. market and we expect even our ProQuad available in limited amounts to support the back-to-school season.  And also I should mention that under ROTATEQ, there will be a vaccine advisory committee this Friday and obviously I think everyone in public health will be waiting to see what the impact of those deliberation."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question is from Tony Butler with Barclays Capital.",10,"Your final question is from Tony Butler with Barclays Capital."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Analysts","Ken, you mentioned nine of 10 countries grew. Which one did not? You also mentioned seven of 10 had double digits, three did not. Can you comment which three those were? And were those out of those four countries, were they above or below plan? And then s",100,"Ken, you mentioned nine of 10 countries grew. Which one did not? You also mentioned seven of 10 had double digits, three did not. Can you comment which three those were? And were those out of those four countries, were they above or below plan? And then second, Peter, and I'm sorry to beat this horse, the revenue guidance you give, $45.4 billion to $46.4 billion for the year, is at the current exchange rates? Does that assume that that doesn't turn negative in the second half? I apologize to hit this again, but I just want to be sure."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Tony, I guess the comment I was making about foreign exchange, the question simply was what's the basis of guidance. And I think at anytime we give guidance, we aren't really forecasting foreign exchange rates so it's really based on the deals place [ph]",216,"Tony, I guess the comment I was making about foreign exchange, the question simply was what's the basis of guidance. And I think at anytime we give guidance, we aren't really forecasting foreign exchange rates so it's really based on the deals place [ph] as we see it right now. And the second question was regarding how revenue will perform in the second half, I think was your question. So obviously haven't given guidance by quarter and so forth [indiscernible], but I think, what I think is fair to say is that we are launching a lot of products on the one hand. We have kind of the organic growth of our core stable of commercial products around the world. On the other hand, we do have COZAAR/HYZAAR going patent so we will see that impact particularly in the second quarter kind of pushing against our trend. In the second half, though, hopefully everything else keeps growing. So I don't want to give specific guidance by quarter at the top line, but that gives you some of the factors that are pushing one way or the other on revenue and ForEx. I think, obviously, everybody -- no one's hold up a crystal ball sort of in the field of play as we see it right now."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","So Tony, we don't usually disclose our talk about our internal plans, but what I can tell you is that the one country in the top 10 that didn't grow this quarter was Italy. And I will say that it did miss by an awful lot getting to the point of being at l",88,"So Tony, we don't usually disclose our talk about our internal plans, but what I can tell you is that the one country in the top 10 that didn't grow this quarter was Italy. And I will say that it did miss by an awful lot getting to the point of being at least flat this quarter. Those are very difficult environments. And what I'm pointing out in Europe, often you have volume growth, but because of the pricing pressures you see not growth on the dollar basis."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken. And certainly in closing, we are off to a strong quarter as you can see for this year. I am extremely pleased with the progress on integration, the progress on the portfolio, the progress that we've made on the commercial side bringing the",89,"Thank you, Ken. And certainly in closing, we are off to a strong quarter as you can see for this year. I am extremely pleased with the progress on integration, the progress on the portfolio, the progress that we've made on the commercial side bringing the organizations together. And so I've lot of work to do yet, but from an execution standpoint and integration standpoint and the leadership standpoint, there's total alignment within the company and we can't wait to get to the second quarter. So thank you again."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, all. Goodbye.",4,"Thank you, all. Goodbye."
288502,100502857,59339,"Merck & Co. Inc., Q1 2010 Earnings Call, May-04-2010",2010-05-04,"Earnings Calls","Merck & Co., Inc.","Operator","Thank you for participating in today's conference call. Thank you, you may now disconnect.",15,"Thank you for participating in today's conference call. Thank you, you may now disconnect."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's Second Quarter 2010 Earnings Conference Call. [Operator Instruction] At this time, I'd like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead.",37,"Good day, everyone, and welcome to Merck's Second Quarter 2010 Earnings Conference Call. [Operator Instruction] At this time, I'd like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Amanda, and good morning, everyone, and welcome to Merck's 2010 Second Quarter Conference Call. There are a number of items in the GAAP results this quarter such as purchase accounting adjustments, merger-related expenses, restructuring cost an",333,"Thank you, Amanda, and good morning, everyone, and welcome to Merck's 2010 Second Quarter Conference Call. There are a number of items in the GAAP results this quarter such as purchase accounting adjustments, merger-related expenses, restructuring cost and also the gain on AstraZeneca's asset option exercise. We excluded those items in our non-GAAP reconciliation table, so you can get a better sense of the underlying performance for the quarter. We've also provided tables to help you understand the revenue trends. 
So this quarter, there are three tables in the press release. Table #1 is the GAAP results. Table #2 is a reconciliation of our GAAP results to a non-GAAP basis for the second quarter and also for the year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for our products and our businesses, as if the company have been combined in 2009. During the call, we will be referring to Table 2 when we discuss the P&L and Table 3 when we discuss the product performance. So you may want to have those available. 
In addition, I would like to remind you that some of the statements we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs  of Merck's management and subject to significant risks and uncertainties. 
Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. 
In addition, you can see the company's SEC filings as well as today's earnings release in the tables at merck.com. This morning, I'm joined by Dick Clark, our Chairman and Chief Executive Officer; Ken Frazier, our President; and Peter Kellogg, our Chief Financial Officer. Now I'd like to introduce Dick Clark."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. Our strong bottom line performance in the second quarter demonstrates Merck's continued success in executing our post-merger strategy. We're now halfway through our first full year as a combined company. Alread",962,"Thank you, Alex, and good morning, everyone. Our strong bottom line performance in the second quarter demonstrates Merck's continued success in executing our post-merger strategy. We're now halfway through our first full year as a combined company. Already, we're seeing positive signs of what can be achieved. Despite patent expiries and a challenging economy, I'm very pleased with what our team has accomplished. 
We remain focused on driving revenue growth, maintaining the momentum of our business, reducing our cost structure and making the right strategic investments globally. All of which are allowing us to make good progress toward Merck's overall goal of becoming the best healthcare company in the world. Strong underlying product performance helped us to realize topline worldwide sales of $11.3 billion, non-GAAP earnings per share of $0.86 and GAAP earnings per share of $0.24 for the quarter. 
Key brands including JANUVIA, JANUMET, REMICADE, ISENTRESS and TEMODAR were again standouts this quarter. In addition, Animal Health and Merck Consumer Care produced strong global sales. With our strong performance for the first half of the year, we continued to have confidence in delivering on our long-term financial targets. We also remain committed to achieving our previously-announced synergy target of $3.5 billion in ongoing annual savings in 2012. 
We have already announced initial phases of the merger restructuring program that will contribute approximately $2.7 billion to $3.1 billion toward the overall target, with procurement savings in excess contagious [ph] to account for the rest. 
In a few moments, Ken will discuss in more detail our global product performance, and then Peter will discuss our full year earnings outlook. But first, let me highlight a few areas. 
Merck's integration remains very much on course. But it will involve more hard work and difficult decisions as we proceed forward with our efforts to capture the full value of the new Merck for patients, customers and shareholders. The announcements we made recently did tell them the plans to integrate Merck's global research and manufacturing operations is another key step, but not the final one, in successfully executing our overall plan to create an industry-leading operating model. 
On the R&D side, our goal is to create a more flexible organization that fuels innovation in our pipeline and excels at external collaboration. On the manufacturing side, we aim to have a more reliable cost-efficient worldwide supply chain to support Merck's broader product portfolio, and meet the demand of a diverse and ever-revolving global health care environment. And while there are still lots of moving parts, we are building our strong track record of quickly executing our integration plans, while launching new products and delivering strong performance from current months. That has what allowed us to drive revenue growth in key brands despite patent expiries and difficult economic conditions. 
In markets around the world, we simultaneously have launches underway for a range of products including SIMPONI in 10 markets, and JANUVIA in Japan and in India. Additionally, our latest asthma dedication, DULERA, was recently approved by the U.S. FDA, and we've begun its launch. 
As we shared with many of you during our R&D Day in May, we also have several falling under late-stage review in the EU. From our robust pipeline, we anticipate making about 20 filings for new compounds and new combinations between now and 2012, including boceprevir, vorapaxar, odanacatib and TREDAPTIVE in the U.S. 
We also remain well positioned in Animal Health, a business that is driven by growing demand for animal proteins, as well as a strong demand for companion animal healthcare. We are on track to bring together sanofi-aventis and our Animal Health businesses into a new joint venture that will create a new global leader in Animal Health. 
Looking ahead, we continue to be excited about the many opportunities before us to serve the rapidly expanding emerging markets. Throughout these markets, I believe we continue to position Merck well by launching new products and making targeted business development investments. 
Examples of our commitment and execution can be found in high-growth markets like China and South Africa. In South Africa, we have a newly formed strategic collaboration with a local partner, Adcock Ingram. Together, we will co-promote and distribute branded products as well as over-the-counter medications. This collaboration will extend our reach into the market. 
Earlier this month, Merck's executive committee members and I spent a busy week in China. It has become one of our most important markets. Providing needed medicine and vaccines to meet the expanding needs of Chinese patients is an exciting growth opportunity for us. So we are focused on building our capabilities in China including our local production capabilities, our product portfolio and R&D. 
As part of our expansion efforts, we recently unveiled joint venture plan with Sinopharm to manufacture and commercialize adult and pediatric vaccines in China, and announced plans for a manufacturing site in Hangzhou, where we'll invest to build local capacity. I've seen firsthand the excitement and hard work underway in our emerging markets around the world, with China being the most recent example. That's why I am confident that we will reach our goal of deriving 25% of our global pharmaceutical and vaccine revenue from emerging markets in 2013. 
Merck's commitment to improving health around the world is not new to us. This commitment dates back decades and most recently, was recognized by the Access to Medicine Index. Merck was ranked second in the global analysis of companies that are making their medicines and vaccines readily available to markets across all income levels. All of these actions support Merck's mission to help patients around the world and to maximize shareholder return by providing innovative medicines, vaccines and consumer and Animal Health products, globally. With that, I'd like to turn the call over to Ken"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and good morning, everyone. As Dick mentioned, we had another successful quarter despite losing the exclusivity of COZAAR and HYZAAR and the economic challenges facing our businesses and customers around the world. In describing our secon",1726,"Thank you, Dick, and good morning, everyone. As Dick mentioned, we had another successful quarter despite losing the exclusivity of COZAAR and HYZAAR and the economic challenges facing our businesses and customers around the world. In describing our second quarter performance, please note that I will refer to supplemental combined non-GAAP results, which include the impact of foreign exchange. 
The Global Human Health business delivered a solid quarter with sales of $9.8 billion. This represents a 2% decline on a supplemental combined non-GAAP basis from the previous year, largely due to the loss of exclusivity of COZAAR and HYZAAR especially in the U.S. If you've been following the weekly prescription trends, then you have seen that there has been rapid erosion of approximately 90% of branded COZAAR and HYZAAR prescription volume in the U.S. Other markets such as the U.K. and Italy have also experienced rapid erosion. 
Excluding the impact of COZAAR and HYZAAR, Global Human Health sales grew 3% year-over-year. Sales were driven by the robust operational growth of key brands such as JANUVIA, JANUMET, REMICADE, TEMODAR and ISENTRESS. We continue to be optimistic about the growth opportunities for these brands. The speed with which we integrated our commercial operations, the diversity of our portfolio and the underlying strength of our global business have been key factors in our successful start to the first half of 2010. 
In the second quarter, we continue to drive growth in many of our markets. International Human Health sales grew by 5% excluding COZAAR and HYZAAR. Our Emerging Markets business grew 12% in the second quarter. We spent a fair amount of time during the business briefing in May discussing our strategy and goals in the emerging markets. As we said then, we believe these markets will grow to represent more than a quarter of our pharmaceutical and vaccine sales by 2013. 
In the second quarter, the emerging markets accounted for 19% of our human health sales. Two of the emerging markets, China and Brazil, are quickly working their way up our list of top 10 markets. Sales in China and Brazil both grew by more than 15% in the quarter. We continue to expect to have significant future growth opportunities across the emerging markets. 
We are well-positioned to drive significant growth with our current portfolio of products, including JANUVIA, SINGULAIR, as well as branded generics like COZAAR and HYZAAR, as well as ZOCOR. We are also exploring multiple strategies to increase our share in the branded generic and patent-protected segments through value-creating partnerships and acquisitions. 
Dick mentioned some of the recent developments in China, including the recent letter of mutual agreement with Sinopharm to develop a joint venture to commercialize pediatric and adult vaccines in China, a very large potential market. 
Now turning to the performance of some of our key brands this quarter. As I drop the individual product performance, you can follow along in Table 3 from our supplemental financial package, as Alex said earlier. Starting with our respiratory franchise, SINGULAIR sales in the second quarter were $1.3 billion, comparable to the second quarter 2009. This year, the spring allergy season peaked early in the U.S. and was overall comparable to the 2009 season. Sales in the U.S. this quarter were also affected by unfavorable fluctuations in trade inventory. Double-digit growth of SINGULAIR in the emerging markets was offset by declines in Japan due to the timing of shipments to our partner. 
For NASONEX, global sales increased 5% driven by the strong growth in the U.S. and Japan. Despite the flat year-over-year comparisons for the allergy season in the U.S., sales of NASONEX grew in the U.S. by 7%. NASONEX continues to be the leading branded nasal-inhaled steroid, and now includes additional congestion labeling in the U.S.  In Japan, we've had robust growth since the launch, and NASONEX is now the market leader. 
Moving on to JANUVIA and JANUMET. Global revenue grew 33% to a combined $818 million. The JANUVIA franchise continues to perform strongly in terms of share and overall growth. Sales in the quarter were driven by double-digit growth across all markets. In Japan, where we recently launched JANUVIA, sales were $69 million, which included supply sales to our partner of about $40 million. We've seen strong initial response to the value proposition JANUVIA represents to Japanese physicians and patients. 
Our Immunology franchise also achieved strong growth during the quarter. REMICADE continues to be a leading immunological therapy with sales of $669 million, an increase of 18% from the previous year. REMICADE continues to deliver growth across all indications, rheumatology, gastroenterology and dermatology. We anticipate REMICADE's double-digit operational growth will continue throughout 2010. 
In addition, sales of SIMPONI were $18 million in the quarter. SIMPONI sales continue to grow as we launch the brand in more countries and take share from other subcutaneous anti-TNF. We've now launched and 10 countries, most recently in Spain. We will launch SIMPONI in other EU markets in the second half of 2010 and launches in the U.K. and France are planned for 2011. 
Turning to ZETIA and VYTORIN. Sales were $1.1 billion this quarter, which in the aggregate represents a 3% decline compared to the previous year primarily due to declines in the U.S. Sequentially, ZETIA and VYTORIN grew 4%, globally. ZETIA and VYTORIN remain a primary focus of our promotional efforts, and we continue to see solid growth in many markets around the world, including 28% year-over-year growth in Japan. We continue to make progress on the IMPROVE-IT study, which is now fully enrolled with over 18,000 patients. 
Moving on to vaccines. For the total Vaccine business, I will focus my comments on sequential comparisons. Total sales for the Vaccine business were $832 million in the second quarter compared to $846 million in the first quarter of 2010. As a reminder, vaccine sales in the first quarter benefited from a $75 million to $100 million inventory build. With that in mind, we had some bright spots in the second quarter specifically with respect to RotaTeq, which benefited from a temporary competitor supply issue and PNEUMOVAX. This, unfortunately, was offset by weaker ZOSTAVAX sales due to supply constraints and the ongoing backorders for the brand. This is a frustrating situation for our teams, our customers and patients. And we have dedicated several hundred engineers and researchers to getting it fixed. We continue to work to resolve our current supply issues and to create redundant capacity in our facilities in North Carolina and Ireland. However, we do expect sales to be negatively affected by the supply issue again in the third quarter this year. 
Moving to GARDASIL. Sales as reported by Merck in the second quarter were $219 million, an 18% decline from the previous year. In the U.S., GARDASIL sales grew sequentially by 5%. We've made good progress with the coverage prevails [ph] and funding is now secured for all states. GARDASIL continues to maintain market share leadership in the U.S., and it also remains the global market leader. 
In Infectious Diseases, ISENTRESS continues its outstanding performance as sales increased 55% to $267 million in the second quarter. The continued growth of ISENTRESS reflects the unique efficacy and tolerability profile of this product, which has been widely embraced by physicians, patients and health organizations around the world. 
While many of our brands reported positive growth trends in the EU during the second quarter, the environment in the EU and across Europe is now more challenging. Many countries have announced austerity measures aimed at reducing costs in areas such as healthcare. While the implementation of pricing actions varies by country, many have announced measures to reduce prices of generic and patented drugs. 
In the short term, we've worked with many of the industry groups and governments to help develop solutions for our customers to improve their budget positions and address the short-term economic issues. While we are taking steps to mitigate the immediate impact in the EU, we anticipate that the austerity measures will affect our revenue performance going forward.  Peter Kellogg will focus on the financial impact of the EU austerity measures in his remarks shortly. 
Moving from the economic environment, I'd like to highlight briefly some recent developments from three of our key R&D programs: DULERA, vorapaxar and boceprevir. As you know, we're in the process of launching many new products this year and we have robust late-stage pipeline with programs that represent significant scientific achievements and first-in-class opportunities. 
In June, as Dick mentioned, we received U.S. FDA approval of DULERA, our combination steroid and long-acting beta agonist for the treatment of asthma. Despite the availability of other combination treatments, there remains some large unmet need in asthma, and we believe DULERA represents a great alternative due to its differentiated profile, which includes the addition of clinically-judged deteriorations in asthma within its label. We are beginning the launch of DULERA now with plans for a full commercial launch late in the third quarter. 
Our Phase III program for vorapaxar, our PAR-1 inhibitor for the prevention of major cardiovascular events is also progressing well. Both Phase III studies are now fully enrolled. The TRA 2P study in secondary prevention is fully enrolled, and patients are being monitored for the accrual of events. The TRA-CER study in patients with acute coronary syndrome is also fully enrolled, and patients are being monitored for the accrual of events. 
Based on current event rates, we anticipate that both studies will be completed in mid-2011. We are pleased with the progress in the Phase III program. Most importantly, we continue to target a 2011 filings for vorapaxar.
Turning to boceprevir, our hepatitis C protease inhibitor, I'm pleased to share with you that both Phase III studies are now completed, and we're in the process of analyzing the results. We plan to submit the Phase III data for presentation at the AASLD meeting in November.  Finally, we remain on track to file boceprevir in 2010. 
In closing, Global Human Health, along with Animal Health and Consumer Health Care, have delivered another solid quarter for Merck. We continue to be excited by our portfolio of products and our robust late-stage pipeline. While the operating environment is constantly changing, we continue to execute on our long-term strategic goals to create the leading healthcare company. Now I will pass the call over to my colleague, Peter Kellogg."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, we continued our performance in the second quarter and our integration efforts are well underway. Our performance this quarter is characterized by solid operational performance, which wa",1386,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, we continued our performance in the second quarter and our integration efforts are well underway. Our performance this quarter is characterized by solid operational performance, which was tampered by the impact of generic entries for COZAAR and HYZAAR and the cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and geographies performed. And now I'd like to cover three areas with you: First, our operating results; second, our restructuring activities; and third, I want to discuss our targets for full year 2010 and beyond. 
So let's begin with our results. As Alex mentioned, we have once again provided data in our earnings release and supplemental charts to help navigate through our non-GAAP adjustments to the P&L. To simplify my remarks today, I will speak the non-GAAP results, which exclude purchase price accounting adjustments, merger-related costs, restructuring charges and the gain on AstraZeneca's asset option exercise. 
On this basis, we reported second quarter non-GAAP earnings per share of $0.86. Total revenue for the quarter was $11.3 billion. On a supplemental combined non-GAAP basis, sales were down 2% versus prior year due primarily to the impact of generic COZAAR/HYZAAR and lower Astra supply sale due to the generic erosion and return of rights to the non-PPI products. These offset solid operational growth in the rest of the business. Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. 
Our Animal Health business grew 9% to $731 million, reflecting growth among cattle, poultry and swine products. We remain on track to complete our Animal Health joint venture with sanofi-aventis in the first quarter of 2011. Consumer Care sales increased 11% to $422 million due to the strong seasonal performance of Claritin and Coppertone. 
Now moving on to the expense items in the P&L. You can see that we did a very good job managing our expenses this quarter in anticipation of additional commercial launches and spending on our late-stage pipeline expected during third and fourth quarter. As you know, the cost of our combined company are represented in our current cost base, whereas only the Merck costs were included in the second quarter of 2009. So it's a little hard to see the underlying trends on a year-over-year basis. As a result, I will speak to sequential trends on the cost lines since those comparisons are more meaningful. 
Let's begin with the materials in production. The non-GAAP gross margin in the second quarter was approximately 76.5%, which is an improvement compared to the first quarter of 2010 where the gross margin was 75.4%. Most of the improvement in the gross margin was driven by product mix, with higher sequential sales of JANUVIA, ISENTRESS and increased sales of seasonal allergy products. 
Moving onto marketing and admin expenses, on an on-GAAP basis, marketing and administrative expenses in the second quarter were $3.1 billion, which is about the same level as in the first quarter of 2010. Research and development expenses for the second quarter was approximately $2 billion, which is also in line with the first quarter. As the year progresses, we see continued investment in late-stage projects such as vorapaxar, telcagepant, odanacatib and TREDAPTIVE. 
Now let's move to equity income. In the second quarter, Merck reported $43 million of equity income, which was a decrease from the first quarter primarily due to inherent variability and the timing of payments for the AstraZeneca joint venture. 
Moving on to other income and expense. The GAAP results include $443 million from AstraZeneca's exercise of the asset option. On a non-GAAP basis, other expense of $153 million was comparable to the first quarter of 2010. 
Moving to tax. The Merck non-GAAP tax rate was 20.5% for the second quarter, better than the rate that we saw in the first quarter. As noted in the earnings release, we continue to expect the full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned cash to shareholders through our dividend and by making progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $1.3 billion to repurchase about 38 million shares of our common stock.  So in summary, we continue on a strong trajectory since merger. 
Now let's talk about the integration activities. This quarter, we made continued progress on our cost synergy capture by reducing our headcount in global infrastructure and generating savings from procurement actions. On July 8, we announced our plans to phase out operations at eight manufacturing facilities and eight research facilities over the next two years. The merger restructuring program also includes consolidating our sites in local markets by closing 58 commercial offices. The actions we have announced so far will bring our number of R&D sites down to 16 and our number of our manufacturing sites down to 48, excluding Animal Health sites. 
We will continue to pursue productivity efficiencies and evaluate our manufacturing supply-chain capabilities on an ongoing basis. Remember, we are planning to create a new Animal Health joint venture, so our Animal Health business is not involved in the Merck merger researching activities. As a result of these and other actions such as procurement savings, we are well on track to realize a $3.5 billion synergy target by the end of 2012. 
Now let's spend the remaining time reviewing our outlook for 2010 and beyond that. Let's start with 2010. With the first six months complete, it's appropriate to provide an update on our earnings targets. We have maintained $3.34 as the midpoint of our range while tightening the EPS range for the full year. Merck is now targeting a full year 2010 non-GAAP EPS range of $3.29 to $3.39, excluding certain items. Factored into this target EPS range is our strong first quarter results, continued benefits from synergies in the second half, the impact of healthcare reform in the U.S., which is unchanged from our previous comments, and the assumption that Merck retains full rights to REMICADE and SIMPONI in our markets. 
In addition, we have assumed top line pressures due to pricing actions in some European countries and foreign exchange, both of which we believe will be a headwind in the second half. In addition, we anticipate increased second half spending for new product launches like DULERA in the U.S., new targeted commercial and R&D investments in the emerging markets and spending to support the late-stage pipeline. 
Let me go into a bit more detail to help you understand what is already factored in to the 2010 targets. As you know, and as Ken mentioned, Greece, Spain, Germany and some other markets have already announced price reductions, which will have an unfavorable impact on our results in the third and fourth quarter of 2010. The impact on European revenues in the first half was about 2% unfavorable. In the second half, we anticipate a mid single-digit unfavorable impact on European sales. 
These updates are included in our 2010 targets and will impact our second half performance relative to what we were modeling at the beginning of the year. As a result, we now expect that EPS in the second half will be similar to the level in the first half. So you should adjust your models accordingly. Logically, these actions in 2010 will also have an impact in 2011 as they annualize. 
Finally, let me touch on our long-term outlook. We remain excited about the future of the new Merck, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities that are already well underway. We continue to target a high single-digit, non-GAAP EPS compound annual growth rate from 2009 to 2013. 
In closing, we are pleased with the solid second quarter results we reported today. We clearly had a strong first half. Our expense management contributed to that performance and will help us manage a tighter environment in Europe. The merger is working, and our results and our short-term and long-term earnings targets demonstrate that we are right on track. 
Thank you. Now I'll turn the call back over to Alex."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Peter. Now we'd like to open up the call to answer your questions. But in order to get through as many as possible, we'd like to ask you to limit yourself to one or two questions, and note that we won't take follow-up questions. But if you do have",64,"Thanks, Peter. Now we'd like to open up the call to answer your questions. But in order to get through as many as possible, we'd like to ask you to limit yourself to one or two questions, and note that we won't take follow-up questions. But if you do have additional questions, you're welcome to rejoin the queue. Amanda, we're ready for the Q&A."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question is Marc Goodman with UBS.",10,"[Operator Instructions] Your first question is Marc Goodman with UBS."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","So given what happened with RELENZA at the panel, I was just curious how you guys were thinking about how TRA plays into that market [indiscernible] there? And second of all, can you give us an update on your Biologics program?",41,"So given what happened with RELENZA at the panel, I was just curious how you guys were thinking about how TRA plays into that market [indiscernible] there? And second of all, can you give us an update on your Biologics program?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So I'll talk about Belinta [ph]. I think from our perspective, I think it's important to recognize that we always study TRA and always anticipated that it would be added to the standard of care whether it was aspirin, PLAVIX or another medicine in PLAVIX",183,"So I'll talk about Belinta [ph]. I think from our perspective, I think it's important to recognize that we always study TRA and always anticipated that it would be added to the standard of care whether it was aspirin, PLAVIX or another medicine in PLAVIX class. So it was always our intent to have it added on top of the standard of care. And so we would think that it would be added on to Belinta [ph] as that became approved at some point and became a competitor of PLAVIX. I also think it's important to recognize that even with the, for example, 16% increase, a great deal of residual risk still remains, cardiovascular risk still remains. And therefore, there's still an important role for medicine like TRA. I also think it's important to remember the product profile, which includes the fact that we have not seen any increase in bleeding unlike some of the other medicines that are being used. So for all of these reasons, I continue to think that there are really robust prospects for our medicine like TRA."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Marc, can you just repeat your second question?",8,"Marc, can you just repeat your second question?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Just an update on the Biologics or Biosimilar [indiscernible].",9,"Just an update on the Biologics or Biosimilar [indiscernible]."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So you remember that back in May, we discussed our MBV strategy, and we updated the status of the PEG-EPO program, which was discontinued. At the same time, we also highlighted the fact that a number of other programs continue on our MBV portfolio, and we",147,"So you remember that back in May, we discussed our MBV strategy, and we updated the status of the PEG-EPO program, which was discontinued. At the same time, we also highlighted the fact that a number of other programs continue on our MBV portfolio, and we also referenced biological programs that are part of our novel Biologics focus, including antibodies against HGF and IGF-1R for oncology, IL-23 for immunological indications, MK-3415A for C. difficile [Clostridium difficile], and of course, ELONVA, which is a noble follicle-stimulating hormone for fertility. So that's sort of a short description of where we are in our Biologics program. But I think it's important to recognize that we see Biologics as an important part of our future, both with respect to what we anticipate will be an abbreviated pathway for the approval of biological similars as well as novel biologics research going forward."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Chris Schott with JPMorgan.",9,"Your next question is from Chris Schott with JPMorgan."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","First question was on ZOSTAVAX. Just can you elaborate a little bit more on what needs to be done to address it?",22,"First question was on ZOSTAVAX. Just can you elaborate a little bit more on what needs to be done to address it?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure, Chris. This is Dick. I think the issue, as Ken mentioned, is that we've put significant amount of technical and engineering resources on this both from a manufacturing and a research standpoint, and certainly, right now we are cautiously optimistic.",215,"Sure, Chris. This is Dick. I think the issue, as Ken mentioned, is that we've put significant amount of technical and engineering resources on this both from a manufacturing and a research standpoint, and certainly, right now we are cautiously optimistic. We have begun production again of varicella. We believe that by starting production, we have a path forward. So that's good news. It's not going to have an impact on 2010 forecast because the product process cycle is significant, so there's many more production steps to go through yet. There's more quality testing to go through. There's more discussions with the agencies to go through. But I am cautiously optimistic due to the fact that, obviously, we've started production that is important. Now the second important aspect is, as Ken mentioned, is that we've started our focus on Durham, and we hope to have that, from a production standpoint, up and running in the second half of this year. And from a pediatric standpoint, with the relaunch of COMVAX, our HIB and Hepatitis B combination vaccines, all of Merck pediatric vaccines will be available in U.S. for the first time since mid-2007. So we are making that type of progress, but we'll keep our fingers crossed on ZOSTAVAX because we did start production again."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","On the emerging market, following this deal with Sinopharm, should we think about Merck looking at these type of partnerships going forward? Or when we think about the emerging market kind of just [ph] the inorganic growth portion of this, will more tradi",91,"On the emerging market, following this deal with Sinopharm, should we think about Merck looking at these type of partnerships going forward? Or when we think about the emerging market kind of just [ph] the inorganic growth portion of this, will more traditional M&A play a larger role, I guess, when I consider the moves that Abbott made, as an example, this quarter? And how are you thinking about what appeared to be fairly rich valuations if you were to consider a larger strategic move as it relates to emerging markets?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","I think the way we look at it as a company is that we don't look at the emerging markets as a entity onto itself. We look upon it as a country-by-country basis. And certainly, our total focus obviously is profitable growth and keeping profitable growth as",135,"I think the way we look at it as a company is that we don't look at the emerging markets as a entity onto itself. We look upon it as a country-by-country basis. And certainly, our total focus obviously is profitable growth and keeping profitable growth as the principal. In some cases, it will be joint ventures and relationships. Sometimes, there won't be inorganic at all, and sometimes there maybe an acquisition out there that may help the foundation of a particular country or via a foundation across other emerging markets. So we really take it case-by-case and what's in the best interest of that particular country. Is there a partner, is there a combination that makes sense from a value standpoint, and most importantly, does it makes sense from a profitable growth standpoint."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from John Boris of Citi.",9,"Your next question is from John Boris of Citi."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Just one for Peter Kellogg. Can you quantify the impact of healthcare reform in the quarter, and then what you anticipate for the full year? And then just building on the previous question on China. When you look at China, especially since you spent a fai",116,"Just one for Peter Kellogg. Can you quantify the impact of healthcare reform in the quarter, and then what you anticipate for the full year? And then just building on the previous question on China. When you look at China, especially since you spent a fair amount of time there this past week, how are you thinking about it from an ability to price your medicines? What do you see is the impact of formularies on your ability to price those medicines going forward? And then any discussions you had on the intellectual property? Obviously, that's a very important component, respecting intellectual property within the Chinese market. But any thoughts you have there would be helpful."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, John, it's Peter. So healthcare reform I think really is moving ahead just the way we had originally anticipated. There's no surprise this quarter. Ballpark, roughly about $44 million impact in the second quarter, and that makes sense given what w",101,"Thanks, John, it's Peter. So healthcare reform I think really is moving ahead just the way we had originally anticipated. There's no surprise this quarter. Ballpark, roughly about $44 million impact in the second quarter, and that makes sense given what we talked about as a full year impact of about $170 million. So really no update, no change really on what we've anticipated or originally modeled. We've always said that, that would probably increase next year to something in the $300 million to $350 million. So it's pretty much in line with what we've always talked about, no new surprises."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So in China. Let me just start by saying that I think we continue to be very excited about the future in China. To look at China in a monolithic way as it relates to pricing or any other aspect of our commercial strategy, I think is not how we are going t",254,"So in China. Let me just start by saying that I think we continue to be very excited about the future in China. To look at China in a monolithic way as it relates to pricing or any other aspect of our commercial strategy, I think is not how we are going to approach it. So let's start with the robust growth that we anticipate in the middle class in the urban areas of China. For those people, healthcare is still likely to be a self-pay exercise, and so we will continue to look at those market segments in a way that we can price competitively with alternative therapies. But I will say that the pricing in China has allowed both a broad access, while at the same time, also allowing strong profit margins in that country. I think the other aspect is through the government. And so there's an essential drug list, which is part of Chinese healthcare reform, and Merck participated in the Essential Drug List placing ZOCOR among other magazines on that drug list. And our experience there has been that while we had to provide substantial discounts to get entree to the Essential Drug List, the volumes have more than compensated for the pricing reductions that we have. So I think what we've seen with ZOCOR right now is an example of how in that market, we have the price in a way that creates value for that market and there's still an opportunity to be profitable in that context."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tim Anderson, Sanford Bernstein.",9,"Your next question is from Tim Anderson, Sanford Bernstein."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","I know you don't like to say much about the REMICADE dispute, but I'm hoping you can give us some more information. You used to talk about being highly confident that you would prevail in the dispute, but I don't really hear that language being used anymo",129,"I know you don't like to say much about the REMICADE dispute, but I'm hoping you can give us some more information. You used to talk about being highly confident that you would prevail in the dispute, but I don't really hear that language being used anymore and I'm wondering if that's still the case. On arbitration, can you run through different options here? Is it all or nothing, or could there be some sort of middle ground or what exactly? And then your comments about not impacting 2013, it's not clear to me why that wouldn't impact your 2013 guidance because it is a pretty material contributor to your financials. And by extension, if it doesn't impact 2013, can we assume that it wouldn't impact 2010 neither?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","We're going to start with Bruce Kuhlik.",8,"We're going to start with Bruce Kuhlik."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","At this point, we provided the information about when we expect the arbitration hearing to begin and the selection of the panel. We're looking at whether we can provide some additional information with respect to the process, and I hope to do that in a re",80,"At this point, we provided the information about when we expect the arbitration hearing to begin and the selection of the panel. We're looking at whether we can provide some additional information with respect to the process, and I hope to do that in a relatively near future. We continue to believe very strongly that we've structured this transaction in a way that's appropriate for the REMICADE distribution agreement. And I'll turn it over with respect to the financial targets."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Tim, it's Peter Kellogg. So I don't think we said it didn't impact one way or the other. What we said was our guidance has this contingency incorporated, so that really our guidance that we provided would be so achievable regardless of the outcome in this",80,"Tim, it's Peter Kellogg. So I don't think we said it didn't impact one way or the other. What we said was our guidance has this contingency incorporated, so that really our guidance that we provided would be so achievable regardless of the outcome in this arbitration or topic. Obviously, depending on the outcome, it will make that guidance number easier or more challenging. But nonetheless, I think we feel comfortable with the guidance that we provided under different scenarios."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","And then 2010?",3,"And then 2010?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Well, for 2010, obviously, the timing is a little unclear and it would be pretty relatively late in the year, but that would be something we have to really depend on the outcome. So I don't think we've said for 2010 that's one way or the other really it -",69,"Well, for 2010, obviously, the timing is a little unclear and it would be pretty relatively late in the year, but that would be something we have to really depend on the outcome. So I don't think we've said for 2010 that's one way or the other really it -- I'd say right now, what we did highlight was our guidance included REMICADE and SIMPONI in our 2010 numbers."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Jami Rubin of Goldman Sachs.",10,"Your next question is from Jami Rubin of Goldman Sachs."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","So Peter, question for you. This quarter, you beat earnings by $0.03 relative to consensus, but not letting to fall through to full year guidance and your clipping the top end by $0.02. So is it fair to assume that the cost of European austerity measures",108,"So Peter, question for you. This quarter, you beat earnings by $0.03 relative to consensus, but not letting to fall through to full year guidance and your clipping the top end by $0.02. So is it fair to assume that the cost of European austerity measures will be about $0.05 this year until we assume about a $0.10 hit next year since the impact will be annualized? And my second question refers to -- you didn't mention SAPHRIS. I know that was recently introduced. We didn't see sales for SAPHRIS or TREDAPTIVE. And Ken, maybe if you can update us on how you're seeing those new launches progress."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. So Jami, yes, I think the key thing is that we obviously -- all we've done is narrowed the range for our guidance for the full year. So we really maintain the midpoint of our guidance range and EPS. Obviously, we have, as I commented and as you poin",391,"Sure. So Jami, yes, I think the key thing is that we obviously -- all we've done is narrowed the range for our guidance for the full year. So we really maintain the midpoint of our guidance range and EPS. Obviously, we have, as I commented and as you pointed out, we've taken into account some of the top line pressures we see in the balance of the year. Obviously, we do expect to see the pricing impact in the second half of the year. The way we look at it, it's about mid single-digit range impact on the European revenues. Translating that to the top line, it's probably in the neighborhood of, I'm guessing, it's about $300 million or so. And obviously, we have to fully annualize that next year. The other thing is, obviously, Forex. Now the impact of Forex for us is a little complex because obviously, you have the Forex impact around the world, not just euro but yen and other currencies. And you have to net that against our hedge program. We anticipate in the second half of the year currency being a slight negative on our top line, probably something in the 1%, 2% range kind of as you go through the second half of the year. Obviously, those rates still move around. So those are the primary factors in addition to the healthcare reform. So that said, going the other way, we have a lot of activity on the expense line in the second half that will actually be driving our business going forward. And as we go into 2011, we'll be launching DULERA, we have a lot of activity going on in Japan, launching products, having a lot of success. We will be, obviously, investing in the emerging markets as you've seen announcements, and we'll continue to grow there. And obviously, our pipeline, which is a big driver for us in the future, continues to move forward with very nice progress. So you can expect to see some spending in that in the second half, a little more in the first half. So all those points combine to lead us to our guidance. But the most important thing is we didn't change the midpoint of our guidance range. We just narrowed the range as we've gone through the first half of the year."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","With SAPHRIS, I think we mentioned earlier that the current performance has been affected by destocking last year. I would say a couple of things. We continue to focus on building the brand awareness, and we're also getting reasonably good unrestricted Ma",252,"With SAPHRIS, I think we mentioned earlier that the current performance has been affected by destocking last year. I would say a couple of things. We continue to focus on building the brand awareness, and we're also getting reasonably good unrestricted Managed Care access about 65%. But the product right now, I would say frankly, is not where we want it to be. On TREDAPTIVE, I would say that obviously for us, the sales have not yet become material in Europe. But the real thing that we're doing on TREDAPTIVE is HPS2-THRIVE and creating a market in the U.S. I think there's still a need -- a growing awareness of HDL as its impact on cardiovascular health going forward. I would say the other issues around launches are, we are very pleased with the way SIMPONI is going, JANUVIA's continuing the launch well around the world including Japan. BRIDION is having a spectacular launch in Japan, and we look forward to DULERA. So I would just say that SAPHRIS and TREDAPTIVE has not yet become material. We continue to think TREDAPTIVE has a great future in the U.S., and we continue to work with SAPHRIS. And then I also -- it was pointed out to me that I forgot to answer quickly the Chinese IP question and I would say that on that one, we continue to proceed carefully with respect to our assets in China to make sure that we get the benefit of that market while also protecting our IP."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","A quick follow-up to Dick. Dick, you spent about $1.3 billion this quarter repurchasing about 38 million shares. What are your plans for share repurchases going forward just given the significant amount of free cash flow you're generating?",39,"A quick follow-up to Dick. Dick, you spent about $1.3 billion this quarter repurchasing about 38 million shares. What are your plans for share repurchases going forward just given the significant amount of free cash flow you're generating?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Peter, you want to answer that?",6,"Peter, you want to answer that?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. So Jami, obviously, we have an authorization to do up to $3 billion of share repurchase, and we haven't worked our way through that entirely. So that's on our agenda going forward, obviously. We like to, generally, on an ongoing basis, stabilize the",142,"Sure. So Jami, obviously, we have an authorization to do up to $3 billion of share repurchase, and we haven't worked our way through that entirely. So that's on our agenda going forward, obviously. We like to, generally, on an ongoing basis, stabilize the shares outstanding; but then periodically, step in when we see a good opportunity to pick up some of our shares. And quite frankly, we see when our stock is down is a very good way of returning cash to shareholders. We know that's a focus of a lot of our key shareholders, and we take that seriously as well. I think over the last five years, as we've said in the past, our track record of returning cash flow to shareholders is phenomenal. We're in the upper 90%, above 90% range. So we could plan to continue that."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tony Butler of Barclays Capital.",10,"Your next question is from Tony Butler of Barclays Capital."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick, I think that you, in your opening statements, made reference to the value, continuously realizing the value of the combined company. I'm curious exactly what you mean by that. Is it just cost? And then by extension of Tim Anderson's question, would",87,"Dick, I think that you, in your opening statements, made reference to the value, continuously realizing the value of the combined company. I'm curious exactly what you mean by that. Is it just cost? And then by extension of Tim Anderson's question, would you be able to make that statement true if in fact the arbitration does not go your way? And then as a follow-up to that, if the arbitration does go your way, how do you think about perhaps moving additional increases to the dividend?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Obviously, I'm not going to make any future comments on the arbitration based on process of where we are in today. But if you go back to why this is such an important merger to the company, it's far beyond the cost synergies. Cost synergies, in many cases",319,"Obviously, I'm not going to make any future comments on the arbitration based on process of where we are in today. But if you go back to why this is such an important merger to the company, it's far beyond the cost synergies. Cost synergies, in many cases, is an afterthought to why we did this merger and why we're still excited about it. First of all, the most important aspect of this merger that we continue to be excited upon is that it's a late-stage pipeline, and the research synergies from the standpoint that you're -- you have complementary franchises, and there's not much overlap and mechanism of actions, and there's great scientific and technological sharing out that is just so important for the future of the company. So the first and foremost reason why this makes sense moving forward is the scientific and research pipeline and the scientific and research technology that we're sharing across mutual franchises as we move forward. The second part to that is the product portfolio. The excitement that we see from our professional reps country-by-country when we visit there about having now a combined portfolio that can really come up with the right resolution for patients and physicians is just incredible. We're no longer a one trick pony when it comes to some franchises or to these states. We have a portfolio that can meet their needs, and I think that capability is extremely important. And then third, I think is the geographical footprint we have. The geographical footprint that we combined with the two companies, as you know, is critical to the future since we're not and will not be a U.S.-centric company. So when you look at all of those evaluations, to us, those are the most important. And obviously, REMICADE and SIMPONI are important as well, but even without those two, this makes a lot of sense to us."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Risinger with Morgan Stanley.",10,"Your next question is from David Risinger with Morgan Stanley."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","First, with respect to SAPHRIS, can you just update us on where the reformulation process stands? And then second, you've discussed branded generics this year. I don't think that you've talked about branded generics in prior years. Can you talk about how",53,"First, with respect to SAPHRIS, can you just update us on where the reformulation process stands? And then second, you've discussed branded generics this year. I don't think that you've talked about branded generics in prior years. Can you talk about how broad of a portfolio you'd like to have in emerging markets?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on the SAPHRIS formulation issue, we're on track, and we plan to launch a new black cherry version to provide patients with a different, better taste option. So that's where we are on that issue. On the branded generics issue, as Dick mentioned before,",171,"So on the SAPHRIS formulation issue, we're on track, and we plan to launch a new black cherry version to provide patients with a different, better taste option. So that's where we are on that issue. On the branded generics issue, as Dick mentioned before, I think it does vary very much market-by-market. But I want to start by saying, we have a very substantial branded generics business right now inside the company, with over 150 products available in the emerging markets based on previous portfolios of the two companies. And we see brands, as I mentioned, like ZOCOR in China just growing phenomenally. So what we intend to do is we intend to look at the branded generics business on a country-by-country basis, look at the opportunities to expand on the current portfolio of products that we have of both our traditional established products as well as our innovative products, and we intend to build on those in ways that create value for customers as well as for our shareholders."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Seamus Fernandez of Leerink Swann.",10,"Your next question is from Seamus Fernandez of Leerink Swann."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","This question is actually for Peter. It might be a little bit unfair, but Peter, you had said that you'll do opportunistic repurchases when your shares are down. Would you characterize your stock as an attractive opportunity today or being down at current",44,"This question is actually for Peter. It might be a little bit unfair, but Peter, you had said that you'll do opportunistic repurchases when your shares are down. Would you characterize your stock as an attractive opportunity today or being down at current levels?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Peter?",1,"Peter?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Seamus, so obviously, I can't comment on that. But I think the key point is that -- what I meant by that is also when we have cash positions and when we see the opportunity from a window standpoint. Obviously, for us to go in the market, we have to have a",69,"Seamus, so obviously, I can't comment on that. But I think the key point is that -- what I meant by that is also when we have cash positions and when we see the opportunity from a window standpoint. Obviously, for us to go in the market, we have to have an open window position. So all those factors come into play, but I can't really comment on that."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Maris with Credit Agricole CLSA.",11,"Your next question is from David Maris with Credit Agricole CLSA."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","The Sinopharm China deal looks very interesting. Can you tell us when will you start to distribute vaccines through their system? The facility that you broke ground on, is that vaccines only or is that oral doses? And also how many salespeople do you have",57,"The Sinopharm China deal looks very interesting. Can you tell us when will you start to distribute vaccines through their system? The facility that you broke ground on, is that vaccines only or is that oral doses? And also how many salespeople do you have in China at this point, and where was that a year ago?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Your question on the new facility in Hangzhou is a pharmaceutical facility beginning with packaging products and then moving on into manufacturing. So that won't be completed in 2012, and we'll employ about 800 employees when we're finished. It's truly to",84,"Your question on the new facility in Hangzhou is a pharmaceutical facility beginning with packaging products and then moving on into manufacturing. So that won't be completed in 2012, and we'll employ about 800 employees when we're finished. It's truly too early to make a comment about Sinopharm and the timing of it and activities like that since we're in, obviously, in negotiations to complete the contract. And so just stay tuned on that, we'll share that with you as soon as we can."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","On the representative levels in China, I think our current complement is about 5,000 people across the country. That's up about 1,000 since last year. So we continue to build our sales force, and we continue to penetrate deeper and deeper into the country",56,"On the representative levels in China, I think our current complement is about 5,000 people across the country. That's up about 1,000 since last year. So we continue to build our sales force, and we continue to penetrate deeper and deeper into the country because it's important to be able to win at the hospital level."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question is from Eric Lo with Bank of America Merrill Lynch.",13,"Your final question is from Eric Lo with Bank of America Merrill Lynch."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Can you run through what your product launches are in Japan over the next 12 months? And also, maybe second question, comment on your priorities for the Consumer division? It's one of the smaller divisions, but growth seems to be improving. Are you guys p",65,"Can you run through what your product launches are in Japan over the next 12 months? And also, maybe second question, comment on your priorities for the Consumer division? It's one of the smaller divisions, but growth seems to be improving. Are you guys planning to grow the business through internal investments or maybe acquisitions? And are there any products that you might consider divesting?"
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So starting with Japan...",5,"So starting with Japan..."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Let's start with Consumer first if we can.",9,"Let's start with Consumer first if we can."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","The consumer business continues to be an important part of our strategy, particularly outside the U.S. There's the complementary nature of having RX products and OTC products. In many cases, using the same distribution channels and wholesalers and pharmac",205,"The consumer business continues to be an important part of our strategy, particularly outside the U.S. There's the complementary nature of having RX products and OTC products. In many cases, using the same distribution channels and wholesalers and pharmacies is extremely important to us. And I think one of our areas of growth is building the business x U.S. and Europe and emerging markets. So we continue to think that's an exciting growth area for us. We're investing in it as we move forward. And obviously, outside the U.S. as well there's an Rx-to-OTC switch capability, which is also important. And there's a synergy where you can use some of the shared services capabilities between the Global Human Health division as well as the Merck Consumer Care division to get some costs synergies at the same time. So it's an important part of our future moving forward. And as you know, some of the products have lives of their own. CLARINEX can be an 80 to 100-year-old product and still perform extremely well on a global platform. We have to resource it right, and make sure that we're supporting it from a promotion end. We're very excited about the Consumer Care research pipeline as well."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on the Japanese launches, I'll just highlight four of them that we think are really important. ZETIA is having a very strong launch with -- it's already gained about 9% share in the Japanese market. JANUVIA, that launch is going extremely well. As we m",103,"So on the Japanese launches, I'll just highlight four of them that we think are really important. ZETIA is having a very strong launch with -- it's already gained about 9% share in the Japanese market. JANUVIA, that launch is going extremely well. As we mentioned, we had sales of almost $70 million this quarter. BRIDION had a very strong initial penetration in Japan. And then lastly, we're in the midst of launching NASONEX. So we have some really strong launches underway in Japan for key products, and we're very hopeful about ongoing launches as well as the future launches that are upcoming."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Okay. Thanks, Ken. Thank you, everyone. That ends our second quarter earnings call. Have a good day.",17,"Okay. Thanks, Ken. Thank you, everyone. That ends our second quarter earnings call. Have a good day."
288502,108814676,70844,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's Second Quarter 2010 Earnings Conference Call. [Operator Instruction] At this time, I'd like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead.",37,"Good day, everyone, and welcome to Merck's Second Quarter 2010 Earnings Conference Call. [Operator Instruction] At this time, I'd like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Amanda, and good morning, everyone, and welcome to Merck's 2010 Second Quarter Conference Call. There are a number of items in the GAAP results this quarter such as purchase accounting adjustments, merger-related expenses, restructuring cost an",333,"Thank you, Amanda, and good morning, everyone, and welcome to Merck's 2010 Second Quarter Conference Call. There are a number of items in the GAAP results this quarter such as purchase accounting adjustments, merger-related expenses, restructuring cost and also the gain on AstraZeneca's asset option exercise. We excluded those items in our non-GAAP reconciliation table, so you can get a better sense of the underlying performance for the quarter. We've also provided tables to help you understand the revenue trends. 
So this quarter, there are three tables in the press release. Table #1 is the GAAP results. Table #2 is a reconciliation of our GAAP results to a non-GAAP basis for the second quarter and also for the year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for our products and our businesses, as if the company have been combined in 2009. During the call, we will be referring to Table 2 when we discuss the P&L and Table 3 when we discuss the product performance. So you may want to have those available. 
In addition, I would like to remind you that some of the statements we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs  of Merck's management and subject to significant risks and uncertainties. 
Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. 
In addition, you can see the company's SEC filings as well as today's earnings release in the tables at merck.com. This morning, I'm joined by Dick Clark, our Chairman and Chief Executive Officer; Ken Frazier, our President; and Peter Kellogg, our Chief Financial Officer. Now I'd like to introduce Dick Clark.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. Our strong bottom line performance in the second quarter demonstrates Merck's continued success in executing our post-merger strategy. We're now halfway through our first full year as a combined company. Alread",962,"Thank you, Alex, and good morning, everyone. Our strong bottom line performance in the second quarter demonstrates Merck's continued success in executing our post-merger strategy. We're now halfway through our first full year as a combined company. Already, we're seeing positive signs of what can be achieved. Despite patent expiries and a challenging economy, I'm very pleased with what our team has accomplished. 
We remain focused on driving revenue growth, maintaining the momentum of our business, reducing our cost structure and making the right strategic investments globally. All of which are allowing us to make good progress toward Merck's overall goal of becoming the best healthcare company in the world. Strong underlying product performance helped us to realize topline worldwide sales of $11.3 billion, non-GAAP earnings per share of $0.86 and GAAP earnings per share of $0.24 for the quarter. 
Key brands including JANUVIA, JANUMET, REMICADE, ISENTRESS and TEMODAR were again standouts this quarter. In addition, Animal Health and Merck Consumer Care produced strong global sales. With our strong performance for the first half of the year, we continued to have confidence in delivering on our long-term financial targets. We also remain committed to achieving our previously-announced synergy target of $3.5 billion in ongoing annual savings in 2012. 
We have already announced initial phases of the merger restructuring program that will contribute approximately $2.7 billion to $3.1 billion toward the overall target, with procurement savings in excess contagious [ph] to account for the rest. 
In a few moments, Ken will discuss in more detail our global product performance, and then Peter will discuss our full year earnings outlook. But first, let me highlight a few areas. 
Merck's integration remains very much on course. But it will involve more hard work and difficult decisions as we proceed forward with our efforts to capture the full value of the new Merck for patients, customers and shareholders. The announcements we made recently did tell them the plans to integrate Merck's global research and manufacturing operations is another key step, but not the final one, in successfully executing our overall plan to create an industry-leading operating model. 
On the R&D side, our goal is to create a more flexible organization that fuels innovation in our pipeline and excels at external collaboration. On the manufacturing side, we aim to have a more reliable cost-efficient worldwide supply chain to support Merck's broader product portfolio, and meet the demand of a diverse and ever-revolving global health care environment. And while there are still lots of moving parts, we are building our strong track record of quickly executing our integration plans, while launching new products and delivering strong performance from current months. That has what allowed us to drive revenue growth in key brands despite patent expiries and difficult economic conditions. 
In markets around the world, we simultaneously have launches underway for a range of products including SIMPONI in 10 markets, and JANUVIA in Japan and in India. Additionally, our latest asthma dedication, DULERA, was recently approved by the U.S. FDA, and we've begun its launch. 
As we shared with many of you during our R&D Day in May, we also have several falling under late-stage review in the EU. From our robust pipeline, we anticipate making about 20 filings for new compounds and new combinations between now and 2012, including boceprevir, vorapaxar, odanacatib and TREDAPTIVE in the U.S. 
We also remain well positioned in Animal Health, a business that is driven by growing demand for animal proteins, as well as a strong demand for companion animal healthcare. We are on track to bring together sanofi-aventis and our Animal Health businesses into a new joint venture that will create a new global leader in Animal Health. 
Looking ahead, we continue to be excited about the many opportunities before us to serve the rapidly expanding emerging markets. Throughout these markets, I believe we continue to position Merck well by launching new products and making targeted business development investments. 
Examples of our commitment and execution can be found in high-growth markets like China and South Africa. In South Africa, we have a newly formed strategic collaboration with a local partner, Adcock Ingram. Together, we will co-promote and distribute branded products as well as over-the-counter medications. This collaboration will extend our reach into the market. 
Earlier this month, Merck's executive committee members and I spent a busy week in China. It has become one of our most important markets. Providing needed medicine and vaccines to meet the expanding needs of Chinese patients is an exciting growth opportunity for us. So we are focused on building our capabilities in China including our local production capabilities, our product portfolio and R&D. 
As part of our expansion efforts, we recently unveiled joint venture plan with Sinopharm to manufacture and commercialize adult and pediatric vaccines in China, and announced plans for a manufacturing site in Hangzhou, where we'll invest to build local capacity. I've seen firsthand the excitement and hard work underway in our emerging markets around the world, with China being the most recent example. That's why I am confident that we will reach our goal of deriving 25% of our global pharmaceutical and vaccine revenue from emerging markets in 2013. 
Merck's commitment to improving health around the world is not new to us. This commitment dates back decades and most recently, was recognized by the Access to Medicine Index. Merck was ranked second in the global analysis of companies that are making their medicines and vaccines readily available to markets across all income levels. All of these actions support Merck's mission to help patients around the world and to maximize shareholder return by providing innovative medicines, vaccines and consumer and Animal Health products, globally. With that, I'd like to turn the call over to Ken
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and good morning, everyone. As Dick mentioned, we had another successful quarter despite losing the exclusivity of COZAAR and HYZAAR and the economic challenges facing our businesses and customers around the world. In describing our secon",1726,"Thank you, Dick, and good morning, everyone. As Dick mentioned, we had another successful quarter despite losing the exclusivity of COZAAR and HYZAAR and the economic challenges facing our businesses and customers around the world. In describing our second quarter performance, please note that I will refer to supplemental combined non-GAAP results, which include the impact of foreign exchange. 
The Global Human Health business delivered a solid quarter with sales of $9.8 billion. This represents a 2% decline on a supplemental combined non-GAAP basis from the previous year, largely due to the loss of exclusivity of COZAAR and HYZAAR especially in the U.S. If you've been following the weekly prescription trends, then you have seen that there has been rapid erosion of approximately 90% of branded COZAAR and HYZAAR prescription volume in the U.S. Other markets such as the U.K. and Italy have also experienced rapid erosion. 
Excluding the impact of COZAAR and HYZAAR, Global Human Health sales grew 3% year-over-year. Sales were driven by the robust operational growth of key brands such as JANUVIA, JANUMET, REMICADE, TEMODAR and ISENTRESS. We continue to be optimistic about the growth opportunities for these brands. The speed with which we integrated our commercial operations, the diversity of our portfolio and the underlying strength of our global business have been key factors in our successful start to the first half of 2010. 
In the second quarter, we continue to drive growth in many of our markets. International Human Health sales grew by 5% excluding COZAAR and HYZAAR. Our Emerging Markets business grew 12% in the second quarter. We spent a fair amount of time during the business briefing in May discussing our strategy and goals in the emerging markets. As we said then, we believe these markets will grow to represent more than a quarter of our pharmaceutical and vaccine sales by 2013. 
In the second quarter, the emerging markets accounted for 19% of our human health sales. Two of the emerging markets, China and Brazil, are quickly working their way up our list of top 10 markets. Sales in China and Brazil both grew by more than 15% in the quarter. We continue to expect to have significant future growth opportunities across the emerging markets. 
We are well-positioned to drive significant growth with our current portfolio of products, including JANUVIA, SINGULAIR, as well as branded generics like COZAAR and HYZAAR, as well as ZOCOR. We are also exploring multiple strategies to increase our share in the branded generic and patent-protected segments through value-creating partnerships and acquisitions. 
Dick mentioned some of the recent developments in China, including the recent letter of mutual agreement with Sinopharm to develop a joint venture to commercialize pediatric and adult vaccines in China, a very large potential market. 
Now turning to the performance of some of our key brands this quarter. As I drop the individual product performance, you can follow along in Table 3 from our supplemental financial package, as Alex said earlier. Starting with our respiratory franchise, SINGULAIR sales in the second quarter were $1.3 billion, comparable to the second quarter 2009. This year, the spring allergy season peaked early in the U.S. and was overall comparable to the 2009 season. Sales in the U.S. this quarter were also affected by unfavorable fluctuations in trade inventory. Double-digit growth of SINGULAIR in the emerging markets was offset by declines in Japan due to the timing of shipments to our partner. 
For NASONEX, global sales increased 5% driven by the strong growth in the U.S. and Japan. Despite the flat year-over-year comparisons for the allergy season in the U.S., sales of NASONEX grew in the U.S. by 7%. NASONEX continues to be the leading branded nasal-inhaled steroid, and now includes additional congestion labeling in the U.S.  In Japan, we've had robust growth since the launch, and NASONEX is now the market leader. 
Moving on to JANUVIA and JANUMET. Global revenue grew 33% to a combined $818 million. The JANUVIA franchise continues to perform strongly in terms of share and overall growth. Sales in the quarter were driven by double-digit growth across all markets. In Japan, where we recently launched JANUVIA, sales were $69 million, which included supply sales to our partner of about $40 million. We've seen strong initial response to the value proposition JANUVIA represents to Japanese physicians and patients. 
Our Immunology franchise also achieved strong growth during the quarter. REMICADE continues to be a leading immunological therapy with sales of $669 million, an increase of 18% from the previous year. REMICADE continues to deliver growth across all indications, rheumatology, gastroenterology and dermatology. We anticipate REMICADE's double-digit operational growth will continue throughout 2010. 
In addition, sales of SIMPONI were $18 million in the quarter. SIMPONI sales continue to grow as we launch the brand in more countries and take share from other subcutaneous anti-TNF. We've now launched and 10 countries, most recently in Spain. We will launch SIMPONI in other EU markets in the second half of 2010 and launches in the U.K. and France are planned for 2011. 
Turning to ZETIA and VYTORIN. Sales were $1.1 billion this quarter, which in the aggregate represents a 3% decline compared to the previous year primarily due to declines in the U.S. Sequentially, ZETIA and VYTORIN grew 4%, globally. ZETIA and VYTORIN remain a primary focus of our promotional efforts, and we continue to see solid growth in many markets around the world, including 28% year-over-year growth in Japan. We continue to make progress on the IMPROVE-IT study, which is now fully enrolled with over 18,000 patients. 
Moving on to vaccines. For the total Vaccine business, I will focus my comments on sequential comparisons. Total sales for the Vaccine business were $832 million in the second quarter compared to $846 million in the first quarter of 2010. As a reminder, vaccine sales in the first quarter benefited from a $75 million to $100 million inventory build. With that in mind, we had some bright spots in the second quarter specifically with respect to RotaTeq, which benefited from a temporary competitor supply issue and PNEUMOVAX. This, unfortunately, was offset by weaker ZOSTAVAX sales due to supply constraints and the ongoing backorders for the brand. This is a frustrating situation for our teams, our customers and patients. And we have dedicated several hundred engineers and researchers to getting it fixed. We continue to work to resolve our current supply issues and to create redundant capacity in our facilities in North Carolina and Ireland. However, we do expect sales to be negatively affected by the supply issue again in the third quarter this year. 
Moving to GARDASIL. Sales as reported by Merck in the second quarter were $219 million, an 18% decline from the previous year. In the U.S., GARDASIL sales grew sequentially by 5%. We've made good progress with the coverage prevails [ph] and funding is now secured for all states. GARDASIL continues to maintain market share leadership in the U.S., and it also remains the global market leader. 
In Infectious Diseases, ISENTRESS continues its outstanding performance as sales increased 55% to $267 million in the second quarter. The continued growth of ISENTRESS reflects the unique efficacy and tolerability profile of this product, which has been widely embraced by physicians, patients and health organizations around the world. 
While many of our brands reported positive growth trends in the EU during the second quarter, the environment in the EU and across Europe is now more challenging. Many countries have announced austerity measures aimed at reducing costs in areas such as healthcare. While the implementation of pricing actions varies by country, many have announced measures to reduce prices of generic and patented drugs. 
In the short term, we've worked with many of the industry groups and governments to help develop solutions for our customers to improve their budget positions and address the short-term economic issues. While we are taking steps to mitigate the immediate impact in the EU, we anticipate that the austerity measures will affect our revenue performance going forward.  Peter Kellogg will focus on the financial impact of the EU austerity measures in his remarks shortly. 
Moving from the economic environment, I'd like to highlight briefly some recent developments from three of our key R&D programs: DULERA, vorapaxar and boceprevir. As you know, we're in the process of launching many new products this year and we have robust late-stage pipeline with programs that represent significant scientific achievements and first-in-class opportunities. 
In June, as Dick mentioned, we received U.S. FDA approval of DULERA, our combination steroid and long-acting beta agonist for the treatment of asthma. Despite the availability of other combination treatments, there remains some large unmet need in asthma, and we believe DULERA represents a great alternative due to its differentiated profile, which includes the addition of clinically-judged deteriorations in asthma within its label. We are beginning the launch of DULERA now with plans for a full commercial launch late in the third quarter. 
Our Phase III program for vorapaxar, our PAR-1 inhibitor for the prevention of major cardiovascular events is also progressing well. Both Phase III studies are now fully enrolled. The TRA 2P study in secondary prevention is fully enrolled, and patients are being monitored for the accrual of events. The TRA-CER study in patients with acute coronary syndrome is also fully enrolled, and patients are being monitored for the accrual of events. 
Based on current event rates, we anticipate that both studies will be completed in mid-2011. We are pleased with the progress in the Phase III program. Most importantly, we continue to target a 2011 filings for vorapaxar.
Turning to boceprevir, our hepatitis C protease inhibitor, I'm pleased to share with you that both Phase III studies are now completed, and we're in the process of analyzing the results. We plan to submit the Phase III data for presentation at the AASLD meeting in November.  Finally, we remain on track to file boceprevir in 2010. 
In closing, Global Human Health, along with Animal Health and Consumer Health Care, have delivered another solid quarter for Merck. We continue to be excited by our portfolio of products and our robust late-stage pipeline. While the operating environment is constantly changing, we continue to execute on our long-term strategic goals to create the leading healthcare company. Now I will pass the call over to my colleague, Peter Kellogg.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, we continued our performance in the second quarter and our integration efforts are well underway. Our performance this quarter is characterized by solid operational performance, which wa",1386,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, we continued our performance in the second quarter and our integration efforts are well underway. Our performance this quarter is characterized by solid operational performance, which was tampered by the impact of generic entries for COZAAR and HYZAAR and the cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and geographies performed. And now I'd like to cover three areas with you: First, our operating results; second, our restructuring activities; and third, I want to discuss our targets for full year 2010 and beyond. 
So let's begin with our results. As Alex mentioned, we have once again provided data in our earnings release and supplemental charts to help navigate through our non-GAAP adjustments to the P&L. To simplify my remarks today, I will speak the non-GAAP results, which exclude purchase price accounting adjustments, merger-related costs, restructuring charges and the gain on AstraZeneca's asset option exercise. 
On this basis, we reported second quarter non-GAAP earnings per share of $0.86. Total revenue for the quarter was $11.3 billion. On a supplemental combined non-GAAP basis, sales were down 2% versus prior year due primarily to the impact of generic COZAAR/HYZAAR and lower Astra supply sale due to the generic erosion and return of rights to the non-PPI products. These offset solid operational growth in the rest of the business. Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. 
Our Animal Health business grew 9% to $731 million, reflecting growth among cattle, poultry and swine products. We remain on track to complete our Animal Health joint venture with sanofi-aventis in the first quarter of 2011. Consumer Care sales increased 11% to $422 million due to the strong seasonal performance of Claritin and Coppertone. 
Now moving on to the expense items in the P&L. You can see that we did a very good job managing our expenses this quarter in anticipation of additional commercial launches and spending on our late-stage pipeline expected during third and fourth quarter. As you know, the cost of our combined company are represented in our current cost base, whereas only the Merck costs were included in the second quarter of 2009. So it's a little hard to see the underlying trends on a year-over-year basis. As a result, I will speak to sequential trends on the cost lines since those comparisons are more meaningful. 
Let's begin with the materials in production. The non-GAAP gross margin in the second quarter was approximately 76.5%, which is an improvement compared to the first quarter of 2010 where the gross margin was 75.4%. Most of the improvement in the gross margin was driven by product mix, with higher sequential sales of JANUVIA, ISENTRESS and increased sales of seasonal allergy products. 
Moving onto marketing and admin expenses, on an on-GAAP basis, marketing and administrative expenses in the second quarter were $3.1 billion, which is about the same level as in the first quarter of 2010. Research and development expenses for the second quarter was approximately $2 billion, which is also in line with the first quarter. As the year progresses, we see continued investment in late-stage projects such as vorapaxar, telcagepant, odanacatib and TREDAPTIVE. 
Now let's move to equity income. In the second quarter, Merck reported $43 million of equity income, which was a decrease from the first quarter primarily due to inherent variability and the timing of payments for the AstraZeneca joint venture. 
Moving on to other income and expense. The GAAP results include $443 million from AstraZeneca's exercise of the asset option. On a non-GAAP basis, other expense of $153 million was comparable to the first quarter of 2010. 
Moving to tax. The Merck non-GAAP tax rate was 20.5% for the second quarter, better than the rate that we saw in the first quarter. As noted in the earnings release, we continue to expect the full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned cash to shareholders through our dividend and by making progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $1.3 billion to repurchase about 38 million shares of our common stock.  So in summary, we continue on a strong trajectory since merger. 
Now let's talk about the integration activities. This quarter, we made continued progress on our cost synergy capture by reducing our headcount in global infrastructure and generating savings from procurement actions. On July 8, we announced our plans to phase out operations at eight manufacturing facilities and eight research facilities over the next two years. The merger restructuring program also includes consolidating our sites in local markets by closing 58 commercial offices. The actions we have announced so far will bring our number of R&D sites down to 16 and our number of our manufacturing sites down to 48, excluding Animal Health sites. 
We will continue to pursue productivity efficiencies and evaluate our manufacturing supply-chain capabilities on an ongoing basis. Remember, we are planning to create a new Animal Health joint venture, so our Animal Health business is not involved in the Merck merger researching activities. As a result of these and other actions such as procurement savings, we are well on track to realize a $3.5 billion synergy target by the end of 2012. 
Now let's spend the remaining time reviewing our outlook for 2010 and beyond that. Let's start with 2010. With the first six months complete, it's appropriate to provide an update on our earnings targets. We have maintained $3.34 as the midpoint of our range while tightening the EPS range for the full year. Merck is now targeting a full year 2010 non-GAAP EPS range of $3.29 to $3.39, excluding certain items. Factored into this target EPS range is our strong first quarter results, continued benefits from synergies in the second half, the impact of healthcare reform in the U.S., which is unchanged from our previous comments, and the assumption that Merck retains full rights to REMICADE and SIMPONI in our markets. 
In addition, we have assumed top line pressures due to pricing actions in some European countries and foreign exchange, both of which we believe will be a headwind in the second half. In addition, we anticipate increased second half spending for new product launches like DULERA in the U.S., new targeted commercial and R&D investments in the emerging markets and spending to support the late-stage pipeline. 
Let me go into a bit more detail to help you understand what is already factored in to the 2010 targets. As you know, and as Ken mentioned, Greece, Spain, Germany and some other markets have already announced price reductions, which will have an unfavorable impact on our results in the third and fourth quarter of 2010. The impact on European revenues in the first half was about 2% unfavorable. In the second half, we anticipate a mid single-digit unfavorable impact on European sales. 
These updates are included in our 2010 targets and will impact our second half performance relative to what we were modeling at the beginning of the year. As a result, we now expect that EPS in the second half will be similar to the level in the first half. So you should adjust your models accordingly. Logically, these actions in 2010 will also have an impact in 2011 as they annualize. 
Finally, let me touch on our long-term outlook. We remain excited about the future of the new Merck, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities that are already well underway. We continue to target a high single-digit, non-GAAP EPS compound annual growth rate from 2009 to 2013. 
In closing, we are pleased with the solid second quarter results we reported today. We clearly had a strong first half. Our expense management contributed to that performance and will help us manage a tighter environment in Europe. The merger is working, and our results and our short-term and long-term earnings targets demonstrate that we are right on track. 
Thank you. Now I'll turn the call back over to Alex.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Peter. Now we'd like to open up the call to answer your questions. But in order to get through as many as possible, we'd like to ask you to limit yourself to one or two questions, and note that we won't take follow-up questions. But if you do have",64,"Thanks, Peter. Now we'd like to open up the call to answer your questions. But in order to get through as many as possible, we'd like to ask you to limit yourself to one or two questions, and note that we won't take follow-up questions. But if you do have additional questions, you're welcome to rejoin the queue. Amanda, we're ready for the Q&A.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question is Marc Goodman with UBS.",10,"[Operator Instructions] Your first question is Marc Goodman with UBS.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","So given what happened with RELENZA at the panel, I was just curious how you guys were thinking about how TRA plays into that market [indiscernible] there? And second of all, can you give us an update on your Biologics program?",41,"So given what happened with RELENZA at the panel, I was just curious how you guys were thinking about how TRA plays into that market [indiscernible] there? And second of all, can you give us an update on your Biologics program?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So I'll talk about Belinta [ph]. I think from our perspective, I think it's important to recognize that we always study TRA and always anticipated that it would be added to the standard of care whether it was aspirin, PLAVIX or another medicine in PLAVIX",183,"So I'll talk about Belinta [ph]. I think from our perspective, I think it's important to recognize that we always study TRA and always anticipated that it would be added to the standard of care whether it was aspirin, PLAVIX or another medicine in PLAVIX class. So it was always our intent to have it added on top of the standard of care. And so we would think that it would be added on to Belinta [ph] as that became approved at some point and became a competitor of PLAVIX. I also think it's important to recognize that even with the, for example, 16% increase, a great deal of residual risk still remains, cardiovascular risk still remains. And therefore, there's still an important role for medicine like TRA. I also think it's important to remember the product profile, which includes the fact that we have not seen any increase in bleeding unlike some of the other medicines that are being used. So for all of these reasons, I continue to think that there are really robust prospects for our medicine like TRA.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Marc, can you just repeat your second question?",8,"Marc, can you just repeat your second question?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Just an update on the Biologics or Biosimilar [indiscernible].",9,"Just an update on the Biologics or Biosimilar [indiscernible].
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So you remember that back in May, we discussed our MBV strategy, and we updated the status of the PEG-EPO program, which was discontinued. At the same time, we also highlighted the fact that a number of other programs continue on our MBV portfolio, and we",147,"So you remember that back in May, we discussed our MBV strategy, and we updated the status of the PEG-EPO program, which was discontinued. At the same time, we also highlighted the fact that a number of other programs continue on our MBV portfolio, and we also referenced biological programs that are part of our novel Biologics focus, including antibodies against HGF and IGF-1R for oncology, IL-23 for immunological indications, MK-3415A for C. difficile [Clostridium difficile], and of course, ELONVA, which is a noble follicle-stimulating hormone for fertility. So that's sort of a short description of where we are in our Biologics program. But I think it's important to recognize that we see Biologics as an important part of our future, both with respect to what we anticipate will be an abbreviated pathway for the approval of biological similars as well as novel biologics research going forward.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Chris Schott with JPMorgan.",9,"Your next question is from Chris Schott with JPMorgan.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","First question was on ZOSTAVAX. Just can you elaborate a little bit more on what needs to be done to address it?",22,"First question was on ZOSTAVAX. Just can you elaborate a little bit more on what needs to be done to address it?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure, Chris. This is Dick. I think the issue, as Ken mentioned, is that we've put significant amount of technical and engineering resources on this both from a manufacturing and a research standpoint, and certainly, right now we are cautiously optimistic.",215,"Sure, Chris. This is Dick. I think the issue, as Ken mentioned, is that we've put significant amount of technical and engineering resources on this both from a manufacturing and a research standpoint, and certainly, right now we are cautiously optimistic. We have begun production again of varicella. We believe that by starting production, we have a path forward. So that's good news. It's not going to have an impact on 2010 forecast because the product process cycle is significant, so there's many more production steps to go through yet. There's more quality testing to go through. There's more discussions with the agencies to go through. But I am cautiously optimistic due to the fact that, obviously, we've started production that is important. Now the second important aspect is, as Ken mentioned, is that we've started our focus on Durham, and we hope to have that, from a production standpoint, up and running in the second half of this year. And from a pediatric standpoint, with the relaunch of COMVAX, our HIB and Hepatitis B combination vaccines, all of Merck pediatric vaccines will be available in U.S. for the first time since mid-2007. So we are making that type of progress, but we'll keep our fingers crossed on ZOSTAVAX because we did start production again.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","On the emerging market, following this deal with Sinopharm, should we think about Merck looking at these type of partnerships going forward? Or when we think about the emerging market kind of just [ph] the inorganic growth portion of this, will more tradi",91,"On the emerging market, following this deal with Sinopharm, should we think about Merck looking at these type of partnerships going forward? Or when we think about the emerging market kind of just [ph] the inorganic growth portion of this, will more traditional M&A play a larger role, I guess, when I consider the moves that Abbott made, as an example, this quarter? And how are you thinking about what appeared to be fairly rich valuations if you were to consider a larger strategic move as it relates to emerging markets?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","I think the way we look at it as a company is that we don't look at the emerging markets as a entity onto itself. We look upon it as a country-by-country basis. And certainly, our total focus obviously is profitable growth and keeping profitable growth as",135,"I think the way we look at it as a company is that we don't look at the emerging markets as a entity onto itself. We look upon it as a country-by-country basis. And certainly, our total focus obviously is profitable growth and keeping profitable growth as the principal. In some cases, it will be joint ventures and relationships. Sometimes, there won't be inorganic at all, and sometimes there maybe an acquisition out there that may help the foundation of a particular country or via a foundation across other emerging markets. So we really take it case-by-case and what's in the best interest of that particular country. Is there a partner, is there a combination that makes sense from a value standpoint, and most importantly, does it makes sense from a profitable growth standpoint.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from John Boris of Citi.",9,"Your next question is from John Boris of Citi.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Just one for Peter Kellogg. Can you quantify the impact of healthcare reform in the quarter, and then what you anticipate for the full year? And then just building on the previous question on China. When you look at China, especially since you spent a fai",116,"Just one for Peter Kellogg. Can you quantify the impact of healthcare reform in the quarter, and then what you anticipate for the full year? And then just building on the previous question on China. When you look at China, especially since you spent a fair amount of time there this past week, how are you thinking about it from an ability to price your medicines? What do you see is the impact of formularies on your ability to price those medicines going forward? And then any discussions you had on the intellectual property? Obviously, that's a very important component, respecting intellectual property within the Chinese market. But any thoughts you have there would be helpful.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, John, it's Peter. So healthcare reform I think really is moving ahead just the way we had originally anticipated. There's no surprise this quarter. Ballpark, roughly about $44 million impact in the second quarter, and that makes sense given what w",101,"Thanks, John, it's Peter. So healthcare reform I think really is moving ahead just the way we had originally anticipated. There's no surprise this quarter. Ballpark, roughly about $44 million impact in the second quarter, and that makes sense given what we talked about as a full year impact of about $170 million. So really no update, no change really on what we've anticipated or originally modeled. We've always said that, that would probably increase next year to something in the $300 million to $350 million. So it's pretty much in line with what we've always talked about, no new surprises.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So in China. Let me just start by saying that I think we continue to be very excited about the future in China. To look at China in a monolithic way as it relates to pricing or any other aspect of our commercial strategy, I think is not how we are going t",254,"So in China. Let me just start by saying that I think we continue to be very excited about the future in China. To look at China in a monolithic way as it relates to pricing or any other aspect of our commercial strategy, I think is not how we are going to approach it. So let's start with the robust growth that we anticipate in the middle class in the urban areas of China. For those people, healthcare is still likely to be a self-pay exercise, and so we will continue to look at those market segments in a way that we can price competitively with alternative therapies. But I will say that the pricing in China has allowed both a broad access, while at the same time, also allowing strong profit margins in that country. I think the other aspect is through the government. And so there's an essential drug list, which is part of Chinese healthcare reform, and Merck participated in the Essential Drug List placing ZOCOR among other magazines on that drug list. And our experience there has been that while we had to provide substantial discounts to get entree to the Essential Drug List, the volumes have more than compensated for the pricing reductions that we have. So I think what we've seen with ZOCOR right now is an example of how in that market, we have the price in a way that creates value for that market and there's still an opportunity to be profitable in that context.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tim Anderson, Sanford Bernstein.",9,"Your next question is from Tim Anderson, Sanford Bernstein.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","I know you don't like to say much about the REMICADE dispute, but I'm hoping you can give us some more information. You used to talk about being highly confident that you would prevail in the dispute, but I don't really hear that language being used anymo",129,"I know you don't like to say much about the REMICADE dispute, but I'm hoping you can give us some more information. You used to talk about being highly confident that you would prevail in the dispute, but I don't really hear that language being used anymore and I'm wondering if that's still the case. On arbitration, can you run through different options here? Is it all or nothing, or could there be some sort of middle ground or what exactly? And then your comments about not impacting 2013, it's not clear to me why that wouldn't impact your 2013 guidance because it is a pretty material contributor to your financials. And by extension, if it doesn't impact 2013, can we assume that it wouldn't impact 2010 neither?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","We're going to start with Bruce Kuhlik.",8,"We're going to start with Bruce Kuhlik.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","At this point, we provided the information about when we expect the arbitration hearing to begin and the selection of the panel. We're looking at whether we can provide some additional information with respect to the process, and I hope to do that in a re",80,"At this point, we provided the information about when we expect the arbitration hearing to begin and the selection of the panel. We're looking at whether we can provide some additional information with respect to the process, and I hope to do that in a relatively near future. We continue to believe very strongly that we've structured this transaction in a way that's appropriate for the REMICADE distribution agreement. And I'll turn it over with respect to the financial targets.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Tim, it's Peter Kellogg. So I don't think we said it didn't impact one way or the other. What we said was our guidance has this contingency incorporated, so that really our guidance that we provided would be so achievable regardless of the outcome in this",80,"Tim, it's Peter Kellogg. So I don't think we said it didn't impact one way or the other. What we said was our guidance has this contingency incorporated, so that really our guidance that we provided would be so achievable regardless of the outcome in this arbitration or topic. Obviously, depending on the outcome, it will make that guidance number easier or more challenging. But nonetheless, I think we feel comfortable with the guidance that we provided under different scenarios.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","And then 2010?",3,"And then 2010?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Well, for 2010, obviously, the timing is a little unclear and it would be pretty relatively late in the year, but that would be something we have to really depend on the outcome. So I don't think we've said for 2010 that's one way or the other really it -",69,"Well, for 2010, obviously, the timing is a little unclear and it would be pretty relatively late in the year, but that would be something we have to really depend on the outcome. So I don't think we've said for 2010 that's one way or the other really it -- I'd say right now, what we did highlight was our guidance included REMICADE and SIMPONI in our 2010 numbers.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Jami Rubin of Goldman Sachs.",10,"Your next question is from Jami Rubin of Goldman Sachs.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","So Peter, question for you. This quarter, you beat earnings by $0.03 relative to consensus, but not letting to fall through to full year guidance and your clipping the top end by $0.02. So is it fair to assume that the cost of European austerity measures",108,"So Peter, question for you. This quarter, you beat earnings by $0.03 relative to consensus, but not letting to fall through to full year guidance and your clipping the top end by $0.02. So is it fair to assume that the cost of European austerity measures will be about $0.05 this year until we assume about a $0.10 hit next year since the impact will be annualized? And my second question refers to -- you didn't mention SAPHRIS. I know that was recently introduced. We didn't see sales for SAPHRIS or TREDAPTIVE. And Ken, maybe if you can update us on how you're seeing those new launches progress.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. So Jami, yes, I think the key thing is that we obviously -- all we've done is narrowed the range for our guidance for the full year. So we really maintain the midpoint of our guidance range and EPS. Obviously, we have, as I commented and as you poin",391,"Sure. So Jami, yes, I think the key thing is that we obviously -- all we've done is narrowed the range for our guidance for the full year. So we really maintain the midpoint of our guidance range and EPS. Obviously, we have, as I commented and as you pointed out, we've taken into account some of the top line pressures we see in the balance of the year. Obviously, we do expect to see the pricing impact in the second half of the year. The way we look at it, it's about mid single-digit range impact on the European revenues. Translating that to the top line, it's probably in the neighborhood of, I'm guessing, it's about $300 million or so. And obviously, we have to fully annualize that next year. The other thing is, obviously, Forex. Now the impact of Forex for us is a little complex because obviously, you have the Forex impact around the world, not just euro but yen and other currencies. And you have to net that against our hedge program. We anticipate in the second half of the year currency being a slight negative on our top line, probably something in the 1%, 2% range kind of as you go through the second half of the year. Obviously, those rates still move around. So those are the primary factors in addition to the healthcare reform. So that said, going the other way, we have a lot of activity on the expense line in the second half that will actually be driving our business going forward. And as we go into 2011, we'll be launching DULERA, we have a lot of activity going on in Japan, launching products, having a lot of success. We will be, obviously, investing in the emerging markets as you've seen announcements, and we'll continue to grow there. And obviously, our pipeline, which is a big driver for us in the future, continues to move forward with very nice progress. So you can expect to see some spending in that in the second half, a little more in the first half. So all those points combine to lead us to our guidance. But the most important thing is we didn't change the midpoint of our guidance range. We just narrowed the range as we've gone through the first half of the year.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","With SAPHRIS, I think we mentioned earlier that the current performance has been affected by destocking last year. I would say a couple of things. We continue to focus on building the brand awareness, and we're also getting reasonably good unrestricted Ma",252,"With SAPHRIS, I think we mentioned earlier that the current performance has been affected by destocking last year. I would say a couple of things. We continue to focus on building the brand awareness, and we're also getting reasonably good unrestricted Managed Care access about 65%. But the product right now, I would say frankly, is not where we want it to be. On TREDAPTIVE, I would say that obviously for us, the sales have not yet become material in Europe. But the real thing that we're doing on TREDAPTIVE is HPS2-THRIVE and creating a market in the U.S. I think there's still a need -- a growing awareness of HDL as its impact on cardiovascular health going forward. I would say the other issues around launches are, we are very pleased with the way SIMPONI is going, JANUVIA's continuing the launch well around the world including Japan. BRIDION is having a spectacular launch in Japan, and we look forward to DULERA. So I would just say that SAPHRIS and TREDAPTIVE has not yet become material. We continue to think TREDAPTIVE has a great future in the U.S., and we continue to work with SAPHRIS. And then I also -- it was pointed out to me that I forgot to answer quickly the Chinese IP question and I would say that on that one, we continue to proceed carefully with respect to our assets in China to make sure that we get the benefit of that market while also protecting our IP.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","A quick follow-up to Dick. Dick, you spent about $1.3 billion this quarter repurchasing about 38 million shares. What are your plans for share repurchases going forward just given the significant amount of free cash flow you're generating?",39,"A quick follow-up to Dick. Dick, you spent about $1.3 billion this quarter repurchasing about 38 million shares. What are your plans for share repurchases going forward just given the significant amount of free cash flow you're generating?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Peter, you want to answer that?",6,"Peter, you want to answer that?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. So Jami, obviously, we have an authorization to do up to $3 billion of share repurchase, and we haven't worked our way through that entirely. So that's on our agenda going forward, obviously. We like to, generally, on an ongoing basis, stabilize the",142,"Sure. So Jami, obviously, we have an authorization to do up to $3 billion of share repurchase, and we haven't worked our way through that entirely. So that's on our agenda going forward, obviously. We like to, generally, on an ongoing basis, stabilize the shares outstanding; but then periodically, step in when we see a good opportunity to pick up some of our shares. And quite frankly, we see when our stock is down is a very good way of returning cash to shareholders. We know that's a focus of a lot of our key shareholders, and we take that seriously as well. I think over the last five years, as we've said in the past, our track record of returning cash flow to shareholders is phenomenal. We're in the upper 90%, above 90% range. So we could plan to continue that.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tony Butler of Barclays Capital.",10,"Your next question is from Tony Butler of Barclays Capital.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick, I think that you, in your opening statements, made reference to the value, continuously realizing the value of the combined company. I'm curious exactly what you mean by that. Is it just cost? And then by extension of Tim Anderson's question, would",87,"Dick, I think that you, in your opening statements, made reference to the value, continuously realizing the value of the combined company. I'm curious exactly what you mean by that. Is it just cost? And then by extension of Tim Anderson's question, would you be able to make that statement true if in fact the arbitration does not go your way? And then as a follow-up to that, if the arbitration does go your way, how do you think about perhaps moving additional increases to the dividend?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Obviously, I'm not going to make any future comments on the arbitration based on process of where we are in today. But if you go back to why this is such an important merger to the company, it's far beyond the cost synergies. Cost synergies, in many cases",319,"Obviously, I'm not going to make any future comments on the arbitration based on process of where we are in today. But if you go back to why this is such an important merger to the company, it's far beyond the cost synergies. Cost synergies, in many cases, is an afterthought to why we did this merger and why we're still excited about it. First of all, the most important aspect of this merger that we continue to be excited upon is that it's a late-stage pipeline, and the research synergies from the standpoint that you're -- you have complementary franchises, and there's not much overlap and mechanism of actions, and there's great scientific and technological sharing out that is just so important for the future of the company. So the first and foremost reason why this makes sense moving forward is the scientific and research pipeline and the scientific and research technology that we're sharing across mutual franchises as we move forward. The second part to that is the product portfolio. The excitement that we see from our professional reps country-by-country when we visit there about having now a combined portfolio that can really come up with the right resolution for patients and physicians is just incredible. We're no longer a one trick pony when it comes to some franchises or to these states. We have a portfolio that can meet their needs, and I think that capability is extremely important. And then third, I think is the geographical footprint we have. The geographical footprint that we combined with the two companies, as you know, is critical to the future since we're not and will not be a U.S.-centric company. So when you look at all of those evaluations, to us, those are the most important. And obviously, REMICADE and SIMPONI are important as well, but even without those two, this makes a lot of sense to us.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Risinger with Morgan Stanley.",10,"Your next question is from David Risinger with Morgan Stanley.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","First, with respect to SAPHRIS, can you just update us on where the reformulation process stands? And then second, you've discussed branded generics this year. I don't think that you've talked about branded generics in prior years. Can you talk about how",53,"First, with respect to SAPHRIS, can you just update us on where the reformulation process stands? And then second, you've discussed branded generics this year. I don't think that you've talked about branded generics in prior years. Can you talk about how broad of a portfolio you'd like to have in emerging markets?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on the SAPHRIS formulation issue, we're on track, and we plan to launch a new black cherry version to provide patients with a different, better taste option. So that's where we are on that issue. On the branded generics issue, as Dick mentioned before,",171,"So on the SAPHRIS formulation issue, we're on track, and we plan to launch a new black cherry version to provide patients with a different, better taste option. So that's where we are on that issue. On the branded generics issue, as Dick mentioned before, I think it does vary very much market-by-market. But I want to start by saying, we have a very substantial branded generics business right now inside the company, with over 150 products available in the emerging markets based on previous portfolios of the two companies. And we see brands, as I mentioned, like ZOCOR in China just growing phenomenally. So what we intend to do is we intend to look at the branded generics business on a country-by-country basis, look at the opportunities to expand on the current portfolio of products that we have of both our traditional established products as well as our innovative products, and we intend to build on those in ways that create value for customers as well as for our shareholders.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Seamus Fernandez of Leerink Swann.",10,"Your next question is from Seamus Fernandez of Leerink Swann.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","This question is actually for Peter. It might be a little bit unfair, but Peter, you had said that you'll do opportunistic repurchases when your shares are down. Would you characterize your stock as an attractive opportunity today or being down at current",44,"This question is actually for Peter. It might be a little bit unfair, but Peter, you had said that you'll do opportunistic repurchases when your shares are down. Would you characterize your stock as an attractive opportunity today or being down at current levels?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Peter?",1,"Peter?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Seamus, so obviously, I can't comment on that. But I think the key point is that -- what I meant by that is also when we have cash positions and when we see the opportunity from a window standpoint. Obviously, for us to go in the market, we have to have a",69,"Seamus, so obviously, I can't comment on that. But I think the key point is that -- what I meant by that is also when we have cash positions and when we see the opportunity from a window standpoint. Obviously, for us to go in the market, we have to have an open window position. So all those factors come into play, but I can't really comment on that.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Maris with Credit Agricole CLSA.",11,"Your next question is from David Maris with Credit Agricole CLSA.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","The Sinopharm China deal looks very interesting. Can you tell us when will you start to distribute vaccines through their system? The facility that you broke ground on, is that vaccines only or is that oral doses? And also how many salespeople do you have",57,"The Sinopharm China deal looks very interesting. Can you tell us when will you start to distribute vaccines through their system? The facility that you broke ground on, is that vaccines only or is that oral doses? And also how many salespeople do you have in China at this point, and where was that a year ago?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Your question on the new facility in Hangzhou is a pharmaceutical facility beginning with packaging products and then moving on into manufacturing. So that won't be completed in 2012, and we'll employ about 800 employees when we're finished. It's truly to",84,"Your question on the new facility in Hangzhou is a pharmaceutical facility beginning with packaging products and then moving on into manufacturing. So that won't be completed in 2012, and we'll employ about 800 employees when we're finished. It's truly too early to make a comment about Sinopharm and the timing of it and activities like that since we're in, obviously, in negotiations to complete the contract. And so just stay tuned on that, we'll share that with you as soon as we can.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","On the representative levels in China, I think our current complement is about 5,000 people across the country. That's up about 1,000 since last year. So we continue to build our sales force, and we continue to penetrate deeper and deeper into the country",56,"On the representative levels in China, I think our current complement is about 5,000 people across the country. That's up about 1,000 since last year. So we continue to build our sales force, and we continue to penetrate deeper and deeper into the country because it's important to be able to win at the hospital level.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question is from Eric Lo with Bank of America Merrill Lynch.",13,"Your final question is from Eric Lo with Bank of America Merrill Lynch.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Can you run through what your product launches are in Japan over the next 12 months? And also, maybe second question, comment on your priorities for the Consumer division? It's one of the smaller divisions, but growth seems to be improving. Are you guys p",65,"Can you run through what your product launches are in Japan over the next 12 months? And also, maybe second question, comment on your priorities for the Consumer division? It's one of the smaller divisions, but growth seems to be improving. Are you guys planning to grow the business through internal investments or maybe acquisitions? And are there any products that you might consider divesting?
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So starting with Japan...",5,"So starting with Japan...
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Let's start with Consumer first if we can.",9,"Let's start with Consumer first if we can.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","The consumer business continues to be an important part of our strategy, particularly outside the U.S. There's the complementary nature of having RX products and OTC products. In many cases, using the same distribution channels and wholesalers and pharmac",205,"The consumer business continues to be an important part of our strategy, particularly outside the U.S. There's the complementary nature of having RX products and OTC products. In many cases, using the same distribution channels and wholesalers and pharmacies is extremely important to us. And I think one of our areas of growth is building the business x U.S. and Europe and emerging markets. So we continue to think that's an exciting growth area for us. We're investing in it as we move forward. And obviously, outside the U.S. as well there's an Rx-to-OTC switch capability, which is also important. And there's a synergy where you can use some of the shared services capabilities between the Global Human Health division as well as the Merck Consumer Care division to get some costs synergies at the same time. So it's an important part of our future moving forward. And as you know, some of the products have lives of their own. CLARINEX can be an 80 to 100-year-old product and still perform extremely well on a global platform. We have to resource it right, and make sure that we're supporting it from a promotion end. We're very excited about the Consumer Care research pipeline as well.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on the Japanese launches, I'll just highlight four of them that we think are really important. ZETIA is having a very strong launch with -- it's already gained about 9% share in the Japanese market. JANUVIA, that launch is going extremely well. As we m",103,"So on the Japanese launches, I'll just highlight four of them that we think are really important. ZETIA is having a very strong launch with -- it's already gained about 9% share in the Japanese market. JANUVIA, that launch is going extremely well. As we mentioned, we had sales of almost $70 million this quarter. BRIDION had a very strong initial penetration in Japan. And then lastly, we're in the midst of launching NASONEX. So we have some really strong launches underway in Japan for key products, and we're very hopeful about ongoing launches as well as the future launches that are upcoming.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Okay. Thanks, Ken. Thank you, everyone. That ends our second quarter earnings call. Have a good day.",17,"Okay. Thanks, Ken. Thank you, everyone. That ends our second quarter earnings call. Have a good day.
"
288502,108814676,70876,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect.

"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's Second Quarter 2010 Earnings Conference Call. [Operator Instruction] At this time, I'd like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead.",37,"Good day, everyone, and welcome to Merck's Second Quarter 2010 Earnings Conference Call. [Operator Instruction] At this time, I'd like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Amanda, and good morning, everyone, and welcome to Merck's 2010 Second Quarter Conference Call. There are a number of items in the GAAP results this quarter such as purchase accounting adjustments, merger-related expenses, restructuring cost an",333,"Thank you, Amanda, and good morning, everyone, and welcome to Merck's 2010 Second Quarter Conference Call. There are a number of items in the GAAP results this quarter such as purchase accounting adjustments, merger-related expenses, restructuring cost and also the gain on AstraZeneca's asset option exercise. We excluded those items in our non-GAAP reconciliation table, so you can get a better sense of the underlying performance for the quarter. We've also provided tables to help you understand the revenue trends. 
So this quarter, there are three tables in the press release. Table #1 is the GAAP results. Table #2 is a reconciliation of our GAAP results to a non-GAAP basis for the second quarter and also for the year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for our products and our businesses, as if the company have been combined in 2009. During the call, we will be referring to Table 2 when we discuss the P&L and Table 3 when we discuss the product performance. So you may want to have those available. 
In addition, I would like to remind you that some of the statements we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs  of Merck's management and subject to significant risks and uncertainties. 
Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those forward-looking statements we make today. Merck undertakes no obligation to publicly update any forward-looking statement. 
In addition, you can see the company's SEC filings as well as today's earnings release in the tables at merck.com. This morning, I'm joined by Dick Clark, our Chairman and Chief Executive Officer; Ken Frazier, our President; and Peter Kellogg, our Chief Financial Officer. Now I'd like to introduce Dick Clark."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. Our strong bottom line performance in the second quarter demonstrates Merck's continued success in executing our post-merger strategy. We're now halfway through our first full year as a combined company. Alread",961,"Thank you, Alex, and good morning, everyone. Our strong bottom line performance in the second quarter demonstrates Merck's continued success in executing our post-merger strategy. We're now halfway through our first full year as a combined company. Already, we're seeing positive signs of what can be achieved. Despite patent expiries and a challenging economy, I'm very pleased with what our team has accomplished. 
We remain focused on driving revenue growth, maintaining the momentum of our business, reducing our cost structure and making the right strategic investments globally. All of which are allowing us to make good progress toward Merck's overall goal of becoming the best healthcare company in the world. Strong underlying product performance helped us to realize topline worldwide sales of $11.3 billion, non-GAAP earnings per share of $0.86 and GAAP earnings per share of $0.24 for the quarter. 
Key brands including JANUVIA, JANUMET, REMICADE, ISENTRESS and TEMODAR were again standouts this quarter. In addition, Animal Health and Merck Consumer Care produced strong global sales. With our strong performance for the first half of the year, we continued to have confidence in delivering on our long-term financial targets. We also remain committed to achieving our previously-announced synergy target of $3.5 billion in ongoing annual savings in 2012. 
We have already announced initial phases of the merger restructuring program that will contribute approximately $2.7 billion to $3.1 billion toward the overall target, with procurement savings in subsequent stages to account for the rest. 
In a few moments, Ken will discuss in more detail our global product performance, and then Peter will discuss our full year earnings outlook. But first, let me highlight a few areas. 
Merck's integration remains very much on course. But it will involve more hard work and difficult decisions as we proceed forward with our efforts to capture the full value of the new Merck for patients, customers and shareholders. The announcements we made recently did tell them the plans to integrate Merck's global research and manufacturing operations is another key step, but not the final one, in successfully executing our overall plan to create an industry-leading operating model. 
On the R&D side, our goal is to create a more flexible organization that fuels innovation in our pipeline and excels at external collaboration. On the manufacturing side, we aim to have a more reliable cost-efficient worldwide supply chain to support Merck's broader product portfolio, and meet the demand of a diverse and ever-revolving global health care environment. And while there are still lots of moving parts, we are building our strong track record of quickly executing our integration plans, while launching new products and delivering strong performance from current months. That has what allowed us to drive revenue growth in key brands despite patent expiries and difficult economic conditions. 
In markets around the world, we simultaneously have launches underway for a range of products including SIMPONI in 10 markets, and JANUVIA in Japan and in India. Additionally, our latest asthma dedication, DULERA, was recently approved by the U.S. FDA, and we've begun its launch. 
As we shared with many of you during our R&D Day in May, we also have several falling under late-stage review in the EU. From our robust pipeline, we anticipate making about 20 filings for new compounds and new combinations between now and 2012, including boceprevir, vorapaxar, odanacatib and TREDAPTIVE in the U.S. 
We also remain well positioned in Animal Health, a business that is driven by growing demand for animal proteins, as well as a strong demand for companion animal healthcare. We are on track to bring together sanofi-aventis and our Animal Health businesses into a new joint venture that will create a new global leader in Animal Health. 
Looking ahead, we continue to be excited about the many opportunities before us to serve the rapidly expanding emerging markets. Throughout these markets, I believe we continue to position Merck well by launching new products and making targeted business development investments. 
Examples of our commitment and execution can be found in high-growth markets like China and South Africa. In South Africa, we have a newly formed strategic collaboration with a local partner, Adcock Ingram. Together, we will co-promote and distribute branded products as well as over-the-counter medications. This collaboration will extend our reach into the market. 
Earlier this month, Merck's executive committee members and I spent a busy week in China. It has become one of our most important markets. Providing needed medicine and vaccines to meet the expanding needs of Chinese patients is an exciting growth opportunity for us. So we are focused on building our capabilities in China including our local production capabilities, our product portfolio and R&D. 
As part of our expansion efforts, we recently unveiled joint venture plans with Sinopharm to manufacture and commercialize adult and pediatric vaccines in China, and announced plans for a manufacturing site in Hangzhou, where we'll invest to build local capacity. I've seen firsthand the excitement and hard work underway in our emerging markets around the world, with China being the most recent example. That's why I am confident that we will reach our goal of deriving 25% of our global pharmaceutical and vaccine revenue from emerging markets in 2013. 
Merck's commitment to improving health around the world is not new to us. This commitment dates back decades and most recently was recognized by the Access to Medicine Index. Merck was ranked second in the global analysis of companies that are making their medicines and vaccines readily available to markets across all income levels. All of these actions support Merck's mission to help patients around the world and to maximize shareholder return by providing innovative medicines, vaccines and consumer and Animal Health products, globally. 
With that, I'd like to turn the call over to Ken."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and good morning, everyone. As Dick mentioned, we had another successful quarter despite losing the exclusivity of COZAAR and HYZAAR and the economic challenges facing our businesses and customers around the world. In describing our secon",1727,"Thank you, Dick, and good morning, everyone. As Dick mentioned, we had another successful quarter despite losing the exclusivity of COZAAR and HYZAAR and the economic challenges facing our businesses and customers around the world. In describing our second quarter performance, please note that I will refer to supplemental combined non-GAAP results, which include the impact of foreign exchange. 
The Global Human Health business delivered a solid quarter with sales of $9.8 billion. This represents a 2% decline on a supplemental combined non-GAAP basis from the previous year, largely due to the loss of exclusivity of COZAAR and HYZAAR especially in the U.S. If you've been following the weekly prescription trends, then you have seen that there has been rapid erosion of approximately 90% of branded COZAAR and HYZAAR prescription volume in the U.S. Other markets such as the U.K. and Italy have also experienced rapid erosion. 
Excluding the impact of COZAAR and HYZAAR, Global Human Health sales grew 3% year-over-year. Sales were driven by the robust operational growth of key brands such as JANUVIA, JANUMET, REMICADE, TEMODAR and ISENTRESS. We continue to be optimistic about the growth opportunities for these brands. The speed with which we've integrated our commercial operations, the diversity of our portfolio and the underlying strength of our global business have been key factors in our successful start to the first half of 2010. 
In the second quarter, we continue to drive growth in many of our markets. International Human Health sales grew by 5% excluding COZAAR and HYZAAR. Our Emerging Markets business grew 12% in the second quarter. We spent a fair amount of time during the business briefing in May discussing our strategy and goals in the emerging markets. As we said then, we believe these markets will grow to represent more than a quarter of our pharmaceutical and vaccine sales by 2013. 
In the second quarter, the emerging markets accounted for 19% of our human health sales. Two of the emerging markets, China and Brazil, are quickly working their way up our list of top 10 markets. Sales in China and Brazil both grew by more than 15% in the quarter. We continue to expect to have significant future growth opportunities across the emerging markets. 
We are well-positioned to drive significant growth with our current portfolio of products, including JANUVIA, SINGULAIR, as well as branded generics like COZAAR and HYZAAR, as well as ZOCOR. We are also exploring multiple strategies to increase our share in the branded generic and patent-protected segments through value-creating partnerships and acquisitions. 
Dick mentioned some of the recent developments in China, including the recent letter of mutual agreement with Sinopharm to develop a joint venture to commercialize pediatric and adult vaccines in China, a very large potential market. 
Now turning to the performance of some of our key brands this quarter. As I drop the individual product performance, you can follow along in Table 3 from our supplemental financial package, as Alex said earlier. Starting with our respiratory franchise, SINGULAIR sales in the second quarter were $1.3 billion, comparable to the second quarter 2009. This year, the spring allergy season peaked early in the U.S. and was overall comparable to the 2009 season. Sales in the U.S. this quarter were also affected by unfavorable fluctuations in trade inventory. Double-digit growth of SINGULAIR in the emerging markets was offset by declines in Japan due to the timing of shipments to our partner. 
For NASONEX, global sales increased 5% driven by the strong growth in the U.S. and Japan. Despite the flat year-over-year comparisons for the allergy season in the U.S., sales of NASONEX grew in the U.S. by 7%. NASONEX continues to be the leading branded nasal-inhaled steroid, and now includes additional congestion labeling in the U.S.  In Japan, we've had robust growth since the launch, and NASONEX is now the market leader. 
Moving on to JANUVIA and JANUMET. Global revenue grew 33% to a combined $818 million. The JANUVIA franchise continues to perform strongly in terms of share and overall growth. Sales in the quarter were driven by double-digit growth across all markets. In Japan, where we recently launched JANUVIA, sales were $69 million, which included supply sales to our partner of about $40 million. We've seen strong initial response to the value proposition JANUVIA represents to Japanese physicians and patients. 
Our Immunology franchise also achieved strong growth during the quarter. REMICADE continues to be a leading immunological therapy with sales of $669 million, an increase of 18% from the previous year. REMICADE continues to deliver growth across all indications, rheumatology, gastroenterology and dermatology. We anticipate REMICADE's double-digit operational growth will continue throughout 2010. 
In addition, sales of SIMPONI were $18 million in the quarter. SIMPONI sales continue to grow as we launch the brand in more countries and take share from other subcutaneous anti-TNF. We've now launched and 10 countries, most recently in Spain. We will launch SIMPONI in other EU markets in the second half of 2010 and launches in the U.K. and France are planned for 2011. 
Turning to ZETIA and VYTORIN. Sales were $1.1 billion this quarter, which in the aggregate represents a 3% decline compared to the previous year primarily due to declines in the U.S. Sequentially, ZETIA and VYTORIN grew 4%, globally. ZETIA and VYTORIN remain a primary focus of our promotional efforts, and we continue to see solid growth in many markets around the world, including 28% year-over-year growth in Japan. We continue to make progress on the IMPROVE-IT study, which is now fully enrolled with over 18,000 patients. 
Moving on to vaccines. For the total Vaccine business, I will focus my comments on sequential comparisons. Total sales for the Vaccine business were $832 million in the second quarter compared to $846 million in the first quarter of 2010. As a reminder, vaccine sales in the first quarter benefited from a $75 million to $100 million inventory build. With that in mind, we had some bright spots in the second quarter specifically with respect to RotaTeq, which benefited from a temporary competitor supply issue and PNEUMOVAX. This, unfortunately, was offset by weaker ZOSTAVAX sales due to supply constraints and the ongoing backorders for the brand. This is a frustrating situation for our teams, our customers and patients. And we have dedicated several hundred engineers and researchers to getting it fixed. We continue to work to resolve our current supply issues and to create redundant capacity in our facilities in North Carolina and Ireland. However, we do expect sales to be negatively affected by the supply issue again in the third quarter this year. 
Moving to GARDASIL. Sales as reported by Merck in the second quarter were $219 million, an 18% decline from the previous year. In the U.S., GARDASIL sales grew sequentially by 5%. We've made good progress with the coverage prevails [ph] and funding is now secured for all states. GARDASIL continues to maintain market share leadership in the U.S., and it also remains the global market leader. 
In Infectious Diseases, ISENTRESS continues its outstanding performance as sales increased 55% to $267 million in the second quarter. The continued growth of ISENTRESS reflects the unique efficacy and tolerability profile of this product, which has been widely embraced by physicians, patients and health organizations around the world. 
While many of our brands reported positive growth trends in the EU during the second quarter, the environment in the EU and across Europe is now more challenging. Many countries have announced austerity measures aimed at reducing costs in areas such as healthcare. While the implementation of pricing actions varies by country, many have announced measures to reduce prices of generic and patented drugs. 
In the short term, we've worked with many of the industry groups and governments to help develop solutions for our customers to improve their budget positions and address the short-term economic issues. While we are taking steps to mitigate the immediate impact in the EU, we anticipate that the austerity measures will affect our revenue performance going forward.  Peter Kellogg will focus on the financial impact of the EU austerity measures in his remarks shortly. 
Moving from the economic environment, I'd like to highlight briefly some recent developments from three of our key R&D programs: DULERA, vorapaxar and boceprevir. As you know, we're in the process of launching many new products this year and we have robust late-stage pipeline with programs that represent significant scientific achievements and first-in-class opportunities. 
In June, as Dick mentioned, we received U.S. FDA approval of DULERA, our combination steroid and long-acting beta agonist for the treatment of asthma. Despite the availability of other combination treatments, there remains some large unmet need in asthma, and we believe DULERA represents a great alternative due to its differentiated profile, which includes the addition of clinically-judged deteriorations in asthma within its label. We are beginning the launch of DULERA now with plans for a full commercial launch late in the third quarter. 
Our Phase III program for vorapaxar, our PAR-1 inhibitor for the prevention of major cardiovascular events is also progressing well. Both Phase III studies are now fully enrolled. The TRA 2P study in secondary prevention is fully enrolled, and patients are being monitored for the accrual of events. The TRA-CER study in patients with acute coronary syndrome is also fully enrolled, and patients are being monitored for the accrual of events. 
Based on current event rates, we anticipate that both studies will be completed in mid 2011. We are pleased with the progress in the Phase III program. Most importantly, we continue to target a 2011 filing for vorapaxar.
Turning to boceprevir, our hepatitis C protease inhibitor, I'm pleased to share with you that both Phase III studies are now completed, and we're in the process of analyzing the results. We plan to submit the Phase III data for presentation at the AASLD meeting in November.  Finally, we remain on track to file boceprevir in 2010. 
In closing, Global Human Health, along with Animal Health and Consumer Health Care, have delivered another solid quarter for Merck. We continue to be excited by our portfolio of products and our robust late-stage pipeline. While the operating environment is constantly changing, we continue to execute on our long-term strategic goals to create the leading healthcare company. 
Now I will pass the call over to my colleague, Peter Kellogg."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, we continued our performance in the second quarter and our integration efforts are well underway. Our performance this quarter is characterized by solid operational performance, which wa",1387,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, we continued our performance in the second quarter and our integration efforts are well underway. Our performance this quarter is characterized by solid operational performance, which was tempered by the impact of generic entries for COZAAR and HYZAAR and the cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and geographies performed. And now I'd like to cover three areas with you: First, our operating results; second, our restructuring activities; and third, I want to discuss our targets for full year 2010 and beyond. 
So let's begin with our results. As Alex mentioned, we have once again provided data in our earnings release and supplemental charts to help navigate through our non-GAAP adjustments to the P&L. To simplify my remarks today, I will speak the non-GAAP results, which exclude purchase price accounting adjustments, merger-related costs, restructuring charges and the gain on AstraZeneca's asset option exercise. 
On this basis, we reported second quarter non-GAAP earnings per share of $0.86. Total revenue for the quarter was $11.3 billion. On a supplemental combined non-GAAP basis, sales were down 2% versus prior year due primarily to the impact of generic COZAAR/HYZAAR and lower Astra supply sale due to the generic erosion and return of rights to the non-PPI products. These offset solid operational growth in the rest of the business. Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. 
Our Animal Health business grew 9% to $731 million, reflecting growth among cattle, poultry and swine products. We remain on track to complete our Animal Health joint venture with sanofi-aventis in the first quarter of 2011. Consumer Care sales increased 11% to $422 million due to the strong seasonal performance of Claritin and Coppertone. 
Now moving on to the expense items in the P&L. You can see that we did a very good job managing our expenses this quarter in anticipation of additional commercial launches and spending on our late-stage pipeline expected during third and fourth quarter. As you know, the cost of our combined company are represented in our current cost base, whereas only the Merck costs were included in the second quarter of 2009. So it's a little hard to see the underlying trends on a year-over-year basis. As a result, I will speak to sequential trends on the cost lines since those comparisons are more meaningful. 
Let's begin with the materials in production. The non-GAAP gross margin in the second quarter was approximately 76.5%, which is an improvement compared to the first quarter of 2010 where the gross margin was 75.4%. Most of the improvement in the gross margin was driven by product mix, with higher sequential sales of JANUVIA, ISENTRESS and increased sales of seasonal allergy products. 
Moving onto marketing and admin expenses, on a non-GAAP basis, marketing and administrative expenses in the second quarter were $3.1 billion, which is about the same level as in the first quarter of 2010. Research and development expenses for the second quarter was approximately $2 billion, which is also in line with the first quarter. As the year progresses, we see continued investment in late-stage projects such as vorapaxar, telcagepant, odanacatib and TREDAPTIVE. 
Now let's move to equity income. In the second quarter, Merck reported $43 million of equity income, which was a decrease from the first quarter primarily due to the inherent variability and the timing of payments for the AstraZeneca joint venture. 
Moving on to other income and expense. The GAAP results include $443 million from AstraZeneca's exercise of the asset option. On a non-GAAP basis, other expense of $153 million was comparable to the first quarter of 2010. 
Moving to tax. The Merck non-GAAP tax rate was 20.5% for the second quarter, better than the rate that we saw in the first quarter. As noted in the earnings release, we continue to expect the full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned cash to shareholders through our dividend and by making progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $1.3 billion to repurchase about 38 million shares of our common stock.  So in summary, we continue on a strong trajectory since merger. 
Now let's talk about the integration activities. This quarter, we made continued progress on our cost synergy capture by reducing our headcount in global infrastructure and generating savings from procurement actions. On July 8, we announced our plans to phase out operations at eight manufacturing facilities and eight research facilities over the next two years. The merger restructuring program also includes consolidating our sites in local markets by closing 58 commercial offices. The actions we have announced so far will bring our number of R&D sites down to 16 and our number of our manufacturing sites down to 48, excluding Animal Health sites. 
We will continue to pursue productivity efficiencies and evaluate our manufacturing supply-chain capabilities on an ongoing basis. Remember, we are planning to create a new Animal Health joint venture, so our Animal Health business is not involved in the Merck merger researching activities. As a result of these and other actions such as procurement savings, we are well on track to realize a $3.5 billion synergy target by the end of 2012. 
Now let's spend the remaining time reviewing our outlook for 2010 and beyond that. Let's start with 2010. With the first six months complete, it's appropriate to provide an update on our earnings targets. We have maintained $3.34 as the midpoint of our range while tightening the EPS range for the full year. Merck is now targeting a full year 2010 non-GAAP EPS range of $3.29 to $3.39, excluding certain items. Factored into this target EPS range is our strong first quarter results, continued benefits from synergies in the second half, the impact of healthcare reform in the U.S., which is unchanged from our previous comments, and the assumption that Merck retains full rights to REMICADE and SIMPONI in our markets. 
In addition, we have assumed top line pressures due to pricing actions in some European countries and foreign exchange, both of which we believe will be a headwind in the second half. In addition, we anticipate increased second half spending for new product launches like DULERA in the U.S., new targeted commercial and R&D investments in the emerging markets and spending to support the late-stage pipeline. 
Let me go into a bit more detail to help you understand what is already factored in to the 2010 targets. As you know, and as Ken mentioned, Greece, Spain, Germany and some other markets have already announced price reductions, which will have an unfavorable impact on our results in the third and fourth quarter of 2010. The impact on European revenues in the first half was about 2% unfavorable. In the second half, we anticipate a mid single-digit unfavorable impact on European sales. 
These updates are included in our 2010 targets and will impact our second half performance relative to what we were modeling at the beginning of the year. As a result, we now expect that EPS in the second half will be similar to the level in the first half. So you should adjust your models accordingly. Logically, these actions in 2010 will also have an impact in 2011 as they annualize. 
Finally, let me touch on our long-term outlook. We remain excited about the future of the new Merck, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities that are already well underway. We continue to target a high single-digit, non-GAAP EPS compound annual growth rate from 2009 to 2013. 
In closing, we are pleased with the solid second quarter results we reported today. We clearly had a strong first half. Our expense management contributed to that performance and will help us manage a tighter environment in Europe. The merger is working, and our results and our short-term and long-term earnings targets demonstrate that we are right on track. 
Thank you. Now I'll turn the call back over to Alex."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, Peter. Now we'd like to open up the call to answer your questions. But in order to get through as many as possible, we'd like to ask you to limit yourself to one or two questions, and note that we won't take follow-up questions. But if you do have",64,"Thanks, Peter. Now we'd like to open up the call to answer your questions. But in order to get through as many as possible, we'd like to ask you to limit yourself to one or two questions, and note that we won't take follow-up questions. But if you do have additional questions, you're welcome to rejoin the queue. Amanda, we're ready for the Q&A."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question is Marc Goodman with UBS.",10,"[Operator Instructions] Your first question is Marc Goodman with UBS."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","So given what happened with RELENZA at the panel, I was just curious how you guys were thinking about how TRA plays into that market [indiscernible] there? And second of all, can you give us an update on your Biologics program?",41,"So given what happened with RELENZA at the panel, I was just curious how you guys were thinking about how TRA plays into that market [indiscernible] there? And second of all, can you give us an update on your Biologics program?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So I'll talk about Belinta [ph]. I think from our perspective, I think it's important to recognize that we always study TRA and always anticipated that it would be added to the standard of care whether it was aspirin, PLAVIX or another medicine in PLAVIX",183,"So I'll talk about Belinta [ph]. I think from our perspective, I think it's important to recognize that we always study TRA and always anticipated that it would be added to the standard of care whether it was aspirin, PLAVIX or another medicine in PLAVIX class. So it was always our intent to have it added on top of the standard of care. And so we would think that it would be added on to Belinta [ph] as that became approved at some point and became a competitor of PLAVIX. I also think it's important to recognize that even with the, for example, 16% increase, a great deal of residual risk still remains, cardiovascular risk still remains. And therefore, there's still an important role for medicine like TRA. I also think it's important to remember the product profile, which includes the fact that we have not seen any increase in bleeding unlike some of the other medicines that are being used. So for all of these reasons, I continue to think that there are really robust prospects for our medicine like TRA."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Marc, can you just repeat your second question?",8,"Marc, can you just repeat your second question?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Just an update on the Biologics or Biosimilar [indiscernible].",9,"Just an update on the Biologics or Biosimilar [indiscernible]."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So you remember that back in May, we discussed our MBV strategy, and we updated the status of the PEG-EPO program, which was discontinued. At the same time, we also highlighted the fact that a number of other programs continue on our MBV portfolio, and we",147,"So you remember that back in May, we discussed our MBV strategy, and we updated the status of the PEG-EPO program, which was discontinued. At the same time, we also highlighted the fact that a number of other programs continue on our MBV portfolio, and we also referenced biological programs that are part of our novel Biologics focus, including antibodies against HGF and IGF-1R for oncology, IL-23 for immunological indications, MK-3415A for C. difficile [Clostridium difficile], and of course, ELONVA, which is a noble follicle-stimulating hormone for fertility. So that's sort of a short description of where we are in our Biologics program. But I think it's important to recognize that we see Biologics as an important part of our future, both with respect to what we anticipate will be an abbreviated pathway for the approval of biological similars as well as novel biologics research going forward."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Chris Schott with JPMorgan.",9,"Your next question is from Chris Schott with JPMorgan."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","First question was on ZOSTAVAX. Just can you elaborate a little bit more on what needs to be done to address it?",22,"First question was on ZOSTAVAX. Just can you elaborate a little bit more on what needs to be done to address it?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure, Chris. This is Dick. I think the issue, as Ken mentioned, is that we've put significant amount of technical and engineering resources on this both from a manufacturing and a research standpoint, and certainly, right now we are cautiously optimistic.",215,"Sure, Chris. This is Dick. I think the issue, as Ken mentioned, is that we've put significant amount of technical and engineering resources on this both from a manufacturing and a research standpoint, and certainly, right now we are cautiously optimistic. We have begun production again of varicella. We believe that by starting production, we have a path forward. So that's good news. It's not going to have an impact on 2010 forecast because the product process cycle is significant, so there's many more production steps to go through yet. There's more quality testing to go through. There's more discussions with the agencies to go through. But I am cautiously optimistic due to the fact that, obviously, we've started production that is important. Now the second important aspect is, as Ken mentioned, is that we've started our focus on Durham, and we hope to have that, from a production standpoint, up and running in the second half of this year. And from a pediatric standpoint, with the relaunch of COMVAX, our HIB and Hepatitis B combination vaccines, all of Merck pediatric vaccines will be available in U.S. for the first time since mid-2007. So we are making that type of progress, but we'll keep our fingers crossed on ZOSTAVAX because we did start production again."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","On the emerging market, following this deal with Sinopharm, should we think about Merck looking at these type of partnerships going forward? Or when we think about the emerging market kind of, I guess the inorganic growth portion of this, will more tradit",91,"On the emerging market, following this deal with Sinopharm, should we think about Merck looking at these type of partnerships going forward? Or when we think about the emerging market kind of, I guess the inorganic growth portion of this, will more traditional M&A play a larger role, I guess, when I consider the moves that Abbott made, as an example, this quarter? And how are you thinking about what appeared to be fairly rich valuations if you were to consider a larger strategic move as it relates to emerging markets?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","I think the way we look at it as a company is that we don't look at the emerging markets as an entity onto itself. We look upon it as a country-by-country basis. And certainly, our total focus obviously is profitable growth and keeping profitable growth a",136,"I think the way we look at it as a company is that we don't look at the emerging markets as an entity onto itself. We look upon it as a country-by-country basis. And certainly, our total focus obviously is profitable growth and keeping profitable growth as the principal. In some cases, it will be joint ventures and relationships. Sometimes, there won't be inorganic at all, and sometimes there may be an acquisition out there that may help the foundation of a particular country or via a foundation across other emerging markets. So we really take it case-by-case and what's in the best interest of that particular country. Is there a partner? Is there a combination that makes sense from a value standpoint? And most importantly, does it makes sense from a profitable growth standpoint?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from John Boris of Citi.",9,"Your next question is from John Boris of Citi."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Just one for Peter Kellogg. Can you quantify the impact of healthcare reform in the quarter, and then what you anticipate for the full year? And then just building on the previous question on China. When you look at China, especially since you spent a fai",116,"Just one for Peter Kellogg. Can you quantify the impact of healthcare reform in the quarter, and then what you anticipate for the full year? And then just building on the previous question on China. When you look at China, especially since you spent a fair amount of time there this past week, how are you thinking about it from an ability to price your medicines? What do you see is the impact of formularies on your ability to price those medicines going forward? And then any discussions you had on the intellectual property? Obviously, that's a very important component, respecting intellectual property within the Chinese market. But any thoughts you have there would be helpful."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Thanks, John, it's Peter. So healthcare reform, I think, really is moving ahead just the way we had originally anticipated. There's no surprise this quarter. Ballpark, roughly about $44 million impact in the second quarter, and that makes sense given what",101,"Thanks, John, it's Peter. So healthcare reform, I think, really is moving ahead just the way we had originally anticipated. There's no surprise this quarter. Ballpark, roughly about $44 million impact in the second quarter, and that makes sense given what we'd talked about as a full year impact of about $170 million. So really no update, no change really on what we've anticipated or originally modeled. We've always said that, that would probably increase next year to something in the $300 million to $350 million. So it's pretty much in line with what we've always talked about, no new surprises."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on China, let me just start by saying that I think we continue to be very excited about the future in China. To look at China in a monolithic way as it relates to pricing or any other aspect of our commercial strategy, I think is not how we are going t",253,"So on China, let me just start by saying that I think we continue to be very excited about the future in China. To look at China in a monolithic way as it relates to pricing or any other aspect of our commercial strategy, I think is not how we are going to approach it. So let's start with the robust growth that we anticipate in the middle class in the urban areas of China. For those people, healthcare is still likely to be a self-pay exercise, and so we will continue to look at those market segments in a way that we can price competitively with alternative therapies. But I will say that the pricing in China has allowed both broad access, while at the same time, also allowing strong profit margins in that country. I think the other aspect is through the government. And so there's an essential drug list, which is part of Chinese healthcare reform, and Merck participated in the Essential Drug List placing ZOCOR among other magazines on that drug list. And our experience there has been that while we had to provide substantial discounts to get entree to the Essential Drug List, the volumes have more than compensated for the pricing reductions that we have. So I think what we've seen with ZOCOR right now is an example of how, in that market, we have to price in a way that creates value for that market and there's still an opportunity to be profitable in that context."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tim Anderson, Sanford Bernstein.",9,"Your next question is from Tim Anderson, Sanford Bernstein."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","I know you don't like to say much about the REMICADE dispute, but I'm hoping at least you can give us some more information. You used to talk about being highly confident that you would prevail in the dispute, but I don't really hear that language being u",131,"I know you don't like to say much about the REMICADE dispute, but I'm hoping at least you can give us some more information. You used to talk about being highly confident that you would prevail in the dispute, but I don't really hear that language being used anymore and I'm wondering if that's still the case. On arbitration, can you run through different options here? Is it all or nothing, or could there be some sort of middle ground or what exactly? And then your comments about not impacting 2013, it's not clear to me why that wouldn't impact your 2013 guidance because it is a pretty material contributor to your financials. And by extension, if it doesn't impact 2013, can we assume that it wouldn't impact 2010 either?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","We're going to start with Bruce Kuhlik.",8,"We're going to start with Bruce Kuhlik."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","At this point, we provided the information about when we expect the arbitration hearing to begin and the selection of the panel. We're looking at whether we can provide some additional information with respect to the process, and I hope to do that in a re",80,"At this point, we provided the information about when we expect the arbitration hearing to begin and the selection of the panel. We're looking at whether we can provide some additional information with respect to the process, and I hope to do that in a relatively near future. We continue to believe very strongly that we've structured this transaction in a way that's appropriate for the REMICADE distribution agreement. And I'll turn it over with respect to the financial targets."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Tim, it's Peter Kellogg. So I don't think we said it didn't impact one way or the other. What we said was our guidance has this contingency incorporated, so that really our guidance that we provided would be so achievable regardless of the outcome in this",80,"Tim, it's Peter Kellogg. So I don't think we said it didn't impact one way or the other. What we said was our guidance has this contingency incorporated, so that really our guidance that we provided would be so achievable regardless of the outcome in this arbitration or topic. Obviously, depending on the outcome, it will make that guidance number easier or more challenging. But nonetheless, I think we feel comfortable with the guidance that we provided under different scenarios."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","And then 2010?",3,"And then 2010?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Well, for 2010, obviously, the timing is a little unclear and it would be pretty relatively late in the year, but that would be something we have to really depend on the outcome. So I don't think we've said for 2010 that's one way or the other really it -",69,"Well, for 2010, obviously, the timing is a little unclear and it would be pretty relatively late in the year, but that would be something we have to really depend on the outcome. So I don't think we've said for 2010 that's one way or the other really it -- I'd say right now, what we did highlight was our guidance included REMICADE and SIMPONI in our 2010 numbers."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Jami Rubin of Goldman Sachs.",10,"Your next question is from Jami Rubin of Goldman Sachs."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","So Peter, question for you. This quarter, you beat earnings by $0.03 relative to consensus, but not letting to fall through to full year guidance and your clipping the top end by $0.02. So is it fair to assume that the cost of European austerity measures",108,"So Peter, question for you. This quarter, you beat earnings by $0.03 relative to consensus, but not letting to fall through to full year guidance and your clipping the top end by $0.02. So is it fair to assume that the cost of European austerity measures will be about $0.05 this year until we assume about a $0.10 hit next year since the impact will be annualized? And my second question refers to -- you didn't mention SAPHRIS. I know that was recently introduced. We didn't see sales for SAPHRIS or TREDAPTIVE. And Ken, maybe if you can update us on how you're seeing those new launches progress."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. So Jami, yes, I think the key thing is that we obviously -- all we've done is narrowed the range for our guidance for the full year. So we really maintain the midpoint of our guidance range and EPS. Obviously, we have, as I commented and as you poin",391,"Sure. So Jami, yes, I think the key thing is that we obviously -- all we've done is narrowed the range for our guidance for the full year. So we really maintain the midpoint of our guidance range and EPS. Obviously, we have, as I commented and as you pointed out, we've taken into account some of the top line pressures we see in the balance of the year. Obviously, we do expect to see the pricing impact in the second half of the year. The way we look at it, it's about mid single-digit range impact on the European revenues. Translating that to the top line, it's probably in the neighborhood of, I'm guessing, it's about $300 million or so. And obviously, we have to fully annualize that next year. The other thing is, obviously, Forex. Now the impact of Forex for us is a little complex because obviously, you have the Forex impact around the world, not just euro but yen and other currencies. And you have to net that against our hedge program. We anticipate in the second half of the year currency being a slight negative on our top line, probably something in the 1%, 2% range kind of as you go through the second half of the year. Obviously, those rates still move around. So those are the primary factors in addition to the healthcare reform. So that said, going the other way, we have a lot of activity on the expense line in the second half that will actually be driving our business going forward. And as we go into 2011, we'll be launching DULERA, we have a lot of activity going on in Japan, launching products, having a lot of success. We will be, obviously, investing in the emerging markets as you've seen announcements, and we'll continue to grow there. And obviously, our pipeline, which is a big driver for us in the future, continues to move forward with very nice progress. So you can expect to see some spending in that in the second half, a little more in the first half. So all those points combine to lead us to our guidance. But the most important thing is we didn't change the midpoint of our guidance range. We just narrowed the range as we've gone through the first half of the year."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","With SAPHRIS, I think we mentioned earlier that the current performance has been affected by destocking last year. I would say a couple of things. We continue to focus on building the brand awareness, and we're also getting reasonably good unrestricted Ma",252,"With SAPHRIS, I think we mentioned earlier that the current performance has been affected by destocking last year. I would say a couple of things. We continue to focus on building the brand awareness, and we're also getting reasonably good unrestricted Managed Care access about 65%. But the product right now, I would say frankly, is not where we want it to be. On TREDAPTIVE, I would say that obviously for us, the sales have not yet become material in Europe. But the real thing that we're doing on TREDAPTIVE is HPS2-THRIVE and creating a market in the U.S. I think there's still a need -- a growing awareness of HDL as its impact on cardiovascular health going forward. I would say the other issues around launches are, we are very pleased with the way SIMPONI is going, JANUVIA's continuing the launch well around the world including Japan. BRIDION is having a spectacular launch in Japan, and we look forward to DULERA. So I would just say that SAPHRIS and TREDAPTIVE has not yet become material. We continue to think TREDAPTIVE has a great future in the U.S., and we continue to work with SAPHRIS. And then I also -- it was pointed out to me that I forgot to answer quickly the Chinese IP question and I would say that on that one, we continue to proceed carefully with respect to our assets in China to make sure that we get the benefit of that market while also protecting our IP."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","A quick follow-up to Dick. Dick, you spent about $1.3 billion this quarter repurchasing about 38 million shares. What are your plans for share repurchases going forward just given the significant amount of free cash flow you're generating?",39,"A quick follow-up to Dick. Dick, you spent about $1.3 billion this quarter repurchasing about 38 million shares. What are your plans for share repurchases going forward just given the significant amount of free cash flow you're generating?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Peter, you want to answer that?",6,"Peter, you want to answer that?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. So Jami, obviously, we have an authorization to do up to $3 billion of share repurchase, and we haven't worked our way through that entirely. So that's on our agenda going forward, obviously. We like to, generally, on an ongoing basis, stabilize the",142,"Sure. So Jami, obviously, we have an authorization to do up to $3 billion of share repurchase, and we haven't worked our way through that entirely. So that's on our agenda going forward, obviously. We like to, generally, on an ongoing basis, stabilize the shares outstanding; but then periodically, step in when we see a good opportunity to pick up some of our shares. And quite frankly, we see when our stock is down is a very good way of returning cash to shareholders. We know that's a focus of a lot of our key shareholders, and we take that seriously as well. I think over the last five years, as we've said in the past, our track record of returning cash flow to shareholders is phenomenal. We're in the upper 90%, above 90% range. So we could plan to continue that."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Tony Butler of Barclays Capital.",10,"Your next question is from Tony Butler of Barclays Capital."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick, I think that you, in your opening statements, made reference to the value, continuously realizing the value of the combined company. I'm curious exactly what you mean by that. Is it just cost? And then by extension of Tim Anderson's question, would",87,"Dick, I think that you, in your opening statements, made reference to the value, continuously realizing the value of the combined company. I'm curious exactly what you mean by that. Is it just cost? And then by extension of Tim Anderson's question, would you be able to make that statement true if in fact the arbitration does not go your way? And then as a follow-up to that, if the arbitration does go your way, how do you think about perhaps moving additional increases to the dividend?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Obviously, I'm not going to make any future comments on the arbitration based on process of where we are in today. But if you go back to why this is such an important merger to the company, it's far beyond the cost synergies. Cost synergies, in many cases",319,"Obviously, I'm not going to make any future comments on the arbitration based on process of where we are in today. But if you go back to why this is such an important merger to the company, it's far beyond the cost synergies. Cost synergies, in many cases, is an afterthought to why we did this merger and why we're still excited about it. First of all, the most important aspect of this merger that we continue to be excited upon is that it's a late-stage pipeline, and the research synergies from the standpoint that you're -- you have complementary franchises, and there's not much overlap and mechanism of actions, and there's great scientific and technological sharing out that is just so important for the future of the company. So the first and foremost reason why this makes sense moving forward is the scientific and research pipeline and the scientific and research technology that we're sharing across mutual franchises as we move forward. The second part to that is the product portfolio. The excitement that we see from our professional reps country-by-country when we visit there about having now a combined portfolio that can really come up with the right resolution for patients and physicians is just incredible. We're no longer a one trick pony when it comes to some franchises or to these states. We have a portfolio that can meet their needs, and I think that capability is extremely important. And then third, I think is the geographical footprint we have. The geographical footprint that we combined with the two companies, as you know, is critical to the future since we're not and will not be a U.S.-centric company. So when you look at all of those evaluations, to us, those are the most important. And obviously, REMICADE and SIMPONI are important as well, but even without those two, this makes a lot of sense to us."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Risinger with Morgan Stanley.",10,"Your next question is from David Risinger with Morgan Stanley."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","First, with respect to SAPHRIS, can you just update us on where the reformulation process stands? And then second, you've discussed branded generics this year. I don't think that you've talked about branded generics in prior years. Can you talk about how",53,"First, with respect to SAPHRIS, can you just update us on where the reformulation process stands? And then second, you've discussed branded generics this year. I don't think that you've talked about branded generics in prior years. Can you talk about how broad of a portfolio you'd like to have in emerging markets?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on the SAPHRIS formulation issue, we're on track, and we plan to launch a new black cherry version to provide patients with a different, better taste option. So that's where we are on that issue. On the branded generics issue, as Dick mentioned before,",173,"So on the SAPHRIS formulation issue, we're on track, and we plan to launch a new black cherry version to provide patients with a different, better taste option. So that's where we are on that issue. On the branded generics issue, as Dick mentioned before, I think it does vary very much market by market. But I want to start by saying, we have a very substantial branded generics business right now inside the company, with over 150 products available in the emerging markets based on previous portfolios of the two companies. And we see brands, as I mentioned, like ZOCOR in China just growing phenomenally. So what we intend to do is we intend to look at the branded generics business on a country-by-country basis, look at the opportunities to expand on the current portfolio of products that we have of both our traditional established products as well as our innovative products, and we intend to build on those in ways that create value for customers as well as for our shareholders."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from Seamus Fernandez of Leerink Swann.",10,"Your next question is from Seamus Fernandez of Leerink Swann."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","This question is actually for Peter. It might be a little bit unfair, but Peter, you had said that you'll do opportunistic repurchases when your shares are down. Would you characterize your stock as an attractive opportunity today or being down at current",44,"This question is actually for Peter. It might be a little bit unfair, but Peter, you had said that you'll do opportunistic repurchases when your shares are down. Would you characterize your stock as an attractive opportunity today or being down at current levels?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Peter?",1,"Peter?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Seamus, so obviously, I can't comment on that. But I think the key point is that -- what I meant by that is also when we have cash positions and when we see the opportunity from a window standpoint. Obviously, for us to go in the market, we have to have a",69,"Seamus, so obviously, I can't comment on that. But I think the key point is that -- what I meant by that is also when we have cash positions and when we see the opportunity from a window standpoint. Obviously, for us to go in the market, we have to have an open window position. So all those factors come into play, but I can't really comment on that."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question is from David Maris with Credit Agricole CLSA.",11,"Your next question is from David Maris with Credit Agricole CLSA."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","The Sinopharm China deal looks very interesting. Can you tell us when will you start to distribute vaccines through their system? The facility that you broke ground on, is that vaccines only or is that oral doses? And also how many salespeople do you have",57,"The Sinopharm China deal looks very interesting. Can you tell us when will you start to distribute vaccines through their system? The facility that you broke ground on, is that vaccines only or is that oral doses? And also how many salespeople do you have in China at this point, and where was that a year ago?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Your question on the new facility in Hangzhou is a pharmaceutical facility beginning with packaging products and then moving on into manufacturing. So that won't be completed until 2012, and we'll employ about 800 employees when we're finished. It's truly",84,"Your question on the new facility in Hangzhou is a pharmaceutical facility beginning with packaging products and then moving on into manufacturing. So that won't be completed until 2012, and we'll employ about 800 employees when we're finished. It's truly too early to make a comment about Sinopharm and the timing of it and activities like that since we're in, obviously, in negotiations to complete the contract. And so just stay tuned on that, we'll share that with you as soon as we can."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","On the representative levels in China, I think our current complement is about 5,000 people across the country. That's up about 1,000 since last year. So we continue to build our sales force, and we continue to penetrate deeper and deeper into the country",56,"On the representative levels in China, I think our current complement is about 5,000 people across the country. That's up about 1,000 since last year. So we continue to build our sales force, and we continue to penetrate deeper and deeper into the country because it's important to be able to win at the hospital level."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","Your final question is from Eric Lo with Bank of America Merrill Lynch.",13,"Your final question is from Eric Lo with Bank of America Merrill Lynch."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Analysts","Can you run through what your product launches are in Japan over the next 12 months? And also, maybe second question, comment on your priorities for the Consumer division? It's one of the smaller divisions, but growth seems to be improving. Are you guys p",65,"Can you run through what your product launches are in Japan over the next 12 months? And also, maybe second question, comment on your priorities for the Consumer division? It's one of the smaller divisions, but growth seems to be improving. Are you guys planning to grow the business through internal investments or maybe acquisitions? And are there any products that you might consider divesting?"
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So starting with Japan...",5,"So starting with Japan..."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Let's start with Consumer first if we can.",9,"Let's start with Consumer first if we can."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","The consumer business continues to be an important part of our strategy, particularly outside the U.S. There's the complementary nature of having RX products and OTC products. In many cases, using the same distribution channels and wholesalers and pharmac",205,"The consumer business continues to be an important part of our strategy, particularly outside the U.S. There's the complementary nature of having RX products and OTC products. In many cases, using the same distribution channels and wholesalers and pharmacies is extremely important to us. And I think one of our areas of growth is building the business x U.S. and Europe and emerging markets. So we continue to think that's an exciting growth area for us. We're investing in it as we move forward. And obviously, outside the U.S. as well there's an Rx-to-OTC switch capability, which is also important. And there's a synergy where you can use some of the shared services capabilities between the Global Human Health division as well as the Merck Consumer Care division to get some costs synergies at the same time. So it's an important part of our future moving forward. And as you know, some of the products have lives of their own. CLARINEX can be an 80 to 100-year-old product and still perform extremely well on a global platform. We have to resource it right, and make sure that we're supporting it from a promotion end. We're very excited about the Consumer Care research pipeline as well."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","So on the Japanese launches, I'll just highlight four of them that we think are really important. ZETIA is having a very strong launch with -- it's already gained about 9% share in the Japanese market. JANUVIA, that launch is going extremely well. As we m",103,"So on the Japanese launches, I'll just highlight four of them that we think are really important. ZETIA is having a very strong launch with -- it's already gained about 9% share in the Japanese market. JANUVIA, that launch is going extremely well. As we mentioned, we had sales of almost $70 million this quarter. BRIDION had a very strong initial penetration in Japan. And then lastly, we're in the midst of launching NASONEX. So we have some really strong launches underway in Japan for key products, and we're very hopeful about ongoing launches as well as the future launches that are upcoming."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Executives","Okay. Thanks, Ken. Thank you, everyone. That ends our second quarter earnings call. Have a good day.",17,"Okay. Thanks, Ken. Thank you, everyone. That ends our second quarter earnings call. Have a good day."
288502,108814676,70972,"Merck & Co. Inc., Q2 2010 Earnings Call, Jul-30-2010",2010-07-30,"Earnings Calls","Merck & Co., Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir.",39,"Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I want to point out a couple of things this morning. First, there are a number of items in the GAAP result",372,"Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I want to point out a couple of things this morning. First, there are a number of items in the GAAP results such as purchase accounting adjustments and merger-related expenses, restructuring costs. There's also a $380 million tax benefit and a $950 million legal reserve. In those GAAP, we have excluded those items from our non-GAAP results, and you could see a reconciliation table from the GAAP to non-GAAP figures in our press release. And that'll give you a better sense of the underlying performance. 
Next, we've also provided tables to help you understand the revenue trends. There are three tables in the press release. The first table, Table 1, is the GAAP results. Table 2 reconciles our GAAP P&L to non-GAAP for the third quarter and year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products as if the company have been combined for 2009, as well as 2010. During the call, we'll refer to Tables 2 when we discuss the P&L and Table 3 for the revenue performance. So you may want to have those available.
Finally, I'd like to remind you that some of the statements we make during the call today may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Act of 1995. Such statements are based upon the current beliefs of management and are subject to significant risks and uncertainties. Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected this morning. Merck undertakes no obligation to publicly update any forward-looking statements.
Our SEC filings, as well as our earnings release are available on merck.com. And with that, I'd like to let you know that I'm joined by Dick Clark, our Chairman and Chief Executive Officer; by Ken Frazier, our President; and also I'm joined by Peter Kellogg, our Chief Financial Officer. 
Now I'd like to introduce Dick Clark."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We had cons",950,"Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We had consistently focused on achieving the benefits of the combination for patients, customers, shareholders and employees. Most important is furthering the science that underpins Merck's ability to address many of the world's most serious, unmet medical needs.
Today, our company has greater geographic reach, one of the industry's broadest product portfolio, and has a tremendous late-stage pipeline that I believe is second to none. As we mark the anniversary of our merger, I want to thank many Merck colleagues who have helped us manage a significant combination so effectively. Throughout the past year, we have continued to drive revenue growth or key products, improve our cost structure and make the right strategic investments in our business. We've accomplished this while successfully taking on a challenging task of integrating our people, systems and cultures to form a powerful, unified organization. And while we still have work to do, Merck is well positioned now and for the future.
Our solid third quarter 2010 financial results illustrate that we are continuing to execute our strategy. We realized top line worldwide sales of $11.1 billion, non-GAAP earnings per share of $0.85 and GAAP earnings per share of $0.11 for the quarter.
Key brands including JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE were each strong performers this quarter. It is Merck's ability to develop and offer these truly differentiated products that will position us to successfully navigate difficult economies, pricing pressures and challenging regulatory environments throughout the world. In a few moments, Ken will discuss our global product performance in more detail. Peter will then provide you with our full earnings outlook.
While our merger has always been about the science, synergies are also important. We are on track to achieve our previously announced synergy target of $3.5 billion in annual savings by the end of 2012. As we continue to integrate, there's exciting activity across all of Merck and the world, particularly R&D and commercial strengths at Merck. In coming months and into next year, we expect some important clinical data from promising candidates in our robust pipeline. You will hear more about these milestones in a few moments.
And this pipeline is coming through in other ways too. As we speak, we have 10 major product launches underway in important markets around the world. And just the last few weeks alone, we have received regulatory approval for BRINAVESS in Europe and signed an important partnership agreement to allow Lundbeck to distribute SYCREST in all markets outside the United States, China and Japan. 
Recently, we also marked our first major U.S. product launch as a combined company with the DULERA launch. With the addition of this exciting new asthma product, Merck now has the widest respiratory portfolio available in the United States. Lastly, I had the pleasure of participating in the DULERA launch. With the addition of this exciting new asthma product, Merck now has the lightest respiratory portfolio available in the United States. 
Last week, I had the pleasure of participating in the DULERA launch meeting, along with our sales and marketing team. It was great to share first-hand the enthusiasm and excitement our sales representatives have to bring this new treatment to our customers. We made excellent progress in the integration of our commercial operations in our major markets throughout the world. Those integrated markets account for about 85% of our Global Human Health sales. It is exciting to see the benefits of our broader, more diversified product portfolio as we engage with physicians and customers. The team is doing an excellent job executing on our commercial sales model in the United States and in key markets in Europe, Japan, Latin America and Asia Pacific. Our overall goal is to outperform our peer pharmaceutical companies and become the clear industry leader in the eyes of our customers.
In fact, our customer survey for the U.S. market indicates that Merck continues to lead in trust and value metrics versus our peers. Our focus is on positioning Merck to become a leader in the key global growth market, and our broad portfolio of healthcare offerings will drive further growth in these emerging markets. We are currently the fifth-largest multinational pharmaceutical player in a fast-growing emerging markets, and we are aiming much higher. By 2013, we seek to drive at least 25% of our Global Human Health in vaccine sales from the emerging markets. We are making good progress and in the third quarter, that number was 18%. 
Over time, we will build further in these efforts by leveraging our advantage using our broad in-line portfolio. Many of these brands are former blockbusters with considerable brand equity such as ZOCOR. But we're also successful relaunching new products in these markets such as JANUVIA. Additionally, we are seeking to globalize the Vaccine business through growth in emerging markets through partnerships and through the introduction of low-cost manufacturing for some of our key products to expand affordable access.
Finally, we are working to tap the significant growth potential for many of our well-regarded consumer care brands by expanding our operations outside the U.S. In summary, we've made great progress, driving growth of key products, achieving our merger synergies, expanding our global reach, launching new products and advancing our late-stage R&D pipeline. One year post-merger, our results demonstrate that we are realizing the benefit of our merger, while ensuring that the company is well positioned for the future. 
Now I'll turn it over to Ken."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity fo",1654,"Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity for COZAAR and HYZAAR. Our commercial performance this quarter was characterized by continuing strong performance of key brands such as JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE, which was complemented by strong growth in key geographic markets and new contributions from our ongoing product launches such as SIMPONI, BRIDION and AFLURIA. 
Before I review the sales performance, I'd like to refer you to Table 3, which provides the supplemental combined non-GAAP results and includes the impact of foreign exchange. As you review Table 3, you'll see that product sales were driven by the robust growth of our key brands, SINGULAIR, JANUVIA, JANUMET, REMICADE and ISENTRESS. These brands grew a combined 17% year-over-year. 
Now let's take a closer look at the performance of some of these key brands starting with SINGULAIR, which grew 12% over the previous year. The increase in sales was driven by growth in most regions. We continue to see volume growth in the U.S. and EU and continued class leadership in Japan. Additionally, SINGULAIR sales in the emerging markets grew 25% in the third quarter. 
Moving on to JANUVIA and JANUMET. Global revenue grew 28%. Sales this quarter were, again, driven by double-digit growth across most regions. We continue to see volume growth in the U.S., and the franchise continues to grow in the EU due largely to new indications and the ongoing launches of JANUMET.
On a combined basis, JANUVIA and JANUMET are the leading branded oral anti-diabetic franchise in roughly 75% of the top 20 markets. We continue to focus on extending the value of this franchise, and we remain on track for filing a JANUMET once-daily formulation with the FDA next year. Actually, this year, I apologize.
REMICADE sales increased 9% in the third quarter. Despite the austerity measures across the EU, REMICADE continues to grow by double digits, excluding the impact of foreign exchange. Even in markets where we've seen a good uptake of SIMPONI, REMICADE continues to grow. 
Turning next to ISENTRESS. After three years on the market, it continues to deliver outstanding performance, gaining market share across all indications. ISENTRESS' strong sales growth in the third quarter was driven by the growth in the  treatment-nave indication and broad utilization of new treatment guidelines in the U.S. We remain on track to file the once-daily dosing regimen with the FDA in 2011.
For the VYTORIN and ZETIA franchise, sales decreased 3% in the third quarter as volume declines in the U.S. were only partially offset by higher sales outside the U.S. The sales growth outside the U.S. was primarily driven by the 30% growth of ZETIA in Japan and 13% growth of VYTORIN in the emerging markets. VYTORIN and ZETIA continue to be an important treatment option to help many patients lower their LDL cholesterol. We understand that researchers from Oxford plan to present the results of the SHARP study at the ASN [American Society of Nephrology] meeting in November. That study, as you know, focus on patients with chronic kidney disease.
Now let's shift to our Vaccine business where we're starting to see signs of progress, including more stable supply. GARDASIL sales grew 2%, benefiting from the timing of shipments to customers. Sales increased sequentially, largely due to the seasonality of the back-to-school period. Sales in PNEUMOVAX were down 15% as a result of the unfavorable seasonal comparison from the H1N1 pandemic last year. We launched our newest vaccine, AFLURIA for the seasonal flu, which posted sales of $35 million in the third quarter. 
We continue to work on the supply issues with ZOSTAVAX. We had limited shipments of the product in Q3, and we anticipate delivering additional shipments to U.S. customers by the end of this year. As you can see, our overall business continues to benefit from the diversity of our product mix and our portfolio of differentiated brands. In addition, our broad global presence is also an asset, providing us with the flexibility to leverage our portfolio in key markets around the world.
In the U.S., sales grew 1% if one excludes the impact of generic erosion for COZAAR and HYZAAR. When you look more closely at the business lines, you'll see that we had double-digit growth in our diabetes franchise, as well as strong growth in our women's health franchise, and we continue to gain market share for products such as ISENTRESS and SINGULAIR. In addition, as Dick mentioned, we are in the process of launching DULERA, our newest treatment for asthma in the U.S. We shipped to pharmacies in July, and we completed our full promotional launch last week. We are encouraged by the early feedback from the field as we focus on the unique attributes of DULERA compared to other combination products.
Now let's turn to the EU, where sales were lower this quarter due to the loss of exclusivity of COZAAR and HYZAAR, as well as the impact of European austerity measures. We continue to believe these measures will have a mid-single digit impact on European sales in 2010. Despite those economic challenges, we continue to see strong growth in key brands such as JANUVIA, JANUMET, ISENTRESS and REMICADE. We're also launching many new products in the EU. SIMPONI, which has been launched in 18 countries, recorded sales of $27 million in the quarter. While we're still working to gain reimbursement in many markets, the early performance indicators are positive.
We also launched BRINAVESS and DAXAS into markets, and we'll have additional launches of those products in 2011. As I said earlier, we saw good performance in key growth markets. In Japan, sales increased 7%, largely driven by ZETIA and SINGULAIR and the strong launches of BRIDION, COSOPT and JANUVIA are also contributing to our growth in Japan. We continue to focus on our business in Japan as we get ready to file and launch many additional brands over the next three years. We also continue to make significant yet disciplined long-term investments in the emerging markets. 
Growth in the quarter was driven by our top six markets where we saw significant gained from countries such as China, which grew 21% in the quarter. We're approaching each emerging market as a separate opportunity to optimize our product mix as we focus on each local market and its specific customer needs, we've seen an ideal match with our diverse product portfolio. Whether it'd be vaccine, products for cardiometabolic disease or the offerings in our women's health franchise, we're seeing growing utilization of Merck products in the emerging markets.
Now people typically think of branded generics as the only key to success in the emerging markets. But JANUVIA is a great example of how an innovative and differentiated product with the right level of educational and promotional support can become a market leader in the Asia Pacific region. While there's a lot of focus on the emerging markets, one shouldn't forget that science and innovation remain at the core of our business in every part of the world. For us to be successful, we have to continue to discover, develop and launch differentiated products with clinical profiles that offer patients and payers proven benefits.
That's why our late-stage pipeline is so critical to our future. In the fourth quarter, we have data presentations for three of these key late-stage programs, which I'd like to discuss with you briefly now. Last week, at the ASBMR [American Society for Bone and Mineral Research] meeting, we presented the four-year BMD [bone mineral density] data for odanacatib or selective Cat [Cathepsin] K Inhibitor for the treatment of osteoporosis. Patients on odanacatib continue to show increases in bone mineral density at the lumbar spine and hip. Odanacatib is currently in Phase III and we will have a long-term fracture study with 16,000 patients, which is fully enrolled. We plan to file odanacatib with regulatory authorities bolstered by that outcome study in 2012.
Starting this weekend and continuing into next week, researchers will present final Phase III data for both boceprevir, our hepatitis C protease inhibitor at the AASLD [American Association for the Study of Liver Diseases] meeting in Boston. We previously announced the top line results of the Phase III program. In those studies, boceprevir added to the current standard of care, double the cure rate in treatment-experienced patients and nearly double the cure rate in treatment-nave patients. With the use of response-guided therapy, we also showed that the addition of boceprevir has the potential to shorten the duration of therapy in both treatment-experienced and treatment-nave patients compared to standard therapy. The data that will be presented at the upcoming liver meeting are compelling, and we look forward to sharing them with you.
We remain on track to complete the filing of boceprevir with regulatory authorities around the world this year. Later in November, we will present study result for anacetrapib, our CETP-Inhibitor for the treatment of atherosclerosis at the AHA [American Heart Association] meeting in Chicago. As expected, the results of this study confirmed our decision to move anacetrapib to the planned outcome study that will begin next year. As you can see, we will be presenting a lot of data in the fourth quarter and beyond as we move many of our late-stage research programs forward.
In summary, we've delivered another good quarter. We continue to be excited by the opportunities to grow our business through our current portfolio of products in key markets and through a robust late-stage pipeline, supported by outcome studies. While the operating environment is constantly changing, we are steadily executing on our strategic goals to create the leading healthcare company in the world. 
And now it is my pleasure to turn the call over to my colleague, Peter Kellogg."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and con",1395,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and continuing cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and markets performed, and now I'd like to cover our third quarter financial performance and our outlook. So let's begin with our results.
Our GAAP financial information can be found in Table 1 of our release. To make it easier to follow my remarks today, I will speak to the non-GAAP results in Table 2a, which exclude purchase accounting adjustments, merger-related costs, restructuring charges, a $380 million tax benefit and a $950 million legal reserve. 
On this basis, we reported third quarter non-GAAP earnings per share of $0.85. Total revenue for the quarter was $11.1 billion, down 4% on the supplemental combined non-GAAP basis. Excluding the impact of generic COZAAR/HYZAAR and the unfavorable impact of foreign exchange, sales were actually up about 2%. This is good performance. Despite the unfavorable impact of austerity measures in Europe and the impact of healthcare reform in the U.S., and we are pleased with the performance of each of our businesses. 
Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. Our Animal Health business grew 3%, 6% FX change to $687 million, reflecting growth in North and South America, as well as growth and poultry, swine and aquaculture. Consumer Care sales also increased 3% to $291 million due to the growth of foot care, respiratory and skin care products. Growth in these areas was partially offset by the impact of generic MiraLAX.
Now moving on to the P&L. You can see that we have done a very good job controlling our expenses again this quarter. We continue to be very pleased with the progress we're making against our merger synergies, and we are doing so while launching new products and making great progress with the R&D pipeline. As you know, the costs of our combined company are represented in our current cost base. Whereas only the legacy Merck costs were included in the third quarter of 2009, which complicates analysis on a year-over-year basis. As a result, I will speak to the sequential trends on the cost line since those comparisons are more meaningful. 
First, materials and production. The non-GAAP gross margin in the third quarter was 74.9%, which was lower than the second quarter of 2010 when the gross margin was 76.5%. As you can see, our gross margin moves a bit quarter-to-quarter mostly due to product mix. This quarter, the mix changes came from a variety of factors, including lower sequential sales of products like NASONEX, CLARINEX and CLARITIN. Sequentially, the second quarter also benefited from a favorable foreign exchange impact, which did not recur in the third quarter.
Moving on to marketing and admin [administrative] expenses. On a non-GAAP basis, marketing and administrative expenses in the third quarter were $3 billion, which was about $100 million lower than the second quarter of 2010. And on a year-to-year basis, we drove significant cost savings in M&A due to the realization of merger synergies. This was partially tempered by increased promotional spending to support new launches like SIMPONI and DULERA. As you know, we are actively launching many new products, and we expect 2011 to be an exciting year for new product launches in the U.S. and around the world. I'll talk more about that later.
Research and development expense for the third quarter was approximately $1.9 billion, which was slightly lower than the first two quarters due to the continued work we are doing to further prioritize our R&D investments. As a result of the prioritization activities, we decided to stop investment in a few additional programs in the third quarter. We also previously announced the plan to rationalize our R&D network. Meanwhile, we continue to invest in our most promising, late-stage projects such as vorapaxar, boceprevir, telcagepant, odanacatib and TREDAPTIVE. And these key programs in our pipeline continue to move forward. 
Now let's move to equity income. In the third quarter, Merck recorded $236 million of equity income. As expected, this was sequentially higher than second quarter. Remember the income from the AZLP [AstraZeneca LP] joint venture in the second quarter was low due to the inherent variability in the timing of income from the AZLP joint venture.
Moving on to other expense. On a non-GAAP basis, other expense of $158 million was comparable to the second quarter of 2010. Our non-GAAP results exclude the impact of a legal reserve of $950 million in connection with an anticipated resolution of a previously disclosed investigation by the U.S. Attorney's Office for District of Massachusetts related to VIOXX. 
Moving to tax. The Merck non-GAAP tax rate was 22.2% for the third quarter, which was higher than the rate that we saw in the second quarter. As noted in the press release, we continue to expect full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned the cash to shareholders through our dividend and by making continued progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $300 million to repurchase roughly 8 million shares of our common stock. So far this year, we have repurchased about 47 million shares for $1.6 billion. 
So in summary, we continue on a strong trajectory since our merger. Now let's spend our remaining time reviewing our outlook for 2010 and beyond, and let's start with our 2010 outlook. Given our strong year-to-date performance, we are only making one change to our 2010 financial targets. We raised the lower end of our EPS target range, resulting in an increase in the midpoint of our EPS range. On a non-GAAP basis, Merck is now targeting a full year 2010 EPS range of $3.31 to $3.39, excluding certain items. Please see our press release for the GAAP guidance.
Factored into this EPS range are the top line pressures in the U.S. and the EU, including the impact of healthcare reform in the U.S., which is unchanged from our previous estimates and the impact of European austerity measures. Recall that we had anticipated a mid-single digit unfavorable impact on European sales in the second half of 2010. We still believe that will be the case.
Our current year EPS range also assumes that Merck retains full rights to REMICADE and SIMPONI in our markets. On the expense side, as I mentioned earlier, we also anticipate increased promotional spending in the fourth quarter and in 2011 for new product launches like DULERA, DAXAS, BRINAVESS and additional launches of SIMPONI around the world, not to mention we are preparing for the prospect of launching boceprevir in 2011. And we continue to make new targeted commercial and R&D investments including those in the emerging markets.
These growth driving investments are a major reason why we expect our operating expenses in the fourth quarter to be sequentially higher than they were in the third quarter of 2010. So while these top line pressures and operating investments put pressure on the fourth quarter, we are comfortable with our full year 2010 EPS guidance range. 
Finally, let me touch on our long-term outlook. We remain excited about our future, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities are already well underway. We continue to target a high single digit non-GAAP EPS compound annual growth rate from 2009 to 2013 regardless of the outcome of the REMICADE arbitration. 
In addition, we are well on track to realize our $3.5 billion synergy target by the end of 2012. So in closing, we're pleased with the solid third quarter results we reported today. Operational growth in our business, our launch of new products and tight expense management each contributed to our results. We have had a strong performance during our first year of the combined operations, demonstrating that the merger is working, and we are right on track. Thank you. 
Now I'll turn the call back over to Alex. Alex?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if",61,"Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if you do have additional questions, you're always welcome to rejoin the queue. Brooke?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank.",12,"[Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective",120,"Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective of the outcome of the J&J arbitration. It's obviously, those products contribute meaningfully today to your earnings. And I would appreciate that over the long haul, you, obviously, have a number of pushes and pulls, so maybe you could speak to us specifically about, whether the offsetting factors, let's assume that you were to lose that litigation and lose the earnings from those products, what would be the offsets that allow you to get to the same place?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect is this, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of varia",144,"Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect is this, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of variables that go into a product range or a guidance range that we present. And the good news from a Merck standpoint is that we have a very robust late-stage pipeline. We have cost synergies that we have in place. We're looking at new operating models. We have new product launches throughout the world now and so we do sensitivity and scenario planning to be able to accomplish that. So we have so many levers to pull and attribute this, this new company that's why we will stay there. Peter, anything you want to add here?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","No, I think you answered it properly, Dick, that's it.",10,"No, I think you answered it properly, Dick, that's it."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Steve Skala with Cowen.",9,"Your next question comes from Steve Skala with Cowen."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm",89,"Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm wondering if you agree. And secondly, on SINGULAIR, what is the benefit to not filing this over the counter? It seems like a strategy that does not fully utilize Merck's largest single asset, and does J&J, Merck think they have rights to OTC SINGULAIR?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to ev",63,"So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to evaluate what their long-term life cycle management value would be, including prospects for over-the-counter switch."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Tim Anderson with Sanford Bernstein.",10,"Your next question comes from Tim Anderson with Sanford Bernstein."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you gu",131,"A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you guys have a 15-valent pneumococcal vaccine in Phase II that would go up against Pfizer's Prevnar, wondering when that might go into Phase III. And also wondering, where you're getting that conjugation technology from? And then on REMICADE, you say it was a strong performer, but it looks like this is three quarters in a row where there's been sequential declines. And I'm wondering what the trajectory is from here, is this all a function of price cuts or are there share losses?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF cate",139,"On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF category. I think the product continues to maintain its share, and it continues to grow notwithstanding the introduction of SIMPONI in those markets, so we feel very good about that. On the pneumococcal one, we have not revealed any new information on the timing of moving that forward. TRA, we've said that we expect generally, that we'll have this data to be revealed in the mid-2011 period. As you know, it's an event-driven trial. And I think that's about all we can say about it right now. And we have an R&D meeting, of course, coming up."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010.",34,"So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Marc Goodman with UBS.",9,"Your next question comes from Marc Goodman with UBS."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to b",116,"You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to be in year one. Are we on track for that? I think it was 60% in SG&A, so that's like $1 billion out of SG&A. Are we seeing that? Obviously, we're seeing SG&A come down. But you're saying you're spending more in advertising and promotion for new products. So just trying to get a flavor for where we are in the cost savings."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A perform",157,"So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A performance, I think your question was are we achieving the first year synergies that we anticipated? I would say, in fact, that's probably one of the areas that we're very proud of so far. The commercial team, speaking for them, if I can, had done a great job actually in beginning of this year rapidly integrating the organizations and finding the right synergies, leveraging the new commercial model around the world. I believe we've commented in the past that at this point, we've got, Ken, I'll turn it over to you, but about 17 of our top 20 markets around the world. Ken, do you want to add any other comments?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on t",50,"That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on the time table we reveal."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Chris Schott with JPMorgan.",9,"Your next question comes from Chris Schott with JPMorgan."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price drive incremental demand for the product? Second",111,"First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price drive incremental demand for the product? Second question, bigger picture just latest thoughts on capital deployment, how you're prioritizing business development, share repo and the potential to increase the dividend? And just as a follow up to that, we're now a year post-Schering, how are we getting much leverage for the overall company given the broader more diversified organization that's been created? I guess those diversification increase your comfort with more permanently carrying leverage at the company?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market.",45,"So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter",392,"So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter. And as I mentioned also that in this quarter, we had about $300 million of share repurchase but on a year-to-date basis, that's $1.3 billion. So I think from the free cash flow of the company, you can see that we're doing good job redeploying cash even this year in the first year of the merger. So that is important to us. That said though, we are very actively looking to make great value creating deals around the world, and I think our business development activity is very active in a number of areas. One is to make sure that we have the best pipeline in the industry. Secondly, looking for great combinations and opportunities to partner around the world on the commercial side. And thirdly, in the emerging markets space, we recognize that we're going to be broadening our footprint and we want to make sure that we work with good partners locally to help create that value. So the BD [ph] size is also active and that does come into play. The last thing I would say is relative to our debt, obviously, what we talked about at the time of the merger was we design the merger to make sure that we landed in about the same place that we were before the merger. And we targeted the credit ratings to allow us to have some flexibility, but to also reinforce the strength of Merck, so that we can handle any kind of issues that come up. But also, more importantly, that we can invest on the strategic opportunities that we have around the world and we intend to continue that. It is true, we are generating solid cash flow and we'll be -- that cash flow performance will be growing. And so we will keep an eye on that. We will be shareholder friendly. But obviously, we will also intend to maintain our credit rating. We work closely with the credit agencies to make sure we're in the right place, and I think we're in about the right place right now."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Jami Rubin with Goldman Sachs.",10,"Your next question comes from Jami Rubin with Goldman Sachs."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE a",112,"Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE arbitration, I know there's a limit to what you can say, but just given the fact that it has been protracted now to more oral arguments the end of this year, if you could provide any color on what this means, your confidence level on the outcomes. And how far apart are the two companies now? And just when we can expect to get a resolution?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, a",149,"To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, and our strategic approach right now is to do that on a global basis. They're good brands, they last a long time. And so we're putting resources behind the growth of it from a global standpoint. I think this is important. It's a natural fit with many of our pharmaceuticals as well. And so from the distribution standpoint, the customer point, we're looking at first growing it organically as we move forward. To your second question, I'll just restate that we remain very confident in our position in this arbitration. And Bruce, if you want to say a few words about that?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel is an orderly way of completing the written and oral submissions before the panel.",39,"Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel is an orderly way of completing the written and oral submissions before the panel."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from David Risinger with Morgan Stanley.",10,"Your next question comes from David Risinger with Morgan Stanley."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, c",76,"The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, could you just update us on the timing of news flow on V710, the Staph [Staphylococcus] vaccine, specifically I'm interested in understanding the efficacy better, and then the BRIDION hypersensitivity data."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Peter, you want to start?",5,"Peter, you want to start?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pul",145,"Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pulls both ways as you go forward. So that's something that's part of our long-term guidance on the EPS line, but we haven't really broken that out and some of that is because it's now crystal clear. I think on the recent developments that were just announced this week in Puerto Rico, obviously we've made a couple of public statements through pharm [ph] and so forth and clearly, it's something we need to get understand better. We are clearly disappointed, but on the other hand, we will work with it. On the pipeline side, let me pass that over to Ken."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to fi",51,"So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to file that in 2011."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from John Boris with Citi Investment Research.",11,"Your next question comes from John Boris with Citi Investment Research."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend incre",121,"First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend increase in quite some time. Can you just help us understand how you're thinking about the dividend and dividend increases going forward? And then a pipeline question on boceprevir. You deployed a strategy for certain assets such as JANUVIA, go-to-market strategy that was pretty quick and pretty rapid. Are you going to use a similar type of strategy on boceprevir? And can you confirm whether the product has been filed or completed the filing as of yet?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","John, this is Peter. As you pointed out, obviously, our dividend is very competitive, pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidance",164,"John, this is Peter. As you pointed out, obviously, our dividend is very competitive, pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidance going forward about our dividend. But as I've mentioned in my script and in one of the earlier questions, we do remain highly focused on returning cash to shareholders in an appropriate manner, while at the same time, making sure we have the cash to drive the science first mindset we have here. We're very proud of the pipeline in our international footprint. We think we're building a great growth surge of future, and we think that's also the priority for us. And so at this point, I think we are, as I've mentioned, we intend going forward to be very shareholder friendly. And that said, also make sure we attend to the strategic needs of the business in a very important way."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Ken, would you like to?",5,"Ken, would you like to?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think",105,"What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think we have a robust strategy. And I think we know how to launch products in the specialty area like ISENTRESS, as well as in primary care like JANUVIA. So we are very excited by the prospects of boceprevir. We look forward to next November 1 and 2 in the Phase III data being presented at AASLD."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Catherine Arnold with Credit Suisse.",10,"Your next question comes from Catherine Arnold with Credit Suisse."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on",188,"I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on J&J, there was, obviously, a lot of misinterpretation potentially about the first press release when you talked about the series of events and that it sort of when people do the math it led to a decision before the end of 2010 and then there was more clarity on that for 2011. I may be splitting hairs, but I guess would like you to comment on the process. Did you change the communication because there was a misunderstanding or did you change it because there was an incremental step in the process? And then second question I have is about the donut hole coverage, and I wondered if you've looked at your portfolio and made some judgments as to what products might have the most upside in 2011 because there's better compliance due to the donut hole coverage."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Bruce, do you want to start?",6,"Bruce, do you want to start?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration pr",75,"Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration proceeding is that the parties and the arbitrators are able to agree on changes to the process as they go along, and that's what we've reflected during our ongoing disclosures."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","And then on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient com",61,"And then on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient compliance when you take away sort of the economic disincentive that was inherent in the donut hole."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Seamus Fernandez with Leerink Swann.",10,"Your next question comes from Seamus Fernandez with Leerink Swann."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the q",160,"Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the quarter. I know these payments are lumpy. But it looks like it brought something to the table here. Also, can you talk about the gross margin weakness in the quarter? What pushed it so low in the quarter? Was it really just kind of mix and seasonality with Schering? Was it the mix of AZLP revenues? And then just the final question really related to AZLP and your long-term guidance. What are the assumptions? Can you just remind us about the assumptions relative to AZLP and the PPI option that AstraZeneca holds for 2012? And I guess when would be the timing of the execution of that option should AstraZeneca actually choose to execute it?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, o",375,"I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, obviously. However, it's a business that continues to do nicely. We haven't really given guidance for these individual businesses and so forth, but there are timing of different seasonality of the products and so forth. On the -- related to that relationship, there is, as you know, in February, there was an option on the non-PPI products that was executed. And you saw a gain in our financials earlier this year from that and obviously, that gain is excluded from our non-GAAP results, it's included in our GAAP results and then some of our tables. The next option timing is two years later. That's for the PPI items, so that'll be roughly in the first part of 2012. And at this point, where we've always assumed that they will exercise that option that said it's their choice and we can't really predict exactly what will happen, but that's the way we thought about it anyway. And then moving to the product gross margins for the quarter, you're right. You put your finger on the two points. One is obviously -- there is some volatility in PGM just naturally because of the mix and some of that mix is because of products or to be -- divisional and so forth, so that does move around a little bit. The other factor that we had in the second and third quarter this year when you compare it in the second and to third quarter was in the same quarter, we did get some foreign exchange benefit and the third quarter that didn't recur. So that also kind of caused the third quarter to look a little weaker versus the second quarter. And obviously the mix also, so we kind of have two factors go against us in the third quarter. I think we have experienced a higher level of volatility in foreign exchange rates this year than normal. And so to that on some timing basis eventually does roll to the cost of goods."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your last question comes from Tony Butler with Barclays Capital.",10,"Your last question comes from Tony Butler with Barclays Capital."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and",115,"Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and excellence with customers in being number one with customers, but if I think back over the last 20 years, the balance of power has really shifted. And I'm curious today who are your principal customers? And please don't just say well, it's patients, it's physicians, it's payers. That we kind of know. But there's been a shift, and I'm just curious how you think about that from a focal point on the sales effort?"
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a mark",99,"So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a marketing standpoint. And in some markets, we actually have separate sales forces, China, for example. I think it varies depending on the actual market characteristics, but to answer the thrust of your question, we actually trying to treat this business line as its own distinct business line to be managed."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","And to your other question, obviously, the folks that we have are physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capa",252,"And to your other question, obviously, the folks that we have are physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capability in each of the franchises that they know they have many choices. And I think we're moving to a more customized customer approach and just the same messages of the same kind of products and services for every customer. But on a more strategic level, Tony, and I think that's a good question. I think one of the things that Merck will have from a competitive advantage standpoint is that when you look at either governments on an international basis, whether it's a nice type organization or whether we're moving to healthcare reform today and the government's going to play a larger role or whether you're looking to some of the larger managed care payers that exist in the United States. The important part is going to be health technology assessment and the ability to have clinical outcomes and be able to approve that whatever product you're thinking about from a regulatory approval and launch standpoint is above the standard of care that exists today. And I think where our competitive advantage is a company is our late-stage pipeline and how much of it has the ability to meet unmet medical needs and it is differentiated products, and we have the clinical outcome studies to prove it."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Okay. Thank you, operator. That concludes our call today. Thank you, everyone.",12,"Okay. Thank you, operator. That concludes our call today. Thank you, everyone."
288502,113992770,83301,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Thank you. This concludes the conference. You may now disconnect.",10,"Thank you. This concludes the conference. You may now disconnect."
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir.",39,"Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I want to point out a couple of things this morning. First, there are a number of items in the GAAP result",372,"Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I want to point out a couple of things this morning. First, there are a number of items in the GAAP results such as purchase accounting adjustments and merger-related expenses, restructuring costs. There's also a $380 million tax benefit and a $950 million legal reserve. In those GAAP, we have excluded those items from our non-GAAP results, and you could see a reconciliation table from the GAAP to non-GAAP figures in our press release. And that'll give you a better sense of the underlying performance. 
Next, we've also provided tables to help you understand the revenue trends. There are three tables in the press release. The first table, Table 1, is the GAAP results. Table 2 reconciles our GAAP P&L to non-GAAP for the third quarter and year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products as if the company have been combined for 2009, as well as 2010. During the call, we'll refer to Tables 2 when we discuss the P&L and Table 3 for the revenue performance. So you may want to have those available.
Finally, I'd like to remind you that some of the statements we make during the call today may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Act of 1995. Such statements are based upon the current beliefs of management and are subject to significant risks and uncertainties. Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected this morning. Merck undertakes no obligation to publicly update any forward-looking statements.
Our SEC filings, as well as our earnings release are available on merck.com. And with that, I'd like to let you know that I'm joined by Dick Clark, our Chairman and Chief Executive Officer; by Ken Frazier, our President; and also I'm joined by Peter Kellogg, our Chief Financial Officer. 
Now I'd like to introduce Dick Clark.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We had cons",950,"Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We had consistently focused on achieving the benefits of the combination for patients, customers, shareholders and employees. Most important is furthering the science that underpins Merck's ability to address many of the world's most serious, unmet medical needs.
Today, our company has greater geographic reach, one of the industry's broadest product portfolio, and has a tremendous late-stage pipeline that I believe is second to none. As we mark the anniversary of our merger, I want to thank many Merck colleagues who have helped us manage a significant combination so effectively. Throughout the past year, we have continued to drive revenue growth or key products, improve our cost structure and make the right strategic investments in our business. We've accomplished this while successfully taking on a challenging task of integrating our people, systems and cultures to form a powerful, unified organization. And while we still have work to do, Merck is well positioned now and for the future.
Our solid third quarter 2010 financial results illustrate that we are continuing to execute our strategy. We realized top line worldwide sales of $11.1 billion, non-GAAP earnings per share of $0.85 and GAAP earnings per share of $0.11 for the quarter.
Key brands including JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE were each strong performers this quarter. It is Merck's ability to develop and offer these truly differentiated products that will position us to successfully navigate difficult economies, pricing pressures and challenging regulatory environments throughout the world. In a few moments, Ken will discuss our global product performance in more detail. Peter will then provide you with our full earnings outlook.
While our merger has always been about the science, synergies are also important. We are on track to achieve our previously announced synergy target of $3.5 billion in annual savings by the end of 2012. As we continue to integrate, there's exciting activity across all of Merck and the world, particularly R&D and commercial strengths at Merck. In coming months and into next year, we expect some important clinical data from promising candidates in our robust pipeline. You will hear more about these milestones in a few moments.
And this pipeline is coming through in other ways too. As we speak, we have 10 major product launches underway in important markets around the world. And just the last few weeks alone, we have received regulatory approval for BRINAVESS in Europe and signed an important partnership agreement to allow Lundbeck to distribute SYCREST in all markets outside the United States, China and Japan. 
Recently, we also marked our first major U.S. product launch as a combined company with the DULERA launch. With the addition of this exciting new asthma product, Merck now has the widest respiratory portfolio available in the United States. Lastly, I had the pleasure of participating in the DULERA launch. With the addition of this exciting new asthma product, Merck now has the lightest respiratory portfolio available in the United States. 
Last week, I had the pleasure of participating in the DULERA launch meeting, along with our sales and marketing team. It was great to share first-hand the enthusiasm and excitement our sales representatives have to bring this new treatment to our customers. We made excellent progress in the integration of our commercial operations in our major markets throughout the world. Those integrated markets account for about 85% of our Global Human Health sales. It is exciting to see the benefits of our broader, more diversified product portfolio as we engage with physicians and customers. The team is doing an excellent job executing on our commercial sales model in the United States and in key markets in Europe, Japan, Latin America and Asia Pacific. Our overall goal is to outperform our peer pharmaceutical companies and become the clear industry leader in the eyes of our customers.
In fact, our customer survey for the U.S. market indicates that Merck continues to lead in trust and value metrics versus our peers. Our focus is on positioning Merck to become a leader in the key global growth market, and our broad portfolio of healthcare offerings will drive further growth in these emerging markets. We are currently the fifth-largest multinational pharmaceutical player in a fast-growing emerging markets, and we are aiming much higher. By 2013, we seek to drive at least 25% of our Global Human Health in vaccine sales from the emerging markets. We are making good progress and in the third quarter, that number was 18%. 
Over time, we will build further in these efforts by leveraging our advantage using our broad in-line portfolio. Many of these brands are former blockbusters with considerable brand equity such as ZOCOR. But we're also successful relaunching new products in these markets such as JANUVIA. Additionally, we are seeking to globalize the Vaccine business through growth in emerging markets through partnerships and through the introduction of low-cost manufacturing for some of our key products to expand affordable access.
Finally, we are working to tap the significant growth potential for many of our well-regarded consumer care brands by expanding our operations outside the U.S. In summary, we've made great progress, driving growth of key products, achieving our merger synergies, expanding our global reach, launching new products and advancing our late-stage R&D pipeline. One year post-merger, our results demonstrate that we are realizing the benefit of our merger, while ensuring that the company is well positioned for the future. 
Now I'll turn it over to Ken.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity fo",1654,"Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity for COZAAR and HYZAAR. Our commercial performance this quarter was characterized by continuing strong performance of key brands such as JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE, which was complemented by strong growth in key geographic markets and new contributions from our ongoing product launches such as SIMPONI, BRIDION and AFLURIA. 
Before I review the sales performance, I'd like to refer you to Table 3, which provides the supplemental combined non-GAAP results and includes the impact of foreign exchange. As you review Table 3, you'll see that product sales were driven by the robust growth of our key brands, SINGULAIR, JANUVIA, JANUMET, REMICADE and ISENTRESS. These brands grew a combined 17% year-over-year. 
Now let's take a closer look at the performance of some of these key brands starting with SINGULAIR, which grew 12% over the previous year. The increase in sales was driven by growth in most regions. We continue to see volume growth in the U.S. and EU and continued class leadership in Japan. Additionally, SINGULAIR sales in the emerging markets grew 25% in the third quarter. 
Moving on to JANUVIA and JANUMET. Global revenue grew 28%. Sales this quarter were, again, driven by double-digit growth across most regions. We continue to see volume growth in the U.S., and the franchise continues to grow in the EU due largely to new indications and the ongoing launches of JANUMET.
On a combined basis, JANUVIA and JANUMET are the leading branded oral anti-diabetic franchise in roughly 75% of the top 20 markets. We continue to focus on extending the value of this franchise, and we remain on track for filing a JANUMET once-daily formulation with the FDA next year. Actually, this year, I apologize.
REMICADE sales increased 9% in the third quarter. Despite the austerity measures across the EU, REMICADE continues to grow by double digits, excluding the impact of foreign exchange. Even in markets where we've seen a good uptake of SIMPONI, REMICADE continues to grow. 
Turning next to ISENTRESS. After three years on the market, it continues to deliver outstanding performance, gaining market share across all indications. ISENTRESS' strong sales growth in the third quarter was driven by the growth in the  treatment-nave indication and broad utilization of new treatment guidelines in the U.S. We remain on track to file the once-daily dosing regimen with the FDA in 2011.
For the VYTORIN and ZETIA franchise, sales decreased 3% in the third quarter as volume declines in the U.S. were only partially offset by higher sales outside the U.S. The sales growth outside the U.S. was primarily driven by the 30% growth of ZETIA in Japan and 13% growth of VYTORIN in the emerging markets. VYTORIN and ZETIA continue to be an important treatment option to help many patients lower their LDL cholesterol. We understand that researchers from Oxford plan to present the results of the SHARP study at the ASN [American Society of Nephrology] meeting in November. That study, as you know, focus on patients with chronic kidney disease.
Now let's shift to our Vaccine business where we're starting to see signs of progress, including more stable supply. GARDASIL sales grew 2%, benefiting from the timing of shipments to customers. Sales increased sequentially, largely due to the seasonality of the back-to-school period. Sales in PNEUMOVAX were down 15% as a result of the unfavorable seasonal comparison from the H1N1 pandemic last year. We launched our newest vaccine, AFLURIA for the seasonal flu, which posted sales of $35 million in the third quarter. 
We continue to work on the supply issues with ZOSTAVAX. We had limited shipments of the product in Q3, and we anticipate delivering additional shipments to U.S. customers by the end of this year. As you can see, our overall business continues to benefit from the diversity of our product mix and our portfolio of differentiated brands. In addition, our broad global presence is also an asset, providing us with the flexibility to leverage our portfolio in key markets around the world.
In the U.S., sales grew 1% if one excludes the impact of generic erosion for COZAAR and HYZAAR. When you look more closely at the business lines, you'll see that we had double-digit growth in our diabetes franchise, as well as strong growth in our women's health franchise, and we continue to gain market share for products such as ISENTRESS and SINGULAIR. In addition, as Dick mentioned, we are in the process of launching DULERA, our newest treatment for asthma in the U.S. We shipped to pharmacies in July, and we completed our full promotional launch last week. We are encouraged by the early feedback from the field as we focus on the unique attributes of DULERA compared to other combination products.
Now let's turn to the EU, where sales were lower this quarter due to the loss of exclusivity of COZAAR and HYZAAR, as well as the impact of European austerity measures. We continue to believe these measures will have a mid-single digit impact on European sales in 2010. Despite those economic challenges, we continue to see strong growth in key brands such as JANUVIA, JANUMET, ISENTRESS and REMICADE. We're also launching many new products in the EU. SIMPONI, which has been launched in 18 countries, recorded sales of $27 million in the quarter. While we're still working to gain reimbursement in many markets, the early performance indicators are positive.
We also launched BRINAVESS and DAXAS into markets, and we'll have additional launches of those products in 2011. As I said earlier, we saw good performance in key growth markets. In Japan, sales increased 7%, largely driven by ZETIA and SINGULAIR and the strong launches of BRIDION, COSOPT and JANUVIA are also contributing to our growth in Japan. We continue to focus on our business in Japan as we get ready to file and launch many additional brands over the next three years. We also continue to make significant yet disciplined long-term investments in the emerging markets. 
Growth in the quarter was driven by our top six markets where we saw significant gained from countries such as China, which grew 21% in the quarter. We're approaching each emerging market as a separate opportunity to optimize our product mix as we focus on each local market and its specific customer needs, we've seen an ideal match with our diverse product portfolio. Whether it'd be vaccine, products for cardiometabolic disease or the offerings in our women's health franchise, we're seeing growing utilization of Merck products in the emerging markets.
Now people typically think of branded generics as the only key to success in the emerging markets. But JANUVIA is a great example of how an innovative and differentiated product with the right level of educational and promotional support can become a market leader in the Asia Pacific region. While there's a lot of focus on the emerging markets, one shouldn't forget that science and innovation remain at the core of our business in every part of the world. For us to be successful, we have to continue to discover, develop and launch differentiated products with clinical profiles that offer patients and payers proven benefits.
That's why our late-stage pipeline is so critical to our future. In the fourth quarter, we have data presentations for three of these key late-stage programs, which I'd like to discuss with you briefly now. Last week, at the ASBMR [American Society for Bone and Mineral Research] meeting, we presented the four-year BMD [bone mineral density] data for odanacatib or selective Cat [Cathepsin] K Inhibitor for the treatment of osteoporosis. Patients on odanacatib continue to show increases in bone mineral density at the lumbar spine and hip. Odanacatib is currently in Phase III and we will have a long-term fracture study with 16,000 patients, which is fully enrolled. We plan to file odanacatib with regulatory authorities bolstered by that outcome study in 2012.
Starting this weekend and continuing into next week, researchers will present final Phase III data for both boceprevir, our hepatitis C protease inhibitor at the AASLD [American Association for the Study of Liver Diseases] meeting in Boston. We previously announced the top line results of the Phase III program. In those studies, boceprevir added to the current standard of care, double the cure rate in treatment-experienced patients and nearly double the cure rate in treatment-nave patients. With the use of response-guided therapy, we also showed that the addition of boceprevir has the potential to shorten the duration of therapy in both treatment-experienced and treatment-nave patients compared to standard therapy. The data that will be presented at the upcoming liver meeting are compelling, and we look forward to sharing them with you.
We remain on track to complete the filing of boceprevir with regulatory authorities around the world this year. Later in November, we will present study result for anacetrapib, our CETP-Inhibitor for the treatment of atherosclerosis at the AHA [American Heart Association] meeting in Chicago. As expected, the results of this study confirmed our decision to move anacetrapib to the planned outcome study that will begin next year. As you can see, we will be presenting a lot of data in the fourth quarter and beyond as we move many of our late-stage research programs forward.
In summary, we've delivered another good quarter. We continue to be excited by the opportunities to grow our business through our current portfolio of products in key markets and through a robust late-stage pipeline, supported by outcome studies. While the operating environment is constantly changing, we are steadily executing on our strategic goals to create the leading healthcare company in the world. 
And now it is my pleasure to turn the call over to my colleague, Peter Kellogg.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and con",1395,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and continuing cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and markets performed, and now I'd like to cover our third quarter financial performance and our outlook. So let's begin with our results.
Our GAAP financial information can be found in Table 1 of our release. To make it easier to follow my remarks today, I will speak to the non-GAAP results in Table 2a, which exclude purchase accounting adjustments, merger-related costs, restructuring charges, a $380 million tax benefit and a $950 million legal reserve. 
On this basis, we reported third quarter non-GAAP earnings per share of $0.85. Total revenue for the quarter was $11.1 billion, down 4% on the supplemental combined non-GAAP basis. Excluding the impact of generic COZAAR/HYZAAR and the unfavorable impact of foreign exchange, sales were actually up about 2%. This is good performance. Despite the unfavorable impact of austerity measures in Europe and the impact of healthcare reform in the U.S., and we are pleased with the performance of each of our businesses. 
Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. Our Animal Health business grew 3%, 6% FX change to $687 million, reflecting growth in North and South America, as well as growth and poultry, swine and aquaculture. Consumer Care sales also increased 3% to $291 million due to the growth of foot care, respiratory and skin care products. Growth in these areas was partially offset by the impact of generic MiraLAX.
Now moving on to the P&L. You can see that we have done a very good job controlling our expenses again this quarter. We continue to be very pleased with the progress we're making against our merger synergies, and we are doing so while launching new products and making great progress with the R&D pipeline. As you know, the costs of our combined company are represented in our current cost base. Whereas only the legacy Merck costs were included in the third quarter of 2009, which complicates analysis on a year-over-year basis. As a result, I will speak to the sequential trends on the cost line since those comparisons are more meaningful. 
First, materials and production. The non-GAAP gross margin in the third quarter was 74.9%, which was lower than the second quarter of 2010 when the gross margin was 76.5%. As you can see, our gross margin moves a bit quarter-to-quarter mostly due to product mix. This quarter, the mix changes came from a variety of factors, including lower sequential sales of products like NASONEX, CLARINEX and CLARITIN. Sequentially, the second quarter also benefited from a favorable foreign exchange impact, which did not recur in the third quarter.
Moving on to marketing and admin [administrative] expenses. On a non-GAAP basis, marketing and administrative expenses in the third quarter were $3 billion, which was about $100 million lower than the second quarter of 2010. And on a year-to-year basis, we drove significant cost savings in M&A due to the realization of merger synergies. This was partially tempered by increased promotional spending to support new launches like SIMPONI and DULERA. As you know, we are actively launching many new products, and we expect 2011 to be an exciting year for new product launches in the U.S. and around the world. I'll talk more about that later.
Research and development expense for the third quarter was approximately $1.9 billion, which was slightly lower than the first two quarters due to the continued work we are doing to further prioritize our R&D investments. As a result of the prioritization activities, we decided to stop investment in a few additional programs in the third quarter. We also previously announced the plan to rationalize our R&D network. Meanwhile, we continue to invest in our most promising, late-stage projects such as vorapaxar, boceprevir, telcagepant, odanacatib and TREDAPTIVE. And these key programs in our pipeline continue to move forward. 
Now let's move to equity income. In the third quarter, Merck recorded $236 million of equity income. As expected, this was sequentially higher than second quarter. Remember the income from the AZLP [AstraZeneca LP] joint venture in the second quarter was low due to the inherent variability in the timing of income from the AZLP joint venture.
Moving on to other expense. On a non-GAAP basis, other expense of $158 million was comparable to the second quarter of 2010. Our non-GAAP results exclude the impact of a legal reserve of $950 million in connection with an anticipated resolution of a previously disclosed investigation by the U.S. Attorney's Office for District of Massachusetts related to VIOXX. 
Moving to tax. The Merck non-GAAP tax rate was 22.2% for the third quarter, which was higher than the rate that we saw in the second quarter. As noted in the press release, we continue to expect full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned the cash to shareholders through our dividend and by making continued progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $300 million to repurchase roughly 8 million shares of our common stock. So far this year, we have repurchased about 47 million shares for $1.6 billion. 
So in summary, we continue on a strong trajectory since our merger. Now let's spend our remaining time reviewing our outlook for 2010 and beyond, and let's start with our 2010 outlook. Given our strong year-to-date performance, we are only making one change to our 2010 financial targets. We raised the lower end of our EPS target range, resulting in an increase in the midpoint of our EPS range. On a non-GAAP basis, Merck is now targeting a full year 2010 EPS range of $3.31 to $3.39, excluding certain items. Please see our press release for the GAAP guidance.
Factored into this EPS range are the top line pressures in the U.S. and the EU, including the impact of healthcare reform in the U.S., which is unchanged from our previous estimates and the impact of European austerity measures. Recall that we had anticipated a mid-single digit unfavorable impact on European sales in the second half of 2010. We still believe that will be the case.
Our current year EPS range also assumes that Merck retains full rights to REMICADE and SIMPONI in our markets. On the expense side, as I mentioned earlier, we also anticipate increased promotional spending in the fourth quarter and in 2011 for new product launches like DULERA, DAXAS, BRINAVESS and additional launches of SIMPONI around the world, not to mention we are preparing for the prospect of launching boceprevir in 2011. And we continue to make new targeted commercial and R&D investments including those in the emerging markets.
These growth driving investments are a major reason why we expect our operating expenses in the fourth quarter to be sequentially higher than they were in the third quarter of 2010. So while these top line pressures and operating investments put pressure on the fourth quarter, we are comfortable with our full year 2010 EPS guidance range. 
Finally, let me touch on our long-term outlook. We remain excited about our future, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities are already well underway. We continue to target a high single digit non-GAAP EPS compound annual growth rate from 2009 to 2013 regardless of the outcome of the REMICADE arbitration. 
In addition, we are well on track to realize our $3.5 billion synergy target by the end of 2012. So in closing, we're pleased with the solid third quarter results we reported today. Operational growth in our business, our launch of new products and tight expense management each contributed to our results. We have had a strong performance during our first year of the combined operations, demonstrating that the merger is working, and we are right on track. Thank you. 
Now I'll turn the call back over to Alex. Alex?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if",61,"Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if you do have additional questions, you're always welcome to rejoin the queue. Brooke?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank.",12,"[Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective",120,"Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective of the outcome of the J&J arbitration. It's obviously, those products contribute meaningfully today to your earnings. And I would appreciate that over the long haul, you, obviously, have a number of pushes and pulls, so maybe you could speak to us specifically about, whether the offsetting factors, let's assume that you were to lose that litigation and lose the earnings from those products, what would be the offsets that allow you to get to the same place?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect is this, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of varia",144,"Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect is this, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of variables that go into a product range or a guidance range that we present. And the good news from a Merck standpoint is that we have a very robust late-stage pipeline. We have cost synergies that we have in place. We're looking at new operating models. We have new product launches throughout the world now and so we do sensitivity and scenario planning to be able to accomplish that. So we have so many levers to pull and attribute this, this new company that's why we will stay there. Peter, anything you want to add here?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","No, I think you answered it properly, Dick, that's it.",10,"No, I think you answered it properly, Dick, that's it.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Steve Skala with Cowen.",9,"Your next question comes from Steve Skala with Cowen.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm",89,"Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm wondering if you agree. And secondly, on SINGULAIR, what is the benefit to not filing this over the counter? It seems like a strategy that does not fully utilize Merck's largest single asset, and does J&J, Merck think they have rights to OTC SINGULAIR?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to ev",63,"So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to evaluate what their long-term life cycle management value would be, including prospects for over-the-counter switch.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Tim Anderson with Sanford Bernstein.",10,"Your next question comes from Tim Anderson with Sanford Bernstein.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you gu",131,"A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you guys have a 15-valent pneumococcal vaccine in Phase II that would go up against Pfizer's Prevnar, wondering when that might go into Phase III. And also wondering, where you're getting that conjugation technology from? And then on REMICADE, you say it was a strong performer, but it looks like this is three quarters in a row where there's been sequential declines. And I'm wondering what the trajectory is from here, is this all a function of price cuts or are there share losses?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF cate",139,"On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF category. I think the product continues to maintain its share, and it continues to grow notwithstanding the introduction of SIMPONI in those markets, so we feel very good about that. On the pneumococcal one, we have not revealed any new information on the timing of moving that forward. TRA, we've said that we expect generally, that we'll have this data to be revealed in the mid-2011 period. As you know, it's an event-driven trial. And I think that's about all we can say about it right now. And we have an R&D meeting, of course, coming up.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010.",34,"So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Marc Goodman with UBS.",9,"Your next question comes from Marc Goodman with UBS.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to b",116,"You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to be in year one. Are we on track for that? I think it was 60% in SG&A, so that's like $1 billion out of SG&A. Are we seeing that? Obviously, we're seeing SG&A come down. But you're saying you're spending more in advertising and promotion for new products. So just trying to get a flavor for where we are in the cost savings.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A perform",157,"So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A performance, I think your question was are we achieving the first year synergies that we anticipated? I would say, in fact, that's probably one of the areas that we're very proud of so far. The commercial team, speaking for them, if I can, had done a great job actually in beginning of this year rapidly integrating the organizations and finding the right synergies, leveraging the new commercial model around the world. I believe we've commented in the past that at this point, we've got, Ken, I'll turn it over to you, but about 17 of our top 20 markets around the world. Ken, do you want to add any other comments?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on t",50,"That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on the time table we reveal.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Chris Schott with JPMorgan.",9,"Your next question comes from Chris Schott with JPMorgan.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price drive incremental demand for the product? Second",111,"First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price drive incremental demand for the product? Second question, bigger picture just latest thoughts on capital deployment, how you're prioritizing business development, share repo and the potential to increase the dividend? And just as a follow up to that, we're now a year post-Schering, how are we getting much leverage for the overall company given the broader more diversified organization that's been created? I guess those diversification increase your comfort with more permanently carrying leverage at the company?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market.",45,"So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter",392,"So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter. And as I mentioned also that in this quarter, we had about $300 million of share repurchase but on a year-to-date basis, that's $1.3 billion. So I think from the free cash flow of the company, you can see that we're doing good job redeploying cash even this year in the first year of the merger. So that is important to us. That said though, we are very actively looking to make great value creating deals around the world, and I think our business development activity is very active in a number of areas. One is to make sure that we have the best pipeline in the industry. Secondly, looking for great combinations and opportunities to partner around the world on the commercial side. And thirdly, in the emerging markets space, we recognize that we're going to be broadening our footprint and we want to make sure that we work with good partners locally to help create that value. So the BD [ph] size is also active and that does come into play. The last thing I would say is relative to our debt, obviously, what we talked about at the time of the merger was we design the merger to make sure that we landed in about the same place that we were before the merger. And we targeted the credit ratings to allow us to have some flexibility, but to also reinforce the strength of Merck, so that we can handle any kind of issues that come up. But also, more importantly, that we can invest on the strategic opportunities that we have around the world and we intend to continue that. It is true, we are generating solid cash flow and we'll be -- that cash flow performance will be growing. And so we will keep an eye on that. We will be shareholder friendly. But obviously, we will also intend to maintain our credit rating. We work closely with the credit agencies to make sure we're in the right place, and I think we're in about the right place right now.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Jami Rubin with Goldman Sachs.",10,"Your next question comes from Jami Rubin with Goldman Sachs.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE a",112,"Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE arbitration, I know there's a limit to what you can say, but just given the fact that it has been protracted now to more oral arguments the end of this year, if you could provide any color on what this means, your confidence level on the outcomes. And how far apart are the two companies now? And just when we can expect to get a resolution?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, a",149,"To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, and our strategic approach right now is to do that on a global basis. They're good brands, they last a long time. And so we're putting resources behind the growth of it from a global standpoint. I think this is important. It's a natural fit with many of our pharmaceuticals as well. And so from the distribution standpoint, the customer point, we're looking at first growing it organically as we move forward. To your second question, I'll just restate that we remain very confident in our position in this arbitration. And Bruce, if you want to say a few words about that?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel is an orderly way of completing the written and oral submissions before the panel.",39,"Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel is an orderly way of completing the written and oral submissions before the panel.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from David Risinger with Morgan Stanley.",10,"Your next question comes from David Risinger with Morgan Stanley.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, c",76,"The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, could you just update us on the timing of news flow on V710, the Staph [Staphylococcus] vaccine, specifically I'm interested in understanding the efficacy better, and then the BRIDION hypersensitivity data.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Peter, you want to start?",5,"Peter, you want to start?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pul",145,"Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pulls both ways as you go forward. So that's something that's part of our long-term guidance on the EPS line, but we haven't really broken that out and some of that is because it's now crystal clear. I think on the recent developments that were just announced this week in Puerto Rico, obviously we've made a couple of public statements through pharm [ph] and so forth and clearly, it's something we need to get understand better. We are clearly disappointed, but on the other hand, we will work with it. On the pipeline side, let me pass that over to Ken.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to fi",51,"So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to file that in 2011.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from John Boris with Citi Investment Research.",11,"Your next question comes from John Boris with Citi Investment Research.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend incre",121,"First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend increase in quite some time. Can you just help us understand how you're thinking about the dividend and dividend increases going forward? And then a pipeline question on boceprevir. You deployed a strategy for certain assets such as JANUVIA, go-to-market strategy that was pretty quick and pretty rapid. Are you going to use a similar type of strategy on boceprevir? And can you confirm whether the product has been filed or completed the filing as of yet?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","John, this is Peter. As you pointed out, obviously, our dividend is very competitive, pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidance",164,"John, this is Peter. As you pointed out, obviously, our dividend is very competitive, pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidance going forward about our dividend. But as I've mentioned in my script and in one of the earlier questions, we do remain highly focused on returning cash to shareholders in an appropriate manner, while at the same time, making sure we have the cash to drive the science first mindset we have here. We're very proud of the pipeline in our international footprint. We think we're building a great growth surge of future, and we think that's also the priority for us. And so at this point, I think we are, as I've mentioned, we intend going forward to be very shareholder friendly. And that said, also make sure we attend to the strategic needs of the business in a very important way.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Ken, would you like to?",5,"Ken, would you like to?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think",105,"What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think we have a robust strategy. And I think we know how to launch products in the specialty area like ISENTRESS, as well as in primary care like JANUVIA. So we are very excited by the prospects of boceprevir. We look forward to next November 1 and 2 in the Phase III data being presented at AASLD.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Catherine Arnold with Credit Suisse.",10,"Your next question comes from Catherine Arnold with Credit Suisse.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on",188,"I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on J&J, there was, obviously, a lot of misinterpretation potentially about the first press release when you talked about the series of events and that it sort of when people do the math it led to a decision before the end of 2010 and then there was more clarity on that for 2011. I may be splitting hairs, but I guess would like you to comment on the process. Did you change the communication because there was a misunderstanding or did you change it because there was an incremental step in the process? And then second question I have is about the donut hole coverage, and I wondered if you've looked at your portfolio and made some judgments as to what products might have the most upside in 2011 because there's better compliance due to the donut hole coverage.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Bruce, do you want to start?",6,"Bruce, do you want to start?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration pr",75,"Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration proceeding is that the parties and the arbitrators are able to agree on changes to the process as they go along, and that's what we've reflected during our ongoing disclosures.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","And then on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient com",61,"And then on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient compliance when you take away sort of the economic disincentive that was inherent in the donut hole.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Seamus Fernandez with Leerink Swann.",10,"Your next question comes from Seamus Fernandez with Leerink Swann.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the q",160,"Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the quarter. I know these payments are lumpy. But it looks like it brought something to the table here. Also, can you talk about the gross margin weakness in the quarter? What pushed it so low in the quarter? Was it really just kind of mix and seasonality with Schering? Was it the mix of AZLP revenues? And then just the final question really related to AZLP and your long-term guidance. What are the assumptions? Can you just remind us about the assumptions relative to AZLP and the PPI option that AstraZeneca holds for 2012? And I guess when would be the timing of the execution of that option should AstraZeneca actually choose to execute it?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, o",375,"I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, obviously. However, it's a business that continues to do nicely. We haven't really given guidance for these individual businesses and so forth, but there are timing of different seasonality of the products and so forth. On the -- related to that relationship, there is, as you know, in February, there was an option on the non-PPI products that was executed. And you saw a gain in our financials earlier this year from that and obviously, that gain is excluded from our non-GAAP results, it's included in our GAAP results and then some of our tables. The next option timing is two years later. That's for the PPI items, so that'll be roughly in the first part of 2012. And at this point, where we've always assumed that they will exercise that option that said it's their choice and we can't really predict exactly what will happen, but that's the way we thought about it anyway. And then moving to the product gross margins for the quarter, you're right. You put your finger on the two points. One is obviously -- there is some volatility in PGM just naturally because of the mix and some of that mix is because of products or to be -- divisional and so forth, so that does move around a little bit. The other factor that we had in the second and third quarter this year when you compare it in the second and to third quarter was in the same quarter, we did get some foreign exchange benefit and the third quarter that didn't recur. So that also kind of caused the third quarter to look a little weaker versus the second quarter. And obviously the mix also, so we kind of have two factors go against us in the third quarter. I think we have experienced a higher level of volatility in foreign exchange rates this year than normal. And so to that on some timing basis eventually does roll to the cost of goods.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your last question comes from Tony Butler with Barclays Capital.",10,"Your last question comes from Tony Butler with Barclays Capital.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and",115,"Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and excellence with customers in being number one with customers, but if I think back over the last 20 years, the balance of power has really shifted. And I'm curious today who are your principal customers? And please don't just say well, it's patients, it's physicians, it's payers. That we kind of know. But there's been a shift, and I'm just curious how you think about that from a focal point on the sales effort?
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a mark",99,"So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a marketing standpoint. And in some markets, we actually have separate sales forces, China, for example. I think it varies depending on the actual market characteristics, but to answer the thrust of your question, we actually trying to treat this business line as its own distinct business line to be managed.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","And to your other question, obviously, the folks that we have are physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capa",252,"And to your other question, obviously, the folks that we have are physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capability in each of the franchises that they know they have many choices. And I think we're moving to a more customized customer approach and just the same messages of the same kind of products and services for every customer. But on a more strategic level, Tony, and I think that's a good question. I think one of the things that Merck will have from a competitive advantage standpoint is that when you look at either governments on an international basis, whether it's a nice type organization or whether we're moving to healthcare reform today and the government's going to play a larger role or whether you're looking to some of the larger managed care payers that exist in the United States. The important part is going to be health technology assessment and the ability to have clinical outcomes and be able to approve that whatever product you're thinking about from a regulatory approval and launch standpoint is above the standard of care that exists today. And I think where our competitive advantage is a company is our late-stage pipeline and how much of it has the ability to meet unmet medical needs and it is differentiated products, and we have the clinical outcome studies to prove it.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Okay. Thank you, operator. That concludes our call today. Thank you, everyone.",12,"Okay. Thank you, operator. That concludes our call today. Thank you, everyone.
"
288502,113992770,83308,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Thank you. This concludes the conference. You may now disconnect.",10,"Thank you. This concludes the conference. You may now disconnect.

"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir.",39,"Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I wanted to point out a couple of things this morning. First, there are a number of items in the GAAP resu",372,"Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I wanted to point out a couple of things this morning. First, there are a number of items in the GAAP results such as purchase accounting adjustments and merger-related expenses, restructuring costs. There's also a $380 million tax benefit and a $950 million legal reserve. In those GAAP, we have excluded those items from our non-GAAP results, and you could see a reconciliation table from the GAAP to non-GAAP figures in our press release. And that'll give you a better sense of the underlying performance. 
Next, we've also provided tables to help you understand the revenue trends. There are three tables in the press release. The first table, Table 1, is the GAAP results. Table 2 reconciles our GAAP P&L to non-GAAP for the third quarter and year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products as if the company have been combined for 2009, as well as 2010. During the call, we'll refer to Tables 2 when we discuss the P&L and Table 3 for the revenue performance. So you may want to have those available.
Finally, I'd like to remind you that some of the statements we make during the call today may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Act of 1995. Such statements are based upon the current beliefs of management and are subject to significant risks and uncertainties. Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected this morning. Merck undertakes no obligation to publicly update any forward-looking statements.
Our SEC filings, as well as our earnings release are available on merck.com. And with that, I'd like to let you know that I'm joined by Dick Clark, our Chairman and Chief Executive Officer; by Ken Frazier, our President; and also I'm joined by Peter Kellogg, our Chief Financial Officer. 
Now I'd like to introduce Dick Clark."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We have con",919,"Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We have consistently focused on achieving the benefits of the combination for patients, customers, shareholders and employees. Most important is furthering the science that underpins Merck's ability to address many of the world's most serious, unmet medical needs.
Today, our company has greater geographic reach, one of the industry's broadest product portfolio, and has a tremendous late-stage pipeline that I believe is second to none. As we mark the anniversary of our merger, I want to thank many Merck colleagues who have helped us manage this significant combination so effectively. Throughout the past year, we have continued to drive revenue growth for key products, improve our cost structure and make the right strategic investments in our business. We've accomplished this while successfully taking on the challenging task of integrating our people, systems and cultures to form a powerful, unified organization. And while we still have work to do, Merck is well positioned now and for the future.
Our solid third quarter 2010 financial results illustrate that we are continuing to execute our strategy. We realized top line worldwide sales of $11.1 billion, non-GAAP earnings per share of $0.85 and GAAP earnings per share of $0.11 for the quarter.
Key brands including JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE were each strong performers this quarter. It is Merck's ability to develop and offer these truly differentiated products that will position us to successfully navigate difficult economies, pricing pressures and challenging regulatory environments throughout the world. In a few moments, Ken will discuss our global product performance in more detail. Peter will then provide you with our full earnings outlook.
While our merger has always been about the science, synergies are also important. We are on track to achieve our previously announced synergy target of $3.5 billion in annual savings by the end of 2012. As we continue to integrate, there's exciting activity across all of Merck and the world, particularly R&D and commercial strengths at Merck. In coming months and into next year, we expect some important clinical data from promising candidates in our robust pipeline. You will hear more about these milestones in a few moments.
And this pipeline is coming through in other ways too. As we speak, we have 10 major product launches underway in important markets around the world. In just the last few weeks alone, we have received regulatory approval for BRINAVESS in Europe and signed an important partnership agreement to allow Lundbeck to distribute SYCREST in all markets outside the United States, China and Japan. 
Recently, we also marked our first major U.S. product launch as a combined company with the DULERA launch. With the addition of this exciting new asthma product, Merck now has the widest respiratory portfolio available in the United States.  Last week, I had the pleasure of participating in the DULERA launch meeting, along with our sales and marketing team. It was great to share first-hand the enthusiasm and excitement our sales representatives have to bring this new treatment to our customers. We made excellent progress in the integration of our commercial operations in our major markets throughout the world. Those integrated markets account for about 85% of our Global Human Health sales. It is exciting to see the benefits of our broader, more diversified product portfolio as we engage with physicians and customers. The team is doing an excellent job executing on our commercial sales model in the United States and in key markets in Europe, Japan, Latin America and Asia Pacific. Our overall goal is to outperform our peer pharmaceutical companies and become the clear industry leader in the eyes of our customers.
In fact, our customer survey for the U.S. market indicates that Merck continues to lead in trust and value metrics versus our peers. Our focus is on positioning Merck to become a leader in the key global growth markets, and our broad portfolio of healthcare offerings will drive further growth in these emerging markets. We are currently the fifth-largest multinational pharmaceutical player in a fast-growing emerging markets, and we are aiming much higher. By 2013, we seek to derive at least 25% of our Global Human Health in vaccine sales from the emerging markets. We are making good progress and in the third quarter, that number was 18%. 
Over time, we will build further in these efforts by leveraging our advantage using our broad in-line portfolio. Many of these brands are former blockbusters with considerable brand equity such as ZOCOR. But we were also successful relaunching new products in these markets such as JANUVIA. Additionally, we are seeking to globalize the Vaccine business through growth in emerging markets through partnerships and through the introduction of low-cost manufacturing for some of our key products to expand affordable access.
Finally, we are working to tap the significant growth potential for many of our well-regarded consumer care brands by expanding our operations outside the U.S. In summary, we've made great progress, driving growth of key products, achieving our merger synergies, expanding our global reach, launching new products and advancing our late-stage R&D pipeline. One year post-merger, our results demonstrate that we are realizing the benefit of our merger, while ensuring that the company is well positioned for the future. 
Now I'll turn it over to Ken."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity fo",1654,"Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity for COZAAR and HYZAAR. Our commercial performance this quarter was characterized by continuing strong performance of key brands such as JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE, which was complemented by strong growth in key geographic markets and new contributions from our ongoing product launches such as SIMPONI, BRIDION and AFLURIA. 
Before I review the sales performance, I'd like to refer you to Table 3, which provides the supplemental combined non-GAAP results and includes the impact of foreign exchange. As you review Table 3, you'll see that product sales were driven by the robust growth of our key brands, SINGULAIR, JANUVIA, JANUMET, REMICADE and ISENTRESS. These brands grew a combined 17% year-over-year. 
Now let's take a closer look at the performance of some of these key brands starting with SINGULAIR, which grew 12% over the previous year. The increase in sales was driven by growth in most regions. We continue to see volume growth in the U.S. and EU and continued class leadership in Japan. Additionally, SINGULAIR sales in the emerging markets grew 25% in the third quarter. 
Moving on to JANUVIA and JANUMET. Global revenue grew 28%. Sales this quarter were, again, driven by double-digit growth across most regions. We continue to see volume growth in the U.S., and the franchise continues to grow in the EU due largely to new indications and the ongoing launches of JANUMET.
On a combined basis, JANUVIA and JANUMET are the leading branded oral anti-diabetic franchise in roughly 75% of the top 20 markets. We continue to focus on extending the value of this franchise, and we remain on track for filing a JANUMET once-daily formulation with the FDA next year. Actually, this year, I apologize.
REMICADE sales increased 9% in the third quarter. Despite the austerity measures across the EU, REMICADE continues to grow by double digits, excluding the impact of foreign exchange. Even in markets where we've seen a good uptake of SIMPONI, REMICADE continues to grow. 
Turning next to ISENTRESS. After three years on the market, it continues to deliver outstanding performance, gaining market share across all indications. ISENTRESS' strong sales growth in the third quarter was driven by the growth in the treatment-nave indication and broad utilization of new treatment guidelines in the U.S. We remain on track to file the once-daily dosing regimen with the FDA in 2011.
For the VYTORIN and ZETIA franchise, sales decreased 3% in the third quarter as volume declines in the U.S. were only partially offset by higher sales outside the U.S. The sales growth outside the U.S. was primarily driven by the 30% growth of ZETIA in Japan and 13% growth of VYTORIN in the emerging markets. VYTORIN and ZETIA continue to be an important treatment option to help many patients lower their LDL cholesterol. We understand that researchers from Oxford plan to present the results of the SHARP study at the ASN [American Society of Nephrology] meeting in November. That study, as you know, focused on patients with chronic kidney disease.
Now let's shift to our Vaccine business where we're starting to see signs of progress, including more stable supply. GARDASIL sales grew 2%, benefiting from the timing of shipments to customers. Sales increased sequentially, largely due to the seasonality of the back-to-school period. Sales in PNEUMOVAX were down 15% as a result of the unfavorable seasonal comparison from the H1N1 pandemic last year. We launched our newest vaccine, AFLURIA for the seasonal flu, which posted sales of $35 million in the third quarter. 
We continue to work on the supply issues for ZOSTAVAX. We had limited shipment for the product in Q3, and we anticipate delivering additional shipments to U.S. customers by the end of this year. As you can see, our overall business continues to benefit from the diversity of our product mix and our portfolio of differentiated brands. In addition, our broad global presence is also an asset, providing us with the flexibility to leverage our portfolio in key markets around the world.
In the U.S., sales grew 1% if one excludes the impact of generic erosion for COZAAR and HYZAAR. When you look more closely at the business lines, you'll see that we had double-digit growth in our diabetes franchise, as well as strong growth in our women's health franchise, and we continue to gain market share for products such as ISENTRESS and SINGULAIR. In addition, as Dick mentioned, we are in the process of launching DULERA, our newest treatment for asthma in the U.S. We shipped to pharmacies in July, and we completed our full promotional launch last week. We are encouraged by the early feedback from the field as we focus on the unique attributes of DULERA compared to other combination products.
Now let's turn to the EU, where sales were lower this quarter due to the loss of exclusivity of COZAAR and HYZAAR, as well as the impact of European austerity measures. We continue to believe these measures will have a mid-single digit impact on European sales in 2010. Despite those economic challenges, we continue to see strong growth in key brands such as JANUVIA, JANUMET, ISENTRESS and REMICADE. We're also launching many new products in the EU. SIMPONI, which has been launched in 18 countries, recorded sales of $27 million in the quarter. While we're still working to gain reimbursement in many markets, the early performance indicators are positive.
We also launched BRINAVESS and DAXAS in two markets, and we'll have additional launches of those products in 2011. As I said earlier, we saw good performance in key growth markets. In Japan, sales increased 7%, largely driven by ZETIA and SINGULAIR and the strong launches of BRIDION, COSOPT and JANUVIA are also contributing to our growth in Japan. We continue to focus on our business in Japan as we get ready to file and launch many additional brands over the next three years. We also continue to make significant yet disciplined long-term investments in the emerging markets. 
Growth in the quarter was driven by our top six markets where we saw significant gains from countries such as China, which grew 21% in the quarter. We're approaching each emerging market as a separate opportunity to optimize our product mix.  As we focused on each local market and its specific customer needs, we've seen an ideal match with our diverse product portfolio. Whether it'd be vaccines, products for cardiometabolic disease or the offerings in our women's health franchise, we're seeing growing utilization of Merck products in the emerging markets.
Now people typically think of branded generics as the only key to success in the emerging markets. But JANUVIA is a great example of how an innovative and differentiated product with the right level of educational and promotional support can become a market leader in the Asia Pacific region. While there's a lot of focus on the emerging markets, one shouldn't forget that science and innovation remain at the core of our business in every part of the world. For us to be successful, we have to continue to discover, develop and launch differentiated products with clinical profiles that offer patients and payers proven benefits.
That's why our late-stage pipeline is so critical to our future. In the fourth quarter, we have data presentations for three of these key late-stage programs, which I'd like to discuss with you briefly now. Last week, at the ASBMR [American Society for Bone and Mineral Research] meeting, we presented the four-year BMD [bone mineral density] data for odanacatib or selective Cat [Cathepsin] K Inhibitor for the treatment of osteoporosis. Patients on odanacatib continue to show increases in bone mineral density at the lumbar spine and hip. Odanacatib is currently in Phase III and we will have a long-term fracture study with 16,000 patients, which is fully enrolled. We plan to file odanacatib with regulatory authorities bolstered by that outcome study in 2012.
Starting this weekend and continuing into next week, researchers will present final Phase III data for boceprevir, our hepatitis C protease inhibitor at the AASLD [American Association for the Study of Liver Diseases] meeting in Boston. We previously announced the top line results of the Phase III program. In those studies, boceprevir added to the current standard of care, double the cure rate in treatment-experienced patients and nearly double the cure rate in treatment-nave patients. With the use of response-guided therapy, we also showed that the addition of boceprevir has the potential to shorten the duration of therapy in both treatment-experienced and treatment-nave patients compared to standard therapy. The data that will be presented at the upcoming liver meeting are compelling, and we look forward to sharing them with you.
We remain on track to complete the filing of boceprevir with regulatory authorities around the world this year. Later in November, we will present study results for anacetrapib, our CETP-Inhibitor for the treatment of atherosclerosis at the AHA [American Heart Association] meeting in Chicago. As expected, the results of this study confirmed our decision to move anacetrapib to the planned outcome study that will begin next year. As you can see, we will be presenting a lot of data in the fourth quarter and beyond as we move many of our late-stage research programs forward.
In summary, we've delivered another good quarter. We continue to be excited by the opportunities to grow our business through our current portfolio of products in key markets and through our robust late-stage pipeline, supported by outcome studies. While the operating environment is constantly changing, we are steadily executing on our strategic goals to create the leading healthcare company in the world. 
And now it is my pleasure to turn the call over to my colleague, Peter Kellogg."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and con",1395,"Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and continuing cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and markets performed, and now I'd like to cover our third quarter financial performance and our outlook. So let's begin with our results.
Our GAAP financial information can be found in Table 1 of our release. To make it easier to follow my remarks today, I will speak to the non-GAAP results in Table 2a, which exclude purchase accounting adjustments, merger-related costs, restructuring charges, a $380 million tax benefit and a $950 million legal reserve. 
On this basis, we reported third quarter non-GAAP earnings per share of $0.85. Total revenue for the quarter was $11.1 billion, down 4% on the supplemental combined non-GAAP basis. Excluding the impact of generic COZAAR/HYZAAR and the unfavorable impact of foreign exchange, sales were actually up about 2%. This is good performance. Despite the unfavorable impact of austerity measures in Europe and the impact of healthcare reform in the U.S., and we are pleased with the performance of each of our businesses. 
Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. Our Animal Health business grew 3%, 6% FX change to $687 million, reflecting growth in North and South America, as well as growth in poultry, swine and aquaculture. Consumer Care sales also increased 3% to $291 million due to the growth of foot care, respiratory and skin care products. Growth in these areas was partially offset by the impact of generic MiraLAX.
Now moving on to the P&L. You can see that we have done a very good job controlling our expenses again this quarter. We continue to be very pleased with the progress we're making against our merger synergies, and we are doing so while launching new products and making great progress with the R&D pipeline. As you know, the costs of our combined company are represented in our current cost base. Whereas only the legacy Merck costs were included in the third quarter of 2009, which complicates analysis on a year-over-year basis. As a result, I will speak to the sequential trends on the cost line since those comparisons are more meaningful. 
First, materials and production. The non-GAAP gross margin in the third quarter was 74.9%, which was lower than the second quarter of 2010 when the gross margin was 76.5%. As you can see, our gross margin moves a bit quarter-to-quarter mostly due to product mix. This quarter, the mix changes came from a variety of factors, including lower sequential sales of products like NASONEX, CLARINEX and CLARITIN. Sequentially, the second quarter also benefited from a favorable foreign exchange impact, which did not recur in the third quarter.
Moving on to marketing and admin [administrative] expenses. On a non-GAAP basis, marketing and administrative expenses in the third quarter were $3 billion, which was about $100 million lower than the second quarter of 2010. And on a year-to-year basis, we drove significant cost savings in M&A due to the realization of merger synergies. This was partially tempered by increased promotional spending to support new launches like SIMPONI and DULERA. As you know, we are actively launching many new products, and we expect 2011 to be an exciting year for new product launches in the U.S. and around the world. I'll talk more about that later.
Research and development expense for the third quarter was approximately $1.9 billion, which was slightly lower than the first two quarters due to the continued work we are doing to further prioritize our R&D investments. As a result of the prioritization activities, we decided to stop investment in a few additional programs in the third quarter. We also previously announced the plan to rationalize our R&D network. Meanwhile, we continue to invest in our most promising, late-stage projects such as vorapaxar, boceprevir, telcagepant, odanacatib and TREDAPTIVE. And these key programs in our pipeline continue to move forward. 
Now let's move to equity income. In the third quarter, Merck recorded $236 million of equity income. As expected, this was sequentially higher than second quarter. Remember the income from the AZLP [AstraZeneca LP] joint venture in the second quarter was low due to the inherent variability in the timing of income from the AZLP joint venture.
Moving on to other expense. On a non-GAAP basis, other expense of $158 million was comparable to the second quarter of 2010. Our non-GAAP results exclude the impact of a legal reserve of $950 million in connection with an anticipated resolution of the previously disclosed investigation by the U.S. Attorney's Office for District of Massachusetts related to VIOXX. 
Moving to tax. The Merck non-GAAP tax rate was 22.2% for the third quarter, which was higher than the rate that we saw in the second quarter. As noted in the press release, we continue to expect full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned the cash to shareholders through our dividend and by making continued progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $300 million to repurchase roughly 8 million shares of our common stock. So far this year, we have repurchased about 47 million shares for $1.6 billion. 
So in summary, we continue on a strong trajectory since our merger. Now let's spend our remaining time reviewing our outlook for 2010 and beyond, and let's start with our 2010 outlook. Given our strong year-to-date performance, we are only making one change to our 2010 financial targets. We raised the lower end of our EPS target range, resulting in an increase in the midpoint of our EPS range. On a non-GAAP basis, Merck is now targeting a full year 2010 EPS range of $3.31 to $3.39, excluding certain items. Please see our press release for the GAAP guidance.
Factored into this EPS range are the top line pressures in the U.S. and the EU, including the impact of healthcare reform in the U.S., which is unchanged from our previous estimates and the impact of European austerity measures. Recall that we had anticipated a mid-single digit unfavorable impact on European sales in the second half of 2010. We still believe that will be the case.
Our current year EPS range also assumes that Merck retains full rights to REMICADE and SIMPONI in our markets. On the expense side, as I mentioned earlier, we also anticipate increased promotional spending in the fourth quarter and in 2011 for new product launches like DULERA, DAXAS, BRINAVESS and additional launches of SIMPONI around the world, not to mention we are preparing for the prospect of launching boceprevir in 2011. And we continue to make new targeted commercial and R&D investments including those in the emerging markets.
These growth driving investments are a major reason why we expect our operating expenses in the fourth quarter to be sequentially higher than they were in the third quarter of 2010. So while these top line pressures and operating investments put pressure on the fourth quarter, we are comfortable with our full year 2010 EPS guidance range. 
Finally, let me touch on our long-term outlook. We remain excited about our future, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities are already well underway. We continue to target a high single digit non-GAAP EPS compound annual growth rate from 2009 to 2013 regardless of the outcome of the REMICADE arbitration. 
In addition, we are well on track to realize our $3.5 billion synergy target by the end of 2012. So in closing, we're pleased with the solid third quarter results we reported today. Operational growth in our business, our launch of new products and tight expense management each contributed to our results. We have had a strong performance during our first year of the combined operations, demonstrating that the merger is working, and we are right on track. Thank you. 
Now I'll turn the call back over to Alex. Alex?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if",61,"Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if you do have additional questions, you're always welcome to rejoin the queue. Brooke?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","[Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank.",12,"[Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective",121,"Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective of the outcome of the J&J arbitration. It's obviously, those products contribute meaningfully today to your earnings. And I would appreciate that over the long haul, you, obviously, have a number of pushes and pulls, so maybe you could speak to us specifically about, what are the offsetting factors, let's assume that you were to lose that litigation and lose the earnings from those products, what would be the offsets that allow you to get to the same place?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect of this is, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of va",147,"Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect of this is, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of variables that go into a product range or a guidance range that we present. And the good news from a Merck standpoint is that we have a very robust late-stage pipeline. We have cost synergies that we have in place. We're looking at new operating models. We have new product launches throughout the world now and so we do sensitivity and scenario planning to be able to accomplish that. So we have so many levers to pull and attribute this, this new company that, that's why we're able to state that. Peter, anything you want to add here?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","No, I think you answered it properly, Dick, that's it.",10,"No, I think you answered it properly, Dick, that's it."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Steve Scala with Cowen.",9,"Your next question comes from Steve Scala with Cowen."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm",89,"Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm wondering if you agree. And secondly, on SINGULAIR, what is the benefit to not filing this over the counter? It seems like a strategy that does not fully utilize Merck's largest single asset, and does J&J, Merck think they have rights to OTC SINGULAIR?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to ev",63,"So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to evaluate what their long-term life cycle management value would be, including prospects for over-the-counter switch."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Tim Anderson with Sanford Bernstein.",10,"Your next question comes from Tim Anderson with Sanford Bernstein."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you gu",131,"A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you guys have a 15-valent pneumococcal vaccine in Phase II that would go up against Pfizer's Prevnar, wondering when that might go into Phase III. And also wondering, where you're getting that conjugation technology from? And then on REMICADE, you say it was a strong performer, but it looks like this is three quarters in a row where there's been sequential declines. And I'm wondering what the trajectory is from here, is this all a function of price cuts or are there share losses?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF cate",139,"On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF category. I think the product continues to maintain its share, and it continues to grow notwithstanding the introduction of SIMPONI in those markets, so we feel very good about that. On the pneumococcal one, we have not revealed any new information on the timing of moving that forward. TRA, we've said that we expect generally, that we'll have this data to be revealed in the mid-2011 period. As you know, it's an event-driven trial. And I think that's about all we can say about it right now. And we have an R&D meeting, of course, coming up."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010.",34,"So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Marc Goodman with UBS.",9,"Your next question comes from Marc Goodman with UBS."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to b",116,"You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to be in year one. Are we on track for that? I think it was 60% in SG&A, so that's like $1 billion out of SG&A. Are we seeing that? Obviously, we're seeing SG&A come down. But you're saying you're spending more in advertising and promotion for new products. So just trying to get a flavor for where we are in the cost savings."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A perform",159,"So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A performance, I think your question was are we achieving the first year synergies that we anticipated? I would say, in fact, that's probably one of the areas that we're very proud of so far. The commercial team, speaking for them, if I can, had done a great job actually in beginning of this year rapidly integrating the organizations and finding the right synergies, leveraging the new commercial model around the world. I believe we've commented in the past that at this point, we've got, Ken, I'll turn it over to you, but about 17 of our top 20 markets around the world now integrated. Ken, do you want to add any other comments?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on t",50,"That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on the time table we reveal."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Chris Schott with JPMorgan.",9,"Your next question comes from Chris Schott with JPMorgan."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price strife incremental demand for the product? Second",113,"First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price strife incremental demand for the product? Second question, bigger picture just latest thoughts on capital deployment, how you're prioritizing business development, share repo and the potential to increase the dividend? And just as a follow up to that, we're now a year post-Schering, how were you thinking about just leverage for the overall company given the broader more diversified organization that's been created? I guess does that diversification increase your comfort with more permanently carrying leverage with that company?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market.",45,"So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter",395,"So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter. And as I mentioned also that in this quarter, we had about $300 million of share repurchase but on a year-to-date basis, that's $1.3 billion. So I think from the free cash flow of the company, you can see that we're doing a good job redeploying cash even this year in the first year of the merger. So that is important to us. That said though, we are very actively looking to make great value creating deals around the world, and I think our business development activity is very active in a number of areas. One is to make sure that we have the best pipeline in the industry. Secondly, looking for great combinations and opportunities to partner around the world on the commercial side. And thirdly, in the emerging markets space, we recognize that we're going to be broadening our footprint and we want to make sure that we work with good partners locally to help create that value. So the BD [ph] size is also active and that does come into play. The last thing I would say is relative to our debt, obviously, what we talked about at the time of the merger was that we designed the merger to make sure that we landed in about the same place that we were before the merger. And we targeted the credit ratings to allow us to have some flexibility, but to also reinforce the strength of Merck, so that we can handle any kind of issues that come up. But also, more importantly, that we can invest on the strategic opportunities that we have around the world and we intend to continue that. It is true, we are generating solid cash flow and we'll be -- that cash flow performance will be growing. And so we will keep an eye on that and we will be shareholder friendly. But obviously, we will also intend to maintain our credit rating. We work closely with the credit agencies to make sure we're in the right place, and I think we're in about the right place right now."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Jami Rubin with Goldman Sachs.",10,"Your next question comes from Jami Rubin with Goldman Sachs."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE a",112,"Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE arbitration, I know there's a limit to what you can say, but just given the fact that it has been protracted now to more oral arguments the end of this year, if you could provide any color on what this means, your confidence level on the outcomes. And how far apart are the two companies now? And just when we can expect to get a resolution?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, a",149,"To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, and our strategic approach right now is to do that on a global basis. They're good brands, they last a long time. And so we're putting resources behind the growth of it from a global standpoint. I think just as important, it's a natural fit with many of our pharmaceuticals as well. And so from the distribution standpoint, the customer point, we're looking at first growing it organically as we move forward. To your second question, I'll just restate that we remain very confident in our position in this arbitration. And Bruce, if you want to say a few words about that?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel as an orderly way of completing the written and oral submissions before the panel.",39,"Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel as an orderly way of completing the written and oral submissions before the panel."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from David Risinger with Morgan Stanley.",10,"Your next question comes from David Risinger with Morgan Stanley."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, c",76,"The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, could you just update us on the timing of news flow on V710, the Staph [Staphylococcus] vaccine, specifically I'm interested in understanding the efficacy better, and then the BRIDION hypersensitivity data."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Peter, you want to start?",5,"Peter, you want to start?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pul",147,"Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pulls both ways as we go forward. So that's something that's part of our long-term guidance on the EPS line, but we really haven't broken that out and some of that is because it's not all crystal clear. I think on the recent developments that were just announced this week in Puerto Rico, obviously we've made a couple of public statements through pharm [ph] and so forth and clearly, it's something we need to get to understand better. We are clearly disappointed, but on the other hand, we will work with it. On the pipeline side, let me pass that over to Ken."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to fi",51,"So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to file that in 2011."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from John Boris with Citi Investment Research.",11,"Your next question comes from John Boris with Citi Investment Research."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend incre",120,"First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend increase in quite some time. Can you just help us understand how you're thinking about the dividend and dividend increases going forward? And then a pipeline question on boceprevir. You deployed a strategy for certain assets such as JANUVIA, go-to-market strategy that was pretty quick and pretty rapid. Are you going to use a similar type of strategy on boceprevir? And can you confirm whether the product's been filed or completed the filing as of yet?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","John, this is Peter. As you pointed out, obviously, our dividend is very competitive, it's a pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give g",168,"John, this is Peter. As you pointed out, obviously, our dividend is very competitive, it's a pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidance going forward about our dividend. But as I've mentioned in my script and in one of the earlier questions, we do remain highly focused on returning cash to shareholders in an appropriate manner, while at the same time, making sure we have the cash to drive the science first mindset we have here. We're very proud of the pipeline in our international footprint. We think we're building a great growth surge for the future, and we think that's also the priority for us. And so at this point, I think we are, as I've mentioned, we intend to going forward to be very shareholder friendly. And that said, also make sure we attend to the strategic needs of the business in a very important way."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Ken, would you like to?",5,"Ken, would you like to?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think",105,"What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think we have a robust strategy. And I think we know how to launch products in the specialty area like ISENTRESS, as well as in primary care like JANUVIA. So we are very excited by the prospects of boceprevir. We look forward to next November 1 and 2 in the Phase III data being presented at AASLD."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Catherine Arnold with Credit Suisse.",10,"Your next question comes from Catherine Arnold with Credit Suisse."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on",188,"I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on J&J, there was, obviously, a lot of misinterpretation potentially about the first press release when you talked about the series of events and that it sort of when people did the math it led to a decision before the end of 2010 and then there was more clarity on that for 2011. It may be splitting hairs, but I guess I'd like you to comment on the process. Did you change the communication because there was a misunderstanding or did you change it because there was an incremental step in the process? And then second question I have is about the donut hole coverage, and I wondered if you've looked at your portfolio and made some judgments as to what products might have the most upside in 2011 because there's better compliance due to the donut hole coverage."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Bruce, do you want to start?",6,"Bruce, do you want to start?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration pr",75,"Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration proceeding is that the parties and the arbitrators are able to agree on changes to the process as they go along, and that's what we've reflected during our ongoing disclosures."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","And on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient complian",60,"And on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient compliance when you take away sort of the economic disincentive that was inherent in the donut hole."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your next question comes from Seamus Fernandez with Leerink Swann.",10,"Your next question comes from Seamus Fernandez with Leerink Swann."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the q",160,"Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the quarter. I know these payments are lumpy. But it looks like it brought something to the table here. Also, can you talk about the gross margin weakness in the quarter? What pushed it so low in the quarter? Was it really just kind of mix and seasonality with Schering? Was it the mix of AZLP revenues? And then just the final question really related to AZLP and your long-term guidance. What are the assumptions? Can you just remind us about the assumptions relative to AZLP and the PPI option that AstraZeneca holds for 2012? And I guess when would be the timing of the execution of that option should AstraZeneca actually choose to execute it?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, o",381,"I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, obviously. However, it's a business that continues to do nicely. We haven't really given guidance for these individual businesses and so forth, but there are timing of different seasonality of the products and so forth. On the -- related to that relationship, there is, as you know, in February, there was an option on the non-PPI products that was executed. And you saw a gain in our financials earlier this year from that and obviously, that gain is excluded from our non-GAAP results, but you can see it in our GAAP results and in some of our tables. The next option timing is two years later. That's for the PPI items, so that would be roughly in the first part of 2012. And at this point, where we've always assumed that they would exercise that option that said it's their choice and we can't really predict exactly what will happen, but that's the way we've always thought about it anyway. And then moving to the product gross margins for the quarter, you're right. You put your finger on the two points. One is obviously -- there is some volatility in PGM just naturally because of the mix and some of that mix is because of products or it could be divisional and so forth, so that does move around a little bit. The other factor that we had in the second and third quarter this year when you compare it from the second and to third quarter was in the second quarter, we did get some foreign exchange benefit and the third quarter that didn't recur. So that also kind of caused the third quarter to look a little weaker versus the second quarter. And obviously the mix also, so we kind of have two factors go against us in the third quarter. I think we have experienced a higher level of volatility in foreign exchange rates this year than normal. And so as to that on some timing basis eventually does roll to the cost of goods."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Your last question comes from Tony Butler with Barclays Capital.",10,"Your last question comes from Tony Butler with Barclays Capital."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts","Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and",115,"Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and excellence with customers and being number one with customers, but if I think back over the last 20 years, the balance of power has really shifted. And I'm curious today who are your principal customers? And please don't just say well, it's patients, it's physicians, it's payers. That we kind of know. But there's been a shift, and I'm just curious how you think about that from a focal point on the sales effort?"
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a mark",100,"So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a marketing standpoint. And in some markets, we actually have separate sales forces, China, for example. I think it varies depending on the actual market characteristics, but to answer the thrust of your question, we are actually trying to treat this business line as its own distinct business line to be managed."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","And to your other question, obviously, the focus that we have on physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capab",253,"And to your other question, obviously, the focus that we have on physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capability in each of the franchises that they know they have many choices. And I think we're moving to a more customized customer approach and just the same messages of the same kind of products and services for every customer. But on a more strategic level, Tony, and I think that's a good question. I think one of the things that Merck will have from a competitive advantage standpoint is that when you look at either governments on an international basis, whether it's a nice type organization or whether we're moving to healthcare reform today and the government's going to play a larger role or whether you're looking to some of the larger managed care payers that exist in the United States. The important part is going to be health technology assessment and the ability to have clinical outcomes and be able to approve that whatever product you're thinking about from a regulatory approval and launch standpoint is above the standard of care that exists today. And I think where our competitive advantage is as a company is our late-stage pipeline and how much of it has the ability to meet unmet medical needs and it is differentiated products, and we have the clinical outcome studies to prove it."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives","Okay. Thank you, operator. That concludes our call today. Thank you, everyone.",12,"Okay. Thank you, operator. That concludes our call today. Thank you, everyone."
288502,113992770,83432,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator","Thank you. This concludes the conference. You may now disconnect.",10,"Thank you. This concludes the conference. You may now disconnect."
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir.",39," Good day, everyone, and welcome to Merck's Third Quarter 2010 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Alex Kelly, Senior Vice President of Investor Relations. Please go ahead, sir.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I want to point out a couple of things this morning. First, there are a number of items in the GAAP resul",372," Thank you, Brooke, and good morning, everyone, and welcome to Merck's 2010 Third Quarter Conference Call. Before I turn the call over to Dick Clark, I want to point out a couple of things this morning. First, there are a number of items in the GAAP results such as purchase accounting adjustments and merger-related expenses, restructuring costs. There's also a $380 million tax benefit and a $950 million legal reserve. In those GAAP, we have excluded those items from our non-GAAP results, and you could see a reconciliation table from the GAAP to non-GAAP figures in our press release. And that'll give you a better sense of the underlying performance.
 Next, we've also provided tables to help you understand the revenue trends. There are three tables in the press release. The first table, Table 1, is the GAAP results. Table 2 reconciles our GAAP P&L to non-GAAP for the third quarter and year-to-date period. Table 3 is a supplemental non-GAAP table, which provides the sales performance for the company, the business units and the products as if the company have been combined for 2009, as well as 2010. During the call, we'll refer to Tables 2 when we discuss the P&L and Table 3 for the revenue performance. So you may want to have those available.
 Finally, I'd like to remind you that some of the statements we make during the call today may be considered forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Act of 1995. Such statements are based upon the current beliefs of management and are subject to significant risks and uncertainties. Our SEC filings, including Item 1A and the 2009 10-K identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected this morning. Merck undertakes no obligation to publicly update any forward-looking statements.
 Our SEC filings, as well as our earnings release are available on merck.com. And with that, I'd like to let you know that I'm joined by Dick Clark, our Chairman and Chief Executive Officer; by Ken Frazier, our President; and also I'm joined by Peter Kellogg, our Chief Financial Officer.
 Now I'd like to introduce Dick Clark.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We had con",950," Thank you, Alex, and good morning, everyone. It's been a year since Merck and Schering-Plough merged to form today's Merck. First, let me say that I'm extremely pleased and proud of all that we have accomplished in such a short period of time. We had consistently focused on achieving the benefits of the combination for patients, customers, shareholders and employees. Most important is furthering the science that underpins Merck's ability to address many of the world's most serious, unmet medical needs.
 Today, our company has greater geographic reach, one of the industry's broadest product portfolio, and has a tremendous late-stage pipeline that I believe is second to none. As we mark the anniversary of our merger, I want to thank many Merck colleagues who have helped us manage a significant combination so effectively. Throughout the past year, we have continued to drive revenue growth or key products, improve our cost structure and make the right strategic investments in our business. We've accomplished this while successfully taking on a challenging task of integrating our people, systems and cultures to form a powerful, unified organization. And while we still have work to do, Merck is well positioned now and for the future.
 Our solid third quarter 2010 financial results illustrate that we are continuing to execute our strategy. We realized top line worldwide sales of $11.1 billion, non-GAAP earnings per share of $0.85 and GAAP earnings per share of $0.11 for the quarter.
 Key brands including JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE were each strong performers this quarter. It is Merck's ability to develop and offer these truly differentiated products that will position us to successfully navigate difficult economies, pricing pressures and challenging regulatory environments throughout the world. In a few moments, Ken will discuss our global product performance in more detail. Peter will then provide you with our full earnings outlook.
 While our merger has always been about the science, synergies are also important. We are on track to achieve our previously announced synergy target of $3.5 billion in annual savings by the end of 2012. As we continue to integrate, there's exciting activity across all of Merck and the world, particularly R&D and commercial strengths at Merck. In coming months and into next year, we expect some important clinical data from promising candidates in our robust pipeline. You will hear more about these milestones in a few moments.
 And this pipeline is coming through in other ways too. As we speak, we have 10 major product launches underway in important markets around the world. And just the last few weeks alone, we have received regulatory approval for BRINAVESS in Europe and signed an important partnership agreement to allow Lundbeck to distribute SYCREST in all markets outside the United States, China and Japan.
 Recently, we also marked our first major U.S. product launch as a combined company with the DULERA launch. With the addition of this exciting new asthma product, Merck now has the widest respiratory portfolio available in the United States. Lastly, I had the pleasure of participating in the DULERA launch. With the addition of this exciting new asthma product, Merck now has the lightest respiratory portfolio available in the United States.
 Last week, I had the pleasure of participating in the DULERA launch meeting, along with our sales and marketing team. It was great to share first-hand the enthusiasm and excitement our sales representatives have to bring this new treatment to our customers. We made excellent progress in the integration of our commercial operations in our major markets throughout the world. Those integrated markets account for about 85% of our Global Human Health sales. It is exciting to see the benefits of our broader, more diversified product portfolio as we engage with physicians and customers. The team is doing an excellent job executing on our commercial sales model in the United States and in key markets in Europe, Japan, Latin America and Asia Pacific. Our overall goal is to outperform our peer pharmaceutical companies and become the clear industry leader in the eyes of our customers.
 In fact, our customer survey for the U.S. market indicates that Merck continues to lead in trust and value metrics versus our peers. Our focus is on positioning Merck to become a leader in the key global growth market, and our broad portfolio of healthcare offerings will drive further growth in these emerging markets. We are currently the fifth-largest multinational pharmaceutical player in a fast-growing emerging markets, and we are aiming much higher. By 2013, we seek to drive at least 25% of our Global Human Health in vaccine sales from the emerging markets. We are making good progress and in the third quarter, that number was 18%.
 Over time, we will build further in these efforts by leveraging our advantage using our broad in-line portfolio. Many of these brands are former blockbusters with considerable brand equity such as ZOCOR. But we're also successful relaunching new products in these markets such as JANUVIA. Additionally, we are seeking to globalize the Vaccine business through growth in emerging markets through partnerships and through the introduction of low-cost manufacturing for some of our key products to expand affordable access.
 Finally, we are working to tap the significant growth potential for many of our well-regarded consumer care brands by expanding our operations outside the U.S. In summary, we've made great progress, driving growth of key products, achieving our merger synergies, expanding our global reach, launching new products and advancing our late-stage R&D pipeline. One year post-merger, our results demonstrate that we are realizing the benefit of our merger, while ensuring that the company is well positioned for the future.
 Now I'll turn it over to Ken.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity f",1654," Thank you, Dick, and thanks, everyone for joining us this morning. As Dick mentioned, we had another successful quarter with Global Human Health reporting sales of $9.7 billion despite the economic challenges in many markets and the loss of exclusivity for COZAAR and HYZAAR. Our commercial performance this quarter was characterized by continuing strong performance of key brands such as JANUVIA, JANUMET, SINGULAIR, ISENTRESS and REMICADE, which was complemented by strong growth in key geographic markets and new contributions from our ongoing product launches such as SIMPONI, BRIDION and AFLURIA.
 Before I review the sales performance, I'd like to refer you to Table 3, which provides the supplemental combined non-GAAP results and includes the impact of foreign exchange. As you review Table 3, you'll see that product sales were driven by the robust growth of our key brands, SINGULAIR, JANUVIA, JANUMET, REMICADE and ISENTRESS. These brands grew a combined 17% year-over-year.
 Now let's take a closer look at the performance of some of these key brands starting with SINGULAIR, which grew 12% over the previous year. The increase in sales was driven by growth in most regions. We continue to see volume growth in the U.S. and EU and continued class leadership in Japan. Additionally, SINGULAIR sales in the emerging markets grew 25% in the third quarter.
 Moving on to JANUVIA and JANUMET. Global revenue grew 28%. Sales this quarter were, again, driven by double-digit growth across most regions. We continue to see volume growth in the U.S., and the franchise continues to grow in the EU due largely to new indications and the ongoing launches of JANUMET.
 On a combined basis, JANUVIA and JANUMET are the leading branded oral anti-diabetic franchise in roughly 75% of the top 20 markets. We continue to focus on extending the value of this franchise, and we remain on track for filing a JANUMET once-daily formulation with the FDA next year. Actually, this year, I apologize.
 REMICADE sales increased 9% in the third quarter. Despite the austerity measures across the EU, REMICADE continues to grow by double digits, excluding the impact of foreign exchange. Even in markets where we've seen a good uptake of SIMPONI, REMICADE continues to grow.
 Turning next to ISENTRESS. After three years on the market, it continues to deliver outstanding performance, gaining market share across all indications. ISENTRESS' strong sales growth in the third quarter was driven by the growth in the  treatment-nave indication and broad utilization of new treatment guidelines in the U.S. We remain on track to file the once-daily dosing regimen with the FDA in 2011.
 For the VYTORIN and ZETIA franchise, sales decreased 3% in the third quarter as volume declines in the U.S. were only partially offset by higher sales outside the U.S. The sales growth outside the U.S. was primarily driven by the 30% growth of ZETIA in Japan and 13% growth of VYTORIN in the emerging markets. VYTORIN and ZETIA continue to be an important treatment option to help many patients lower their LDL cholesterol. We understand that researchers from Oxford plan to present the results of the SHARP study at the ASN [American Society of Nephrology] meeting in November. That study, as you know, focus on patients with chronic kidney disease.
 Now let's shift to our Vaccine business where we're starting to see signs of progress, including more stable supply. GARDASIL sales grew 2%, benefiting from the timing of shipments to customers. Sales increased sequentially, largely due to the seasonality of the back-to-school period. Sales in PNEUMOVAX were down 15% as a result of the unfavorable seasonal comparison from the H1N1 pandemic last year. We launched our newest vaccine, AFLURIA for the seasonal flu, which posted sales of $35 million in the third quarter.
 We continue to work on the supply issues with ZOSTAVAX. We had limited shipments of the product in Q3, and we anticipate delivering additional shipments to U.S. customers by the end of this year. As you can see, our overall business continues to benefit from the diversity of our product mix and our portfolio of differentiated brands. In addition, our broad global presence is also an asset, providing us with the flexibility to leverage our portfolio in key markets around the world.
 In the U.S., sales grew 1% if one excludes the impact of generic erosion for COZAAR and HYZAAR. When you look more closely at the business lines, you'll see that we had double-digit growth in our diabetes franchise, as well as strong growth in our women's health franchise, and we continue to gain market share for products such as ISENTRESS and SINGULAIR. In addition, as Dick mentioned, we are in the process of launching DULERA, our newest treatment for asthma in the U.S. We shipped to pharmacies in July, and we completed our full promotional launch last week. We are encouraged by the early feedback from the field as we focus on the unique attributes of DULERA compared to other combination products.
 Now let's turn to the EU, where sales were lower this quarter due to the loss of exclusivity of COZAAR and HYZAAR, as well as the impact of European austerity measures. We continue to believe these measures will have a mid-single digit impact on European sales in 2010. Despite those economic challenges, we continue to see strong growth in key brands such as JANUVIA, JANUMET, ISENTRESS and REMICADE. We're also launching many new products in the EU. SIMPONI, which has been launched in 18 countries, recorded sales of $27 million in the quarter. While we're still working to gain reimbursement in many markets, the early performance indicators are positive.
 We also launched BRINAVESS and DAXAS into markets, and we'll have additional launches of those products in 2011. As I said earlier, we saw good performance in key growth markets. In Japan, sales increased 7%, largely driven by ZETIA and SINGULAIR and the strong launches of BRIDION, COSOPT and JANUVIA are also contributing to our growth in Japan. We continue to focus on our business in Japan as we get ready to file and launch many additional brands over the next three years. We also continue to make significant yet disciplined long-term investments in the emerging markets.
 Growth in the quarter was driven by our top six markets where we saw significant gained from countries such as China, which grew 21% in the quarter. We're approaching each emerging market as a separate opportunity to optimize our product mix as we focus on each local market and its specific customer needs, we've seen an ideal match with our diverse product portfolio. Whether it'd be vaccine, products for cardiometabolic disease or the offerings in our women's health franchise, we're seeing growing utilization of Merck products in the emerging markets.
 Now people typically think of branded generics as the only key to success in the emerging markets. But JANUVIA is a great example of how an innovative and differentiated product with the right level of educational and promotional support can become a market leader in the Asia Pacific region. While there's a lot of focus on the emerging markets, one shouldn't forget that science and innovation remain at the core of our business in every part of the world. For us to be successful, we have to continue to discover, develop and launch differentiated products with clinical profiles that offer patients and payers proven benefits.
 That's why our late-stage pipeline is so critical to our future. In the fourth quarter, we have data presentations for three of these key late-stage programs, which I'd like to discuss with you briefly now. Last week, at the ASBMR [American Society for Bone and Mineral Research] meeting, we presented the four-year BMD [bone mineral density] data for odanacatib or selective Cat [Cathepsin] K Inhibitor for the treatment of osteoporosis. Patients on odanacatib continue to show increases in bone mineral density at the lumbar spine and hip. Odanacatib is currently in Phase III and we will have a long-term fracture study with 16,000 patients, which is fully enrolled. We plan to file odanacatib with regulatory authorities bolstered by that outcome study in 2012.
 Starting this weekend and continuing into next week, researchers will present final Phase III data for both boceprevir, our hepatitis C protease inhibitor at the AASLD [American Association for the Study of Liver Diseases] meeting in Boston. We previously announced the top line results of the Phase III program. In those studies, boceprevir added to the current standard of care, double the cure rate in treatment-experienced patients and nearly double the cure rate in treatment-nave patients. With the use of response-guided therapy, we also showed that the addition of boceprevir has the potential to shorten the duration of therapy in both treatment-experienced and treatment-nave patients compared to standard therapy. The data that will be presented at the upcoming liver meeting are compelling, and we look forward to sharing them with you.
 We remain on track to complete the filing of boceprevir with regulatory authorities around the world this year. Later in November, we will present study result for anacetrapib, our CETP-Inhibitor for the treatment of atherosclerosis at the AHA [American Heart Association] meeting in Chicago. As expected, the results of this study confirmed our decision to move anacetrapib to the planned outcome study that will begin next year. As you can see, we will be presenting a lot of data in the fourth quarter and beyond as we move many of our late-stage research programs forward.
 In summary, we've delivered another good quarter. We continue to be excited by the opportunities to grow our business through our current portfolio of products in key markets and through a robust late-stage pipeline, supported by outcome studies. While the operating environment is constantly changing, we are steadily executing on our strategic goals to create the leading healthcare company in the world.
 And now it is my pleasure to turn the call over to my colleague, Peter Kellogg.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and co",1395," Thank you, Ken, and good morning. As you've heard from Dick and Ken, our performance this quarter was, once again, characterized by solid operating performance in our business, which continues to help offset the impact of generic COZAAR and HYZAAR and continuing cost management and benefits of merger synergies in our cost base. Ken discussed how our key brands and markets performed, and now I'd like to cover our third quarter financial performance and our outlook. So let's begin with our results.
 Our GAAP financial information can be found in Table 1 of our release. To make it easier to follow my remarks today, I will speak to the non-GAAP results in Table 2a, which exclude purchase accounting adjustments, merger-related costs, restructuring charges, a $380 million tax benefit and a $950 million legal reserve.
 On this basis, we reported third quarter non-GAAP earnings per share of $0.85. Total revenue for the quarter was $11.1 billion, down 4% on the supplemental combined non-GAAP basis. Excluding the impact of generic COZAAR/HYZAAR and the unfavorable impact of foreign exchange, sales were actually up about 2%. This is good performance. Despite the unfavorable impact of austerity measures in Europe and the impact of healthcare reform in the U.S., and we are pleased with the performance of each of our businesses.
 Ken discussed our Global Human Health sales, so let me just comment on our Animal Health and Consumer businesses. Our Animal Health business grew 3%, 6% FX change to $687 million, reflecting growth in North and South America, as well as growth and poultry, swine and aquaculture. Consumer Care sales also increased 3% to $291 million due to the growth of foot care, respiratory and skin care products. Growth in these areas was partially offset by the impact of generic MiraLAX.
 Now moving on to the P&L. You can see that we have done a very good job controlling our expenses again this quarter. We continue to be very pleased with the progress we're making against our merger synergies, and we are doing so while launching new products and making great progress with the R&D pipeline. As you know, the costs of our combined company are represented in our current cost base. Whereas only the legacy Merck costs were included in the third quarter of 2009, which complicates analysis on a year-over-year basis. As a result, I will speak to the sequential trends on the cost line since those comparisons are more meaningful.
 First, materials and production. The non-GAAP gross margin in the third quarter was 74.9%, which was lower than the second quarter of 2010 when the gross margin was 76.5%. As you can see, our gross margin moves a bit quarter-to-quarter mostly due to product mix. This quarter, the mix changes came from a variety of factors, including lower sequential sales of products like NASONEX, CLARINEX and CLARITIN. Sequentially, the second quarter also benefited from a favorable foreign exchange impact, which did not recur in the third quarter.
 Moving on to marketing and admin [administrative] expenses. On a non-GAAP basis, marketing and administrative expenses in the third quarter were $3 billion, which was about $100 million lower than the second quarter of 2010. And on a year-to-year basis, we drove significant cost savings in M&A due to the realization of merger synergies. This was partially tempered by increased promotional spending to support new launches like SIMPONI and DULERA. As you know, we are actively launching many new products, and we expect 2011 to be an exciting year for new product launches in the U.S. and around the world. I'll talk more about that later.
 Research and development expense for the third quarter was approximately $1.9 billion, which was slightly lower than the first two quarters due to the continued work we are doing to further prioritize our R&D investments. As a result of the prioritization activities, we decided to stop investment in a few additional programs in the third quarter. We also previously announced the plan to rationalize our R&D network. Meanwhile, we continue to invest in our most promising, late-stage projects such as vorapaxar, boceprevir, telcagepant, odanacatib and TREDAPTIVE. And these key programs in our pipeline continue to move forward.
 Now let's move to equity income. In the third quarter, Merck recorded $236 million of equity income. As expected, this was sequentially higher than second quarter. Remember the income from the AZLP [AstraZeneca LP] joint venture in the second quarter was low due to the inherent variability in the timing of income from the AZLP joint venture.
 Moving on to other expense. On a non-GAAP basis, other expense of $158 million was comparable to the second quarter of 2010. Our non-GAAP results exclude the impact of a legal reserve of $950 million in connection with an anticipated resolution of a previously disclosed investigation by the U.S. Attorney's Office for District of Massachusetts related to VIOXX.
 Moving to tax. The Merck non-GAAP tax rate was 22.2% for the third quarter, which was higher than the rate that we saw in the second quarter. As noted in the press release, we continue to expect full year tax rate to be in the range of 22% to 24% on a non-GAAP basis. In addition to the solid operational performance this quarter, we also returned the cash to shareholders through our dividend and by making continued progress on our share repurchase program. During the quarter, we paid $1.2 billion in dividends and spent approximately $300 million to repurchase roughly 8 million shares of our common stock. So far this year, we have repurchased about 47 million shares for $1.6 billion.
 So in summary, we continue on a strong trajectory since our merger. Now let's spend our remaining time reviewing our outlook for 2010 and beyond, and let's start with our 2010 outlook. Given our strong year-to-date performance, we are only making one change to our 2010 financial targets. We raised the lower end of our EPS target range, resulting in an increase in the midpoint of our EPS range. On a non-GAAP basis, Merck is now targeting a full year 2010 EPS range of $3.31 to $3.39, excluding certain items. Please see our press release for the GAAP guidance.
 Factored into this EPS range are the top line pressures in the U.S. and the EU, including the impact of healthcare reform in the U.S., which is unchanged from our previous estimates and the impact of European austerity measures. Recall that we had anticipated a mid-single digit unfavorable impact on European sales in the second half of 2010. We still believe that will be the case.
 Our current year EPS range also assumes that Merck retains full rights to REMICADE and SIMPONI in our markets. On the expense side, as I mentioned earlier, we also anticipate increased promotional spending in the fourth quarter and in 2011 for new product launches like DULERA, DAXAS, BRINAVESS and additional launches of SIMPONI around the world, not to mention we are preparing for the prospect of launching boceprevir in 2011. And we continue to make new targeted commercial and R&D investments including those in the emerging markets.
 These growth driving investments are a major reason why we expect our operating expenses in the fourth quarter to be sequentially higher than they were in the third quarter of 2010. So while these top line pressures and operating investments put pressure on the fourth quarter, we are comfortable with our full year 2010 EPS guidance range.
 Finally, let me touch on our long-term outlook. We remain excited about our future, and we have many opportunities between our commercial launches, our R&D pipeline and the merger restructuring activities are already well underway. We continue to target a high single digit non-GAAP EPS compound annual growth rate from 2009 to 2013 regardless of the outcome of the REMICADE arbitration.
 In addition, we are well on track to realize our $3.5 billion synergy target by the end of 2012. So in closing, we're pleased with the solid third quarter results we reported today. Operational growth in our business, our launch of new products and tight expense management each contributed to our results. We have had a strong performance during our first year of the combined operations, demonstrating that the merger is working, and we are right on track. Thank you.
 Now I'll turn the call back over to Alex. Alex?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But i",61," Yes, thanks, Peter. Now we'd like to open up the call to take your questions. But in order to get through as many questions as possible, we ask that you please limit yourself to one or two questions, we don't plan on taking any follow-up questions. But if you do have additional questions, you're always welcome to rejoin the queue. Brooke?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," [Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank.",12," [Operator Instructions] Your first question comes from Barbara Ryan with Deutsche Bank.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective",120," Maybe it's for you, Dick, and possibly Peter. The comments that you've made this morning relative to 2013 guidance, which specifically is the high single digit CAGR using that 2009 as the base. You consistently said that, that guidance holds irrespective of the outcome of the J&J arbitration. It's obviously, those products contribute meaningfully today to your earnings. And I would appreciate that over the long haul, you, obviously, have a number of pushes and pulls, so maybe you could speak to us specifically about, whether the offsetting factors, let's assume that you were to lose that litigation and lose the earnings from those products, what would be the offsets that allow you to get to the same place?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect is this, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of vari",144," Well, first of all, Barbara, I'll turn it over to Peter in a second, but I think the most important aspect is this, that we do remain very confident in our position in this arbitration, and I think that's important. And as you know, there's a lot of variables that go into a product range or a guidance range that we present. And the good news from a Merck standpoint is that we have a very robust late-stage pipeline. We have cost synergies that we have in place. We're looking at new operating models. We have new product launches throughout the world now and so we do sensitivity and scenario planning to be able to accomplish that. So we have so many levers to pull and attribute this, this new company that's why we will stay there. Peter, anything you want to add here?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," No, I think you answered it properly, Dick, that's it.",10," No, I think you answered it properly, Dick, that's it.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Steve Skala with Cowen.",9," Your next question comes from Steve Skala with Cowen.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm",89," Should we assume that if there were any negative aspects in the SHARP data, such as cancer signal or progression of disease that Oxford group would reveal the data immediately? So I guess the conclusion should be that there are no such negatives, and I'm wondering if you agree. And secondly, on SINGULAIR, what is the benefit to not filing this over the counter? It seems like a strategy that does not fully utilize Merck's largest single asset, and does J&J, Merck think they have rights to OTC SINGULAIR?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to e",63," So on the first question, I think when a particular data is revealed, it's up to the Oxford group, and we look forward to seeing the data next week when it's revealed in two weeks. On the SINGULAIR question, we constantly look at all of our products to evaluate what their long-term life cycle management value would be, including prospects for over-the-counter switch.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Tim Anderson with Sanford Bernstein.",10," Your next question comes from Tim Anderson with Sanford Bernstein.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you g",131," A couple of pipeline question since you won't be having an R&D meeting, and then a question on REMICADE. On TRA, can you just narrow the timing of seeing results from the two Phase II trials in 2011? And then second pipeline question, it looks like you guys have a 15-valent pneumococcal vaccine in Phase II that would go up against Pfizer's Prevnar, wondering when that might go into Phase III. And also wondering, where you're getting that conjugation technology from? And then on REMICADE, you say it was a strong performer, but it looks like this is three quarters in a row where there's been sequential declines. And I'm wondering what the trajectory is from here, is this all a function of price cuts or are there share losses?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF cat",139," On REMICADE the growth would have been without exchange issues, 13%. I think the other issue that we're dealing with since we have the European territories is we have the general austerity measures and measures that are aimed actually at the anti-TNF category. I think the product continues to maintain its share, and it continues to grow notwithstanding the introduction of SIMPONI in those markets, so we feel very good about that. On the pneumococcal one, we have not revealed any new information on the timing of moving that forward. TRA, we've said that we expect generally, that we'll have this data to be revealed in the mid-2011 period. As you know, it's an event-driven trial. And I think that's about all we can say about it right now. And we have an R&D meeting, of course, coming up.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010.",34," So yes, Tim, normally Merck has done a history of having an R&D Day in December. There will not be one in 2010, since we just had an R&D update in May of 2010.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Marc Goodman with UBS.",9," Your next question comes from Marc Goodman with UBS.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to",116," You mentioned that in R&D, you had stopped work on a couple of programs. Can you mention which ones they were? And then second of all, in cost savings, can you tell us where we are so far? I know that of the $3.5 billion about half of it was supposed to be in year one. Are we on track for that? I think it was 60% in SG&A, so that's like $1 billion out of SG&A. Are we seeing that? Obviously, we're seeing SG&A come down. But you're saying you're spending more in advertising and promotion for new products. So just trying to get a flavor for where we are in the cost savings.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A perfor",157," So the first question about the R&D pipeline decisions, those affected -- AVEO, which I think we announced earlier for a program we had with them catazine [ph] and a program numbered SCH 900105, which is in the oncology space. In terms of the SG&A performance, I think your question was are we achieving the first year synergies that we anticipated? I would say, in fact, that's probably one of the areas that we're very proud of so far. The commercial team, speaking for them, if I can, had done a great job actually in beginning of this year rapidly integrating the organizations and finding the right synergies, leveraging the new commercial model around the world. I believe we've commented in the past that at this point, we've got, Ken, I'll turn it over to you, but about 17 of our top 20 markets around the world. Ken, do you want to add any other comments?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on",50," That's correct, and I think that we've been able to do it quickly with the least amount of disruption possible given the size of these two organizations that we're bringing together. So we feel very confident that we'll continue to meet our synergies on the time table we reveal.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Chris Schott with JPMorgan.",9," Your next question comes from Chris Schott with JPMorgan.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price drive incremental demand for the product? Second",111," First question was on GARDASIL. I believe your competitor announced a price cut in Canada. Just wondering on your thoughts on that move and would you consider in markets, in certain markets, lowering price drive incremental demand for the product? Second question, bigger picture just latest thoughts on capital deployment, how you're prioritizing business development, share repo and the potential to increase the dividend? And just as a follow up to that, we're now a year post-Schering, how are we getting much leverage for the overall company given the broader more diversified organization that's been created? I guess those diversification increase your comfort with more permanently carrying leverage at the company?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market.",45," So starting with the cervix question, we won't, obviously, be in a position to talk about what our pricing strategy is going forward, but I think it is important to recognize that we are the market leader with greater than 90% share in that market.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarte",392," So on the questions of capital deployment, good question, and as you know, we have talked in the past about how we have a fairly strong dividend and as I mentioned in my discussion, we actually had a dividend that amounts to about $1.2 billion per quarter. And as I mentioned also that in this quarter, we had about $300 million of share repurchase but on a year-to-date basis, that's $1.3 billion. So I think from the free cash flow of the company, you can see that we're doing good job redeploying cash even this year in the first year of the merger. So that is important to us. That said though, we are very actively looking to make great value creating deals around the world, and I think our business development activity is very active in a number of areas. One is to make sure that we have the best pipeline in the industry. Secondly, looking for great combinations and opportunities to partner around the world on the commercial side. And thirdly, in the emerging markets space, we recognize that we're going to be broadening our footprint and we want to make sure that we work with good partners locally to help create that value. So the BD [ph] size is also active and that does come into play. The last thing I would say is relative to our debt, obviously, what we talked about at the time of the merger was we design the merger to make sure that we landed in about the same place that we were before the merger. And we targeted the credit ratings to allow us to have some flexibility, but to also reinforce the strength of Merck, so that we can handle any kind of issues that come up. But also, more importantly, that we can invest on the strategic opportunities that we have around the world and we intend to continue that. It is true, we are generating solid cash flow and we'll be -- that cash flow performance will be growing. And so we will keep an eye on that. We will be shareholder friendly. But obviously, we will also intend to maintain our credit rating. We work closely with the credit agencies to make sure we're in the right place, and I think we're in about the right place right now.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Jami Rubin with Goldman Sachs.",10," Your next question comes from Jami Rubin with Goldman Sachs.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE",112," Dick, on the Consumer business, I'm just wondering if you could remind us what your strategic plans are for that. Relative to the overall company, it's very small. And is the plan to scale this up or to spin it off? And then secondly, regarding REMICADE arbitration, I know there's a limit to what you can say, but just given the fact that it has been protracted now to more oral arguments the end of this year, if you could provide any color on what this means, your confidence level on the outcomes. And how far apart are the two companies now? And just when we can expect to get a resolution?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States,",149," To your first question, I think we look at the Consumer Care business as still an important part of our future. And the fact that I think Schering-Plough did a tremendous job of taking those brands and seeing the growth that we had in the United States, and our strategic approach right now is to do that on a global basis. They're good brands, they last a long time. And so we're putting resources behind the growth of it from a global standpoint. I think this is important. It's a natural fit with many of our pharmaceuticals as well. And so from the distribution standpoint, the customer point, we're looking at first growing it organically as we move forward. To your second question, I'll just restate that we remain very confident in our position in this arbitration. And Bruce, if you want to say a few words about that?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel is an orderly way of completing the written and oral submissions before the panel.",39," Sure. Jami, it's Bruce Kuhlik. I would not read anything into the post-hearing process. It's simply something that we've agreed to with the arbitration panel is an orderly way of completing the written and oral submissions before the panel.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from David Risinger with Morgan Stanley.",10," Your next question comes from David Risinger with Morgan Stanley.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline,",76," The first is with respect to the tax rate outlook, can you just frame how you're thinking about the longer-term tax rate? And the trigger for my question is the tax rate development in Puerto Rico recently. And then second, with respect to the pipeline, could you just update us on the timing of news flow on V710, the Staph [Staphylococcus] vaccine, specifically I'm interested in understanding the efficacy better, and then the BRIDION hypersensitivity data.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Peter, you want to start?",5," Peter, you want to start?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pu",145," Sure. I'll start with the tax rate, David, and I'll pass it over to someone else for the pipeline questions. On the tax rate, obviously we haven't given long-term guidance on our tax rate and articulated obviously there's a lot of different pushes and pulls both ways as you go forward. So that's something that's part of our long-term guidance on the EPS line, but we haven't really broken that out and some of that is because it's now crystal clear. I think on the recent developments that were just announced this week in Puerto Rico, obviously we've made a couple of public statements through pharm [ph] and so forth and clearly, it's something we need to get understand better. We are clearly disappointed, but on the other hand, we will work with it. On the pipeline side, let me pass that over to Ken.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to f",51," So on the Staph vaccine, as you know, the ongoing study is an endpoint-driven study. And I think our view is that we'd expect to see the interim look in 2011. On BRIDION, we are now discussing hypersensitivity and coagulation, and we plan to be able to file that in 2011.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from John Boris with Citi Investment Research.",11," Your next question comes from John Boris with Citi Investment Research.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend incr",121," First question, just really on the dividend, if I can just press there a little bit in an environment where some of your peers are paying a higher dividend and/or most of your peers are consistently raising their dividend. You haven't had a dividend increase in quite some time. Can you just help us understand how you're thinking about the dividend and dividend increases going forward? And then a pipeline question on boceprevir. You deployed a strategy for certain assets such as JANUVIA, go-to-market strategy that was pretty quick and pretty rapid. Are you going to use a similar type of strategy on boceprevir? And can you confirm whether the product has been filed or completed the filing as of yet?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," John, this is Peter. As you pointed out, obviously, our dividend is very competitive, pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidanc",164," John, this is Peter. As you pointed out, obviously, our dividend is very competitive, pretty attractive yield obviously and a good dividend payout ratio. That said, obviously it's something that we're asked about on a regular basis. We don't give guidance going forward about our dividend. But as I've mentioned in my script and in one of the earlier questions, we do remain highly focused on returning cash to shareholders in an appropriate manner, while at the same time, making sure we have the cash to drive the science first mindset we have here. We're very proud of the pipeline in our international footprint. We think we're building a great growth surge of future, and we think that's also the priority for us. And so at this point, I think we are, as I've mentioned, we intend going forward to be very shareholder friendly. And that said, also make sure we attend to the strategic needs of the business in a very important way.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Ken, would you like to?",5," Ken, would you like to?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I thin",105," What we said about the status of boceprevir with the FDA and the EMEA is that we plan to file that we are on track to complete the submissions in 2010. I think on the commercial side, we can't reveal, obviously, what our marketing strategy is. But I think we have a robust strategy. And I think we know how to launch products in the specialty area like ISENTRESS, as well as in primary care like JANUVIA. So we are very excited by the prospects of boceprevir. We look forward to next November 1 and 2 in the Phase III data being presented at AASLD.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Catherine Arnold with Credit Suisse.",10," Your next question comes from Catherine Arnold with Credit Suisse.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one o",188," I just have one more housekeeping question in regards to the J&J arbitration because I know you've covered that a lot, but I just want to be very direct in my question on something. And then I'd like to ask you another question after that, which is one on J&J, there was, obviously, a lot of misinterpretation potentially about the first press release when you talked about the series of events and that it sort of when people do the math it led to a decision before the end of 2010 and then there was more clarity on that for 2011. I may be splitting hairs, but I guess would like you to comment on the process. Did you change the communication because there was a misunderstanding or did you change it because there was an incremental step in the process? And then second question I have is about the donut hole coverage, and I wondered if you've looked at your portfolio and made some judgments as to what products might have the most upside in 2011 because there's better compliance due to the donut hole coverage.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Bruce, do you want to start?",6," Bruce, do you want to start?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration p",75," Sure, Catherine. In response to the question about the timing of the arbitration, what we've done is make the disclosure with reference to the timing as it stood at the time and in terms of averages. For example, one of the advantages in an arbitration proceeding is that the parties and the arbitrators are able to agree on changes to the process as they go along, and that's what we've reflected during our ongoing disclosures.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," And then on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient co",61," And then on the donut hole, we, obviously, look at our entire portfolio. Some of our products are more subject to Medicaid than others like the chronic care products. But overall, we think that, that has a benefit because you could see greater patient compliance when you take away sort of the economic disincentive that was inherent in the donut hole.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your next question comes from Seamus Fernandez with Leerink Swann.",10," Your next question comes from Seamus Fernandez with Leerink Swann.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the",160," Can you just discuss for us the contribution to earnings from AZLP. We saw, I think, pretty strong revenue number from AZLP this quarter and just wondering what kind of contribution on the revenue, and then the equity income also was quite strong in the quarter. I know these payments are lumpy. But it looks like it brought something to the table here. Also, can you talk about the gross margin weakness in the quarter? What pushed it so low in the quarter? Was it really just kind of mix and seasonality with Schering? Was it the mix of AZLP revenues? And then just the final question really related to AZLP and your long-term guidance. What are the assumptions? Can you just remind us about the assumptions relative to AZLP and the PPI option that AstraZeneca holds for 2012? And I guess when would be the timing of the execution of that option should AstraZeneca actually choose to execute it?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income,",375," I think those are all headed my way. This is Peter. So first on the AZLP, you've got it right. Obviously, from a quarter-to-quarter standpoint, that is an operation that does have inherent variability in the timing of payments and recognition of income, obviously. However, it's a business that continues to do nicely. We haven't really given guidance for these individual businesses and so forth, but there are timing of different seasonality of the products and so forth. On the -- related to that relationship, there is, as you know, in February, there was an option on the non-PPI products that was executed. And you saw a gain in our financials earlier this year from that and obviously, that gain is excluded from our non-GAAP results, it's included in our GAAP results and then some of our tables. The next option timing is two years later. That's for the PPI items, so that'll be roughly in the first part of 2012. And at this point, where we've always assumed that they will exercise that option that said it's their choice and we can't really predict exactly what will happen, but that's the way we thought about it anyway. And then moving to the product gross margins for the quarter, you're right. You put your finger on the two points. One is obviously -- there is some volatility in PGM just naturally because of the mix and some of that mix is because of products or to be -- divisional and so forth, so that does move around a little bit. The other factor that we had in the second and third quarter this year when you compare it in the second and to third quarter was in the same quarter, we did get some foreign exchange benefit and the third quarter that didn't recur. So that also kind of caused the third quarter to look a little weaker versus the second quarter. And obviously the mix also, so we kind of have two factors go against us in the third quarter. I think we have experienced a higher level of volatility in foreign exchange rates this year than normal. And so to that on some timing basis eventually does roll to the cost of goods.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Your last question comes from Tony Butler with Barclays Capital.",10," Your last question comes from Tony Butler with Barclays Capital.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Analysts"," Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and",115," Ken, on diversified brands, is that managed independent of other areas of business? And secondly, do you actually have a dedicated sales force to sell those diversified brands? And then secondly, Dick, big picture, I've heard you talk about customers and excellence with customers in being number one with customers, but if I think back over the last 20 years, the balance of power has really shifted. And I'm curious today who are your principal customers? And please don't just say well, it's patients, it's physicians, it's payers. That we kind of know. But there's been a shift, and I'm just curious how you think about that from a focal point on the sales effort?
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a mar",99," So let me start with diversified products. I would say that first of all, we have been trying to focus on those brands as a separate business line. They have their own separate customer segments, and so we have a GM to manage it as a franchise from a marketing standpoint. And in some markets, we actually have separate sales forces, China, for example. I think it varies depending on the actual market characteristics, but to answer the thrust of your question, we actually trying to treat this business line as its own distinct business line to be managed.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," And to your other question, obviously, the folks that we have are physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust cap",252," And to your other question, obviously, the folks that we have are physicians is still very important for us, mainly from an education standpoint. So the physicians know about our products or vaccines and now with the merger that we have such a robust capability in each of the franchises that they know they have many choices. And I think we're moving to a more customized customer approach and just the same messages of the same kind of products and services for every customer. But on a more strategic level, Tony, and I think that's a good question. I think one of the things that Merck will have from a competitive advantage standpoint is that when you look at either governments on an international basis, whether it's a nice type organization or whether we're moving to healthcare reform today and the government's going to play a larger role or whether you're looking to some of the larger managed care payers that exist in the United States. The important part is going to be health technology assessment and the ability to have clinical outcomes and be able to approve that whatever product you're thinking about from a regulatory approval and launch standpoint is above the standard of care that exists today. And I think where our competitive advantage is a company is our late-stage pipeline and how much of it has the ability to meet unmet medical needs and it is differentiated products, and we have the clinical outcome studies to prove it.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Executives"," Okay. Thank you, operator. That concludes our call today. Thank you, everyone.",12," Okay. Thank you, operator. That concludes our call today. Thank you, everyone.
"
288502,113992770,86619,"Merck & Co. Inc., Q3 2010 Earnings Call, Oct 29, 2010",2010-10-29,"Earnings Calls","Merck & Co., Inc.","Operator"," Thank you. This concludes the conference. You may now disconnect.",10," Thank you. This concludes the conference. You may now disconnect.
 
"
